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CHAPTER 1: 
GENERAL INTRODUCTION AND OUTLINE OF THESIS 
Th is year, 2007, marks the 30th anniversary of the fi rst percutaneous coronary intervention, in the form 
of a percutaneous transluminal coronary angioplasty (PTCA) or balloon angioplasty, by Andreas Gru-
entzig.1 It is also the 20th anniversary of the fi rst report of the use of a stent to maintain vessel patency 
following balloon angioplasty.2 
Up until recently, the major limitation to stent implantation was restenosis, or renarrowing, at the site 
of stent implantation, leading to recurrence of angina. Th is occurred in between 10 to 50% of patients. 
In 2000, the fi rst reports of a revolutionary new stent, the drug-eluting stent began to emerge, with early 
promises of zero restenosis.3 In 2003, the fi rst drug-eluting stent was commercialised, coated with the 
immunosuppressive agent sirolimus, leading to the sirolimus-eluting stent, and followed in 2004 by the 
paclitaxel-eluting stent. 
Th e trials performed that led to the commercialisation of drug-eluting stents were in simple lesions, to 
reduce the number of confounding factors.4 Th e patients studied in these trials make up only 25% of the 
typical patient population seen in a cardiac catheterisation laboratory. For the remaining 75%, it was 
extrapolated that these drug-eluting stents would be safe and effi  cacious, but that assumption required 
proving. 
At the Th oraxcentre, a decision was made to implant these drug-eluting stents in all patients suitable 
for stent implantation, irrespective of clinical or angiographic fi ndings, and to research the effi  cacy and 
safety of these stents in these untested patient populations.5 All patients receiving drug-eluting stents 
were thus enrolled into the RESEARCH registry (which enrolled from April 2002 to February 2003), 
and the T-SEARCH registry (from February 2003 onwards).6 
Th e aims of this thesis are multiple: (1) fi rstly, to consolidate the research that emanated from the RE-
SEARCH and T-SEARCH registries, by providing an independent assessment of the effi  cacy, safety and 
cost-eff ectiveness of drug-eluting stents as used in the real-world; (2) to provide the setting for coronary 
artery stenting as a viable alternative to bypass surgery, and fi nally; (3) to provide some insights into 
newer second generation agents.
Part 1 introduces the reader to percutaneous coronary intervention by providing a historical and scien-
tifi c account of coronary artery stenting and drug-eluting stents in Chapters 2 and 3 respectively. In Part 
2, the overall one-year results comparing paclitaxel- and sirolimus-eluting stents are presented, as well 
as longer term results comparing sirolimus-eluting stents to bare metal stents. Importantly, these are 
the overall results of the T-SEARCH and RESEARCH registries respectively. We then go into detail and 
study specifi c subgroups of patients and lesions, in particular, those patients and lesions that were not 
studied in the initial randomized controlled trials that led to the approval of the device. It was important 
Andrew BW.indd   17 28-08-2007   09:49:45
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to be able to provide early and timely data to reassure the interventional community regarding the safety 
of these new devices.
Part 3 has now become an extremely important topic. As we write in Chapter 2, the initial period of 
overblown enthusiasm with new technologies is quickly followed by a period of intellectual reproach. 
Within the RESEARCH registry initially, then with the T-SEARCH registry, we began to see a pe-
culiar late complication of drug-eluting stents, namely late stent thrombosis. We also saw early stent 
thrombosis, which we reported as occurring with the same incidence as in bare metal stents. But it was 
the late thrombosis that has now become a highly important topic, and recognised as occurring more 
commonly with drug-eluting stents. We were able to fi rst report its occurrence (Chapter 16) and to 
provide an incidence (Chapters 15 and 17) to go along with it from our data.
Part 4, which although only consists of one chapter, is also highly important as it explores the cost-
eff ectiveness of drug-eluting stents with respect to bare metal stents. Contrary to the fi ndings of 
company sponsored studies, we demonstrated that at the prices we paid, drug-eluting stents were not 
cost eff ective. We then, in a proactive and provocative paper propose a cost-eff ective unit price, the fi rst 
manuscript to do so with real-world data.
Part 5 consolidates the knowledge obtained from the ARTS I and II trials, comparing surgery versus 
stenting in multivessel disease and utilises it to go forward in the design of the most advanced trial, the 
SYNTAX trial, comparing surgery versus drug-eluting stenting in left  main and /or triple vessel disease. 
A section emphasising the need for complete revascularisation is included in this section.
Th e fi nal section of the main body of this thesis (Part 6) deals with new challengers to the established 
fi rst generation eluting stents. Everolimus is an analogue of sirolimus used as an immunosuppressive 
agent following kidney transplantation. Th e result of the fi rst randomized trial of everolimus with a 
durable polymer constitutes Chapter 26. Lastly, the one-year result of a novel paclitaxel-eluting stent 
with drug- reservoirs is presented. Th is chapter is important because it demonstrates the relationship 
between drug pharmacokinetics (i.e. duration of drug delivery) and clinical outcome. 
Andrew BW.indd   18 28-08-2007   09:49:45
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T he use of percutaneously introduced prosthetic devices to maintain the luminal integrity of diseased blood vessels was proposed by Dotter and Judkins in 1964,1 well before the introduction of coronary angio-
plasty by Grüntzig et al. in 1977.2 Palmaz et al. introduced the use of balloon-
mounted stents (as used in coronary arteries today) in peripheral arteries in 1985.3 
Schatz et al. subsequently modified the Palmaz stent, which led to the development 
of the first commercially successful stent, the Palmaz–Schatz stent.4 Puel and Sig-
wart were the first to implant a stent in humans in March 1986; they used a self-
expanding mesh device. Sigwart and colleagues were also the first to describe the 
use of this stent in 1987 for emergency vessel closure during balloon angioplasty,5 
on the basis of the ability of the device to act as a scaffold to move intimal and 
medial flaps away from the lumen and maintain radial support to offset elastic 
recoil.6 Early observational trials highlighted problems associated with the use of 
stents, in particular, a high incidence of subacute occlusion, despite aggressive 
anticoagulation regimens that prolonged hospital stays and were also associated 
with bleeding complications that were difficult to control and occasionally led to 
serious events.7 Subsequent reports involving larger numbers of patients confirmed 
the utility and efficacy of stenting as a means to avoid emergency bypass surgery.8
In 1993, two important randomized clinical trials compared the Palmaz–Schatz 
stent with balloon angioplasty, establishing the elective placement of coronary stents 
as a standard treatment. The 520-patient Belgium Netherlands Stent (BENESTENT) 
study9 and the 410-patient North American Stent Restenosis Study (STRESS)10 sepa-
rately demonstrated that intracoronary stents significantly reduced the incidence 
of angiographic restenosis (defined as more than 50 percent narrowing of a previ-
ously stented site, as measured by quantitative coronary angiography) and repeated 
angioplasty in patients with discrete, new lesions in large target vessels, leading 
to the era of elective stent implantation. By 1999, stenting comprised 84.2 percent 
of percutaneous coronary interventions.11 Although the implantation of an intra-
coronary stent prevents the acute recoil and postinjury arterial shrinkage (constric-
tive remodeling) associated with balloon angioplasty, it increases the risk of sub-
acute thrombosis and, more important, replaces atherosclerotic coronary disease with 
the more severe iatrogenic condition of in-stent neointimal hyperplasia — that is, the 
growth of scar tissue inside the stent through the cell-cycle pathway and as a result 
of the proliferation and migration of vascular smooth-muscle cells (Fig. 1).
At the time of the STRESS and BENESTENT trials, despite the use of an inten-
sive anticoagulation regimen, subacute occlusion occurred in 3.7 percent of patients, 
a value higher than that seen with balloon angioplasty alone. The use of high bal-
loon pressures to optimize apposition of the stent strut to the vessel wall, together 
with dual antiplatelet therapy with aspirin and ticlopidine (a thienopyridine) rather 
than anticoagulation resulted in a dramatic reduction in the rates of stent throm-
bosis.12 Currently, clopidogrel is the more popular thienopyridine, owing to its bet-
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ter safety profile, with a lower incidence of rash 
and neutropenia.13 A recent meta-analysis of 29 
published, randomized studies involving 9918 
patients and comparing balloon angioplasty 
with routine coronary stenting with bare stents 
confirmed that stenting reduces restenosis and 
repeated intervention, but does not reduce mor-
tality or myocardial infarction.14 Once a role for 
elective stent implantation was established, the 
next goal was to overcome the complications of 
subacute stent thrombosis and neointimal hy-
perplasia through pharmacologic and physical 
means.
B a r r ier a nd Bioac t i v e 
S ten t Coat ings
Barrier Stent Coatings
Stent implantation, inherently a thrombogenic pro-
cedure, initiates a complex interaction between the 
blood components and the metal surface of the 
stent, which includes the deposition of protein; 
the activation of platelets, the complement system, 
and coagulation factors; and the eventual propa-
gation of thrombi over the surface of the stent15 
and the establishment of a confluent endothelial 
monolayer. Various biologically inert surface coat-
ings, such as carbon, platinum, phosphorylcho-
line, and gold, have been applied to stainless-steel 
stents in an attempt to reduce thrombosis and re-
stenosis, but the effectiveness of these strategies 
has not been proven in clinical trials. Indeed, gold 
coatings result in increased rates of restenosis.16
Active Stent Coating to Prevent Thrombosis
In contrast to barrier laminates, heparin coatings 
provide a biologically active surface that interacts 
with circulating blood. The BENESTENT II ran-
domized trial demonstrated that heparin-coated 
stents resulted in a lower rate of adverse events at 
one year than did balloon angioplasty (11 percent 
vs. 21 percent, P = 0.004).17 Analysis of data from 
a large, single-center registry demonstrated that, 
as compared with bare-metal stents, heparin-coat-
ed stents significantly reduced the rate of stent 
thrombosis.18
DRUG -ELU TING S TEN T S
Considerable efforts have gone into the develop-
ment of stents with an active coating to inhibit 
in-stent restenosis — the drug-eluting stent. The 
components of a drug-eluting stent can be divided 
into a platform (the stent), a carrier (usually a poly-
mer), and an agent (a drug) to prevent restenosis. 
Stents are ideal delivery systems because they al-
low the local delivery of the active agent to the 
area of vascular injury, averting the need to de-
liver high doses systemically. The development of 
a suitable carrier to transport an appropriate agent 
has been challenging, since it must have mechan-
ical resistance to abrasion during implantation, be 
suitable for sterilization, allow time- and dose-
controlled drug release, and not promote throm-
bogenesis and inflammation of the vessel wall 
and tissue.19 Various coatings have been devel-
oped, including phosphorylcholine; biocompat-
ible nonerodable, biodegradable, or bioabsorbable 
polymers; and ceramic layers.20-25 Polymers are 
the most commonly used carriers. A drug that is 
successfully eluted should inhibit the complex 
cascade of events that leads to neointimal forma-
tion after stent implantation (Fig. 1). The inflam-
matory and proliferative mechanisms of the gen-
eral tissue-healing response and specific blood 
and vessel-wall components of the vascular re-
parative processes are potential targets for thera-
peutic approaches aimed at reducing neointimal 
proliferation.
The success of eluting devices is highly depen-
dent on each component of the complex, as well 
as on the interactions among these elements. It is 
therefore unlikely that drug-eluting stents have a 
class effect, since there are myriad possible thera-
peutic combinations. Different drug-eluting stents 
vary in their ability to inhibit neointimal growth.26 
Finally, because the results of experiments in 
animal models cannot be directly translated to 
humans, specific clinical trials of safety and ef-
ficacy are required for each device.27
Successful Drug-Eluting Stents
Sirolimus-Eluting Stents
The first positive clinical data on drug-eluting 
stents came from trials examining sirolimus-coat-
ed stents. Sirolimus, a natural macrocyclic lactone 
with potent antiproliferative, antiinflammatory, 
and immunosuppressive effects, acts by inhibiting 
the activation of the mammalian target of rapa-
mycin (mTOR), ultimately causing arrest of the 
cell cycle (Fig. 1).28,29
The Cypher sirolimus-eluting stent (Cordis, 
Johnson & Johnson) is produced by coating a stain-
less-steel stent with a thin layer of a nonerodable 
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polymer containing sirolimus. The seminal first 
implantations of slow- and fast-release sirolimus-
eluting stents, in the First in Man (FIM) clinical 
study, were performed in São Paulo, Brazil,20 and 
Rotterdam, the Netherlands.30 Four months after 
implantation, both types of stents were associ-
ated with minimal neointimal hyperplasia, as 
measured by intravascular ultrasonography and 
quantitative coronary angiography. The slow-
release formulation was subsequently used. In the 
Brazilian study, intravascular ultrasonography at 
four years revealed continued suppression of inti-
mal hyperplasia in the group of 30 patients with 
the slow-release sirolimus-eluting stent, with an 
event-free survival rate of 87 percent.20
The results of four randomized trials involv-
ing sirolimus-eluting stents have been published 
and are summarized in Figures 2 and 3 and in 
Table 1 of the Supplementary Appendix (available 
with the full text of this article at www.nejm.org). 
The Randomized Study with the Sirolimus-elut-
ing Bx Velocity Balloon Expandable Stent (RAVEL) 
demonstrated a remarkable 0 percent rate of re-
stenosis and complete inhibition of neointimal 
hyperplasia in the group that received a siroli-
mus-eluting stent, as measured by angiography, 
and led to the approval of the device in Europe.31 
Percutaneous revascularization of the treated le-
sion was required in 0 percent of the group that 
received a sirolimus-eluting stent group, as com-
pared with 23 percent of the control group at one 
year. The results of the randomized, double-blind 
Sirolimus Eluting Stent in de Novo Coronary Le-
sions (SIRIUS) trial, involving 1055 patients, were 
used to gain approval of the device by the Food 
and Drug Administration (FDA) in the United 
States in 2003.32 The SIRIUS trial confirmed the 
safety and efficacy of the sirolimus-eluting stent 
in single, previously untreated coronary artery le-
sions, with a lower rate of in-stent restenosis than 
found with otherwise identical bare-metal stents 
(3.2 percent vs. 35.4 percent, P<0.001). The small-
er European and Latin American (E-SIRIUS)33 and 
Canadian (C-SIRIUS)34 multicenter SIRIUS trials 
confirmed the results of the SIRIUS trial. Most 
recently, the single-group Arterial Revasculariza-
tion Therapies Study Part II (ARTS II), involving 
a cohort of patients with highly complex condi-
tions who received an average of 3.7 sirolimus-
eluting stents, reported low rates of repeated inter-
vention rates — 8.5 percent — at one year, with 
an event-free survival rate of 89.5 percent.35
Polymeric Paclitaxel–Eluting Stents
Paclitaxel is a potent antiproliferative agent that 
inhibits the disassembly of microtubules (Fig. 1). 
A series of studies — the Randomized, Double-
Blind Trial of a Slow-Release Paclitaxel-Eluting 
Stent for de Novo Coronary Lesions (TAXUS) stud-
ies — were conducted to collect data on two 
paclitaxel-eluting stents, the NIR stent and the Ex-
press stent (Boston Scientific). A copolymer coat-
ing (Translute, Angiotech) is used for the bipha-
sic release of paclitaxel, with an initial burst in 
the first 2 days, followed by lower-level release for 
10 days. Three randomized trials of this device 
have been published (Fig. 2 and 3, and Table 1 of 
the Supplementary Appendix). TAXUS-I evaluated 
the feasibility and safety of paclitaxel-eluting stents 
as compared with bare-metal stents and found 
similar six-month rates of restenosis of 0 and 
10 percent, respectively.21
TAXUS-II investigated two formulations of 
paclitaxel-eluting stents: slow- and moderate-
release.36 Although both devices carry the same 
total dose of medication, drug release from the 
moderate-release device is eight times as high in 
the first 10 days. Excellent results were achieved 
with both formulations; only the slow-release 
formulation was readied for commercial use and 
received European approval partly on the basis of 
the results of this trial. The randomized, double-
blind TAXUS-IV, involving 1314 patients, assessed 
the safety and efficacy of the slow-release pacli-
taxel-eluting stent in single, previously untreated 
lesions and led to FDA approval in 2004.37 Nine 
months after stenting, the need for a repeated 
procedure in the treated vessel was 4.7 percent in 
the group that received paclitaxel-eluting stents, 
as compared with 12.0 percent in the groups that 
received bare-metal stents (P<0.001). TAXUS-V 
and TAXUS-VI subsequently confirmed the effi-
cacy of this stent in small vessels (less than 2.5 
mm in diameter) and long lesions and the safety 
of procedures involving overlapping paclitaxel-
eluting stents (Table 2 of the Supplementary Ap-
pendix).
Real-World Experience
Concern that the results of the clinical trials might 
not translate into daily practice were addressed 
in the Rapamycin-Eluting Stent Evaluated At Rot-
terdam Cardiology Hospital (RESEARCH) sequen-
tial registry.38 A total of 508 consecutive patients 
with previously untreated coronary lesions exclu-
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sively treated with sirolimus-eluting stents were 
compared with a control group of 450 patients 
who had received bare-metal stents in the period 
immediately preceding the introduction of drug-
eluting stents. Patients who received sirolimus-
eluting stents had a lower rate of adverse events 
at one year (9.7 percent vs. 14.8 percent, P = 0.008), 
with the difference largely accounted for by a re-
duction in the rate of clinically driven reinterven-
tions (3.7 percent vs. 10.9 percent, P<0.001). The 
two-year results of this study confirmed the du-
rability of this device, with rates of adverse events 
of 15.4 percent in the group given sirolimus-elut-
ing stents, as compared with 22.0 percent in the 
group given bare-metal stents (P<0.01).39 The 
randomized Basel Stent Kosten Effektivitäts Trial 
(BASKET) confirmed the superiority of drug-elut-
ing stents over bare-metal stents at six months.40
Comparative Trials
The Prospective, Randomized, Multi-Center Com-
parison Study of the Cypher Sirolimus-Eluting and 
TAXUS Paclitaxel-Eluting Stent Systems (REALITY) 
compared sirolimus-eluting stents and paclitaxel-
eluting stents.26 The rate of late loss (a measure 
of neointimal hyperplasia assessed by means of 
quantitative coronary angiography) was lower with 
sirolimus-eluting stents than with paclitaxel-
eluting stents, but the rates of angiographic re-
stenosis and, more important, the need for re-
intervention in the treated lesion did not differ 
significantly between groups (5.0 percent vs. 5.4 
percent, P = 0.8). The two-center Randomized 
Comparison of Sirolimus with Paclitaxel Eluting 
Stents for Coronary Revascularization of All Com-
ers (SIRTAX)41 reported better outcomes with si-
rolimus-eluting stents than with paclitaxel-eluting 
stents. The single-center Taxus-Stent Evaluated at 
Rotterdam Cardiology Hospital (T-SEARCH) study, 
a sequential monocentric registry of patients who 
received drug-eluting stents without any restric-
tions, reported no significant difference in the inci-
dence of adverse cardiac events between the two 
devices.42 Two smaller randomized trials demon-
strated that sirolimus-eluting stents were more 
efficacious than paclitaxel-eluting stents in spe-
cific types of patients: those with restenosis in 
bare-metal stents (the Intracoronary Stenting and 
Angiographic Results: Drug-Eluting Stents for In-
Stent Restenosis [ISAR-DESIRE] study) and those 
with diabetes (the ISAR: Do Diabetic Patients 
Derive Similar Benefit from Paclitaxel-Eluting 
and Sirolimus-Eluting Stents [ISAR-DIABETES] 
study).43,44
Investigative Agents
Zotarolimus
Zotarolimus is a sirolimus analogue that blocks 
the function of mTOR and is currently being 
investigated (Fig. 1, and Table 2 of the Supple-
mentary Appendix). A series of clinical trials 
— Trial to Evaluate the Safety and Efficacy of 
the Medtronic AVE ABT-578 Eluting Driver Cor-
onary Stent in de Novo Native Coronary Artery 
Lesions (ENDEAVOR) — have been designed to 
examine the safety and efficacy of zotarolimus 
released from a phosphorylcholine-delivery ma-
trix on the cobalt-based alloy Driver stent (Medtron-
ic).22 The single-group ENDEAVOR-I safety study 
was followed by the randomized, multicenter 
ENDEAVOR-II trial, involving 1197 patients, which 
confirmed the efficacy of this device, with reste-
nosis rates of 9.5 percent, as compared with 32.7 
percent for bare-metal stents (P<0.001).45 The im-
plications of a mean in-stent late loss of 0.62 mm, 
which was consistently seen in both trials and 
is higher than that reported in trials of siroli-
mus-eluting and paclitaxel-eluting stents, are un-
known.
The Zomaxx stent (Abbott) contains zotaroli-
mus on a low-profile, trilayer stent composed of 
tantalum and stainless steel (TriMaxx), with a 
modified phosphorylcholine coating to allow slow-
er drug release than afforded by the Medtronic 
device. The first of Abbott’s clinical trials has 
completed enrollment, and a second is under way 
(Table 2 of the Supplementary Appendix).
Everolimus
As a sirolimus analogue, everolimus inhibits mTOR 
(Fig. 1). Trials involving everolimus-coated stents 
are split into two: the First Use to Underscore 
Restenosis Reduction with Everolimus (FUTURE) 
and A Randomized Comparison of a Durable 
Polymer Everolimus-Eluting Stent with a Bare-
Metal Coronary Stent (SPIRIT) studies (Tables 1 
and 2 of the Supplementary Appendix). The small 
FUTURE-I study was a prospective, randomized, 
single-blind trial that evaluated the safety of an 
everolimus-eluting stent with an ultrathin coat-
ing of a polyhydroxyacid bioabsorbable polymer 
used for drug delivery (Biosensors International). 
As compared with bare-metal stents in previously 
untreated lesions, everolimus-eluting stents sig-
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nificantly reduced the extent of late loss (0.11 
mm vs. 0.85 mm, P<0.001).23 The results of the 
FUTURE-II trial have yet to be published. The 
SPIRIT FIRST trial confirmed the safety and ef-
ficacy of everolimus coupled with a durable poly-
mer on a chromium–cobalt stent and has led to 
the initiation of SPIRIT-II outside and SPIRIT-III 
within the United States.24
Other Agents
Other agents that appear promising and are cur-
rently undergoing safety and efficacy trials include 
biolimus A9 (a sirolimus analogue),25 tacrolimus 
(a sirolimus analogue), and paclitaxel contained 
in reservoirs within the stent. If shown to be suc-
cessful, they will then undergo larger comparative 
trials, most likely with one or more of the estab-
lished devices used as a benchmark.
Indic ations for the Use 
of Corona r y S ten t s
Currently, better equipment and drug-eluting stents 
have changed percutaneous coronary intervention 
so that 90 to 95 percent involve stent implanta-
tion. However, most published data originated in 
the era of bare-metal stents. Given the lack of long-
term follow-up with drug-eluting stents, careful 
scrutiny of the literature is necessary before con-
vincing recommendations can be made.
Primary Revascularization after Myocardial 
Infarction Involving ST-Segment Elevation 
Randomized trials have compared stent implan-
tation with balloon angioplasty as the primary 
revascularization strategy for myocardial infarc-
tion involving ST-segment elevation,46-48 with 
meta-analyses reporting the superiority of stent-
ing, as reflected by a reduced need for reinterven-
tion in the treated vessel for up to 12 months.49 
More recently, two major studies, Danish Multi-
center Randomized Study of Fibrinolytic Therapy 
vs. Acute Coronary Angioplasty in Acute Myocar-
dial Infarction 2 (DANAMI-2)50 and Primary An-
gioplasty in Patients Transferred from General 
Community Hospitals to Specialized Percutane-
ous Transluminal Coronary Angioplasty (PTCA) 
Units with or without Emergency Thrombolysis 2 
(PRAGUE-2),51 have indicated the superiority of 
stenting over thrombolytic therapy, primarily as 
a result of the ability of stenting to reduce re-
infarction rates. Drug-eluting stents are superi-
or to bare-metal stents because they further re-
duce the need for reintervention in the treated 
vessel.52
Focal Lesions in Vessels 3.0 mm or More in Diameter
The trials comparing balloon angioplasty with 
stent implantation have been confined to patients 
with vessels with diameters of 3.0 mm or greater 
on visual assessment (smaller-diameter stents were 
not available in the past). Results of such trials 
have consistently shown a reduction in adverse 
events with the use of stenting.9,10,17 A notable 
finding is that a sizable number of patients who 
received stents had vessel diameters smaller than 
3.0 mm when later measured with the use of 
quantitative coronary angiography.
Focal Lesions in Saphenous-Vein Grafts
Both observational and randomized trials have 
indicated a high rate of procedural success with 
vein-graft stenting, improved clinical outcomes 
during hospitalization, and improved long-term 
graft patency.53 The Randomized Evaluation of 
Polytetrafluoroethylene Covered Stents in Saphe-
nous Vein Grafts (RECOVERS) study54 demon-
strated that stents covered with a polytetrafluo-
roethylene membrane conferred no advantage 
over bare-metal stents for the treatment of vein-
graft disease. Distal embolization is a major prob-
lem in old and friable vein grafts, and the use of 
devices placed downstream of the treated area 
to catch vascular debris has improved the safety 
of vein-graft interventions.55,56
Treatment of Chronic Total Occlusions
Various trials comparing stenting with balloon 
angioplasty for coronary-artery occlusions have 
reported that stenting reduces the rate of angio-
graphic and clinical restenosis and reocclusion.57 
More recently, registry series comparing drug-elut-
ing stents with bare-metal stents have confirmed 
the superior efficacy of the former.58
Treatment of Restenosis after Balloon Angioplasty
The randomized Restenosis Stent Trial (REST) 
demonstrated that in patients with restenosis af-
ter balloon angioplasty, the implantation of a stent 
was associated with a lower rate of angiographic 
restenosis and repeated intervention than was bal-
loon angioplasty.59
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Segmental Lesions for Which Coronary 
Stenting is Probably Beneficial
Although stents are used for long lesions, vessels 
that are less than 3.0 mm in diameter, and lesions 
at bifurcations, there is less evidence to support 
their use.
Long Lesions
The length of the stented segment is a recog-
nized independent risk factor for restenosis.60 In 
a nonrandomized comparison, balloon angioplas-
ty with intravascular-ultrasound–guided placement 
of multiple small stents to cover stenoses along 
vessel lesions (“spot” stenting) had a better long-
term outcome than stenting the entire portion of 
a diseased vessel.61 One randomized trial com-
pared the use of stents with balloon angioplasty 
for long lesions and found lower rates of angio-
graphic restenosis in the stent group than in the 
angioplasty group at six months (27 percent vs. 
42 percent, P<0.05) but no significant difference 
in clinical benefit at nine months.62 Placing se-
quential overlapping stents in long lesions in-
creases the length of the stented area within the 
vessel and is associated with increased rates of 
restenosis. Evidence to date indicates that drug-
eluting stents may be safely used in this manner 
and are seemingly associated with markedly re-
duced rates of restenosis. Thus, drug-eluting stents 
appear to be associated with a substantially small-
er risk of restenosis than bare-metal stents, espe-
cially in long lesions.63
Small Vessels
The benefit of stenting vessels smaller than 3.0 mm 
in diameter is unclear; a meta-analysis indicated 
that stenting significantly reduced the rates of re-
peated revascularization, as compared with balloon 
angioplasty, with similar rates of adverse events.64 
The recent subgroup analyses of TAXUS-V and 
TAXUS-VI suggest that drug-eluting stents reduce 
the rate of restenosis in small vessels, without as-
sociated side effects.
Lesions at Bifurcations
Different stenting techniques, each with their own 
advantages and indications, have been used to 
treat lesions at bifurcations.65 Observational stud-
ies have suggested that stenting both branches of 
bifurcated lesions confers no advantage over stent-
ing one branch and performing balloon angioplasty 
on the other.66 Currently, the most appropriate 
technique for treating lesions at bifurcations re-
mains to be determined. As compared with his-
torical results with bare-metal stents, drug-eluting 
stents are associated with a lower overall rate of 
restenosis, although the rates remain higher in 
side branches than in the main vessel.67
Unresolved Issues
Stenosis of an Unprotected Left Main 
Coronary Artery
Safety studies and early efficacy studies have shown 
that stenting of a previously ungrafted stenosis 
in the left main stem may be a promising alter-
native to bypass surgery in selected patients.68,69 
Analysis of recent registries suggests a potential 
role for drug-eluting stents in left main lesions,70,71 
with the ongoing Synergy between Percutaneous 
Coronary Intervention with Taxus and Cardiac 
Surgery (SYNTAX) Study designed to address the 
role of drug-eluting stents as compared with by-
pass surgery in a randomized manner.72
Multivessel Disease
Long-term follow-up of patients with multivessel 
disease in the ARTS trial found no significant dif-
ference in mortality rates between patients treat-
ed with bare-metal stents and those treated with 
bypass surgery, but the former group had a high-
er rate of repeated procedures.73 The SYNTAX 
study will address the role of drug-eluting stents, 
as compared with bypass surgery, in three-vessel 
disease.72
Diabetes Mellitus
Diabetes has repeatedly been shown to confer an 
independent risk of restenosis and adverse clini-
cal events after stent implantation in multiple tri-
als of bare-metal and drug-eluting stents.32,37 
Although as compared with bare-metal stents, 
drug-eluting stents appear to reduce the reinter-
vention rate by up to two thirds among patients 
with diabetes with bare stents, the reintervention 
rate in this subgroup remains up to twice as fre-
quent as that among patients without diabetes 
who receive stents.35 A randomized trial is under 
way — the Future Revascularization Evaluation 
in Patients with Diabetes Mellitus: Optimal Man-
agement of Multivessel Disease (FREEDOM) study 
— that specifically compares drug-eluting stents 
with bypass surgery in patients with diabetes who 
have multivessel disease.
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In-Stent Restenosis
Both sirolimus-eluting stents74 and paclitaxel-elut-
ing stents75 have been examined as treatments 
for restenosis. Although definitively better than 
balloon angioplasty in reducing the rate of recur-
rent restenosis,43 they appear similar to conven-
tional intracoronary brachytherapy (radiation de-
livered intravascularly through a catheter within 
the stent borders).76 The TAXUS-V–In-Stent Reste-
nosis randomized trial is comparing drug-eluting 
stents with brachytherapy for in-stent restenosis 
to confirm these results. 
Biodegradable Stents
The development of biodegradable stents has been 
hampered by difficulties in replicating the prop-
erties of stainless-steel stents. There has been a 
revival of interest in developing a fully biodegrad-
able stent that has pharmacologically active agents 
incorporated into the polymeric matrix. An ef-
fective drug-releasing, biodegradable stent must 
not cause an inflammatory reaction or release 
toxic breakdown products. The release of the drug 
from the stent must be safe and reliable, and the 
stent must have high radial strength similar to 
that of metal. Biodegradation should occur with-
in a reasonable period (12 to 24 months). The 
Duke biodegradable stent77 and the Igaki–Tamai 
biodegradable stent78 are made from a special form 
of poly-L-lactide and are capable of incorporating 
pharmacologically active agents. The Igaki–Tamai 
stent has been successfully loaded with tranilast, 
a drug that inhibits the migration and prolifera-
tion of vascular smooth-muscle cells.79 This type 
of stent has also been loaded with paclitaxel, and 
although effective in reducing the rate of resteno-
sis in an animal model, it incites a considerable 
inflammatory response.80 Another promising de-
gradable stent undergoing clinical evaluation is 
made from magnesium alloy.81
C av e at s a nd Conclusions
The three major milestones in the evolution of in-
terventional cardiology were the development of 
the angioplasty balloon by Andreas Grüntzig, the 
introduction of the coronary-artery stent, and most 
recently, the development of drug-eluting stents. 
In the past three years, the use of drug-eluting 
stents has had an unprecedented effect on the 
practice of interventional cardiology. The accep-
tance of drug-eluting stents has followed the same 
course as all newly introduced techniques, with 
the initial period of overblown enthusiasm quick-
ly followed by a period of intellectual reproach.
Recent results of longer-term studies in broad-
er patient populations have highlighted troubling 
clinical issues. In studies in animals, the pres-
ence of fibrin, inflammatory cells, and incomplete 
endothelialization has been noted and at three 
months, when the drug has been completely eluted 
from the stent, neointimal growth at levels simi-
lar to those for bare-metal stents,27 arousing con-
cern about the possibility of late restenosis.82 De-
layed endothelialization has been seen in human 
arteries treated with drug-eluting stents83; this 
complete inhibition of healing may prevent en-
capsulation of the stent but, in one study, did not 
translate into adverse events at one year.84 There 
have been rare instances of hypersensitivity reac-
tions to the polymer, which can be fatal.85
The consequences of these findings have been 
clinically observed as stent thrombosis, a poten-
tially fatal complication of stent implantation. 
Thrombosis within the stent may occur early, 
within the first 30 days after implantation, or 
late, if after this period, with differing causes. 
The most common cause of early stent thrombo-
sis is mechanical (unrecognized dissection or 
underexpansion of the stent), whereas late stent 
thrombosis is potentially due to a mismatch 
between the stent and the vessel (stent malap-
position), hypersensitivity,85 or abnormal re-
endothelialization. A recently recognized poten-
tial predisposing factor for stent thrombosis is 
resistance to aspirin and clopidogrel; this asso-
ciation requires more investigation. The rates of 
early stent thrombosis probably do not differ sig-
nificantly between drug-eluting and bare-metal 
stents, occurring in 1.0 to 1.5 percent of pa-
tients.86,87 Whether this is also true for late stent 
thrombosis is unclear; however, caution must be 
exercised, given the lack of comparative data and 
the difference in the duration of dual antiplatelet 
therapy between devices (one month for bare-
metal stents and three to six months for drug-
eluting stents).88
Most important, after the implantation of a 
drug-eluting stent, patients must strictly adhere 
to their regimen of dual antiplatelet therapy and, 
on completion, take aspirin monotherapy.89 Pa-
tients with drug-eluting stents who require sur-
gery, elective or otherwise, irrespective of the time 
since implantation, must continue to take aspirin 
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perioperatively unless it is absolutely contraindi-
cated, since cessation of antiplatelet therapy, even 
if it occurs long after the implantation of the 
stent, may precipitate stent thrombosis, which car-
ries a high risk of death or myocardial infarction.
As a solution, coatings that are more biologi-
cally friendly and promote rather than inhibit 
natural healing processes are rapidly being de-
veloped.90,91 One example is the use of immobi-
lized antibodies against circulating endothelial 
progenitor cells as a means of “self-seeding” in-
travascular devices.90 Such techniques show prom-
ise for use in combination with drug-eluting stents 
and may provide a more physiologic alternative. 
With the development of better devices, uniquely 
engineered to be specific for each subgroup of 
lesions, the treatment of coronary artery disease 
will improve.
No potential conflict of interest relevant to this article was 
reported.
We are indebted to Eric Boersma, Ph.D., for assistance in the 
preparation of the figures.
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Technology Insight: an overview of research 
in drug-eluting stents
Andrew TL Ong and Patrick W Serruys*
INTRODUCTION
Following the commercialization of drug-eluting 
stents (DESs) in April 2002 in Europe, and in 
March 2003 in the US, there has been a rapid 
uptake of this new technology—more than 
2.5 million stents had been implanted world-
wide up to February 2005.1,2 In Europe, DESs 
are currently estimated to account for 40% of 
all stent sales, and in the US the market penetra-
tion has reached 80%. Two devices are currently 
commercially available in both continents, with 
others at various stages of product development. 
In this review, we discuss the data available so 
far for the two commercially available devices, 
summarize the findings for other DESs being 
tested or developed, and look at the possible 
future applications for these devices.
DRUG-ELUTING-STENT COMPONENTS
The components of a DES are the platform (the 
stent itself), the carrier (usually a polymer) 
and the agent (a drug that prevents restenosis). 
Metallic coronary stents alleviate coronary 
obstructions and preserve the luminal area by 
providing a mechanical scaffold to prevent the 
elastic recoil seen with balloon angioplasty. The 
structure provides an ideal way to locally deliver 
the active agent to the area of vascular injury, 
thus avoiding the need for high systemic doses.
The development of a suitable carrier for 
the agent has been challenging.3 Prerequisites 
include suitability for sterilization, mechanical 
resistance to abrasion during the laborious 
process of stent implantation, controllable 
drug release (both in concentration and time), 
and no thrombogenic or inflammatory effects 
on the vessel wall and tissue. Different agents 
might require different delivery vehicles. Most 
commonly, this vehicle has been a polymer 
coating. Various coatings have been developed, 
including phosphorylcholine, biocompatible 
nonerodible, biodegradable or bioabsorbable 
polymers and ceramic layers.
A successful agent should inhibit the complex 
cascade of events that leads to neointimal 
Drug-eluting stents (DESs) have revolutionized interventional cardiology 
over the past few years to the extent that balloon angioplasty and bare 
stents did in the 1980s and 1990s. The first DESs became commercially 
available in Europe in 2002 and in the US in 2003, and it is estimated that 
up to 80% of patients who undergo stent implantation in the US now 
receive a DES. Two devices, Cypher® sirolimus-eluting stents (Cordis 
Corporation, Miami Lakes, FL) and Taxus® paclitaxel-eluting stents 
(Boston Scientific Corporation, Natick, MN), are currently licensed for 
sale in both regions. Multiple new devices using different drugs, carriers 
and stents are currently undergoing clinical trials to establish their 
efficacy and obtain approval for commercialization. While the remarkable 
reduction of restenosis has accounted for the success of DESs, concerns 
remain regarding long-term follow-up; published 3-year follow-up results 
are available for fewer than 200 patients overall. Reports of late stent 
thrombosis have emerged, particularly in relation to discontinuation 
of antiplatelet therapy. In patients treated with DESs, long-term 
administration of at least one antiplatelet agent must be continued 
following completion of the mandatory dual antiplatelet regimen. In 
this review, we summarize the findings available for DESs so far, discuss 
emerging safety and efficacy data, and look at the future directions for 
these devices.
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 formation after stent implantation. The inflam-
matory and proliferative mechanisms of the 
general tissue-healing response, and the specific 
role of blood and vessel-wall components in 
the vascular-reparative processes, are poten-
tial targets for therapeutic approaches aimed at 
reducing neointimal proliferation. The clinical 
effect of DESs is highly dependent on each indi-
vidual component, as well as on the interactions 
between these elements. A class effect of DESs 
is therefore unlikely, because of the myriad of 
possible therapeutic combinations. Different 
DESs vary, for example, in their ability to inhibit 
neointimal growth.4
AVAILABLE DRUG-ELUTING STENTS
Polymer-coated sirolimus-eluting stents 
The Cypher® sirolimus-eluting stent (SES; Cordis 
Corporation, Miami Lakes, FL) has had the 
longest follow-up of the available DES systems. 
It is produced by coating a stainless steel stent 
with a thin layer of a  nonerodible  methacrylate 
Table 1 In-stent late loss and restenosis outcomes from company-sponsored, randomized, double-blind, placebo-controlled, 
multicenter trials comparing polymer-coated sirolimus-eluting or paclitaxel-eluting stents with bare-metal stents. 
Study (inclusion criteria) Stent platform and carriera Mean (SD) 
in-stent late loss 
(mm) and P value
Proportion of 
in-stent binary 
restenosis (%)
Angiographic/
clinical follow-
up (months)
Sirolimus
RAVEL8,12 (one de novo native coronary 
lesion <18 mm, single-stent, vessel 
diameter 3.0–3.5 mm)
Bx Velocity™ with 140 μg/cm2 slow-
release sirolimus; Cypher® stent
–0.01 (0.33) 
vs 0.80 (0.53), 
P <0.001
0 vs 26.2, 
P <0.001
6/36
SIRIUS9,63 (one de novo native coronary 
lesion 15–30 mm, up to two stents, 
vessel diameter 2.5–3.5 mm)
Bx Velocity™ with 140 μg/cm2 slow-
release sirolimus; Cypher® stent
0.17 (0.45) vs 1.00 
(0.70), P <0.001
3.2 vs 35.4, 
P <0.001
8/12
E-SIRIUS10 (one de novo native 
coronary lesion 15–32 mm, up to two 
stents, vessel diameter 2.5–3.0 mm)
Bx Velocity™ with 140 μg/cm2 slow-
release sirolimus; Cypher® stent
0.20 (0.38) vs 1.05 
(0.61), P <0.0001
3.9 vs 41.7, 
P <0.0001
8/9
C-SIRIUS11 (one de novo native 
coronary lesion 15–32 mm, up to two 
stents, vessel diameter 2.5–3.0 mm)
Bx Velocity™ with 140 μg/cm2 slow-
release sirolimus; Cypher® stent
0.12 (0.37) vs 1.02 
(0.69), P <0.001
0 vs 45.5, 
P <0.001
8/9
Paclitaxel
TAXUS I15 (one restenotic or de novo 
native coronary lesion ≤12 mm, one 
stent, vessel diameter 3.0–3.5 mm)
NIRx with 1 μg/mm2 slow-release 
paclitaxel 
0.36 (0.48) vs 0.71 
(0.47), P = 0.008
0 vs 10, P = NS 6/12
TAXUS II16 (one de novo native coronary 
lesion ≤12 mm, one stent, vessel 
diameter 3.0–3.5 mm)
NIRx with 1 μg/mm2 slow-release 
and moderate-release paclitaxel 
Slow release 0.31 
(0.38) vs 0.79 
(0.45), P <0.0001; 
moderate release 
0.30 (0.39) vs 0.77 
(0.50), P <0.0001
Slow release 
2.3 vs 17.9, 
P <0.0001; 
moderate release 
4.7 vs 20.2, 
P = 0.0002
6/12
TAXUS IV17,64 (one de novo native 
coronary lesions 10–28 mm, one stent, 
vessel diameter 2.5–3.75 mm)
Taxus® Express2™ with 1μg/mm2 
slow-release paclitaxel
0.39 (0.50) vs 0.92 
(0.58), P <0.001
5.5 vs 24.4, 
P <0.001
9/12
TAXUS V18 (One de novo native 
coronary lesions 10–46 mm, multiple 
stents allowed, vessel diameter 2.25–
4.0 mm)
Taxus® Express2™ with 1μg/mm2 
slow-release paclitaxel
0.49 (0.61) vs 0.90 
(0.62), P <0.0001
13.7 vs 31.9, 
P <0.0001
9/9
TAXUS VI19 (de novo native coronary 
lesions 18–40 mm, multiple stents 
allowed, vessel diameter 2.5–3.75 mm)
Taxus® Express2™ with 1μg/mm2 
moderate-release paclitaxel
0.39 (0.56) vs 0.99 
(0.59), P <0.0001
9.1 vs 32.9, 
P <0.0001
9/9
aAll drugs in nonerodible polymer matrix. C-SIRIUS, Canadian SIRolImUS-Eluting Bx Velocity™ Balloon-Expandable Stent trial; E-SIRIUS, European 
SIRolImUS-Eluting Bx Velocity™ Balloon-Expandable Stent trial; RAVEL, Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent 
in the Treatment of Patients with De Novo Native Coronary Artery Lesions trial.
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and a mixture of 50% polyethylene vinyl acetate 
and 50% poly(n-butyl metha crylate) polymer 
containing sirolimus. This stent was first 
implanted in December 1999, as part of a first-
in-man study in 45 patients with non-complex 
de novo lesions treated in São Paulo, Brazil, and 
Rotterdam, The Netherlands.5,6 The 4-year 
results for the 30 São Paulo patients showed 
persistent suppression of intimal hyperplasia 
(mean in-stent late loss 0.09 mm for slow-release 
stents and 0.41 mm for fast-release stents), 
confirmed by intra vascular  ultrasonography; 
event-free survival was 87%.7 
Four randomized trials comparing the 
outcomes in patients treated with SESs and 
those who received conventional bare-metal 
stents (BMSs) have been published (Tables 1 and 
2).8–11 The positive results of the Randomized 
Study with the Sirolimus-Eluting Bx Velocity 
Balloon-Expandable Stent in the Treatment 
of Patients with De Novo Native Coronary 
Artery Lesions (RAVEL) trial,8 with no reste-
nosis detected in any patient at 6 months, led to 
SESs being approved for commercialization in 
Europe. The 3-year follow-up data demonstrate 
the continued benefit of reduced target-lesion 
revascularization in the SES group compared 
with the BMS group (95.0% versus 85.6%, 
P = 0.01).12
The pivotal SIRolImUS-Eluting Bx Velocity™ 
Balloon-Expandable Stent (SIRIUS) trial 
randomized 1,101 patients with de novo lesions 
to SESs or BMSs. The findings confirmed the 
clinical efficacy of the SES and led to FDA 
approval of the device in the US in 2003. Long-
term follow-up data of up to 3 years from the 
SIRIUS trial have also confirmed the sustained 
benefit. Two smaller SIRIUS trials in Europe10 
and Canada11 further reinforced the efficacy of 
SESs. The Canadian study reported no harmful 
effects with direct stenting. 
The Rapamycin Eluting Stent Evaluated At 
Rotterdam Cardiology Hospital (RESEARCH) 
study13 was a single-center registry with a non-
restrictive inclusion criterion into which patients 
treated with SESs were enrolled. At 1 year, SESs 
reduced clinically driven repeat intervention by 
65% compared with BMSs (3.7% versus 10.9%, 
P <0.01), thus reducing the 1-year risk of major 
cardiac events by 38% (9.7% versus 14.8%, 
P <0.01). This beneficial effect was maintained at 
2 years, with a major adverse cardiac event rate of 
15.4% for SESs compared with 22.0% for BMSs 
(P = 0.01).14 Importantly, these patients were 
Table 2 Revascularization and major adverse coronary events outcomes from company-sponsored, randomized, double-blind, 
placebo-controlled, multicenter trials comparing polymer-coated sirolimus-eluting or paclitaxel-eluting stents with bare-metal stents. 
Study TLR (%) TVR (%) MACE (%)
Sirolimus
RAVEL8,12 5.3 vs 15.0, P = 0.02 (clinically 
driven); 6.1 vs 25.7, P <0.001 
(all TLR)
0.8 vs 23.7, P <0.001a 10.5 vs 23.9, P = 0.008 (death, MI, clinically driven 
TVR); 11.4 vs 33.6, P <0.001 (death, MI, TVR)
SIRIUS9,63 4.9 vs 20.0, P <0.001 N/A 9.8 vs 24.8, P <0.001 (cardiac death, MI, TVR); 8.3 vs 
22.3, P <0.001 (death, MI, TLR)
E-SIRIUS10 4.0 vs 20.9, P <0.0001 N/A 8.0 vs 22.6, P = 0.002 (death, MI, TLR)
C-SIRIUS11 4.0 vs 18.0, P = 0.05 N/A 4.0 vs 18.0, P = 0.05 (death, MI, clinically driven TLR)
Paclitaxel
TAXUS I15 0 vs 10, P = 0.2 3 vs 10, P = 0.6 3 vs 10, P = 0.6 (death, MI TVR)
TAXUS II16 Slow release 4.7 vs 12.9, 
P = 0.03; moderate release 3.8 
vs 16.0, P = 0.002
Slow release 10.1 vs 15.9, 
P = 0.2; moderate release 6.9 
vs 19.1, P = 0.005 
Slow release 10.9 vs 22.0, P = 0.02 (cardiac death, MI, 
TVR); moderate release 9.9 vs 21.4, P = 0.02 (cardiac 
death, MI, TVR)
TAXUS IV17,64 4.4 vs 15.1, P <0.0001 7.1 vs 17.1, P <0.0001 10.8 vs 20.0, P <0.0001 (cardiac death, MI, ischemia-
driven TVR)
TAXUS V18 8.6 vs 15.7, P = 0.0003 12.1 vs 17.3, P = 0.02 15.0 vs 21.2, P = 0.008 (cardiac death, MI, TVR)
TAXUS VI19 6.8 vs 18.9, P = 0.0001 9.1 vs 19.4, P = 0.003 16.4 vs 22.5, P = 0.12 (cardiac death, MI, TVR)
C-SIRIUS, Canadian SIRolImUS-Eluting Bx Velocity™ Balloon-Expandable Stent trial; E-SIRIUS, European SIRolImUS-Eluting Bx Velocity™ Balloon-Expandable 
Stent trial; MACE, major adverse coronary events; MI, myocardial infarction; N/A, not available; RAVEL, Randomized Study with the Sirolimus-Eluting Bx Velocity 
Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions trial; TLR, target-lesion revascularization; TVR target-vessel 
revascularization. 
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Table 3 Clinical studies with new drug-eluting stents.
Trial name Inclusion criteria Stent platform 
and carrier
In-stent 
late-loss 
(mm)
Binary 
restenosis 
(%)
Duration of 
angiographic/
clinical follow-
up (months)
TLR (%) TVR (%) MACE (%)
Zotarolimus (ABT-578)
ENDEAVOR 
I20 
Single de novo 
native coronary 
lesions, lesion length 
<15 mm, vessel 
diameter 3.0–3.5 mm
Endeavor® 
phosphorylcholine-
coated, ABT-578-eluting 
Driver® cobalt alloy stent
~0.60 5.4 12/12 1 1 2
ENDEAVOR 
II21
Single de novo 
native coronary 
lesions, lesion 
length 14–27 mm, 
vessel diameter 
2.25–3.5 mm
Endeavor® 
phosphorylcholine-
coated, ABT-578-eluting 
Driver® cobalt alloy stent 
0.62 vs 
1.03, 
P <0.0001
9.5 vs 
32.7, 
P <0.0001
8/9 4.6 vs 
12.1, 
P <0.0001
5.7 vs 
12.8, 
P <0.0001
8.1 vs 15.4, 
P <0.0005 
(cardiac 
death, MI, 
TVR)
Everolimus
FUTURE I25 Single de novo 
lesions, lesion 
length <18 mm, 
vessel diameter 
2.75–4.0 mm
Bioabsorbable, polymer-
coated, everolimus-
eluting S-Stent 
(197 μg everolimus/mm2)
0.11 
(0.23) 
vs 0.85 
(0.32), 
P <0.0001
0 vs 9.1, 
P = NS
6/6 3.8 vs 
7.1, 
P = NS
3.8 vs 
7.1, 
P = NS
7.7 vs 7.1, 
P = NS 
(death, MI, 
TLR, TVR-
CABG)
FUTURE II65 Single de novo 
lesions, lesion 
length <18 mm, 
vessel diameter 
2.75–4.0 mm
Bioabsorbable, polymer-
coated, everolimus-
eluting S-Stent 
(197 μg everolimus/mm2)
0.12 vs 
0.85, 
P <0.0001
N/A 6/12 4.8 vs 
14.0, 
P = N/A
N/A 4.8 vs 18.6, 
P = N/A 
(death, MI, 
TLR, TVR-
CABG)
SPIRIT 
FIRST23
Single de novo 
native coronary 
lesions, lesion length 
<18 mm, vessel 
diameter 3.0 mm
Xience® V durable, 
polymer-coated, 
everolimus-eluting 
Vision® chromium–cobalt 
stent
0.10 
(0.21) 
vs 0.87 
(0.37), 
P <0.001
0 vs 25.9, 
P = 0.01
6/6 3.8 vs 
21.4, 
P = NS
3.8 vs 
21.4, 
P = NS
7.7 vs 21.4, 
P = NS 
(death, MI, 
TVR)
Biolimus A9®
STEALTH24 De novo native 
coronary lesion, 
lesion length 
<24 mm, vessel 
diameter 2.75–
4.0 mm
Biolimus A9® in a 
biodegradable polymer 
coated stainless steel 
S-Stent (15.6 μg/mm stent 
length)
0.26 
(0.43) 
vs 0.74 
(0.45), 
P <0.001
3.9 vs 7.7, 
P = 0.4
6/6 1.3 vs 0, 
P = 0.99
1.3 vs 0, 
P = 0.99
3.8 vs 2.5, 
P = 0.99 
(death, MI, 
TLR, TVR 
CABG)
Nitric-oxide-drug-elution
TiNOx61 Single de novo 
native coronary 
lesions, lesion length 
<15 mm, vessel 
diameter 2.5–3.5 mm
Titanium, nitric-oxide-
coated stainless steel 
stent
0.55 
(0.63) 
vs 0.90 
(0.76), 
P = 0.03 
15 vs 33, 
P = 0.07
6/6 7 vs 23, 
P = 0.07
N/A 7 vs 27, 
P = 0.02 
(death, MI, 
clinically 
driven TLR)
17β-estradiol
EASTER 
trial66
Single de novo 
lesions, lesion length 
<18 mm, vessel size 
2.5–3.5 mm
Phosphorylcholine-coated, 
17β-estradiol-eluting stent 
(2.54 μg/ mm2) 
0.31 
(0.38)
6.6 6/12 3.3 3.3 3.3
Dexamethasone
STRIDE67 Single de novo 
lesions, lesion 
length <15 mm, 
vessel diameter 
2.75–4.0 mm
Phosphorylcholine-
coated stent immersed in 
dexamethasone solution 
(0.5 μg/mm2 stent) 
0.47 
(0.47)
13.3 6/6 2.8 N/A 5.6 (death, 
MI, TLR)
CABG, coronary-artery-bypass grafting; EASTER, Estrogen And Stents To Eliminate Restenosis trial; FUTURE, First Use To Underscore restenosis Reduction 
with Everolimus trial; MACE, major adverse coronary events; MI, myocardial infarction; STEALTH, Stent Eluting A9 BioLimus Trial in Humans; STRIDE, Study of 
antirestenosis with the BiodivYsio dexamethasone-eluting stent; TiNOx, The Randomized Comparison of a Titanium-Nitride-Oxide-Coated Stent With a Stainless 
Steel Stent for Coronary Revascularization Trial; TLR, target-lesion revascularization; TVR, target-vessel revascularization. 
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representative of those seen in daily practice, with 
approximately 68% of those in the registry not 
meeting the inclusion criteria of earlier clini cal 
trials (e.g. previous coronary surgery, acute 
myocardial infarction and multivessel stenting).
Polymer-coated paclitaxel-eluting stents 
Randomized clinical studies of a durable polymer-
coated paclitaxel-eluting stent (PES; Taxus®, 
Boston Scientific Corporation, Natick, MN) have 
consistently demonstrated better outcomes than 
those of BMSs (Tables 1 and 2). This stainless 
steel stent is coated with a durable co polymer 
(Translute®, Boston Scientific Corporation, 
Natick, MN) to provide biphasic paclitaxel release, 
with an initial burst in the first 2 days, followed by 
lower-level release sustained over 10 days. In total, 
more than 3,500 patients with de novo lesions have 
been randomized in the TAXUS I,15 II,16 IV,17 V18 
and VI19 trials. The TAXUS program commenced 
in October 2000, with TAXUS I15 (a safety study) 
followed by TAXUS II,16 which tested two 
different release formulations: slow release and 
moderate release. The moderate-release formu-
lation released eight times more paclitaxel in the 
first 10 days than the slow-release formulation, 
and the slow-release formulation was commer-
cialized as it was the lowest effective dose required; 
based on this trial, European approval of the slow-
release formulation was obtained. The 2-year 
follow-up data from TAXUS II have confirmed 
the safety profile of the PES.
The pivotal trial that led to FDA approval for 
the PES was the TAXUS IV trial conducted in the 
US,17 in which 1,314 patients were randomized to 
PESs or BMSs with a different platform (Express™ 
stent, Boston Scientific Corporation, Natick, MN) 
and confirmed the angiographic and clinical effi-
cacy of the Taxus® device. Subsequently, TAXUS 
V,18 which studied the moderate-release formula-
tion, and TAXUS VI,19 which studied the slow-
release formulation, were initiated to expand the 
clinical indication for PESs. These studies were 
primarily designed to confirm the efficacy of 
PESs in small vessels (2.25–2.50 mm) and in long 
lesions (up to 46 mm). 
DRUG-ELUTING STENTS COMING TO THE 
MARKET
Zotarolimus
The DES that is currently most advanced in 
phase III clinical trials is the zotarolimus-coated 
stent (Table 3). Zotarolimus, previously called 
ABT-578, is a sirolimus analog developed by 
Abbott Pharmaceuticals (Abbott Park, IL) and 
licensed to two companies: its own subsid-
iary, Abbott Vascular (Redwood City, CA), and 
Medtronic (Minneapolis, MN). Medtronic 
have actively pursued the development of this 
agent through its ENDEAVOR series of trials, 
using the Endeavor® device, which consists of 
a cobalt chromium stent, zotarolimus and a 
phosphorylcholine polymer coating (Table 3). 
ENDEAVOR I20 was a safety study conducted 
in Australia and New Zealand, and was followed 
by the ENDEAVOR II21 multicenter, random-
ized trial in countries other than the US. In this 
study, the Endeavor® device was better than 
BMSs (8.1 versus 15.4%, P <0.0005 for major 
adverse cardiovascular events), and the device was 
granted European approval in July 2005. Results 
of the non- inferiority ENDEAVOR III trial are 
expected to be announced at the Transcatheter 
Cardiovascular Therapeutics (TCT) meeting in 
October 2005 (Table 4), and ENDEAVOR IV is 
currently enrolling participants.
Abbott Vascular, the colicensee of zotarolimus, 
has also started clinical trials with the Zomaxx® 
stent (Abbott Park, IL), which comprises zotaro-
limus on a low-profile, tri-layer, tantalum and 
stainless steel stent (TriMaxx™), with an addi-
tional phosphorylcholine polymer coating 
(Pharmacoat®, Biocompatibles International 
Plc., Farnham, UK) for drug elution, differen-
tiating it from the Endeavor® device. Abbott 
Vascular’s clinical trials are Zomaxx I and II 
(Table 4); enrolment is complete for Zomaxx I 
but is still in progress for Zomaxx II. 
Everolimus
The immunosuppressant everolimus has 
been tested in two sets of trials: First Use To 
Underscore restenosis Reduction with Everolimus 
(FUTURE) and SPIRIT. FUTURE I22 was a first-
in-man study that evaluated the safety and effi-
cacy of  everolimus-eluting stents coated with a 
bio absorbable polymer compared with BMSs. The 
findings from FUTURE I and II are detailed in 
Table 3. More trials were initially planned for the 
FUTURE series, but the company has chosen to 
suspend further investment on this set of studies 
and, instead, to focus on their second arm, the 
SPIRIT trials, using the Xience® V stent (Advanced 
Cardiovascular Systems, Inc., Santa Clara, CA), 
which employs everolimus on a chromium–cobalt 
alloy stent (Vision®, Guidant, Indianapolis, IN) 
with a durable polymer as carrier. The SPIRIT 
FIRST23 safety and efficacy trial demonstrated 
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 superiority with the primary endpoint of in-
stent late loss at 6 months. SPIRIT II will begin 
enrollment soon, and SPIRIT III has received FDA 
approval to begin. The impending commercial 
acquisition of Guidant Corporation by Johnson 
& Johnson (the parent company of Cordis 
Corporation, which manufactures Cypher® stents) 
has created uncertainty in the future  development 
of the  everolimus-based stent.
IN THE PIPELINE
Biolimus
The Stent Eluting A9 BioLimus Trial in Humans 
(STEALTH) trial of Biolimus A9® (Biosensors 
International, Newport Beach, CA), a sirolimus 
analog coupled to a BMS on a bioabsorbable 
polymer, demonstrated superiority of the device 
over BMSs (Table 3).24 Biosensors International 
has a joint marketing and  development 
Table 4 Major randomized multicenter clinical trials currently being planned or in progress.
Trial name Trial description Stent and drug Control Location Number of 
patients/
centers
Primary 
endpoint
COSTAR II Randomized (3:2) non-
inferiority trial in de novo 
lesions
CoStar® biodegradable 
polymer and paclitaxel 
in reservoirs
Taxus® PES US, outside 
USa
1,700/90 8-month major 
adverse cardiac 
events
ENDEAVOR III Randomized (3:1) non-
inferiority trial in de novo 
lesions
Endeavor® 
phosphorylcholine-
coated ABT-578-eluting
Cypher® SES US 436/30 8-month late 
loss
ENDEAVOR IV Randomized non-
inferiority trial in de novo 
lesions
Endeavor® 
phosphorylcholine-
coated ABT-578-eluting
Taxus® PES US 1,548/80 9-month target-
vessel failure
FREEDOM Randomized nested-
registries non-inferiority 
trial in de novo lesions, 
two-or three-vessel 
disease in diabetic 
patients
Cypher® durable 
polymeric SES; Taxus® 
durable polymeric PES
CABG US, Europe 2,400 
randomized, 
2,000 
registries/100 
5-year mortality
NOBORI Randomized non-
inferiority trial in de novo 
lesions
Nobori™ biodegradable 
polymer-coated 
Biolimus A9®-eluting 
Taxus® PES Outside USa 400/30 9-month in-
stent late loss
SPIRIT II Randomized non-
inferiority trial in de novo 
lesions
Xience® V durable 
polymer-coated 
everolimus-eluting
Taxus® PES Outside USa 300/32 6-month in-
stent late loss
SPIRIT III Randomized non-
inferiority trial in de novo 
lesions
Xience® V durable 
polymer-coated 
everolimus-eluting
Taxus® PES US, Japan 1,380/92 9-month in-
segment late 
loss
SYNTAX58 Randomized nested-
registries non-inferiority 
trial in de novo lesions, 
two-or three-vessel 
disease in diabetic 
patients
Taxus® durable 
polymeric PES
CABG US, Europe 1,500 
randomized, 
2,800 
registries/90 
12-month 
major adverse 
cardiac and 
cerebrovascular 
events
TAXUS V-ISR Randomized trial in bare 
stent in-stent restenosis
Taxus® durable 
polymeric PES
Brachytherapy US 488/40 9-month 
target-vessel 
revascularization
ZOMAXX I Randomized non-
inferiority trial in de novo 
lesions
Zomaxx® 
phosphorylcholine-
coated with extra cap, 
ABT-578-eluting
Taxus® PES Outside USa 400/30 9-month in-
segment late 
loss
ZOMAXX II Randomized non-
inferiority trial in de novo 
lesions
Zomaxx® 
phosphorylcholine-
coated with extra cap, 
ABT-578-eluting
Taxus® PES US 1,670/80 9-month 
target-vessel 
revascularization
aTypically Europe, Australia and New Zealand. CABG, coronary-artery-bypass grafting; COSTAR, CObalt chromium STent with Antiproliferative for Restenosis; 
FREEDOM, Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease; PES, paclitaxel-eluting stent; 
SES, sirolimus-eluting stent; SYNTAX, Synergy between Taxus™ PCI and Bypass Surgery trial.
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 agreement with Terumo Corporation, Japan, and 
the NOBORI1 randomized non-inferiority trial 
is the first  collaboration (Table 4).
Paclitaxel-eluting stents with 
bioabsorbable polymer reservoirs
Conor Medsystems (Menlo Park, CA) uses a 
unique technology in which the stent is punc-
tured with holes throughout, into which drugs 
and a carrier can be loaded, like a reservoir. 
Development of this system began with the 
PISCES (Paclitaxel In-Stent Controlled Elution 
Study),25 SCEPTER (Study of Controlled 
Elution of Paclitaxel for the Elimination of 
Restenosis) (paclitaxel in a resorbable polymer in 
BMSs) and COSTAR I (paclitaxel in a resorbable 
polymer on a CoStar™ cobalt chromium stent) 
dose-finding safety studies. Based on the results 
of PISCES, The European Cobalt Chromium 
Stent with Antiproliferative for Restenosis Trial 
(EUROSTAR)26 was started. This two-dose 
multicenter registry investigates the CoStar® 
stent, containing paclitaxel within a resorbable 
polymer set in holes within a chromium–cobalt 
stent. A 12-month target lesion revascularization 
rate of 3.5% has so far been reported in the low-
dose study group. COSTAR II, a 1,700-patient 
multicenter, randomized, non-inferiority trial, 
will compare the CoStar® stent with the Taxus® 
stent (Table 4).
Tacrolimus
The Sorin Group (Milan, Italy) have begun 
clinical trials with tacrolimus-coated stents, 
but their results have been neither published 
nor presented as final results to date. Whether 
any clinical success has been achieved with this 
device is unclear. Previous trials with tacrolimus 
have been unsuccessful (Table 5).
Preliminary studies
Pimecrolimus is a sirolimus analog currently 
used in dermatology.27 Several companies have 
begun preliminary animal experiments to assess 
its suitability for use in DESs.
COMPARATIVE TRIALS
The most notable comparative trials so far 
have compared SESs with PESs (Table 6). In 
the REALITY trial,4 the only true multicenter 
comparative randomized trial yet done, 1,386 
patients with one or two de novo lesions were 
randomized to SESs or PESs.4 The primary 
endpoint of this superiority trial, binary 
re stenosis at 9 months, was not met because no 
significant differences were observed between the 
two devices (7.0 versus 8.3%, P = 0.3). The rate 
of late loss, an angiographic secondary endpoint 
surrogate for neointimal inhibition, was lower 
in the sirolimus than in the paclitaxel group 
(0.09 mm versus 0.31 mm, P <0.001). 
The SirTax (A Randomized Comparison of 
SIRolimus With PacliTAXel Eluting Stents for 
Coronary Revascularization of All Comers) 
trial,28 a two-center trial enrolling nonselected 
individuals, reported that patients random-
ized to SESs had lower 9-month rates of major 
adverse coronary events than those assigned 
Table 5 Stent devices that have proved unsuccessful in trials.
Trial Agent Vehicle Stent platform Reason for clinical failure
SCORE49 Taxol derivative QP2 
(4,000 μg) 
Polymer sleeves QuaDS-QP2 stent Excessive stent thrombosis and 
myocardial infarction due to the 
polymer sleeves and high dose
ACTION50 Actinomycin-D (10 and 
2.5 μg/mm2) 
Polymeric coating Multilink tetra Lack of efficacy
BRILLIANT-EU Batimastat Phosphorylcholine 
coating
BiodivYsio® stent Lack of efficacy
PRESENT I, II 
and PRESET
Tacrolimus (60 and 
230 μg) 
Nanoporous ceramic 
coating
FlexMaster ceramic stent Lack of efficacy
EVIDENT Tacrolimus (352 g) PTFE PTFE-covered graft stent Lack of efficacy
DELIVER I53 Paclitaxel (3 μg/mm2) Direct binding Multilink penta Lack of efficacy
ACTION, ACTinomycin eluting stent Improves Outcomes by reducing Neointimal Hyperplasia trial; BRILLIANT-EU, Batimastat (BB-94) antiRestenosis trIaL 
utiLizIng the BiodivYsio local drug delivery PC stent; DELIVER-I, Drug-Eluting Coronary Stent System In the Treatment of Patients With De NoVo NativE CoronaRy 
Lesions study; EVIDENT, Endo-Vascular Investigation Determining the Safety of a New Tacrolimus Eluting Stent Graft; PRESENT, PREliminary Safety Evaluation of 
Nanoporous Tacrolimus eluting stents; SCORE, Study to COmpare REstenosis rate between QueST and QuaDS-QP2; PTFE, polytetrafluoroethylene. 
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to PESs (6.2% versus 10.8%, P = 0.009). The 
T-SEARCH (Taxus-Stent Evaluated at Rotterdam 
Cardiology Hospital) single-center registry29 
compared PESs with SESs in an unselected 
population and reported no differences between 
stent types (adjusted hazard ratio 1.16, P = 0.4). 
Other single-center, randomized studies have 
compared the two devices in selected popula-
tions (ISAR DESIRE [Intracoronary Stenting 
and Angiographic Results: Drug-Eluting Stents 
for In-Stent Restenosis]30 for patients with 
in-stent restenosis and ISAR-DIABETES [the 
Intracoronary Stenting and Angiographic 
Results: Do Diabetic Patients Derive Similar 
Benefit from Paclitaxel- Eluting and Sirolimus-
Eluting Stent]31 in diabetic patients) and demon-
strated better results with SESs than with PESs. 
For the DESs that are yet to be approved, the 
previously prerequisite comparison trials with 
BMS are thought to be unethical because of the 
consistently superior results with existing DESs 
compared with BMSs. The upcoming phase III 
trials are predominantly non- inferiority studies 
comparing the new device with an incumbent 
(usually Taxus®), and are conducted with the 
approval of the FDA. In the future, numerous 
comparative trials between different DESs will 
emerge (Table 4).
CELLULAR INSIGHTS INTO SIROLIMUS 
AND PACLITAXEL
At a cellular level, restenosis occurs through 
a complex interaction within the vessel wall 
involving endothelial cells, smooth-muscle 
cells, fibroblasts, lymphocytes and macro-
phages.32 Following stenting, endothelial cells 
are damaged, and the underlying extracellular 
matrix is exposed. Sirolimus and paclitaxel have 
been the most extensively studied drugs in this 
setting.33 Sirolimus has been found to inhibit 
smooth-muscle-cell proliferation and migra-
tion, and endothelial-cell proliferation, but not 
migration, via a complicated sirolimus–FK-
binding protein–mammalian target of rapamycin 
complex. The different ‘limus’ analogs might vary 
in their potency and effect, and this issue needs 
further investigation.34 Paclitaxel nonselectively 
stabilizes microtubules, and inhibits smooth-
muscle-cell proliferation and migration, as well 
as endothelial-cell migration, but not prolifera-
tion. Computational mathematics has been used 
to model achievable effects of DES use. In one 
study, such modeling has demonstrated that the 
presence of thrombus can influence drug uptake; 
it might either act as a barrier, thereby decreasing 
drug availability, or prevent washout of drug, thus 
increasing local drug  concentrations.35 
Table 6 Comparative trials of sirolimus-eluting and polymeric paclitaxel-eluting stents. 
Study 
(study type)
Number 
of centers 
(country)
Population Number 
of 
patients
Duration 
and type 
of follow-up 
Angiographic 
outcome (binary 
restenosis)
MACE
TAXI68 
(randomized)
1 (Switzerland) In practice, ~50% 
of treated patients 
randomized
202 6 months clinical — No difference 
(underpowered)
T-SEARCH29 
(registry)
1 (The 
Netherlands)
Nonselected patients 
with de novo lesions
1,024 12 months 
clinical
— No difference
REALITY4 
(randomized)
88 (European) Patients with ≤2 
lesions
1,353 8 months 
angiographic, 9 
months clinical
No difference No difference
SirTax28 
(randomized)
2 (Switzerland) Nonselected patients 1,012 9 months clinical Sirolimus better Sirolimus better
ISAR-DESIRE30 
(randomized)
1 (Germany) Bare-stent restenosis 300 6–8 months 
angiographic, 12 
months clinical
No difference Sirolimus better
ISAR-DIABETES31 
(randomized)
1 (Germany) Patients with 
diabetes
250 6–8 months 
angiographic, 9 
months clinical
Sirolimus better No difference 
(underpowered)
ISAR-DESIRE, Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis; ISAR-DIABETES, the Intracoronary Stenting 
and Angiographic Results: Do Diabetic Patients Derive Similar Benefit from Paclitaxel-Eluting and Sirolimus-Eluting Stent; MACE, major adverse cardiac 
events; SIRTAX, A Randomized Comparison of SIRolimus With PacliTAXel Eluting Stents for Coronary Revascularization of All Comers; TAXI, A Prospective 
Randomized Comparison Between Paclitaxel and Sirolimus Stents in the Real World of Interventional Cardiology; T-SEARCH, Taxus-Stent Evaluated At 
Rotterdam Cardiology Hospital.
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Although necessary for the preclinical safety 
evaluation and understanding of the pharmaco-
kinetics of different drug-eluting devices, results 
from preclinical studies on DESs might not be 
completely transferable to human studies.36 
For example, porcine models of sirolimus stents 
demonstrated a late catch-up phase whereby 
neointimal growth was suppressed in the short 
term. In long-term models, however, growth was 
similar to that for BMSs, a finding that has not 
been observed in human trials.37 This disparity 
emphasizes the need for separate safety and 
 efficacy human studies for each particular device.
PITFALLS WITH DRUG-ELUTING STENTS
Stent thrombosis
Stent thrombosis can be classified as early 
(within the first 30 days after stent  implantation) 
or late (longer than 30 days after implanta-
tion). Early stent thrombosis is most commonly 
due to a mechanical factor (underexpansion 
or un recognized intimal dissection), whereas 
late stent thrombosis is thought to be due to 
an ab normality in re-endothelialization after 
stenting, particularly following DES implantation 
given the actions of the agents used, as described 
above. Late angiographic stent thrombosis was 
initially reported with brachytherapy38 and 
resulted in long-term prescription of dual anti-
platelet therapy. Early stent thrombosis appears to 
occur with similar frequency with DESs and BMSs 
in randomized trials and in practice.39 The rate is 
reported to be between 1% and 2%, with allow-
ance for a wide confidence interval, and varies 
depending on the definition (angio graphic only, 
or including clinically suspected cases).4,28,39,40 
Late angiographic stent thrombosis has led to 
concern over the potent effects of DESs on the cell 
cycle—and, therefore, on endothelial cells—and 
over hyper sensitivity re actions to the polymer.41 
Comparative studies of the incidence of late angio-
graphic stent thrombosis with BMSs and DESs are 
lacking, but the frequency for the latter is probably 
below 1%,40,42 which is similar to that in histor-
ical reports for the former.43,44 The duration of 
antiplatelet therapy differs, however, between 
groups: 1 month with BMSs versus 3–6 months 
with DESs. More investigation is required to 
elicit the true etiology of late angiographic stent 
thrombosis. We reported late  angiographic 
stent thrombosis in DES in four patients 
who suddenly stopped antiplatelet therapy 
11–14.5 months after implantation;  provocatively, 
BMSs implanted at a similar time in two of the 
four patients were widely patent.45 Physicians 
should endeavor to ensure, therefore, that all 
patients treated with a DES fully adhere to long-
term antiplatelet therapy. Periprocedural admin-
istration of antiplatelet therapy is also essential 
in all surgery patients—elective or otherwise and 
regardless of time since stent implantation—
because of the risk of potentially fatal early or 
late angiographic stent thrombosis. 
Incomplete stent apposition
In the RAVEL trial, incomplete stent apposi-
tion, as seen by intravascular ultrasound, was 
more frequent at 6 months in patients who 
received SESs than in controls.46 In TAXUS II,16 
however, patients treated with BMSs or PESs 
had similar rates of late-acquired malapposition. 
Nevertheless, these intravascular ultrasound 
observations have not been associated with any 
adverse events throughout the follow-up period 
in these studies.47,48
Unsuccessful programs
Not all DES programs have worked. Multiple 
attempts with different carriers and agents have 
been unsuccessful (Table 6). With the exception 
of the Study to COmpare REstenosis rate between 
QueST and QuaDS-QP2 (SCORE),49 and the 
ACTinomycin eluting stent Improves Outcomes 
by reducing Neointimal Hyperplasia (ACTION) 
trial,50 many of the negative trials have not been 
published. The failed QP2 stent (Boston Scientific) 
used a high-dose paclitaxel derivative loaded onto 
polymer ribbons placed circumferentially around 
the stent. Use of this device was associated with 
an excess of myocardial infarctions, and early 
and late stent thrombosis, resulting in the device 
being abandoned.49 Similarly, Guidant’s failed 
 actinomycin-coated stent was studied in the first-
in-humans randomized ACTION trial.50 Patients 
treated with the DESs underwent more target-
lesion  revascularization, and further  development 
was halted.
Clinical trials with non-polymeric-bonded pacli-
taxel on stainless steel stents have not demonstrated 
consistent clinical efficacy.51–53 The European 
Evaluation of Paclitaxel Eluting Stent (ELUTES) 
trial51 and the ASian Paclitaxel-Eluting stent 
Clinical Trial (ASPECT)52 showed a significant, 
dose- dependent  reduction in restenosis, but the 
larger RX Achieve™ Drug-Eluting Coronary Stent 
System In the Treatment of Patients With De NoVo 
NativE CoronaRy Lesions (DELIVER-I) study53 
 demonstrated no beneficial effect of these devices.
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COST-EFFECTIVENESS
The costs of the currently marketed DESs have 
been perceived as a major limitation for the more 
widespread use of these devices. In an analysis 
from the RAVEL trial,54 based on costs in the 
Netherlands the use of an SES resulted in a mean 
additional procedural cost of €1,286, on top of 
therapy costs, in the control group. The decrease 
in reinterventions attributable to the SES at the 
end of the first year of follow-up, however, led to 
the estimated cost difference being only €54; in 
other words, the reduction of major event risk 
from 28.8% to 5.8% after SES implantation was 
accomplished at an extra cost of €54 per patient. 
Moreover, data from the SIRIUS trial55 have 
shown that at 1 year the costs of SES implantation 
were approximately US$300 higher per patient 
than those for treatment of controls, with an incre-
mental cost-effectiveness ratio of approximately 
$1,650 per repeat revascularization avoided. This 
finding compares favorably with other medical 
treatments for patients with cardiovascular disease. 
Cost-and-effect estimations derived from the 
RAVEL and SIRIUS trials cannot be extrapolated 
to daily practice. Data have been presented from 
the RESEARCH registry and demonstrate that in 
real-world practice, DESs are not cost-effective at 
1 or 2 years on the basis of the actual prices paid.56 
This finding was confirmed by the randomized 
Basel Stent Cost-effectiveness (BASKET) trial,57 
albeit with only 6 months of follow-up. To achieve 
cost-effectiveness with DESs requires further 
 significant price  reductions in the devices.56
THE FUTURE
New indications
In a scientific attempt to expand the indica-
tions, two new trials—Synergy between Taxus™ 
PCI and Bypass Surgery (SYNTAX),58 and 
Future Revascularization Evaluation in Patients 
with Diabetes Mellitus: Optimal Management 
of Multivessel Disease (FREEDOM)—will 
address the role of DESs for three-vessel and 
left-main disease, and in diabetic patients with 
multivessel disease, respectively. Coronary-
artery-bypass surgery is the gold standard for 
the treatment of both these conditions,59 and 
these two trials will randomize eligible patients 
to either DES  implantation or coronary-artery-
bypass grafting. 
New agents
Parallel to the development of new drugs and 
optimization of carriers, other methods are 
currently being investigated to treat the injured 
vessel wall locally. An appealing method to 
contain the harmful effects of vessel-wall injury 
after percutaneous intervention is to restore the 
integrity of the endothelial cell lining as soon as 
possible. In this way, the attraction of inflam-
matory cytokines, as well as activated plate-
lets and macrophages, can be limited. In the 
Healthy Endothelial Accelerated Lining Inhibits 
Neointimal Growth-First In Man (HEALING-
FIM) registry,60 antibodies to CD34 receptors, 
surface-cell receptors found on endothelial 
progenitor cells, were used to coat metal stents. 
The aim was to capture circulating endothelial 
progenitor cells from the circulation to allow 
local differentiation into endothelial-like cells 
and provide early re-endothelialization on the 
stent surface. This study has been followed by 
the HEALING II registry, which is in progress. 
The Randomized Comparison of a Titanium-
Nitride-Oxide-Coated Stent With a Stainless 
Steel Stent for Coronary Revascularization 
(TiNOX) Trial61 has demonstrated that nitric-
oxide-coated stents have significantly lower 
late loss than BMSs. Finally, in animal models, 
local delivery via gene-eluting stent of naked 
plasmid DNA encoding human vascular endo-
thelial growth factor-2 has been successfully 
shown to reduce neointima formation while 
accelerating re-endothelialization compared 
with BMSs.62
CONCLUSIONS
The final frontier remains the long-term viability 
of all devices, whether already commercially 
available or impending, as demonstrated by 
long-term safety results. From the multiple 
studies with results published for follow-up of 
longer than 1 year, the beneficial effects of these 
devices occurred in the first year after implan-
tation.7,12,14 Mandatory extended follow-up of 
5–10 years is required to confirm the safety 
profile for the agent and carrier components in 
terms of late thrombosis, acquired malapposition 
and changes to the vessel wall. Given the poten-
tially fatal complication of in-stent thrombosis, 
it is imperative that DES-treated patients strictly 
adhere to their mandatory dual-antiplatelet-
therapy regimen and, following completion, 
continue to take aspirin long term. Finally, the 
results of numerous clinically and commercially 
unsuccessful devices and trials have not been 
published, which precludes a thorough critique 
of the data.
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The Unrestricted Use of Paclitaxel-
Versus Sirolimus-Eluting Stents for
Coronary Artery Disease in an Unselected Population
One-Year Results of the Taxus-Stent Evaluated At
Rotterdam Cardiology Hospital (T-SEARCH) Registry
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Georgios Sianos, MD, PHD, Willem J. van der Giessen, MD, PHD, Pim J. de Feyter, MD, PHD, FACC,
Ron T. van Domburg, PHD
Rotterdam, the Netherlands
OBJECTIVES We investigated the efﬁcacy of paclitaxel-eluting stents (PES) compared to sirolimus-eluting
stents (SES) when used without restriction in unselected patients.
BACKGROUND Both SES and PES have been separately shown to be efﬁcacious when compared to bare
stents. In unselected patients, no direct comparison between the two devices has been
performed.
METHODS Paclitaxel-eluting stents have been used as the stent of choice for all percutaneous coronary
interventions in the prospective Taxus-Stent Evaluated At Rotterdam Cardiology Hospital
(T-SEARCH) registry. A total of 576 consecutive patients with de novo coronary artery
disease exclusively treated with PES were compared with 508 patients treated with SES from
the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH)
registry.
RESULTS The PES patients were more frequently male, more frequently treated for acute myocardial
infarction, had longer total stent lengths, and more frequently received glycoprotein IIb/IIIa
inhibitors. At one year, the raw cumulative incidence of major adverse cardiac events was
13.9% in the PES group and 10.5% in the SES group (unadjusted hazard ratio [HR] 1.33,
95% conﬁdence interval [CI] 0.95 to 1.88, p  0.1). Correction for differences in the two
groups resulted in an adjusted HR of 1.16 (95% CI 0.81 to 1.64, p  0.4, using signiﬁcant
univariate variables) and an adjusted HR of 1.20 (95% CI 0.85 to 1.70, p  0.3, using
independent predictors). The one-year cumulative incidence of clinically driven target vessel
revascularization was 5.4% versus 3.7%, respectively (HR 1.38, 95% CI 0.79 to 2.43, p 0.3).
CONCLUSIONS The universal use of PES in an unrestricted setting is safe and is associated with a similar
adjusted outcome compared to SES. The inferior trend in crude outcome seen in PES was
due to its higher-risk population. A larger, randomized study enrolling an unselected
population may assist in determining the relative superiority of either device. (J Am Coll
Cardiol 2005;45:1135–41) © 2005 by the American College of Cardiology Foundation
Sirolimus-eluting stents (SES, Cypher, Cordis, Johnson
and Johnson, Miami Lakes, Florida) (1) and paclitaxel-
eluting stents (PES, TAXUS, Boston Scientiﬁc Corp.,
Natick, Massachusetts) (2) have both been independently
shown to reduce the need for repeat intervention when
compared to bare-metal stents (BMS) in separate random-
ized clinical trials. The Food and Drug Administration
approvals for these devices were granted in 2003 and 2004,
respectively, and it is estimated that drug-eluting stents
(DES) currently comprise 70% of the stent market in the
U.S. The randomized controlled trials on which approval
was granted enrolled highly selected patients with single
lesions that could be covered with one DES and were
compared against BMS which is not representative of daily
clinical practice.
Our group has previously published the results of the
Rapamycin-Eluting Stent Evaluated At Rotterdam Cardi-
ology Hospital (RESEARCH) registry, which demon-
strated that routine implantation of SES resulted in a
reduction in major adverse cardiac events (MACE), princi-
pally driven by a reduction in target vessel revascularization
(TVR) when compared with a historical BMS control group
(3). The PES were commercialized subsequent to SES, based
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
Study supported by the Erasmus Medical Center, Rotterdam, and by unrestricted
institutional grants from Boston Scientiﬁc Corporation and Cordis, Johnson &
Johnson company.
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on the results of randomized controlled trials (4,5). The
beneﬁcial effect of PES in patients treated in daily practice
remains to be deﬁned. The aim of this study was to report the
one-year outcomes of unrestricted/universal use of PES in
patients with de novo coronary artery lesions and to compare
its efﬁcacy against our historical SES cohort (3).
METHODS
Study design and patient population. The Taxus-Stent
Evaluated At Rotterdam Cardiology Hospital (T-SEARCH)
registry is a prospective single-center registry with the main
purpose of evaluating the safety and efﬁcacy of PES implan-
tation for consecutive unselected patients treated in daily
practice. Its conceptual design and methodology are similar to
that of the RESEARCH registry (6) and follows the dynamic
registry design described by Rothman and Greenland (7).
Since February 16, 2003, when PES was granted Con-
formité Européenne approval, it replaced SES as the default
stent for every percutaneous coronary intervention. Up until
September 30, 2003, a total of 576 patients with de novo
lesions were treated exclusively with PES and are included
in the present report (PES group). This comprised 83.7% of
all patients with de novo disease who received coronary
stents. In this period, only 12 patients received BMS
exclusively (11 were due to requirement for stents 3.5mm,
1 patient had elevated liver enzymes that precluded long-
term clopidogrel therapy). Patients treated with PES and
BMS in the same procedure (20 patients), those treated
with PES and SES (20 patients), those treated with SES
only (15 patients), and patients enrolled in other drug-
eluting trials (44 patients) were not included in the present
report. The PES are available in diameters of 2.25 mm, 2.5
mm, 3.0 mm, and 3.5 mm and in lengths of 8 to 32 mm in
4-mm increments for each available diameter.
This PES group was compared with a control group that
comprised the active arm of the RESEARCH registry, that
is the 508 patients with de novo disease treated solely with
SES (SES group). Thus, the report consists of 1,084
patients treated with DES, differentiated by the type of drug
coating on the stent, either sirolimus or paclitaxel.
Procedures and postintervention medications. Interven-
tions were performed according to current standard proce-
dures, with the ﬁnal interventional strategy (including direct
stenting, postdilation, periprocedural glycoprotein IIb/IIIa
inhibitor, and use of intravascular ultrasound) left entirely
up to the operator’s discretion (6). Angiographic success was
deﬁned as residual stenosis 30% by visual analysis in the
presence of Thrombolysis In Myocardial Infarction (TIMI)
ﬂow grade 3. Patients were advised to maintain lifelong
aspirin (at least 80 mg/day) and were pretreated with 300
mg clopidogrel. Postprocedural clopidogrel treatment dif-
fered between the two groups. Patients treated with PES
were prescribed at least six months of clopidogrel (75
mg/day), based on existing data from randomized, con-
trolled trials (5). For patients treated with SES, clopidogrel
was prescribed for at least three months, unless one of the
following was present (in which case clopidogrel was main-
tained for at least six months): multiple SES implantation
(3 stents), total stent length 36 mm, chronic total
occlusion, and bifurcations.
End point deﬁnitions and clinical follow-up. The pri-
mary outcome was the occurrence of MACE, deﬁned as a
composite of: 1) all cause death, 2) nonfatal myocardial
infarction (MI), or 3) TVR. Myocardial infarction was
diagnosed by a rise in the creatine kinase-MB fraction
(CK-MB) of more than three times the upper limit of
normal according to American Heart Association/American
College of Cardiology guidelines (8). In patients who
underwent coronary artery bypass surgery during the
follow-up period, a periprocedural MI was diagnosed by a
rise in the CK-MB level of ﬁve times the upper limit of
normal (9). For patients who presented with an acute MI, a
diagnosis of re-MI in the acute phase required a fall and rise
of CK-MB of 50% above the previous level (10). Target
lesion revascularization was deﬁned as a repeat intervention
(surgical or percutaneous) to treat a luminal stenosis within
the stent or in the 5-mm distal or proximal segments
adjacent to the stent. Target vessel revascularization was
deﬁned as a re-intervention driven by any lesion located in
the same epicardial vessel. Thrombotic stent occlusion was
deﬁned as angiographically documented complete occlusion
(TIMI ﬂow grade 0 or 1) or ﬂow-limiting thrombus (TIMI
ﬂow grade 1 or 2) in a previously successfully treated artery.
A committee of three cardiologists (A.O., J.A., and E.M.F.)
reviewed all MACE.
All patients underwent clinical follow-up. Information
about the in-hospital outcomes was obtained from our
institutional electronic clinical database and by review of
the hospital records for those discharged to referring hos-
pitals (patients were referred from a total of 14 local
hospitals). Postdischarge survival status was obtained from
the Municipal Civil Registries at 1, 6, and 12 months. All
repeat interventions (surgical and percutaneous) and re-
hospitalizations were prospectively collected during the
Abbreviations and Acronyms
BMS  bare-metal stent
CI  conﬁdence interval
CK-MB  creatine kinase-MB
DES  drug-eluting stent
HR  hazard ratio
MACE  major adverse cardiac event
MI  myocardial infarction
PES  paclitaxel-eluting stent
RESEARCH  Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
T-SEARCH  Taxus-Stent Evaluated At Rotterdam
Cardiology Hospital
TVR  target vessel revascularization
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follow-up. Questionnaires regarding adverse events, anginal
status, and medication use were sent to all living patients at
6 and 12 months. Referring physicians and institutions were
contacted for additional information if required.
In both groups, follow-up coronary angiography was
clinically driven by symptoms or signs suggestive of myo-
cardial ischemia or mandated by the operator at the end of
the index procedure predominantly for complex procedures.
In the PES group, three speciﬁc subgroups were restudied:
left main stem stenting, crush-bifurcation procedures, and
patients who were concomitantly in a vulnerable plaque
study involving non-treated vessels (in total, 27% [n  154]
of PES patients underwent re-study during follow-up,
including 14% [n  81] that were clinically driven). In the
SES group, the following “complex patient” subgroups were
re-studied: bifurcation lesions, left main stem stenting,
chronic total occlusions, very small vessels, long stent length
(36 mm), and acute MI (in total, 40% [n  204] of SES
patients were re-studied, including 8% [n  40] that were
clinically driven). Because of the well-known effect of
angiographic re-evaluation in increasing the incidence of
repeat revascularization (11), all re-interventions were ret-
rospectively adjudicated and classiﬁed as either clinically
driven or non-clinically driven. Clinically driven repeat
revascularization was deﬁned as any intervention motivated
by a signiﬁcant luminal stenosis (50% diameter stenosis)
in the presence of anginal symptoms and/or proven myo-
cardial ischemia in the target vessel territory by noninvasive
testing.
Statistical analysis. Continuous variables are presented as
mean  standard deviation, and were compared using the
Student unpaired t test. Categorical variables are presented
as counts and percentages and compared by means of the
Fisher exact test. All statistical tests were two-tailed. Pa-
tients lost to follow-up were considered at risk until the date
of last contact, at which point they were censored. The
cumulative incidence of adverse events was estimated ac-
cording to the Kaplan-Meier method, and Cox proportional
hazards models were used to assess differences between the
two strategies. Separate Cox regression analyses were per-
formed to identify independent predictors of adverse events,
using clinical, angiographic, and procedural variables con-
tained in Tables 1 and 2. The Cox proportional hazards
regression models were used to control for differences
between groups, and the ﬁnal results are presented as
adjusted hazard ratios (HRs).
RESULTS
Baseline and procedural characteristics. The PES pa-
tients were more often male, had more MI as their present-
ing symptom, more cardiogenic shock, more complex le-
sions treated, longer total stent lengths, and more frequently
received glycoprotein IIb/IIIa inhibitors (Tables 1 and 2).
Fewer PES patients had a history of previous bypass
surgery, and fewer segments per patient were stented,
although the number of vessels treated per patient was
identical. Other baseline and procedural characteristics were
similar.
Clinical outcome. FIRST 30 DAYS. No signiﬁcant differ-
ences were noted between groups with respect to the
incidences of death, death or MI, TVR, or MACE in the
ﬁrst month (Table 3). Mortality in the ﬁrst 30 days was
2.1% in the PES group and 1.6% in the SES group (p 
0.7). In both groups, most deaths occurred in patients with
cardiogenic shock. Angiographically proven stent thrombo-
sis occurred in six patients in the PES group, four of whom
were treated for AMI, the other two presented with
unstable angina. Two patients with AMI also underwent
bifurcation stenting, as did one with unstable angina. In
total, three patients with bifurcation stenting experienced
stent thrombosis. In the SES group, two patients were
diagnosed with stent thrombosis. One patient died as a
result of stent thrombosis in the PES group.
ONE YEAR. The MACE components are presented in Fig-
ures 1 and 2. At one year, 5.3% of patients in the PES group
and 3.4% in the SES group had died (HR 1.69, 95%
conﬁdence interval [CI] 0.93 to 3.00, p  0.08). In total,
8.8% of patients in the PES group versus 7.0% in the SES
group had either died or suffered a nonfatal re-MI (HR
1.28, 95% CI 0.84 to 1.95, p 0.3). The incidence of TVR
was similar in the SES and PES groups: 7.3% versus 5.1%
(HR 1.31, 95% CI 0.81 to 2.13, p  0.3). Clinically driven
TVR was reduced by a similar magnitude in both groups,
speciﬁcally 3.7% versus 5.4%, respectively (HR 1.38, 95%
CI 0.79 to 2.43, p  0.3). Post-hoc analysis of clinically
driven TVR demonstrates that conﬁdence limits crossed
unity, with point estimates close to unity in the subgroups
Table 1. Baseline Characteristics
SES Group
(n  508)
PES Group
(n  576) p Value
Male, % 68 74 0.04
Age, yrs  SD 61  11 62  11 0.4
Diabetes, % 18 18 0.8
Non–insulin-dependent, % 12 13 0.5
Insulin-dependent, % 6 5 0.7
Hypertension, % 41 42 0.9
Hypercholesterolemia, % 56 62 0.03
Current smoking, % 31 29 0.6
Previous myocardial
infarction, %
30 35 0.13
Previous angioplasty, % 19 18 0.8
Previous coronary bypass
surgery, %
9 6 0.05
Single-vessel disease, % 46 44 0.5
Multivessel disease, % 54 56 0.5
Clinical presentation  0.001
Stable angina, % 45 45
Unstable angina, % 37 27
Acute myocardial
infarction, %
18 28
Cardiogenic shock, %* 10 13
*Relative to patients with acute myocardial infarction.
PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.
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analyzed (Fig. 3). Regarding the primary end point of
MACE (the composite of death, MI, or TVR), Kaplan-
Meier estimates were 13.9% in the PES group versus 10.5%
in the SES group (unadjusted HR 1.33, 95% CI 0.95 to
1.88, p  0.10).
There were two cases of late (6 months to 1 year) stent
thrombosis documented angiographically in the PES group.
In one, it occurred eight months after the index procedure
while the patient was on antiplatelet monotherapy with
aspirin. The second occurred 11 months after the index
procedure after the patient had temporarily suspended
antiplatelet therapy (aspirin) for noncardiac surgery.
Predictors of adverse events. To assess the independent
predictors of MACE at one year, two separate multivariate
analyses were performed. First, a model was built using all
baseline and procedural characteristics shown in Tables 1
and 2. Forward stepwise regression was performed with
entry and stay criteria of 0.05 and 0.10, respectively. The
following variables were signiﬁcant: cardiogenic shock, fe-
male gender, multivessel disease, diabetes mellitus, left main
stenting, bifurcation stenting, and lesion type B2/C (Table
4). A second model built using the same variables with the
end point of TVR at one year revealed bifurcation stenting
was the only signiﬁcant independent predictor of TVR.
Adjustment for differences between groups. The Cox
regression models were used to adjust the two groups by
correcting for multiple potential confounders in the baseline
and procedural characteristics. First, a model was built
forcing stent type and all independent predictors from Table
4 (see Table 5). All previously signiﬁcant variables remained
signiﬁcant except for lesion type B2/C. The adjusted HR
for use of PES became even less signiﬁcant, decreasing from
1.33 (95% CI 0.95 to 1.88, p  0.10) to 1.20 (95% CI 0.85
to 1.70, p  0.3), after controlling for the increased
complexity in the PES group.
A second model was then built forcing stent type and
signiﬁcant univariate variables (independent predictors plus
total stent length and number of stents), and the adjusted
outcome of MACE at one year was similar between SES
and PES (adjusted HR 1.16, 95% CI 0.81 to 1.64, p 0.4).
Finally, stent type was also not a signiﬁcant predictor of
TVR when adjusted for bifurcation stenting (adjusted HR
1.33, 95% CI 0.82 to 2.15, p  0.25).
DISCUSSION
The major ﬁnding of this report is that the unrestricted use
of PES in de novo lesions is associated with a nonsigniﬁcant
difference in outcome compared to SES, both unadjusted
and when controlled for signiﬁcant baseline and procedural
characteristics. The trend toward an inferior crude outcome
Table 2. Procedural Characteristics
SES Group
(n  508)
PES Group
(n  576) p Value
Treated vessel
Left anterior descending, % 59 55 0.3
Left circumﬂex, % 32 33 0.6
Right coronary artery, % 39 38 0.9
Left main coronary, % 3 4 0.3
Bypass graft, % 3 3 1.0
Lesion type*
Type A or B1, % 47 32  0.001
Type B2 or C, % 76 87  0.001
Multivessel treatment, % 32 29 0.3
Glycoprotein IIb/IIIa inhibitor, % 19 28 0.002
Clopidogrel prescription, months  SD 4.0  2.0 6  0  0.05
Bifurcation stenting, % 16 16 0.9
No. of stented segments  SD 2.0  1.0 1.7  0.9  0.001
No. of stented vessels  SD 1.3  0.6 1.3  0.6 0.8
No. of implanted stents  SD 2.1  1.4 2.2  1.5 0.09
Total stented length per patient, mm  SD 38.7  23.7 42.9  31.2 0.02
Nominal stent diameter 2.5 mm, % 36 35 0.7
Total stent length 33 mm, % 45 48 0.5
Angiographic success of all lesions, % 97 97 0.9
*Percentage of patients with at least 1 lesion type within the category.
Abbreviations as in Table 1.
Table 3. Major Adverse Cardiac Events in the First Month
Following Stent Implantation
0 to 1 Month
SES Group
(n  508)
PES Group
(n  576) p Value*
Death, n (%) 8 (1.6) 12 (2.1) 0.7
Nonfatal myocardial
infarction, n (%)
12 (2.4) 17 (3.0) 0.6
Target lesion revascularization,
n (%)
6 (1.2) 7 (1.2) 1.0
Target vessel revascularization,
n (%)†
6 (1.2) 13 (2.3) 0.2
Any event, n (%) 23 (4.5) 34 (5.9) 0.3
Stent thrombosis, n (%)‡ 2 (0.4) 6 (1.0) 0.3
*By Fisher exact test. †Includes target lesion revascularization. ‡Angiographically
documented stent thrombosis requiring repeat intervention.
Abbreviations as in Table 1.
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with PES was due to the more complex characteristics of the
group.
The two sequential registries were separated by a four-
month interval. Several differences in baseline characteristics
were noted. More MIs including patients in cardiogenic
shock were treated in the T-SEARCH registry because of
the implementation of a local pre-hospital protocol that
triaged more patients to primary percutaneous coronary
intervention. More complex lesions were treated in the
T-SEARCH registry, with a shift from type A/B1 to B2/C
lesions, with more stents being implanted in the T-SEARCH
registry. This in part reﬂects the increased complexity of cases
being performed with time and as operators and referring
physicians becoming more aware and familiar with DES.
The primary end point of this trial was overall MACE,
and the results for this comparison are presented both unad-
justed and following adjustment for signiﬁcant predictive
variables (Table 5). With the commercialization of PES, our
institution switched completely from SES to PES, precluding
randomization. Therefore, it was intuitive to present the data
as such and imperative to statistically correct by using signiﬁ-
cant predictive variables to account for the increased complex-
ity seen in the PES group. To preserve the prospective,
consecutive, and unselected nature of both registries, and the
requirement to control for multiple signiﬁcant variables, the
Cox regression model was used. Our results demonstrate that,
following adjustment, the HR was closer to unity compared to
the crude result, further conﬁrming the increased complexity in
the PES group.
The multivariate analysis (Table 4) for independent
predictors of MACE is unique as it is an analysis of 1,084
DES patients treated in an unrestricted setting. In a total
cohort of DES patients, cardiogenic shock, female gender,
multivessel disease, diabetes mellitus, left main stenting,
Figure 1. Unadjusted Kaplan-Meier event curves at one year. (A) Cumulative risk of death. (B) Cumulative risk of death or myocardial infarction. (C)
Cumulative risk of death, myocardial infarction, or target vessel revascularization. CI  conﬁdence interval; PES  paclitaxel-eluting stent; SES 
sirolimus-eluting stent.
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bifurcation stenting, and treatment of a complex lesion
signiﬁcantly predicted an adverse outcome. From this list,
patients who possess these characteristics should undergo
more regular clinical surveillance.
The major advantage of DES has been to reduce the need
for repeat revascularization (1–3). In our study, the inci-
dence TVR at one year with PES was not signiﬁcantly
different from the results obtained with SES. Furthermore,
when the adjusted end point of clinically driven TVR was
used (Fig. 2), similar outcomes were reproduced, thus
conﬁrming that both drug-eluting systems serve to reduce
clinical restenosis in an unselected population.
A nonsigniﬁcantly higher incidence of angiographic stent
thrombosis in the ﬁrst 30 days was noted in the PES cohort
(1.0% in SES vs. 0.4% in PES, p  0.3). However, it is
important to emphasize that, owing to the infrequent
occurrence of this event, large numbers of patients are
required to assess this complication properly. We have
shown that in a larger population, the incidence rates in
both DES were in the same range: 1.0% (95% CI 0.6% to
1.9%) in PES and 1.0% (95% CI 0.5% to 1.8%) in SES (12).
At the time the T-SEARCH registry was conducted,
TAXUS II (5) and the Randomized Comparison of a
Sirolimus-Eluting Stent with a Standard Stent for Coronary
Revascularization (RAVEL) (13) were the two published
trials available with one-year MACE results from the eluting
stent arms of 10.9% (slow-release arm) and 5.8%, respectively.
Based on those results, the group sample sizes of our study
would have been adequately powered to show a difference.
Subsequent to that, the results of larger trials of both
devices—TAXUS IV and Sirolimus-Eluting Stent in Cor-
onary Lesions (SIRIUS)—were published and demon-
strated a smaller difference (8.4% vs. 7.1%, respectively).
The population of this registry is an all-inclusive unre-
stricted one, a sample that is representative of the popula-
tion seen in a tertiary catheterization laboratory. Therefore,
this population is directly comparable to daily practice and
the results do not require extrapolation as for randomized
trials. The results of this registry complement published
randomized trials.
Figure 2. Unadjusted one-year cumulative risk of clinically driven target
vessel revascularization. Abbreviations as in Figure 1.
Figure 3. Hazard ratios (HR) of stent type at one-year follow-up for clinically driven target vessel revascularization in subgroups of patients according to
baseline and procedural characteristics. MI  myocardial infarction; other abbreviations as in Figure 1.
Table 4. Multivariate Predictors of Major Adverse Cardiac
Events at One Year (Cox Proportional Hazards Model)
HR 95% CI p Value
Major adverse cardiac events*
Cardiogenic shock (stable angina
as reference variable)
4.54 2.44–8.48  0.001
Female gender 1.72 1.22–2.43 0.002
Multivessel disease 1.74 1.19–2.55 0.005
Diabetes mellitus 1.65 1.12–2.42 0.01
Left main stenting 1.96 1.10–3.48 0.02
Bifurcation stenting 1.59 1.06–2.38 0.03
Lesion type B2 or C 1.85 1.01–3.40 0.047
Target vessel revascularization
Bifurcation stenting 2.77 1.68–4.57  0.001
*Major adverse cardiac events: death, myocardial infarction, or target vessel revascu-
larization.
CI  conﬁdence interval; HR  hazard ratio.
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CONCLUSIONS
The universal use of PES in an unrestricted setting is safe,
and associated with a non-signiﬁcant adjusted difference in
outcome at one year compared to SES, with a trend toward
worse outcomes in the PES cohort, in part owing to its
higher-risk proﬁle. Both DES reduce the need for repeat
intervention in the real world setting of complex patient and
procedural characteristics.
Reprint requests and correspondence: Prof. Patrick W. Serruys,
Thoraxcenter, Bd-406, Dr. Molewaterplein 40, 3015-GD Rotter-
dam, the Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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of MACE
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1.16 0.81–1.64 0.4
TVR
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Sirolimus-Eluting Stents Remain
Superior to Bare-Metal Stents at Two Years
Medium-Term Results From the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry
Andrew T. L. Ong, MBBS, FRACP, Ron T. van Domburg, PHD, Jiro Aoki, MD, Karel Sonnenschein,
Pedro A. Lemos, MD, PHD, Patrick W. Serruys, MD, PHD, FACC
Rotterdam, the Netherlands
OBJECTIVES The purpose of this study was to investigate the medium-term (two year) outcome of the
unrestricted utilization of sirolimus-eluting stents (SES) in an all-comer population.
BACKGROUND Despite the implantation of SES in over a million patients to date, limited data exist on
long-term outcomes.
METHODS Sirolimus-eluting stents were used as the default strategy as part of the Rapamycin-Eluting
Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. A total of 508
consecutive patients with de novo lesions exclusively treated with SES were compared with
450 patients who received bare stents in the immediately preceding period (pre-SES group).
RESULTS Patients in the SES group more frequently had multivessel disease, more type C lesions,
received more stents, and had more bifurcation stenting. At two years, the cumulative rate of
major adverse cardiac events (death, myocardial infarction, or target vessel revascularization)
was 15.4% in the SES group and 22.0% in the pre-SES group (hazard ratio [HR] 0.68, 95%
conﬁdence interval [CI] 0.50 to 0.91; p  0.01). The two-year risk of target vessel
revascularization in the SES group and in the pre-SES group was 8.2% and 14.8%,
respectively (HR 0.53, 95% CI 0.36 to 0.79; p  0.002).
CONCLUSIONS In an unrestricted population, the beneﬁcial effects of sirolimus-eluting stent implantation
extend out to two years compared with bare-metal stents, driven by a reduction in
re-intervention rates. These ﬁndings should be conﬁrmed by the results of the large
randomized trials. (J Am Coll Cardiol 2006;47:1356–60) © 2006 by the American College
of Cardiology Foundation
In the two years since the introduction of drug-eluting
stents worldwide, the take-up has been astounding. Drug-
eluting stents now comprise at least 70% of the stent market
in the U.S. and 40% in Europe, and they are increasing with
See page 1361
time. To date, over 1 million patients have received 1.5
million sirolimus-eluting stents (SES) worldwide despite a
paucity of long-term follow-up data (1). For simple lesions,
encouraging two-year results were reported by the ﬁrst
investigations in humans (2,3), as was the recent publication
of the three-year results in the Randomized Study With the
Sirolimus-Eluting Velocity Balloon-Expandable Stent in
the Treatment of Patients With de Novo Native Coronary
Artery Lesions (RAVEL), the ﬁrst randomized trial on SES
(4). However, fewer than 200 patients with simple lesions
treated with a single 18-mm SES were studied in both trials
combined.
In porcine models, there have been some concerns re-
garding a late catch-up phenomenon whereby the initial
beneﬁts of SES disappear with time (5). Furthermore,
initial attempts at developing an antirestenosis device using
a radioactive stent demonstrated that in humans restenosis
and neointimal hyperplasia were delayed but not prevented
(6). Late “unpredictable” events have been anecdotally
reported with drug-eluting stents (7,8).
In the treatment of unselected “all-comer” patients with
complex disease, our group has previously reported on the
intermediate results of the Rapamycin-Eluting Stent Eval-
uated at Rotterdam Cardiology Hospital (RESEARCH)
registry, demonstrating that the use of SES is associated
with signiﬁcantly lower incidence of major adverse cardiac
events (MACE) and target vessel revascularization (TVR)
when compared with bare-metal stents (BMS) at one year
in patients with de novo coronary artery lesions (9). The
purpose of this report is to investigate whether the beneﬁcial
effects of SES extend beyond one year and to detail the
major adverse cardiac events that have occurred between one
and two years.
METHODS
Study design and patient population. The methodology
of the RESEARCH registry has been reported previously
(10). Brieﬂy, RESEARCH is a single-center registry con-
ducted with the main purpose of evaluating the safety and
efﬁcacy of SES implantation for patients treated in daily
practice. Since April 16, 2002, our institution adopted a
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policy of using SES (Cypher; Johnson & Johnson-Cordis
unit, Cordis Europa, Roden, the Netherlands) as the default
strategy for every percutaneous coronary intervention. In the
ﬁrst six months of enrollment, 508 patients with de novo
lesions were treated exclusively with SES (SES group) and
compared with a group of 450 consecutive patients treated
with bare stents for de novo lesions in the preceding six
months (pre-SES group). The total study population thus
comprised 958 patients divided into two sequential cohorts,
primarily distinguished by the interventional strategy applied
(BMS or SES implantation, respectively) (9). This protocol
was approved by the hospital ethics committee and is in
accordance with the Declaration of Helsinki. Written in-
formed consent was obtained from every patient.
Procedures and postintervention medications. All inter-
ventions were performed according to current standard
guidelines with the ﬁnal interventional strategy (including
use of periprocedural glycoprotein IIb/IIIa inhibitors) at the
operator’s discretion. Angiographic success was deﬁned as
residual stenosis 30% by visual analysis in the presence of
Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade 3.
All patients were advised to maintain lifelong aspirin. At
least one-month clopidogrel treatment (75 mg/day) was
recommended for patients treated in the pre-SES phase.
For patients treated with SES, clopidogrel was prescribed for at
least three months, unless one of the following was present (in
which case clopidogrel was maintained for at least 6 months):
multiple SES implantation (3 stents), total stented length
36 mm, chronic total occlusion, and bifurcations.
Deﬁnition of major adverse cardiac events. Major ad-
verse cardiac events were deﬁned as: 1) death; 2) nonfatal
myocardial infarction (MI); or 3) TVR. Myocardial infarc-
tion was diagnosed by a rise in the creatine kinase-MB
fraction of more than three times the upper limit of normal
(11). Target lesion revascularization (TLR) was deﬁned as a
repeat intervention (surgical or percutaneous) to treat a
luminal stenosis within the stent or in the 5-mm distal or
proximal segments adjacent to the stent. Target vessel
revascularization was deﬁned as a re-intervention driven by
any lesion located in the same epicardial vessel.
Two-year follow-up data. For the two-year follow-up,
survival data for all patients were obtained from municipal
civil registries. A health questionnaire was sent to all living
patients with speciﬁc questions on rehospitalization and
major adverse cardiac events. As the principal referral center
within the region, repeat procedures (percutaneous and
surgical) are normally performed at our institution and
recorded prospectively in our database. For patients who
suffered an adverse event at another center, medical records
or discharge summaries from the other institutions were
systematically reviewed. General practitioners, referring car-
diologists, and patients were contacted as necessary if
further information was required.
Statistical analysis. Continuous variables are presented as
mean  SD and were compared by means of the Student
unpaired t test. Categorical variables are presented as counts
and percentages and compared by means of the Fisher exact
test. All statistical tests were two tailed. The cumulative
incidence of adverse events was estimated according to the
Kaplan-Meier method, and Cox proportional hazards mod-
els were used to assess risk reduction of adverse events.
Patients lost to follow-up were considered at risk until the
date of last contact, at which point they were censored.
Multivariate analyses were performed to identify independent
predictors of adverse events, using all clinical, angiographic,
and procedural variables included in Tables 1 and 2.
Table 1. Baseline Characteristics of Patients Treated With
Conventional Bare-Metal Stents Before the Introduction of SES
(Pre-SES Group) and Patients Treated Exclusively With SES
Implantation (SES Group)
Pre-SES
Group
(n  450)
SES
Group
(n  508) p Value
Male, % 72 68 0.4
Age, yrs  SD 61  11 61  11 0.7
Diabetes, % 15 18 0.3
Non–insulin-dependent, % 11 12 0.7
Insulin-dependent, % 4 6 0.2
Hypertension, % 48 41 0.2
Hypercholesterolemia, % 55 56 1.0
Current smoking, % 34 31 0.3
Previous myocardial infarction, % 40 30 0.01
Previous angioplasty, % 18 19 0.8
Previous coronary bypass surgery, % 8 9 0.5
Single-vessel disease, % 52 46 0.05
Multivessel disease, % 48 54 0.05
Clinical presentation — — 0.7
Stable angina, % 48 45 —
Unstable angina, % 35 37 —
Acute myocardial infarction, % 18 18 —
Cardiogenic shock, %* 12 10 0.7
*Relative to patients with acute myocardial infarction.
SES  sirolimus-eluting stent.
Abbreviations and Acronyms
BMS  bare-metal stent
CI  conﬁdence interval
HR  hazard ratio
MACE  major adverse cardiac event
MI  myocardial infarction
RAVEL  Randomized Study With the Sirolimus-
Eluting Velocity Balloon-Expandable
Stent in the Treatment of Patients
With de Novo Native Coronary Artery
Lesions
RESEARCH  Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularization
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RESULTS
Baseline and procedural characteristics. The baseline and
procedural characteristics have been previously described
and are included in Tables 1 and 2 for reference. Brieﬂy,
approximately half of the patients in both groups were
admitted with acute coronary syndromes, and diabetes was
present in 16% of cases. Patients treated with SES had
signiﬁcantly more multivessel disease, more type C lesions,
more bifurcation stenting, more segments stented, and more
stents used. Also, in the SES group, long stents and stents with
smaller diameters were more frequently used. Periprocedural
administration of glycoprotein IIb/IIIa inhibitors was more
frequent in the pre-SES phase (33% vs. 19%; p  0.01). The
angiographic success rate was similar in both groups.
One-year follow-up. At one year, the cumulative inci-
dence of death and death or myocardial infarction was
similar between groups. Patients treated with SES had
signiﬁcantly less death, MI, or TLR at one year than
patients treated in the pre-SES phase (8.8% vs. 12.6%,
respectively; hazard ratio [HR] 0.66, 95% conﬁdence inter-
val [CI] 0.45 to 0.97; p  0.03). Similarly, the one-year
cumulative risk of MACE (death, MI, or TVR) was
signiﬁcantly reduced in the SES group (9.7% vs. 14.8% in
the pre-SES group; HR 0.62, 95% CI 0.44 to 0.89; p 
0.008). The difference in outcomes between groups was
mainly due to a decrease in the need for TVR in the SES
group (5.1% vs. 10.9% in the pre-SES group; HR 0.49, 95%
CI 0.29 to 0.82; p  0.007).
Two-year follow-up. Follow-up information was obtained
in 97.7% of patients. At two years, there were no signiﬁcant
differences in mortality between the SES and pre-SES groups,
(5.8% vs. 6.3%; HR 0.92, 95% CI 0.55 to 1.54; p  0.7)
Figure 1. Two-year adverse events in patients treated with bare stents
before the introduction of sirolimus-eluting stents (SES) (pre-SES group)
and in patients treated exclusively with SES implantation (SES group). (A)
Cumulative risk of death. (B) Death or myocardial infarction. (C) Death,
myocardial infarction, or target vessel revascularization.
Table 2. Angiographic and Procedural Characteristics of
Patients Treated With Conventional Bare-Metal Stents Before
the Introduction of SES (Pre-SES Group) and Patients Treated
Exclusively With SES Implantation (SES Group)
Pre-SES
Group
(n  450)
SES
Group
(n  508)
p
Value
Treated vessel
Left anterior descending, % 59 59 0.8
Left circumﬂex, % 33 32 0.7
Right coronary artery, % 34 39 0.2
Left main coronary, % 2 3 0.6
Bypass graft, % 2 3 0.2
Lesion type
A, % 20 22 0.4
B1, % 32 31 0.7
B2, % 50 49 0.8
C, % 30 43 0.01
Glycoprotein IIb/IIIa inhibitor, % 33 19 0.01
Clopidogrel prescription,
months  SD
2.9  2.0 4.0  2.0 0.01
Bifurcation stenting, % 8 16 0.01
Number of stented segments  SD 1.8  0.9 2.0  1.0 0.01
Number of implanted stents  SD 1.9  1.2 2.1  1.4 0.01
Individual stent length
33 mm, %
10 35 0.01
Total stented length per patient,
mm  SD
30.1  19.6 38.7  28.7 0.01
Nominal stent diameter
2.5 mm, %
23 36 0.01
Post-dilation with a balloon
0.5 mm larger, %
19 55 0.01
Angiographic success of all lesions, % 97 97 1.0
SES  sirolimus-eluting stent.
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(Fig. 1A). The combined end point of death or MI were
also similar (9.7% vs. 10.9%, respectively; HR 0.89, 95% CI
0.60 to 1.33; p  0.6) (Fig. 1B). The two-year incidence of
the combined end point of MACE was lower in the SES
group than in the pre-SES group (15.4% vs. 22.0%; HR
0.68, 95% CI 0.50 to 0.91; p  0.01) (Fig. 1C), driven by
a signiﬁcantly lower incidence of TVR in the SES group
(8.2% vs. 14.8%, respectively; HR 0.53, 95% CI 0.36 to
0.79; p  0.002) (Fig. 2).
Events from one to two years. Between one and two years,
53 events occurred (Table 3). There were 12 deaths in the
SES group and 9 deaths in the pre-SES group. Two MIs
occurred in the SES group compared with ﬁve in the
pre-SES group (p  0.3). Target lesion revascularizations
were infrequent in both the SES group (n  11) and the
pre-SES group (n  14) (p  0.4). Including TLRs, there
were 13 TVRs in the SES group versus 18 in the pre-SES
group (p  0.3). Overall MACE occurred in 23 patients in
the SES phase and 30 in the pre-SES phase (p  0.16). In
this RESEARCH registry cohort of 958 patients, no
patient in either group experienced late angiographic stent
thrombosis out to 24 months. Between one and two years,
a further ﬁve patients in the SES group and six in the
pre-SES group required a repeat intervention for a lesion in
a different vessel (p  1.0).
Multivariate predictors of outcomes. Cox regression
analysis was performed to identify predictors of MACE at
two years (Table 4). Cardiogenic shock at entry, stenting of
the left main stem, diabetes, history of previous interventions,
and longer stented lengths were all associated with adverse
occurrences of MACE (Table 4). A separate Cox regression
analysis was performed, and predictors of TVR were diabetes,
previous interventions, and longer stented lengths, whereas
acute coronary syndromes at entry was protective. When
adjusted for independent predictors, the use of SES conferred
a signiﬁcant protective effect against both TVR (HR 0.45, 95%
CI 0.29 to 0.68; p  0.001) and MACE (HR 0.58, 95%
CI 0.43 to 0.80; p  0.001) at two-year follow-up.
DISCUSSION
This present paper reports that the beneﬁcial effects of SES
compared to BMS are maintained out to two years in a
real-world population. At the end of two years, signiﬁcantly
less MACE occurred in the SES group compared to the
pre-SES group. In the second year following stent implan-
tation, a trend toward fewer repeat revascularizations oc-
curred in the SES arm with no late catch-up seen.
The reduction in the composite end point of MACE in
the SES group was entirely driven by the component of
TVR; the incidences of death and MI were similar in both
groups in the follow-up period. This extends the ﬁnding of
a large meta-analysis of drug-eluting trials that demon-
strated no reduction in death or MI out to one year with
drug-eluting stents (12).
In this study, although there was a trend toward fewer
events in SES-treated patients (p  0.16) between one and
Figure 2. Two-year cumulative risk of target vessel revascularization in
patients treated with bare stents before the introduction of sirolimus-
eluting stents (SES) (pre-SES group) and in patients treated exclusively
with SES implantation (SES group).
Table 3. Number of Events Between One and Two Years
Events Between
1 and 2 Years
Pre-SES
Group
(n  450)
SES
Group
(n  508) p Value
Death, n (%) 9 (2.0) 12 (2.4) 0.8
MI, n (%) 5 (1.1) 2 (0.4) 0.3
TLR, n (%) 14 (3.1) 11 (2.2) 0.4
TVR (includes TLR), n (%) 18 (4.0) 13 (2.6) 0.3
Non-TVR, n (%) 5 (1.1) 6 (1.2) 1.0
Total MACE, n (%) 30 (6.7) 23 (4.5) 0.16
MACE  major adverse cardiac event; MI  myocardial infarction; SES 
sirolimus-eluting stent; TLR  target lesion revascularization; TVR  target vessel
revascularization.
Table 4. Separate Cox Regression Analyses Performed to
Determine Independent Predictors of MACE and TVR
at Two-Year Follow-Up
HR 95% CI p Value
MACE*
Use of SES 0.58 0.43–0.80 0.001
Total stented length
(per 10-mm increment)
1.12 1.06–1.18 0.001
Previous PCI 1.71 1.20–2.43 0.003
Diabetes mellitus 2.00 1.42–2.80 0.001
Left main stenting 2.23 1.19–4.16 0.01
Cardiogenic shock at entry 4.19 2.04–8.59 0.001
TVR†
Use of SES 0.45 0.37–0.68 0.001
Acute coronary syndrome at entry 0.56 0.37–0.83 0.004
Total stented length
(per 10-mm increment)
1.14 1.07–1.22 0.001
Previous PCI 1.73 1.11–2.69 0.016
Diabetes mellitus 2.05 1.33–3.17 0.001
*Tested variables: age, gender, multivessel disease, hypertension, current smoking,
right coronary artery stenting, type C lesion, number of stents, number of segments
treated, use of 33-mm stent, total stent length, previous intervention, diabetes, left
main stenting, cardiogenic shock, stent type. †Tested variables: current smoking,
bifurcation stenting, number of segments treated, number of stents, acute coronary
syndrome at entry, total stented length, previous intervention, diabetes, stent type.
Variables were included if signiﬁcant on univariate analysis or if clinically relevant.
CI  conﬁdence interval; HR  hazard ratio; PCI  percutaneous coronary
intervention; other abbreviations as in Table 3.
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two years, the beneﬁcial effect seen with SES at two years
was driven primarily by the reduction in events in the ﬁrst
year. Thus, once the important beneﬁcial effect of neointi-
mal suppression had occurred during the period after
stenting, the next step was to detect whether a later rebound
phenomenon (as seen in porcine models) occurred in hu-
mans. This ﬁrst-in-man study with serial angiographic and
intravascular ultrasound studies was encouraging, demon-
strating in a small population that neointimal suppression
was preserved out to two years. In the RAVEL study,
however, some nonsigniﬁcant late catch-up effect was noted
in the SES arm, with six TLR versus none in the bare group
seen between one- and three-year follow-ups; however, the
overall incidence of TLR in the SES arm of remained
signiﬁcantly less than the bare group at three years (4,13).
In our registry, we did not observe any late catch-up
phenomenon such as seen with radioactive stents and brachy-
therapy. In fact, during the second year, a trend toward a lower
TVR rate was seen in the SES group compared with the
pre-SES group (4.0% vs. 2.6%, respectively; p  0.3) (Table
3). In addition to the previously described events, approxi-
mately 1% of patients in each group required repeat interven-
tion for progressive disease in a previously nontreated vessel
(non-TVR revascularization). Because these lesions do not
beneﬁt from the beneﬁcial local effects of SES, it is imperative
that intensive risk factor reduction, both physical and pharma-
ceutical, are implemented to reduce the potential for progres-
sion of remote lesions (14).
Although it was encouraging that no late angiographic
stent thrombosis events were seen in either group out to two
years, observation and interpretation of this rare and unex-
pected late complication requires a much larger sample size
and longer term follow-up (15).
Conclusions. The medium-term follow-up of the
RESEARCH registry demonstrates that in the real world SES
reduce the incidence of major adverse cardiac events at two
years of follow-up, primarily by a smaller need for repeat
revascularization of the target vessel compared to bare-metal
stents, already evident during the ﬁrst year. The reduction in
events was maintained during the second year with no evidence
of a late-catch up effect. No late angiographic stent thrombosis
was seen out to two years in this cohort of patients studied.
Reprint requests and correspondence: Prof. Patrick W. Serruys,
Thoraxcenter, Ba-583, Dr. Molewaterplein 40, 3015-GD Rotter-
dam, the Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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Three-Year Clinical Follow-Up of the Unrestricted Use of Sirolimus-Eluting
Stents as Part of the Rapamycin-Eluting Stent Evaluated at Rotterdam
Cardiology Hospital (RESEARCH) Registry
Joost Daemen, MD, Andrew T.L. Ong, MBBS, Giulio G. Stefanini, MD,
Keiichi Tsuchida, MD, PhD, Helle Spindler, BSc, Georgios Sianos, MD, PhD,
Peter P.T. de Jaegere, MD, PhD, Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD*
Sirolimus-eluting stents (SESs) have been shown to decrease restenosis compared with bare
metal stents (BMSs). Currently, there are limited data on the long-term efﬁcacy of these
devices in a real-world patient population. Furthermore, the potential of a late restenotic
phenomenon has not yet been excluded. From April to October 2002, 508 consecutive
patients with de novo lesions exclusively treated with SESs were enrolled and compared
with 450 patients treated with BMSs in the preceding 6 months (control group). Patients in
the SES group more frequently had multivessel disease and type C lesions, received more
stents, and had more bifurcation stenting. After 3 years, the cumulative incidence of major
adverse cardiac events (comprising death, myocardial infarction, and target vessel revas-
cularization) was signiﬁcantly lower in the SES group compared with the pre-SES group
(18.9% vs 24.7%, hazards ratio 0.73, 95% conﬁdence interval 0.56 to 0.96, p  0.026). The
3-year risk of target lesion revascularization was 7.5% in the SES group versus 12.6% in the
pre-SES group (hazards ratio 0.57, 95% conﬁdence interval 0.38 to 0.87, p  0.01). In
conclusion, the unrestricted use of SESs is safe and superior to the use of BMSs. The
beneﬁcial effects, reported after 1 and 2 years in reducing major adverse cardiac events,
persisted with no evidence of a clinical late restenotic “catch-up” phenomenon. © 2006
Elsevier Inc. All rights reserved. (Am J Cardiol 2006;98:895–901)
Sirolimus-eluting stents (SESs) have been shown to mark-
edly decrease neointimal hyperplasia compared with bare
metal stents (BMSs).1–7 Although there was no signiﬁcant
change in neointimal thickness at 2 to 4 years of follow-up
in the ﬁrst-in-human trial,8 other data have suggested a
possible delayed healing response that might result in a late
restenotic phenomenon. Examples of this phenomenon are a
few reports of delayed neointimal growth, a local hypersen-
sitivity reaction with late in-stent thrombosis, and some
cases of stent fracture with local tissue proliferation.9–12
Although a recent meta-analysis demonstrated the efﬁcacy
of drug-eluting stents in general in decreasing restenosis,13
no difference was seen in rates of death and myocardial
infarction after relatively short-term follow-up. This study
presents the 3-year clinical outcome of the unrestricted use
of the SES compared with a BMS in a real-world patient
population that was treated for de novo lesions. Our objec-
tives were to investigate whether the positive 2-year results
were still present after 3 years and to describe the events
that occurred between the second and third years.14
Methods and Results
Methods of the Rapamycin-Eluting Stent Evaluated at Rot-
terdam Cardiology Hospital (RESEARCH) registry have
been previously reported.15 Brieﬂy, the RESEARCH is a
single-center registry evaluating the safety and efﬁcacy of
SES implantation in patients treated in daily practice. On
April 16, 2002, our institution commenced the use of SESs
(Cypher, Cordis Corporation, Warren, New Jersey) as the
default strategy for every percutaneous coronary interven-
tion, with the aim of including a patient population repre-
senting the “real world.” In the ﬁrst 6 months of enrollment,
508 patients with de novo lesions were treated exclusively
with SESs (SES group) and compared with a group of 450
consecutive patients treated with BMSs for de novo lesions
in the preceding 6 months (pre-SES group) matched for
stent diameter.16 This protocol was approved by the hospital
ethics committee and was in accordance with the Declara-
tion of Helsinki. Written informed consent was obtained
from every patient.
All procedures were performed according to current
standard procedural guidelines, and their details have been
previously reported.17 Angiographic success was deﬁned as
residual stenosis30% by visual analysis in the presence of
Thrombolysis In Myocardial Infarction grade 3 ﬂow. All
patients were advised to maintain lifelong aspirin. At least
1-month of clopidogrel treatment (75 mg/day) was recom-
mended for patients treated in the pre-SES phase. For pa-
tients treated with SESs, clopidogrel was prescribed for 3
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months, unless 1 of the following was present: multiple SES
implantation (3 stents), total stented length 36 mm,
persistent total occlusion, and bifurcations. In these cases,
clopidogrel was maintained for 6 months.
Our primary end point was major adverse clinical events
(MACEs) at 3-year follow-up. MACEs were deﬁned as a
composite of all-cause death, nonfatal myocardial infarc-
tion, or target vessel revascularization. Target vessel revas-
cularization was deﬁned as a reintervention driven by any
lesion located in the same coronary vessel. A secondary end
point was target lesion revascularization, deﬁned as treat-
ment of a lesion in the stent or within 5 mm of the stent
borders. Myocardial infarction was diagnosed by an in-
crease in creatine kinase-MB fraction of 3 times the upper
limit of normal, according to American Heart Association/
American College of Cardiology guidelines.18,19 Late stent
thrombosis was deﬁned as angiographically deﬁned throm-
bosis with Thrombolysis In Myocardial Infarction grade 0
or 1 ﬂow or the presence of a ﬂow-limiting thrombus,
occurring 1 month after drug-eluting stent implantation
accompanied by acute symptoms.20 Hypercholesterolemia
was deﬁned as a fasting serum cholesterol level5.5 mmol/L
or use of lipid-lowering therapy at the time of the procedure.
Patients were contacted at 6 months and at 1, 2, and 3
years. Follow-up will continue yearly until 5 years. Survival
status was obtained through municipal civil registries.
Health questionnaires inquiring about postdischarge repeat
coronary interventions (surgical or percutaneous), myocar-
dial infarction, and medication usage were subsequently
sent to all living patients. Follow-up information was pro-
spectively entered into a dedicated database. If a patient had
a myocardial infarction or reintervention at another center,
medical records or discharge letters were requested and
systematically reviewed. Local cardiologists or general
practitioners were also contacted as necessary. Follow-up
was available for 97.5% of our patients at a mean time of
1,095  265 days.
Continuous variables are presented as mean  SD and
were compared by Student’s t test. Categorical variables are
presented as counts and percentages and were compared by
Fisher’s exact test. The cumulative incidence of adverse events
was estimated according to the Kaplan-Meier method, and
curves were compared using log-rank test. Separate Cox
regression analyses were performed to identify independent
predictors of adverse events using clinical, angiographic,
and procedural variables listed in Tables 1 and 2. Cox
proportional hazards regression models were used to control
for differences between groups and independent predictors
of outcome. Final results are presented as adjusted hazard
ratios. Patients lost to follow-up were considered at risk
until the date of ﬁnal contact, at which point they were
censored.
Baseline and procedural characteristics have been previ-
ously described and are presented in Tables 1 and 2. Ap-
proximately 50% of patients in the 2 groups were admitted
with acute coronary syndromes, and diabetes was present in
16%. Patients treated with SESs had signiﬁcantly more mul-
tivessel disease, more type C lesions, more bifurcation stent-
ing, more segments stented, and more stents used (p 0.01).
Table 1
Baseline clinical characteristics
Variable Pre-SES Group SES Group p
Value(n  450) (n  508)
Men 72% 68% 0.4
Age (yrs), mean  SD 61  11 61 11 0.7
Diabetes mellitus 15% 18% 0.3
Non–insulin-dependent mellitus 11% 12% 0.7
Insulin-dependent mellitus 4% 6% 0.2
Hypertension 48% 41% 0.2
Hypercholesterolemia* 55% 56% 1.0
Current smoking 34% 31% 0.3
Previous myocardial infarction 40% 30% 0.01
Previous angioplasty 18% 19% 0.8
Previous coronary bypass surgery 8% 9% 0.5
Single-vessel disease 52% 46% 0.05
Multivessel disease 48% 54% 0.05
Clinical presentation — — 0.7
Stable angina pectoris 48% 45% —
Unstable angina pectoris 35% 37% —
Acute myocardial infarction 18% 18% —
Cardiogenic shock† 12% 10% 0.7
* Deﬁned as a fasting cholesterol level 5.5mmol/L or use of lipid-
lowering therapy.
† Compared with patients with acute myocardial infarction.
Table 2
Angiographic and procedural characteristics
Pre-SES Group SES Group p
Value(n  450) (n  508)
Treated coronary vessel*
Left anterior descending artery 59% 59% 0.8
Left circumﬂex artery 33% 32% 0.7
Right artery 34% 39% 0.2
Left main artery 2% 3% 0.6
Bypass graft 2% 3% 0.2
Lesion type
A 20% 22% 0.4
B1 32% 31% 0.7
B2 50% 49% 0.8
C 30% 43% 0.01
Glycoprotein IIb/IIIa inhibitor 33% 19% 0.01
Clopidogrel prescription (mo) 2.9 2.0 4.0  2.0 0.01
Bifurcation stenting 8% 16% 0.01
No. of stented segments 1.8  0.9 2.0  1.0 0.01
No. of implanted stents 1.9  1.2 2.1 1.4 0.01
Individual stent length 33 mm 10% 35% 0.01
Total stented length per patient
(mm)
30.1  19.6 38.7 28.7 0.01
Nominal stent diameter 2.5
mm
23% 36% 0.01
Postdilatation with a balloon
0.5 mm larger
19% 55% 0.01
Angiographic success of all
lesions
97% 97% 1.0
Values are numbers (percentages) or means  SDS.
* Expressed as percentage of patients with vessel type treated. Total
exceeds 100%.
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Further, in the SES group, long stents and stents with
smaller diameters were more frequently used. Periproce-
dural administration of glycoprotein IIb/IIIa inhibitors was
more frequent in the pre-SES phase (33% vs 19%;
p 0.01). The angiographic success rate was similar in the
2 groups.
The 1-, 2-, and 3-year results are shown in Figure 1. At
1 year, the cumulative risk of MACEs (a composite of
death, myocardial infarction, or target vessel revasculariza-
tion) was signiﬁcantly decreased in the SES group (9.7% vs
14.8% in the pre-SES group, hazard ratio 0.62, 95% conﬁ-
dence interval 0.44 to 0.89, p  0.008). This difference
remained signiﬁcant after 2 years, with an incidence of
15.4% in the SES group versus 22% in the pre-SES group
(hazard ratio 0.68, 95% conﬁdence interval 0.50 to 0.91,
p  0.01). The difference in outcomes between groups was
mainly due to a decreased need for target vessel revascu-
larization in the SES group. The cumulative incidence of
death and death or myocardial infarction remained similar
between groups after 1 and 2 years of follow-up.
At 3 years, there were no signiﬁcant differences in cu-
mulative mortality between the SES and pre-SES groups
(8.7% vs 7.9%, hazard ratio 1.09, 95% conﬁdence interval
0.70 to 1.71, p  0.69; Figure 2). The combined end point
of death or myocardial infarction was also similar at 12.9%
in the SES group versus 12.6% in the pre-SES group (haz-
ard ratio 1.02, 95% conﬁdence interval 0.71 to 1.45, p 
0.93; Figure 2). The 3-year incidence of the combined end
point of MACEs remained lower in the SES group com-
pared with the pre-SES group (18.9% vs 24.7%, unadjusted
hazard ratio 0.73, 95% conﬁdence interval 0.56 to 0.96, p
0.026; Figure 2) and was driven by a signiﬁcantly lower
incidence of target vessel revascularization in the SES
group (9.4% vs 16.6% respectively, hazard ratio 0.54, 95%
conﬁdence interval 0.37 to 0.78, p  0.001; Figure 2).
Similarly, the difference in target lesion revascularization
remained signiﬁcantly lower at 7.5% in the SES group
compared with 12.6% in the pre-SES group (hazard ratio
0.57, 95% conﬁdence interval 0.38 to 0.87, p  0.01).
Between 2 and 3 years, 31 events occurred (Table 3).
Fourteen patients in the SES group died: 3 were classiﬁed as
cardiac and 6 as noncardiac. Four patients died suddenly of
unknown causes and in 1 case the cause of death was
unknown. Seven patients in the pre-SES population died: 4
died of cardiac death and 3 died from an unknown cause.
Three myocardial infarctions occurred in the SES group
compared with 2 in the pre-SES group. Further, in the SES
group, 6 target vessel revascularizations occurred compared
with 7 in the pre-SES group. Target lesion revascularization
occurred in 3 patients in the SES group versus 5 in the
pre-SES group. Overall, MACE rates were 18 versus 12 in
the SES and pre-SES groups, respectively, between 2 and 3
years of follow-up. In addition, 2 patients in the SES group
versus 3 in the pre-SES group underwent revascularization
in a different vessel. There was no signiﬁcant difference
between groups for any of these different event rates. Two
cases of angiographically documented late stent thrombosis
occurred in the SES group. The ﬁrst patient, a 60-year-old
woman, was admitted 36 months after a procedure with
acute myocardial infarction. Clopidogrel was contraindi-
cated because of gastrointestinal bleeding of unknown ori-
gin after the procedure. The second patient, a 71-year-old
man, was admitted with cardiogenic shock 26 months after
the procedure and died.
Figure 1. Cumulative incidence of adverse events at 1, 2, and 3 years in patients treated with SESs (black bars) and BMSs (gray bars). MI  myocardial
infarction; TVR  target vessel revascularization.
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To identify independent predictors of MACEs and target
vessel revascularization at 3 years, Cox regression analyses
were performed for all baseline and procedural characteris-
tics listed in Tables 1 and 2 (Table 4). Age, diabetes, hyper-
tension, previous angioplasty, multivessel disease, cardiogenic
shock at presentation, lesion type B2 or C, treatment of the
left main coronary artery, and total stented length (per
10-mm increment) were signiﬁcant predictors of MACEs at
3 years. In addition, saphenous graft treatment and the use
of SESs were protective. Further, diabetes, hypertension,
previous percutaneous coronary intervention, acute coro-
nary syndrome at presentation, lesion type B2 or C, and
total stented length (per 10-mm increment) were signiﬁcant
predictors of target vessel revascularization, whereas acute
coronary syndrome at entry and the use of SESs were
protective.
When adjusted for these independent predictors of
MACE and target vessel revascularization, the use of SESs
remained signiﬁcantly protective for MACEs (hazard ratio
0.61, 95% conﬁdence interval 0.46 to 0.81, p  0.001) and
target vessel revascularization (hazard ratio 0.44, 95% con-
ﬁdence interval 0.30 to 0.65, p 0.001) at 3 years of
follow-up.
Discussion
Currently, there are no long-term results of the unrestricted
use of SESs in a real-world patient population. The present
report shows that SESs remain superior to BMSs in decreas-
ing the need for reinterventions in the long term, even after
adjustment for independent predictors of adverse events. At
3 years, the use of SESs resulted in a relative decrease of
Figure 2. Three-year adverse events in patients treated with BMSs (pre-SES) and SESs: (A) cumulative risk of death, (B) death or myocardial infarction
(MID), (C) target vessel revascularization, (D) death, myocardial infarction, or target vessel revascularization. CI  conﬁdence interval; other abbreviations
as in Figure 1.
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39% in MACEs, whereas target vessel revascularization
was decreased by 56% compared with the use of BMSs.
No difference was found between groups in terms of
death and myocardial infarction. These ﬁndings are par-
ticularly noteworthy because patients treated with SESs
generally had more complex disease than those treated
with BMSs; however, they are in accordance with the
ﬁndings of a large meta-analysis on drug-eluting stents
and many other publications that showed no difference in
long-term survival outcome, not even compared with
medical therapy.13,21,22
Between 2 and 3 years of follow-up, relatively few non-
target vessel revascularizations occurred in the 2 groups (3
in the pre-SES group vs 2 in the SES group). Twenty-one
patients died. Whether the 4 patients in the SES group who
died suddenly of an unknown cause between 2 and 3 years
died of stent thrombosis remains an important question.
However, because of the low frequency of postmortems, a
detailed analysis of the exact causes of death was not fea-
sible. In terms of overall causes of death, our results concur
with those of several trials, which reported an almost equal
incidence of cardiac and noncardiac causes of death after
2 years of follow-up in this type of population.1–5
Patients treated for left main stenosis or complex lesions
(type B2/C) were independently associated with a worse
MACE outcome at 3 years. Several trials, such as the Future
Revascularization Evaluation in patients with Diabetes
mellitus: Optimal management of Multivessel disease
(FREEDOM), COMparison of Bypass Surgery and Angio-
plasTy Using Sirolimus-eluting Stent in Patients With Un-
protected Left Main Coronary Artery Disease (COMBAT),
Synergy between Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery (SYNTAX), and Coronary Ar-
tery Revascularisation in Diabetes (CARDIA) trials, are
currently ongoing to investigate whether these patients
would beneﬁt more from coronary artery bypass sur-
gery.23,24
Several post hoc subanalyses were performed and, al-
though they concern relatively small numbers of patients,
the results give an impression of the outcome of different
patient groups treated with SES after 3 years of follow-up
(Figure 3). In patients treated for acute coronary syndromes
at entry, the use of SESs demonstrated a decrease of 70%
in clinically driven target vessel revascularization (p 
0.006) at 1 year.16 At 3 years, we found a risk decrease in
target vessel revascularization of 38%, with only a trend
toward a more favorable outcome with the use of SESs
(p  0.1; Figure 3). The same ﬁnding was observed in
patients presenting with an acute myocardial infarction
and patients treated for multivessel disease and bifurca-
tion lesions. Further, the beneﬁt of SESs was not statis-
tically signiﬁcant after 1 year or at 3 years in women and
diabetic patients. Although limited to 1 year of follow-
up, previous studies showed that diabetic patients treated
with SESs had a better outcome than those treated in a
conventional way.25 This was a post hoc subgroup anal-
ysis with small numbers of patients, and the results jus-
tify larger, longer term, and more detailed studies with
these subpopulations.
With MACE rates remaining constant between 1 and 3
years, no late clinical restenotic phenomenon was observed.
It is clear that the long-term beneﬁcial effects of SESs are
mainly due to the marked decrease in restenosis rates in the
ﬁrst year. After 1 year, the Kaplan-Meier curves for target
vessel revascularization and MACEs remain essentially par-
allel, but, more importantly, the beneﬁcial results are sus-
tained. These ﬁndings are in accordance with the 2-year
angiographic follow-up data after SES implantation and
with the recently published 3-year results of the Random-
ized study with the sirolimus-eluting Velocity balloon-ex-
pandable stent in the treatment of patients with de novo
native coronary artery Lesions (RAVEL) trial.6,26,27 The
present study extends these observations to a population that
is representative of 1 treated in a tertiary intervention center
with the unrestricted use of SESs.
Table 3
Events between two and three years of clinical follow-up
Variable Pre-SES Group SES Group p
Value(n  450) (n  508)
Death 7 (1.6%) 14 (2.8%) 0.27
Myocardial infarction 2 (0.4%) 3 (0.6%) 1.00
TLR 5 (1.1%) 3 (0.6%) 0.48
Target vessel revascularization
(including TLR)
7 (1.8%) 6 (1.2%) 0.78
Nontarget vessel revascularization 3 (0.7%) 2 (0.4%) 0.67
MACEs 12 (2.7%) 18 (3.5%) 0.46
TLR  target lesion revascularization.
Table 4
Independent predictors of major adverse cardiac events and target vessel
revascularization by Cox separate regression analysis
HR 95% CI
MACEs
Cardiogenic shock 3.61 1.91–6.82
Left main treatment 2.70 1.47–4.95
Diabetes mellitus 2.08 1.53–2.84
Lesion type B2 or C 1.74 1.22–2.47
Multivessel disease 1.63 1.23–2.16
Previous angioplasty 1.57 2.14–2.16
Hypertension 1.38 1.05–1.81
Total stented length (per 10-mm increment) 1.10 1.05–1.15
Age 1.02 1.00–1.03
Use of SESs 0.73 0.56–0.96
Saphenous graft treatment 0.41 0.23–0.74
Target vessel revascularization
Diabetes mellitus 2.21 1.48–3.31
Lesion type B2 or C 1.69 1.06–2.69
Previous intervention 1.55 1.02–2.36
Hypertension 1.49 1.04–2.15
Total stented length (per 10-mm increment) 1.11 1.05–1.18
Acute coronary syndrome at presentation 0.60 0.41–0.86
Use of SESs 0.54 0.37–0.78
CI  conﬁdence interval; HR  hazard ratio.
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Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes
of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With
Diabetes Mellitus (from the RESEARCH and T-SEARCH Registries)
Andrew T. L. Ong, MBBS, Jiro Aoki, MD, Carlos A. G. van Mieghem, MD,
Gaston A. Rodriguez Granillo, MD, Marco Valgimigli, MD, Keiichi Tsuchida, MD,
Karel Sonnenschein, Evelyn Regar, MD, PhD, Willem J. van der Giessen, MD, PhD,
Peter P. T. de Jaegere, MD, PhD, Georgios Sianos, MD, PhD,
Eugene P. McFadden, MBChB, MD, Pim J. de Feyter, MD, PhD,
Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD*
This study evaluated and compared the efﬁcacy of sirolimus-eluting stents (n  145
patients) with that of paclitaxel-eluting stents (n  148 patients) in 293 consecutive
unselected patients who had diabetes mellitus. Baseline clinical characteristics and
presentations were similar: mean age of 64 years, 50% presented with unstable angina
or myocardial infarction, and 66% had multivessel disease. Angiographic and pro-
cedural characteristics differed, with more complex lesions and more vein grafts
managed in the paclitaxel-eluting stent group. Overall mean stented length was 46 
32 mm. There were no differences in unadjusted outcomes by stent type (1-year major
adverse cardiac event rates of 20.4% for sirolimus-eluting stents vs 15.6% for pacli-
taxel-eluting stents, p  0.12) or when adjusted for multivariate predictors (adjusted
hazard ratio 0.68, 95% conﬁdence interval 0.37 to 1.24, p  0.21). Independent
predictors of outcome in patients who had diabetes mellitus were stenting of the left
main artery, stenting of the left anterior descending artery, creatinine clearance, and
female gender. Patients who required insulin had a signiﬁcantly higher, crude major
adverse cardiac event rate at 1 year compared with those who used oral agents, but
this rate became nonsigniﬁcant when adjusted for independent predictors of
outcome. © 2005 Elsevier Inc. All rights reserved. (Am J Cardiol 2005;96:358–362)
The Rapamycin-Eluting Stent Evaluated At Rotterdam Car-
diology Hospital (RESEARCH) and Taxus-Stent Evaluated
At Rotterdam Cardiology Hospital (T-SEARCH) registries
are identical sequential prospective registries that were spe-
ciﬁcally set up to evaluate the universal utilization of siroli-
mus- and paclitaxel-eluting stents (SESs and PESs, respec-
tively) in an unrestricted population.1,2 The present study
evaluated short- (1 month) and long-term (12 months) efﬁca-
cies of SESs and PESs in patients with diabetes mellitus (DM).
• • •
We performed a prospective cohort study to investigate the
outcomes of drug-eluting stent implantation in patients who
had DM. Since April 2002, our institution has adopted a
policy of universal drug-eluting stent implantation for all
patients who undergo percutaneous coronary intervention
that requires stenting. All patients are prospectively entered
into a dedicated database. The initial results of this approach
have been published elsewhere.1,2 Until February 2003,
SESs (Cypher, Cordis, a Johnson & Johnson Company,
Miami Lakes, Florida) were exclusively used; subsequently,
PESs (Taxus, Boston Scientiﬁc Corp., Natick, Massachu-
setts) became the default stent.
Follow-up was complete for 98% of patients. Survival
status was obtained from municipal civil registries at 1, 6,
and 12 months. All repeat interventions (surgical and per-
cutaneous) and rehospitalizations were prospectively col-
lected during follow-up. Questionnaires concerning anginal
status and medication use were sent to all living patients at
6 and 12 months. Referring physicians and institutions were
contacted for additional information, if required. Written
informed consent was obtained from every patient.
From April 2002 to December 2003, 293 unselected
consecutive patients who had DM and de novo coronary
artery disease were treated exclusively with drug-eluting
stents; 145 patients received SESs and 148 received PESs. The
2 groups were sequential and are part of the RESEARCH and
T-SEARCH prospective registries, respectively. Patients
who have DM constitute 18% of the patient population
treated percutaneously at our institution and were deﬁned by
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Manuscript received December 28, 2004; revised manuscript received and
accepted March 25, 2005.
This study was supported by the Erasmus MC, Rotterdam, The
Netherlands, and by unrestricted institutional grants from Boston Scientiﬁc
Corp., Natick, Massachusetts, and Cordis, a Johnson & Johnson Company,
Miami Lakes, Florida.
* Corresponding author. Tel.: 31-10-463-5260; fax: 31-10-436-9154.
E-mail address: p.w.j.c.serruys@erasmusmc.nl (P.W. Serruys).
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therapy; those on oral medications were classiﬁed as requir-
ing noninsulin and those on insulin therapy as requiring
insulin.
All interventions were performed according to current
standard procedures using routine high-pressure balloon in-
ﬂations, with the ﬁnal interventional strategy (including
direct stenting, postdilatation, use of periprocedural glyco-
protein IIb/IIIa inhibitors, and use of intravascular ultra-
sound) at the operator’s discretion.3 Angiographic success
was deﬁned as a residual stenosis 30% by visual analysis
in the presence of Thrombolysis In Myocardial Infarction
grade 3 ﬂow. All patients were advised to maintain lifelong
use of aspirin (80 mg/day). All patients were pretreated
with 300 mg of clopidogrel. Postprocedurally, patients who
received PESs were prescribed 6 months of clopidogrel
(75 mg/day),4 and those who received SESs were prescribed
clopidogrel for 3 or 6 months depending on the complex-
ity of the procedure.1
The primary outcome was the occurrence of major ad-
verse cardiac events, deﬁned as a composite of all-cause
death, nonfatal myocardial infarction, or target vessel re-
vascularization. Myocardial infarction was diagnosed by an
increase in creatine kinase-MB fraction of 3 times the
upper limit of normal.5 In patients who underwent coronary
artery bypass surgery during follow-up, periprocedural
myocardial infarction was diagnosed by an increase in cre-
atine kinase-MB level of 5 times the upper limit of normal.6
For patients who presented with an acute myocardial infarc-
tion, a diagnosis of repeat myocardial infarction in the acute
phase required a decrease and then increase in creatine
kinase-MB of 50% above the previous level.7 Target lesion
revascularization was deﬁned as a repeat intervention (sur-
gical or percutaneous) to control a luminal stenosis within
the stent or in the 5-mm distal or proximal segments adja-
cent to the stent. Target vessel revascularization was deﬁned
as a reintervention that was inﬂuenced by any lesion in the
same epicardial vessel. Angiographic stent thrombosis was
deﬁned as an angiographically documented complete occlu-
sion (Thrombolysis In Myocardial Infarction grade 0 or 1
ﬂow) or a ﬂow-limiting thrombus (Thrombolysis In Myo-
cardial Infarction grade 1 or 2 ﬂow) in a previously suc-
cessfully stented artery in the ﬁrst 30 days. Suspected stent
thrombosis was deﬁned as unexplained sudden death or
nonfatal myocardial infarction that was unrelated to a
periprocedural complication without repeat angiography.
Two independent cardiologists (AO and JA) reviewed all
major adverse cardiac events.
Continuous variables are presented as mean  SD and
were compared with Student’s unpaired t test. Categorical
variables are presented as counts and percentages and were
compared by Fisher’s exact test. All statistical tests were
2-tailed. Cox’s proportional hazards analysis was performed
to identify independent predictors of major adverse cardiac
events using signiﬁcant univariate variables and clinically
important variables listed in Tables 1 and 2 (tested variables
were age, gender, insulin requirement, creatinine clearance,
Table 1
Baseline clinical characteristics
Variable SES Group PES Group p Value
(n  145) (n  148)
Men 66% 67% 0.8
Age (yrs) 62.6 10.2 64.6  10.3 0.08
Non–insulin-requiring DM 73% 77% 0.4
Insulin-requiring DM 27% 23% 0.4
Hypertension 68% 70% 0.7
Hypercholesterolemia* 66% 85% 0.001
Current smoking 23% 20% 0.7
Previous myocardial infarction 37% 42% 0.5
Previous coronary angioplasty 23% 21% 0.8
Previous coronary bypass
grafting
10% 14% 0.5
Single-vessel coronary disease 34% 31% 0.7
Multivessel coronary disease 66% 69% 0.7
Clinical presentation 0.4
Stable angina pectoris 49% 56%
Unstable angina pectoris 38% 34%
Acute myocardial infarction 13% 10%
Hemoglobin-A1c (%) 7.3 1.3 7.6  1.5 0.09
Creatinine clearance (ml/min) 87.6 33.0 80.8 33.4 0.10
Body mass index (kg/m2) 28.4  4.1 27.9 3.8 0.3
Values are means  SD or percentages.
* Deﬁned as a fasting cholesterol level 5.5mmol/L or use of lipid-
lowering therapy.
Table 2
Angiographic and procedural characteristics
Variable SES Group PES Group p Value
(n  145) (n  148)
Treated coronary vessel*
Left anterior descending artery 60% 48% 0.05
Left circumﬂex artery 40% 34% 0.3
Right artery 32% 42% 0.11
Left main artery 8% 8% 1.0
Bypass graft 3% 10% 0.02
Lesion type†
A 17% 8% 0.02
B1 37% 24% 0.02
B2 45% 47% 0.7
C 47% 56% 0.13
No. of coronary vessels treated 0.5
1 61% 64%
2 35% 28%
3 4% 8%
Multivessel treatment 39% 36% 0.6
Bifurcation stenting 19% 14% 0.4
No. of stented vessels 1.4 0.6 1.4 0.7 0.9
No. of implanted stents 2.4 1.5 2.3 1.4 0.6
Total stented length per patient
(mm)
45.3  32.1 48.5 33.8 0.4
Nominal stent diameter 2.5 mm 40% 47% 0.2
Chronic total occlusion (3 mos) 14% 12% 0.6
Glycoprotein IIb/IIIa inhibitor use 18% 28% 0.04
Angiographic success of all
lesions
94% 97% 0.4
Values are means  SD or percentages.
* Expressed as percentage of patients with vessel type treated. Total
exceeds 100%.
† Expressed as percentage of patients with lesion type. Total exceeds
100%.
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presenting symptoms, lesion type, multivessel disease, bi-
furcation stenting, stenting of the left main artery, stenting
of the left anterior descending artery, stent type, number of
stents, total stent length, and minimum stent diameter).
Stent type and requirement for insulin were forced into the
model, whereas other variables were entered in a forward
stepwise method (entry and removal criteria of 0.05 and
0.10, respectively). The cumulative incidence of adverse
events was estimated according to the Kaplan-Meier method.
Baseline clinical characteristics were similar for the 2
groups with the exception of hypercholesterolemia (Table 1).
Sixty-six percent were men and 25% required insulin. Mul-
tivessel coronary disease was present in 66% of patients,
and 50% presented with an acute coronary syndrome (un-
stable angina or acute myocardial infarction). Mean hemo-
globin A1c levels were 7.6  1.5% in the PES group and
7.3  1.3% in the SES group. More patients in the PES
group were classiﬁed as having hypercholesterolemia (de-
ﬁned as a fasting serum cholesterol level 5.5mmol/L or
use of lipid-lowering therapy at the time of the procedure)
due to the more widespread use of lipid-lowering agents in
the latter period.
Signiﬁcant differences were noted in terms of angio-
graphic and procedural characteristics (Table 2). In the PES
group, more patients received treatment in a bypass graft
(10% vs 3% in the SES group, p  0.02) and fewer patients
received treatment in the left anterior descending artery
(48% vs 60% respectively, p  0.05). The use of glyco-
protein IIb/IIIa inhibitors was greater in the PES group (28%
vs 18%, p  0.04). More complex lesions were treated in the
PES group, with fewer type A or B1 lesions treated (p 0.02).
Multivessel treatment was performed in 40% of patients. Total
stented length was similar in the 2 groups (48.5 33.8 mm in
the PES group and 45.3  32.1 mm in the SES group, p 
0.4), as was the number of stents implanted (2.3  1.3 vs 2.4
 1.5 stents, respectively, p  0.6).
In the ﬁrst month after stent implantation, there were 10
deaths that were equally divided between groups (Table 3).
Three deaths were clinically suspected to be due to stent
thrombosis (Table 3). There were 8 myocardial infarctions,
5 in the SES group and 3 in the PES group. Of the 6 target
lesion revascularizations, 4 were for stent thrombosis and 2
were the result of a procedural complication that required
urgent coronary surgery. In total, 4 patients (2.8%) in the
SES group and 3 (2.0%) in the PES group had suspected or
Figure 1. Event curves at 1 year for cumulative risks of (A) death, (B) death
or myocardial infarction, and (C) death, myocardial infarction, or target
vessel revascularization.
Table 3
Major adverse cardiac events in the ﬁrst month after stent implantation
Patients With Events at 0–1
month
SES Group PES Group p Value*
(n  143) (n  148)
Death 5 (3.4%) 5 (3.4%) 1.0
Nonfatal myocardial infarction 5 (4.1%) 3 (2.0%) 0.3
Target lesion revascularization 5 (3.4%) 1 (0.7%) 0.1
Target vessel revascularization† 5 (3.4%) 3 (2.0%) 0.5
Any event 14 (9.7%) 9 (6.1%) 0.3
Angiographically proved stent
thrombosis
3 (2.1%) 1 (0.7%) 0.4
Suspected stent thrombosis 1 (0.7%) 2 (1.4%) 1.0
Total stent thrombosis 4 (2.8%) 3 (2.0%) 0.7
* By Fisher’s exact test.
† Includes target lesion revascularization.
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proved stent thrombosis (p  0.7). A major adverse cardiac
event occurred in 9.7% of patients in the SES group and
6.1% of patients in the PES group within the ﬁrst 30 days.
At 1 year, there were no differences in the incidence of
death between groups (SES 7.7%, PES 7.2%, p  0.9;
Figure 1). The incidence of death or myocardial infarction
was also similar (SES 14.1%, PES 10.0%, p  0.3). The
composite end point of death, myocardial infarction, or
target vessel revascularization was also nonsigniﬁcantly dif-
ferent (SES 20.4%, PES 15.6%, p  0.12), with a trend
favoring PES. Incidences of target lesion revascularization
were 8.8% in the SES group and 5.7% in the PES group
(p  0.08; Figure 2
When patients were classiﬁed by insulin requirement,
patients who required insulin (n  72) developed more
events compared with those who did not require insulin
(n  221, crude major adverse cardiac events 27.4% vs
14.6%, respectively, p 0.008; Figure 3). Hemoglobin A1c
levels were higher in the insulin-requiring DM group than in
the non–insulin-requiring DM group, although not signiﬁ-
cantly (7.6% vs 7.2%, p  0.4).
Stenting of the left anterior descending artery, stenting of
the left main coronary artery, and female gender were in-
dependently associated with worse outcomes, whereas bet-
ter renal function (deﬁned as milliliter-per-minute incre-
Figure 2. One-year cumulative risks of (A) target lesion revascularization
and (B) target vessel revascularization.
Table 4
Multivariate predictors of major adverse cardiac events at one year
(Cox’s proportional hazards model)
Variable Adjusted HR 95% CI p Value
Stenting of left anterior
descending artery
2.79 1.44–5.39 0.002
Stenting of left main artery 2.78 1.24–6.25 0.013
Creatinine clearance (/ml/min
increment)
0.99 0.98–1.00 0.03
Women 1.90 1.02–3.53 0.04
Use of PES 0.68 0.37–1.24 0.21
Use of insulin 1.48 0.80–2.74 0.22
CI  conﬁdence interval; HR  hazard ratio.
Figure 3. Cumulative risks of (A) death and (B) major adverse cardiac
events stratiﬁed by diabetic type. IRDM  insulin-requiring DM; NIRDM 
non–insulin-requiring DM.
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ment in creatinine clearance) was associated with improved
outcomes (Table 4). Insulin requirement, signiﬁcant in uni-
variate analysis, became nonsigniﬁcant in the multivariate
model (adjusted hazard ratio 1.48, 95% conﬁdence interval
0.80 to 2.74, p  0.22), and no signiﬁcant differences were
noted with stent type (adjusted hazard ratio 0.68, 95%
conﬁdence interval 0.37 to 1.24, p  0.21).
• • •
The major ﬁnding of this study is that unrestricted use of
PESs in a universal drug-eluting stent environment is asso-
ciated with a nonsigniﬁcantly lower incidence of major
adverse cardiac events at 1 year compared with SESs (ad-
justed hazard ratio 0.68, 95% conﬁdence interval 0.37 to
1.24, p  0.21). Patients with DM and who required insulin
had a signiﬁcantly higher crude incidence of major adverse
cardiac events compared with those who did not require
insulin in a combined drug-eluting population; this signiﬁ-
cance became nonsigniﬁcant after adjustment for multivar-
iate predictors.
Mortality rate at 1 year between groups in our study was
similar (7.7% in SES group and 7.2% in PES group, p 
0.9). It is difﬁcult to compare between studies; however, as
a guide, this result lies between that reported in the stent arm
of the randomized Arterial Revascularization Therapy
Study (6.3%)8 and a multivessel report from the database of
the Cardiovascular Research Foundation (14% to 15%),9
with the caveat that baseline demographics were different.
For a population that had DM, the use of glycoprotein
IIb/IIIa inhibitors in this study was very low; more frequent
use may have improved mortality rates.10
This study has described the experience of a single-
center registry of drug-eluting stents in a moderate number
of patients. Routine angiographic follow-up was not per-
formed, thus precluding an assessment of restenotic rates.
The low use of glycoprotein IIb/IIIa inhibitors is a limitation
but was a reﬂection of the “real-world” practice of the
operators. The results of this study should be viewed as an
exploratory analysis that reported outcomes after the unre-
stricted use of drug-eluting stents in the real world in pa-
tients who had DM.
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INTERVENTIONAL CARDIOLOGY AND SURGERY
One year clinical follow up of paclitaxel eluting
stents for acute myocardial infarction compared with
sirolimus eluting stents
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Objective: To compare clinical outcome of paclitaxel eluting stents (PES) versus sirolimus eluting stents
(SES) for the treatment of acute ST elevation myocardial infarction.
Design and patients: The first 136 consecutive patients treated exclusively with PES in the setting of
primary percutaneous coronary intervention for acute myocardial infarction in this single centre registry
were prospectively clinically assessed at 30 days and one year. They were compared with 186 consecutive
patients treated exclusively with SES in the preceding period.
Setting: Academic tertiary referral centre.
Results: At 30 days, the rate of all cause mortality and reinfarction was similar between groups (6.5% v
6.6% for SES and PES, respectively, p = 1.0). A significant difference in target vessel revascularisation
(TVR) was seen in favour of SES (1.1% v 5.1% for PES, p = 0.04). This was driven by stent thrombosis
(n = 4), especially in the bifurcation stenting (n = 2). At one year, no significant differences were seen
between groups, with no late thrombosis and 1.5% in-stent restenosis (needing TVR) in PES versus no
reinterventions in SES (p = 0.2). One year survival free of major adverse cardiac events (MACE) was
90.2% for SES and 85% for PES (p = 0.16).
Conclusions: No significant differences were seen in MACE-free survival at one year between SES and PES
for the treatment of acute myocardial infarction with very low rates of reintervention for restenosis.
Bifurcation stenting in acute myocardial infarction should, if possible, be avoided because of the increased
risk of stent thrombosis.
T
he efficacy of drug eluting stents to treat coronary artery
stenosis in stable patients has been proved in recent trials
with single digit restenosis rates for non-complex
lesions.1–4
The potential risk of higher thrombogenicity, however, has
led to prolonged antiplatelet treatment and cautious use of
these stents for acute coronary syndromes. We have recently
shown that the use of sirolimus eluting stents (SES) for acute
myocardial infarction is safe and not associated with higher
thrombogenicity.5 The safety and efficacy of paclitaxel eluting
stents (PES) in this setting has not been reported yet.
A recent meta-analysis clearly showed the benefit of
primary percutaneous coronary intervention (PCI) over
administration of thrombolytics for the treatment of acute
myocardial infarction.6 The superiority of (bare metal)
stenting over balloon angioplasty has been well documented
in the setting of acute myocardial infarction.7
We report the one year clinical outcome of a consecutive
patient cohort treated solely with PES in the setting of
primary PCI for acute ST elevation myocardial infarction. We
compared their outcome with that of an earlier published
patient population treated with SES.
METHODS
Patients
Since 16 February 2003, PES (Taxus; Boston Scientific,
Galway, Ireland) has been implemented in our hospital as
the default stent for all patients. Data were collected for the
T-SEARCH (Taxus stent evaluated at Rotterdam Cardiology
Hospital) registry.8 This is a prospective single centre registry
set up with the main purpose of evaluating the safety and
efficacy of PES implantation for patients treated in daily
practice. Until September 2003, 136 consecutive patients
received exclusively PES in the setting of primary PCI for
acute myocardial infarction. All patients were enrolled in the
analysis including patients in cardiogenic shock (defined as
persistent systolic blood pressure , 90 mm Hg or the need
for vasopressors or intra-aortic balloon pumping required to
maintain blood pressure . 90 mm Hg with evidence of end
organ failure and increased left ventricular filling pressures).
Patients who underwent rescue PCI after failed thrombolysis
were not included in this study.
One year clinical outcome was compared with the one year
data from the first 186 patients treated exclusively with SES
in the setting of primary PCI for acute myocardial infarction
between April 2002 and January 2003, when SES was the
default stent in our centre.5
This study protocol was approved by the local ethics
committee, and written informed consent was obtained from
every patient.
Treatment strategy and definitions
The interventional strategy and use of glycoprotein IIb/IIIa
inhibitors was left entirely to the discretion of the operator.
Clopidogrel was recommended for six months, in addition to
Abbreviations: ASA, acetylsalicylic acid; MACE, major adverse
cardiac events; PCI, percutaneous coronary intervention; PES, paclitaxel
eluting stents; SES, sirolimus eluting stents; T-SEARCH, Taxus stent
evaluated at Rotterdam Cardiology Hospital; TIMI, thrombolysis in
myocardial infarction; TVR, target vessel revascularisation
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lifelong acetylsalicylic acid (ASA) 80 mg. The loading dose of
300 mg clopidogrel was given before the intervention. If the
patient was not taking ASA, 250 mg of intravenous ASA was
given at the start of the procedure.
The occurrence of major adverse cardiac events (MACE)
was evaluated at one year. MACE were all cause mortality,
non-fatal myocardial infarction, and target lesion revascular-
isation or target vessel revascularisation (TVR).
Reinfarction was defined as new symptoms or new ECG
changes in association with an increase in creatine kinase MB
fraction concentrations of 1.5 times the previous value if
measured within 48 hours or . 3 times the upper normal limit
if measured. 48 hours after the index infarction. Target lesion
revascularisation was defined as a repeat intervention (surgical
or percutaneous) to treat a luminal stenosis within the stent or
in the 5 mm distal or proximal segments adjacent to the stent.
TVR was defined as a repeat intervention driven by any lesion
located in the same epicardial vessel treated at the index
procedure. Thrombotic stent occlusion was angiographically
documented as a complete occlusion (TIMI (thrombolysis in
myocardial infarction) flow grade 0 or 1) or a flow limiting
thrombus (with TIMI flow 1 or 2) of a previously successfully
treated artery.
Follow up
All patients were clinically followed up. Repeat angiography
was clinically driven by symptoms or signs of ischaemia.
Information about in-hospital outcomes was obtained from
our institutional electronic clinical database and by review of
the hospital records for patients discharged to referring
hospitals (patients were referred from 14 local hospitals).
Postdischarge survival status was obtained from the muni-
cipal civil registries at one, six, and 12 months. Data on all
repeat interventions (surgical and percutaneous) and repeat
Table 1 Baseline characteristics
SES (n = 186) PES (n = 136) p Value
Men 74.7% 83.8% 0.06
Age (years) 59.7 (11.7) 59.2 (12.1) 0.7
Diabetes 10.8% 3.7% 0.02
Current smoking 45.7% 44.9% 0.9
Hypercholesterolaemia 33.9% 30.1% 0.5
Hypertension 24.2% 20.6% 0.5
Previous myocardial infarction 14.4% 10.6% 0.4
Previous PCI 6.5% 5.9% 1.0
Previous CABG 1.6% 2.2% 0.7
Coronary artery disease 0.9
1 vessel 54.8% 52.2%
2 vessel 27.4% 28.7%
3 vessel 17.7% 19.1%
Cardiogenic shock 13.4% 11.8% 0.7
Time from symptom onset to PCI (hours) 3.2 (1.9) 3.1 (2.4) 0.7
Infarct related vessel 0.6
LAD 52.7% 51.5%
LCx 8.2% 8.8%
RCA 37.4% 36.0%
Left main stem 1.6% 2.2%
Saphenous vein graft 0% 1.5%
Bifurcation lesion 8.6% 9.6% 0.8
Number of vessels treated 1.0
1 84.9% 86.0%
.1 15.1% 14.0%
TIMI flow baseline grade 0.4
0–1 73.1% 78.7%
2 16.5% 11.0%
3 10.4% 10.3%
TIMI flow final grade 0.7
0–1 2.1% 2.2%
2 14.8% 11.8%
3 83.0% 86.0%
Number of stents 1.9 (1.2) 1.8 (1.1) 0.4
Total stented length (mm) 34.7 (23.5) 35.9 (22.9) 0.6
Mean nominal stent diameter (mm) 2.89 (0.16) 3.11 (0.33) ,0.001
Glycoprotein IIb/IIIa inhibitor 36.6% 55.1% 0.001
Peak CK (IU) 3126 (3126) 3234 (2567) 0.8
Peak CK-MB (IU) 296 (255) 359 (330) 0.2
Data are mean (SD) or percentage.
CABG, coronary artery bypass graft; CK, creating kinase; LAD, left anterior descending coronary artery; LCx, left
circumflex artery; PCI, percutaneous coronary intervention; PES, paclitaxel eluting stents; RCA, right coronary
artery; SES, sirolimus eluting stents; TIMI, thrombolysis in myocardial infarction.
Table 2 Major adverse cardiac events at 30 days and
one year
SES
(n = 186)
PES
(n = 136) p Value*
0–1 month
Death 5.9% 5.9% 1.0
Death or re-MI 6.5% 6.6% 1.0
TLR 1.1% 4.4% 0.07
TVR 1.1% 5.1% 0.04
Death, re-MI, or TVR 7.5% 10.3% 0.4
Stent thrombosis 0% 2.9% 0.03
0–12 months
Death 8.1% 8.1% 1.0
Death or re-MI 9.2% 10.3% 0.7
TLR 1.1% 5.9% 0.02
TVR 1.1% 6.6% 0.01
Death, re-MI, or TVR 9.7% 14.7% 0.22
Stent thrombosis 0% 2.9% 0.03
*By Fisher’s exact test.
re-MI, reinfarction; TLR, target lesion revascularisation; TVR, target vessel
revascularisation.
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hospitalisations were prospectively collected during follow
up. Questionnaires regarding anginal status and medication
use were sent to all living patients at six and 12 months.
Referring physicians and institutions were contacted for
additional information if required.
Statistical analysis
Continuous variables are presented as mean (SD) and were
compared by Student’s unpaired t test. Categorical variables
are presented as counts and percentages and compared by
Fisher’s exact test. All statistical tests were two tailed. The
cumulative incidence of adverse events was estimated
according to the Kaplan-Meier method and compared by
the log rank test. Cox proportional hazards survival models
were used to assess risk reduction. Multivariate analyses
were performed to identify independent predictors of long
term MACE. Significant baseline and procedural character-
istics at univariate analysis (tested variables: age, diabetes,
cardiogenic shock, multivessel disease, left main stem as the
infarct related artery, postprocedural TIMI flow, bifurcation
treatment, multivessel treatment, and duration of pain), sex,
and stent type were tested for their multivariate predictive
value. The first model was built by backwards stepwise
variable selection with the exit criteria set at the p = 0.1
level; the final model was built by forcing stent type together
with all significant predictors.
RESULTS
In total 136 patients were treated with PES only in the setting
of primary PCI for acute myocardial infarction in the study
period. These patients were compared with 186 patients
treated with SES for the same indication in the period before
our centre switched to PES as the default strategy. Follow up
of the 186 patients with SES from our earlier report5 was
extended from 300 days to one year for the comparison. At
one year after the procedure, follow up was available for
98.4% of patients.
Table 1 lists baseline characteristics. Fewer PES patients
had diabetes (3.7% v 10.8%, p = 0.02). PES patients had a
larger nominal stent size (3.11 v 2.89 mm, p , 0.001) and a
higher percentage of periprocedural glycoprotein IIb/IIIa
inhibitor use (55.1% v 36.6%, p = 0.001). Despite inclusion
of consecutive patients in both SES and PES groups, the
prevalence of diabetes differed significantly. This does not
reflect selection bias. The smaller nominal stent size in the
SES group reflects the unavailability of SES . 3.0 mm at the
time of the study.
MACE were analysed at one month and one year. Table 2
shows the results. No significant difference was seen in death
and death or reinfarction between the two groups either in
the first month or at late follow up. However, a significant
difference in TVR was seen in favour of SES, which was
already apparent at 30 days driven by stent thrombosis.
Six of seven patients with TVR within 30 days in the PES
group received target lesion reintervention. Of these, four
interventions were necessary because of subacute stent
thrombosis (table 3). Only one of these patients had been
treated with periprocedural glycoprotein IIb/IIIa inhibitor
during the index procedure.
Two of four stent thromboses were in patients treated with
bifurcation lesions (one patient with crush bifurcation
stenting without kissing balloon postdilatation but with
periprocedural glycoprotein IIb/IIIa inhibitor and one patient
with T stent bifurcation stenting without kissing balloon
postdilatation and without glycoprotein IIb/IIIa inhibitor).
The two remaining cases were caused by stent under-
expansion, diagnosed at reintervention.
Table 3 Characteristics of individual cases of PES stent thrombosis
Patient number
1 2 3 4
Patient age (years) 59 50 52 47
Sex Male Male Female Female
Time to thrombosis 1 hour 4 days 4 days 6 days
Lesion type (AHA classification) B2 B2 C C
Number of stents 1 1 2 2
Total stent length (mm) 28 24 44 36
Smallest stent diameter (mm) 3.0 3.5 2.25 2.5
Treated vessel RCA LAD LCx, OMCx LAD, 1st diagonal
Bifurcation stenting No No T stent Crush
Kissing balloon postdilatation NA NA No No
Abciximab during index procedure No No No Yes
AHA, American Heart Association; NA, not applicable; OMCx, obtuse marginal branch of the left circumflex
artery.
Table 4 Bifurcation lesions: treatment strategy
SES (n = 16) PES (n = 13) p Value
Main branch stent only 3 (18.8%) 3 (23.1%) 0.4*
Crush 2 (12.5%) 4 (30.8%)
Culotte 0 1 (7.7%)
T stent 9 (56.3%) 3 (23.1%)
V stent 2 (12.5%) 2 (15.4%)
Final kissing balloon 6 (42.9%) 8 (61.5%) 0.3
*Across all strategies by x2 test.
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Figure 1 Survival free of death, reinfarction, or target vessel
revascularisation of patients who received a sirolimus eluting stent (SES)
versus a paclitaxel eluting stent (PES) by Kaplan-Meier estimate.
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The bifurcation stenting percentage was not significantly
different between groups (8.6% v 9.6% for SES and PES,
respectively, p = 0.8). Although across all strategies no
significant difference was found in bifurcation lesion treat-
ment between SES and PES patients, a trend was seen
towards more crush stenting and less T stenting in PES
patients (table 4).
MACE-free survival at 12 months was 90.2% for SES and
85% for PES patients (p = 0.16, by Kaplan-Meier estimate)
(fig 1).
On multivariate analysis, stent type was not an indepen-
dent predictor of MACE at one year and, when forced into the
model of significant predictors, remained non-significant
(p = 0.14) (table 5). However, independent predictors were
TIMI flow 0 or 1 (hazard ratio (HR) 10.2), cardiogenic shock
(HR 4.4), and diabetes mellitus (HR 4.8).
DISCUSSION
The main finding of this sequential registry report is that
patients treated with drug eluting stents for acute myocardial
infarction have a very low rate of repeat revascularisation for
restenosis at one year’s follow up.
Although no significant difference in MACE at one year
was found between the two drug eluting stents, a trend to
worse outcome was seen in the patients treated with PES,
despite more favourable baseline characteristics such as less
diabetes, higher use of glycoprotein IIb/IIIa inhibitors, and
larger nominal stent diameter.
Short term follow up
The largest difference between the groups was TVR in the
first 30 days. These were mainly driven by stent thrombosis.
With respect to these observations of two of 13 stent
thromboses in bifurcation lesions and two of 123 in non-
bifurcation lesions, it seems prudent to try to avoid using two
stents for bifurcation treatment in acute myocardial infarc-
tion. If this is unavoidable, the risk for stent thrombosis may
be reduced by kissing balloon postdilatation and periproce-
dural glycoprotein IIb/IIIa inhibitor. In a separate study of
2500 patients we confirmed that bifurcation stenting in acute
myocardial infarction was a significant predictor of stent
thrombosis and conferred a 13-fold increase in risk.9 It may
be advisable to keep procedures short and simple for patients
undergoing angioplasty for acute myocardial infarction.
The overall rate of stent thrombosis was 1.2% (four of 322)
for drug eluting stent use in acute myocardial infarction. This
is comparable with the stent thrombosis rate with bare
stents9 10 and drug eluting stents9 used in the treatment of
patients for stable coronary lesions.
Long term follow up
Between 30 days and one year two patients treated with PES
were referred for TVR, both for in-stent restenosis (1.5%),
compared with no additional interventions for the SES
patients.
No late stent thrombosis was diagnosed in either group. In
this study, the risk for late stent thrombosis after stopping
clopidogrel, which was prescribed for six months for the PES
and 3–6 months for the SES group, does not seem to be
increased for treatment of patients with acute coronary
syndromes with drug eluting stents. It is important that, to
address this potential problem conclusively, larger studies
specifically looking at this end point be performed.
Furthermore, until more is known, complete cessation of
antiplatelets should be avoided if possible to avoid the risk of
late thrombosis, as McFadden et al11 recently pointed out.
Early and one year mortality was identical in both groups
(5.9% at 30 days and 8.1% at one year for SES and PES). This
is very comparable with earlier studies6 despite the presence
of cardiogenic shock in 12% of patients and multivessel
disease in almost half. As shown before, mortality is not
changed by the use of drug eluting stents.5 Their benefit is
reduction of reintervention as in elective PCI.
The recommendations in the most recent National
Institute for Health and Clinical Excellence guidelines
explicitly exclude acute myocardial infarction and lesions
with visible thrombus as indications for use of drug eluting
stents.12 Our results are reassuring and do not indicate that
patients with acute myocardial infarction should be denied
the benefit of the very low reintervention rates with drug
eluting stents.
Conclusions
The use of PES for the treatment of acute myocardial
infarction seems safe. No significant differences were seen
with the results of SES at one year’s follow up with a very low
rate of reintervention for restenosis. However, a trend
towards more early reinterventions was evident, mainly due
to stent thrombosis. Bifurcation stenting should be avoided
in the setting of primary PCI, if possible.
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Abstract
Aims: Randomized trials of drug-eluting stents (DES) have demonstrated their ability to improve clinical out-
come in relatively simple lesion/patient subsets. Their potential in patients for whom the risk of coronary
bypass grafting is judged prohibitive, remains largely unexplored. To investigate periprocedural and one-
year outcome of percutaneous coronary intervention (PCI) using DES in patients refused for coronary artery
bypass grafting (CABG). 
Methods and results: At our institution, the therapeutic approach for all patients with multi-vessel disease
is decided, by consensus at a conjoint session with the clinical cardiologist, interventionalist and cardiotho-
racic surgeon enabling unequivocal identification of patients, refused surgery, who were referred for PCI.
The EuroSCORE was used to predict peri-operative mortality. From April 2002 to December 2003 we iden-
tified 84 such patients. The mean age was 70.9±10.1 years and 68% were men. More than one third had
prior CABG. Most patients presented with stable or unstable angina pectoris. The reasons for refusal for
CABG were: unsuitable coronary anatomy (37%), poor functional status (28%), patent grafts other than
the culprit vessel (25%), prior CABG (28%), severe left ventricular dysfunction (13%), co-existing malig-
nancy (18%), prior disabling stroke (12%) and morbid obesity (11%). Using the standard and logistic
EuroSCORE methods, the predicted in-hospital mortality rates were 7.8±3.3% and 13.2±11.1% respec-
tively. In this study, the actual mortality rate was 1.2% at 30 days, 3.6% at 6 months and 4.8% at 1 year
follow-up. 
Conclusions: PCI in high risk patients who were refused for CABG in the DES-era resulted in an early and
1-year mortality rate that was significantly lower than the predicted operative mortality.
KEYWORDS
Coronary disease,
drug-eluting stents,
mortality, CABG,
EuroSCORE
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Introduction
Percutaneous coronary intervention (PCI) has evolved to become
the preferred alternative to coronary artery bypass grafting (CABG)
in many lesion/patient subsets1 and the advent of drug eluting
stents (DES), which dramatically reduce the need for reinterven-
tion2, may soon extend these indications to patients with more com-
plex or extensive lesions in whom CABG has traditionally been the
recommended approach3-7. 
Given the less invasive nature of percutaneous intervention, it is
often used as a “bailout” procedure in patients, in whom the site or
extent of the vascular lesions would normally be considered an indi-
cation for surgery, but who are judged to have a prohibitively high
risk of adverse outcomes with CABG because of cardiac or extrac-
ardiac comorbidities. 
The Angina With Extremely Serious Operative Mortality Evaluation
(AWESOME) trial compared CABG with PCI in patients at high risk
for CABG with medically refractory ischemia; bare stents were
implanted in 54% of patients; the authors concluded that PCI was
a safe alternative to CABG with comparable survival, but a higher
rate of reintervention in the PCI group8,9. We evaluated procedural
and 1-year outcome in patients in whom CABG was not considered
an option for revascularization, based on a consensus decision of
the referring cardiologist, interventionalist and cardiothoracic sur-
geon, who were subsequently treated with PCI with a DES as the
default stent. The expected in-hospital mortality rate was calculated
with both the standard and logistic EuroSCORE, a validated surgical
outcome tool and compared with the observed mortality10-15. 
Methods
Our institutional policy requires that the revascularization strategy,
for patients referred to our center, for elective treatment of multi-
vessel coronary artery disease be decided, by consensus at a mul-
tidisciplinary case conference, where the referring cardiologist, an
interventional cardiologists and a cardiothoracic surgeon are pres-
ent. For emergent referrals, a similar strategy is applied on an ad-
hoc basis in the catheterization laboratory. 
Since April 2002, our institution has implemented a policy of univer-
sal DES utilization for all patients requiring coronary stent implanta-
tion. Until February 2003, sirolimus-eluting stents (Cypher®, Cordis,
a Johnson & Johnson Company, Miami Lakes, FL, USA) were used,
since then we have used paclitaxel-eluting stents (Taxus™, Boston
Scientific Corporation, Natick, MA, USA). Clinical, procedural and
follow-up data for all patients receiving DES have been prospective-
ly collected as part of the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH)3 and Taxus-Stent
Evaluated At Rotterdam Cardiology Hospital (T-SEARCH)4 registries
respectively.
The study population comprised consecutive patients treated
between April 2002 and December 2003, by percutaneous coro-
nary intervention, after a consensus decision, that surgical interven-
tion (or re-intervention) carried an unacceptably high risk.
The EuroSCORE, a validated tool to assess surgical risk, was used
to obtain an objective assessment of the expected post-operative
mortality in the group10,13,15. Both the standard and the logistic
score were calculated11,12,14.
Follow-up and endpoint definition
Clinical follow-up was obtained for all patients. Clinical endpoints
were all-cause mortality and major adverse cardiac events (MACE),
defined as a composite of death, myocardial infarction and target
vessel revascularization (TVR) at one year. Survival status was
obtained from the the Municipal Civil Registries at 6 months and
1 year post-procedure. Myocardial infarction was defined as a rise
in creatinine kinase-MB fraction more than 3 times the upper limit
of normal; TVR was defined as any re-intervention within the stent-
ed vessel. Myocardial infarctions and re-interventions were
prospectively recorded on our institutional database. Surviving
patients received a health questionnaire at 6 months and one year.
Further clinical information was obtained from the referring cardiol-
ogist or general practitioners, where required.
Results
Baseline and procedural characteristics are presented in Tables 1
and 2. The mean age of the patients was 70.9±10.1 years and 68%
were men. More than a third (37%) had prior CABG. Glycoprotein
IIb/IIla-blockers were used in 24% of patients. Drug-eluting stents
were used in 88% of patients; in 15% of the patients bare metal
stents were used due to the unavailability of large diameter DES for
the treated vessels. The mean number of implanted stents was
2.8±1.8 mm, with a total length of 55.5±37.6 mm. Mean stent
diameter was 2.97±0.50 mm. 
The reasons for refusal for CABG were: unsuitable coronary anato-
my (37%), poor general condition (28%, mostly due to advanced
age), patent grafts other than the culprit vessel (25%), prior CABG
(28%), severe left ventricular (LV) dysfunction (13%), co-existing
malignancy (18%), prior disabling stroke (12%) and morbid obesi-
ty ( BMI > 35 kg/m2) (11%). Multiple reasons were present in 62%.
The reasons for surgical refusal are detailed in Table 3.
The predicted in-hospital mortality rate, calculated using the stan-
dard and logistic EuroSCORE, was 7.8±3.3% and 13.2±11.1%
respectively. The observed mortality was, however, significantly
lower: 1.2% at 30 days, 3.6% at 6 months and 4.8% at 1 year fol-
low-up (Table 4 and Figure 1). The incidence of myocardial infarc-
tion was 1.2% at 30 days, 3.6% at 6 months and 3.6% at 1 year.
Repeat revascularization of the target vessel occurred in no patient
at 30 days, 1.2% at 6 months, and in 3.6% at 1 year. Overall MACE
was relatively low: 2.4%, 7.1% and 10.7% at 30 days, 6 months
and 1 year follow-up respectively (Table 4 and Figure 2). 
Discussion
The randomized controlled trials that compared PCI with CABG or
that compared bare metal stents with DES excluded patients with
high risk features, such as prior CABG, unsuitable anatomy or poor
LV function. The AWESOME investigators randomized a subgroup of
such patients to PCI or CABG and concluded that PCI was an alter-
native to CABG, with comparable survival, although the reintervention
rate was, as expected, higher in the PCI group8,9. During the study
period, stents were used in just over half of the patients. The advent
of DES with their dramatic effect on the need for reintervention led us
to evaluate outcome in consecutive patients who were refused CABG
but were treated in our institution with PCI and default DES use3,4. 
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Table 1. Baseline characteristics (N=84)
Age, years±SD 70.9±10.1
Male, % 68
Diabetes, % 34
Hypercholesterolemia, % 61
Current smoker, % 10
Hypertension, % 48
BMI, kg/m2±SD 27±4
Previous MI, % 38
Previous PCI, % 22
Previous CABG, % 37
Time from first CABG, years±SD 12.5±5.4
Serum creatinine, mmol/L±SD 123±129
1-vessel, % 7
2-vessel, % 32
3-vessel, % 57
Left main, % 4
Left ventricular dysfunction, % 48
Standard EuroSCORE, mean±SD 7.8±3.3
Logistic EuroSCORE, mean±SD 13.2±11.1
Table 2. Procedural characteristics
Indication for the procedure
Stable Angina, % 50
Unstable angina, % 43
Acute myocardial infarction, % 7
Time to procedure, days±SD 38±54
IIb/IIIa-antagonist use, % 24
Any drug-eluting stent use, % 88
Sirulimus-eluting stents, % 51
Paclitaxel-eluting stents, % 36
Bare metal stents, % 15
Mean stent diameter, mm±SD 2.97±37.6
Total stent length, mm±SD 55.5±37.6
Number of stents, mean±SD 2.8±1.8
Use of small stents (≤ 2,5 mm), % 30
Vein grafts, % 12
Bifurcations, % 13
TIMI-0 flow pre-intervention, % 8
Table 3. Reason for surgical refusal (%)
Unsuitable anatomy 37
Poor functional status 28
Patent grafts 25
Grafts adherent to sternum 4
Re-thoracotomy 22
Re-re-thoracotomy 6
Severe LV dysfunction 13
Concomitant valvular disease 4
No suitable venous material 5
Malignancy 18
Neurologic 12
Morbid obesity (BMI >35 kg/m2) 11
Renal failure 7
Severe lung disease 6
Other extra-cardiac co-morbidity 9
Multiple risk factors 62
Table 4. Components of MACE at 30 days, 6 months and one year
30 Days 6 Months 1 Year
Death, n (%) 1 (1.2%) 3 (3.6%) 4 (4.8%)
Myocardial infarction, n (%) 1 (1.2%) 3 (3.6%) 3 (3.6%)
Target vessel revascularization, n (%) 0 (0%) 1 (1.2%) 3 (3.6%)
Major adverse cardiac events, n (%) 2 (2.4%) 6 (7.1%) 9 (10.7%)
Figure 1. Kaplan-Meier curve for cumulative all cause mortality plot
for patients refused for CABG; the dotted line indicates the peri-oper-
ative mortality derived from the standard Euroscore.
Figure 2. Kaplan-Meier curve for MACE (death/ MI/ TVR) in patients
refused for CABG.
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The major finding of the study was that PCI in high-risk patients
refused CABG and subsequently treated with DES was associated
with low periprocedural and 1-year mortality rates, that were signif-
icantly lower than the mortality rates predicted by the EuroSCORE
method, a validated tool for surgical risk assessment. 
To estimate the peri-operative mortality, we used the standard (or
additive) and logistic EuroSCORE, a validated surgical outcome tool.
The logistic EuroSCORE is more suitable for patients with very high
risk features, i.e. patients with a standard EuroSCORE of 6 or more
or patients with CABG and concomitant valve surgery14. In a single
centre report, the standard EuroSCORE score had significantly bet-
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ter discriminatory power to predict 30-day mortality rate than the
Society of Thoracic Surgeons (STS) risk score system15. 
In this study unsuitable anatomy, prior CABG, patent grafts and LV
dysfunction were the most important cardiac factors for the heart
team to decline surgical revascularization in a patient. The extra-
cardiac factors were poor functional status, malignancy, neurologi-
cal disability, morbid obesity, renal failure and chronic obstructive
pulmonary disease. Overall, two-thirds of patients had multiple risk
factors that precluded CABG. 
The major randomised controlled trails comparing PCI with bare
stents versus CABG concluded that no statistical differences are
observed between CABG and stenting for mortality or acute myocar-
dial infarction, but that CABG is associated with reduced rates of
major adverse cardiac events, mostly driven by reduced repeat
revascularisation1,16. With the extended use of DES, the rate of
repeat revascularisation in our study was very low at 1-year
(Table 4); in former studies a major drawback compared with sur-
gery, although the long term results are not yet known in our partic-
ular group of patients. 
A recent trial randomized patients with carotid stenosis to percuta-
neous intervention with stent implantation or to surgery showed that
the outcome did not differ significantly17. This study had parallel
registries documenting outcome in patients, refused for surgery or
for percutaneous intervention, who were subsequently treated with
either method. Interestingly, the outcome in patients refused for sur-
gery who were treated percutaneously, did not differ significantly
from that of the patients who were judged suitable for randomisa-
tion. Our study highly suggests that in the DES era, PCI is a reason-
able alternative for patients requiring revascularization in whom the
risk of adverse outcomes with CABG is judged to be unacceptably
high. Further studies are needed to confirm our results, although
randomized controlled trials in this group of patients would be diffi-
cult, especially if compared with medical therapy.
Limitations
The present study has several limitations: it is non-randomized, has
an observational design and a heterogenous study population. Not
all patients were strictly inoperable; i.e. patients with patent grafts to
the LAD were not reoperated on at the first instance. Other patients
would have been operative candidates, albeit at a much higher risk,
if percutaneous treatment was not an option. Although the decision
is reached by consensus, it is very operator dependent as the com-
position of the heart team changes and there are no accepted
guidelines. Also, a control group of conservative, medically treated
patients were not available.
Conclusions
Percutaneous coronary intervention in high risk patients refused
CABG and subsequently treated with drug-eluting stents is associ-
ated with low early and 1-year mortality, significantly lower than
EuroSCORE predicted rates. The 1-year incidence of major adverse
cardiac events, especially the repeat revascularisation, is low as
compared to former trials comparing bare stents versus CABG. 
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‘‘Full metal jacket’’ (stented length _>64 mm) using
drug-eluting stents for de novo coronary artery lesions
Jiro Aoki, MD, Andrew T.L. Ong, MBBS, FRACP, Gaston A. Rodriguez Granillo, MD,
Euge`ne P. McFadden, MD, FRCPI, Carlos A.G. van Mieghem, MD, Marco Valgimigli, MD,
Keiichi Tsuchida, MD, Georgios Sianos, MD, PhD, Evelyn Regar, MD, PhD, Peter P.T. de Jaegere, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pim J. de Feyter, MD, PhD, Ron T. van Domburg, PhD, and
Patrick W. Serruys, MD, PhD Rotterdam, The Netherlands
Background Stented segment length was a predictive factor for restenosis in the bare metal stent era. The
objective of the study was to evaluate the medium-term clinical outcome and the potential for adverse effects when
very long segments (ie, z64 mm of stented length) are treated by drug-eluting stent (DES) implantation, an approach
colloquially referred to as a ’’full metal jacket.’’
Methods Since April 2002, we have used DES as the default stent for all percutaneous coronary interventions.
From our prospective institutional database we identified 122 consecutive patients, with de novo coronary lesions, in
whom a coronary artery was treated with at least 64 mm of overlapping DES: 81 patients were treated with
sirolimus-eluting stents and 41 with paclitaxel-eluting stents.
Results The mean number of stents per lesion was 3.3 F 1.1, and the median stented length was 79 mm (range
64-168 mm). Periprocedural Q-wave myocardial infarction (MI) occurred in 2 patients (1.6%) and subacute stent
thrombosis in 1 patient (0.8%). During 1-year follow-up, 5 patients (4.1%), including 3 patients treated for acute MI with
cardiogenic shock, died and 10 patients (8.2%) had nonfatal MI (creatine kinase–MB N3 times). The 1-year target
vessel revascularization rate was 7.5% and the overall incidence of major adverse cardiac events was 18%.
Outcomes in sirolimus-eluting stents and paclitaxel-eluting stents groups did not differ statistically.
Conclusions The use of DES for the treatment of diffuse lesions was associated with a low rate of repeat
revascularization, irrespective of stent type. No safety concerns were raised at medium-term follow-up. (Am Heart J
2005;150:994-9.)
In the bare metal stent era, the length of a stented
segment was an independent predictor of in-stent
restenosis.1-3 Recent randomized trials, in low-risk
patient/lesion cohorts, showed that drug-eluting stents
(DES) reduce the need for repeat intervention com-
pared with bare metal stents.4-7 Drug-eluting stents are
rapidly replacing bare metal stents and there has been
a tendency toward longer stented segment lengths,
given the full lesion coverage from a proximal to a
distal bangiographically normalQ segment to avoid stent
gaps and the incomplete coverage of lesions which
have been associated with restenosis after DES im-
plantation.5,8 However, the clinical effect of very long
and overlapping DES implantation in the so-called full
metal jacket approach and the potential effects of
increased metal and local drug exposures are un-
known. In this report, we investigate the clinical
outcome after very long sirolimus-eluting stent (SES)
and paclitaxel-eluting stent (PES) implantations in a
consecutive group of 122 patients (124 lesions) who
were treated with at least 64 mm of DES without any
gap in the same vessel.
Methods
Patient selection and procedure
Since April 2002, we have adopted a policy of universal
DES implantation for all percutaneous coronary interventions
requiring stents at our center, irrespective of clinical
presentation or lesion morphology. Sirolimus-eluting stents
were exclusively used until March 2003. Since March 2003,
PES has been exclusively used. In total, 122 consecutive
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patients were treated with at least 64 mm of DES without any
gap in the same vessel for diffuse coronary lesions, chronic
total occlusion, or extensive dissections; this represents 7% of
our patients treated exclusively with DES in the same period.
The longest available individual stent length was 33 mm in
SES and 32 mm in PES. We defined a full metal jacket as
64 mm of continuous stent, calculated as the total of the
2 longest PES lengths.
All interventions were performed using standard techniques.
Written informed consent was obtained from all patients as
part of the prospective consecutive database. Periprocedural
use of glycoprotein IIb/IIIa and intravascular ultrasound (IVUS)
was at the discretion of the operator. All patients received a
loading dose of 300-mg clopidogrel followed by a daily dosage
of 75 mg for 6 months, in addition to life-long aspirin therapy.
End point definition and clinical follow-up
Patients were followed up prospectively and major
adverse cardiac events (MACEs) were evaluated. Major
adverse cardiac event was defined as death, nonfatal
myocardial infarction (MI), or target vessel revascularization
(TVR). Myocardial infarction was defined as a creatine
kinase–MB (CK-MB) level that was N3 times the upper limit
of normal, based on the recommendations in the American
College of Cardiology/American Heart Association guide-
lines.9 For patients who presented with an acute coronary
syndrome and elevated baseline enzyme, a diagnosis of
periprocedural MI required a fall and rise of CK-MB of 50%
above the previous level.10 Target vessel revascularization
was defined as a reintervention in the treated vessel. Stent
thrombosis was angiographically documented as a complete
occlusion or a flow-limiting thrombus of a successfully
stented segment. Information regarding repeat interventions
was prospectively collected by means of an electronic
database. Survival status was assessed by written inquiries to
the Civil Registry. Questionnaires to assess clinical status
were sent to all living patients. The patient, referring
physician, and peripheral hospitals were directly approached
whenever necessary for additional information. Follow-up
angiography was planned only in patients who were
enrolled during the first 6 months (n = 38).
Statistical analysis
Continuous variables were expressed as mean F SD.
Discrete variables were presented as percentages. Continuous
variables were compared with Student t test or Wilcoxon
ranked scores when applicable. The Fisher exact test was used
for categorical variables. The cumulative incidence of adverse
events was calculated according to the Kaplan-Meier method
and differences were assessed using the log-rank test. All
statistical tests were 2-tailed, and P b .05 was considered
statistically significant. Patient, lesion, and procedural charac-
teristics associated with 1-year MACE on univariate analysis
(P value for selection b.2) were tested for their multivariate
predictive value (tested values were cardiogenic shock, female
sex, multivessel disease, bifurcation stenting, and use of IIb/IIIa
inhibitors). The final model was built by backward stepwise
variable selection with entry and exit criteria set at the P = .05
and P = .1 levels, respectively.
Results
Patient characteristics
Of the 122 consecutive patients, 81 patients (82
lesions) were treated with SES (SES group) and 41
patients (42 lesions) were treated with PES (PES group).
Patient characteristics are reported in Table I; 19% had
diabetes and 39% underwent the index procedure for an
acute coronary syndrome. There were no statistical
differences between groups, apart from a higher
proportion of men in the PES group. Figure 1 presents
the distribution of stented length in this study.
Procedural characteristics
Lesion and procedural characteristics are presented in
Table II. The mean number of stents implanted per
lesion was 3.3 F 1.1 (range 2-7 stents), and the median
Table I. Patient characteristics
All
(n = 122)
SES
(n = 81)
PES
(n = 41)
Age (y) 63 F 11 62 F 12 63 F 11
Male (%) 75 69 88T
Hypertension (%) 42 43 39
Hyperlipidemia (%) 67 62 76
Current smoking (%) 25 26 24
Diabetes mellitus (%) 19 20 17
Prior MI (%) 44 43 46
Prior CABG (%) 5 5 5
Prior PCI (%) 19 17 22
Multivessel disease (%) 70 70 68
Unstable angina (%) 26 31 17
AMI (%) 11 11 12
AMI with shock (%) 3 2 5
CABG, Coronary artery bypass graft surgery; PCI, percutaneous coronary
intervention; AMI, acute MI.
TP b .05 for the comparison between SES and PES groups.
Figure 1
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total stented length was 79 mm (range 64-168 mm).
Glycoprotein IIb/IIIa inhibitors were used in 37% of
patients. In the PES group, the mean stent diameter was
larger (3.0F 0.3 vs 2.7F 0.2 mm, P b .001), with longer
median stented length (77 vs 84 mm, P = .03),
compared with the SES group.
Clinical outcome
Complete clinical follow-up information was avail-
able for all patients. Table III shows 30-day clinical
outcomes as estimated by the Kaplan-Meier method.
A periprocedural MI occurred in 5 patients (4.0%).
Each CK-MB level was 191, 141, 82, 338, and
159 U/L (normal upper limit of CK-MB is 23 U/L in
our institute). Among these patients, 2 patients (1.6%)
had Q-wave MI. The causes of periprocedural MI were
side-branch occlusion (1 patient), distal embolism
(1 patient), distal dissection (1 patient), and dissec-
tion of other treated lesion (2 patients). Subacute
stent thrombosis occurred in 1 patient (0.8%) in the
SES group.
One-year clinical outcomes, estimated by the Kaplan-
Meier method, are presented in Table III. Five patients
(4.1%) died during the first year, 2 received SES, and
3 received PES. In the SES group, 1 patient who received
SES for acute MI with cardiogenic shock died the next
day from cardiogenic shock and the other died of a
pulmonary embolism 275 days after the procedure. In
the PES group, 1 patient who presented with acute MI
Table III. Thirty days and 1 year clinical outcomes cumulative
events rate estimated by Kaplan-Meier
All
(n = 122)
SES
(n = 81)
PES
(n = 41) PT
30 d
Death (%) 1.6 1.2 2.4 .63
MI (%) 5.8 6.2 4.9 .77
TVR (%) 1.7 2.5 0 –
Death, MI (%) 7.4 7.4 7.3 .97
MACE (%) 8.2 8.6 7.3 .79
1 year
Death (%) 4.1 2.5 7.3 .20
MI (%) 10.0 11.2 7.4 .53
TVR (%) 7.5 7.5 7.6 .96
Death, MI (%) 12.3 12.3 12.2 .98
MACE (%) 18.0 18.5 17.1 .87
TVR, target vessel revascularization; MACE, major adverse cardiac events.
TComparison between SES and PES groups (log rank).
Table IV. Paired quantitative angiographic analysis
(mandatory angiographic follow-up group)
SES (n = 38) Pre Post Follow-up
RD (mm) 2.56 F 0.53 2.68 F 0.44 2.76 F 0.37
MLD (mm) 0.43 F 0.58 2.24 F 0.38 2.13 F 0.58
DS (%) 81.9 F 24.6 16.2 F 9.4 23.4 F 19.5
Late loss (mm) 0.12 F 0.58
Binary restenosis
rate (%)
5.3
RD, reference diameter; MLD, minimal lumen diameter; DS, diameter stenosis.
Table II. Lesion and procedural characteristics
All (n = 124) SES (n = 82) PES (n = 42)
Treated vessel
LAD (%) 25 29 17
LCX (%) 12 16 5
RCA (%) 63 55 79*
Lesion type
B1 (%) 1 1 0
B2 (%) 2 2 0
C (%) 98 96 100
CTO (%) 40 38 43
Total occluded length (mm F SD) 23.2 F 10.9 22.9 F 11.2 23.7 F 10.6
Stent number/vessel 3.3 F 1.1 3.1 F 1.0 3.7 F 1.1*
Mean stent diameter (mm) 2.9 F 0.3 2.7 F 0.2 3.0 F 0.3*
Median stent length/vessel (mm) (range) 79 (64-168) 77 (64-140) 84 (64-168)*
Bifurcation stenting (%) 13 15 10
Use of IIb/IIIa inhibitor (%) 37 38 36
Pre-RD (mm) 2.61 F 0.55 2.55 F 0.52 2.74 F 0.60
MLD (mm) 0.44 F 0.52 0.46 F 0.52 0.40 F 0.51
DS (%) 82.3 F 20.6 80.8 F 21.6 85.2 F 18.4
Post-RD (mm) 2.73 F 0.49 2.67 F 0.47 2.86 F 0.51*
MLD (mm) 2.26 F 0.46 2.20 F 0.42 2.37 F 0.52*
DS (%) 17.4 F 10.9 17.4 F 10.8 17.2 F 11.4
LAD, Left descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; CTO, chronic total occlusion; RD, reference diameter;MLD, minimal lumen
diameter; DS, diameter stenosis.
TP b .05 comparison between SES and PES groups.
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with cardiogenic shock died 6 days later from ongoing
heart failure. The second patient underwent an unsuc-
cessful percutaneous coronary intervention 55 days after
the initial procedure to treat another lesion, requiring
emergent coronary artery bypass surgery and died 1 day
after surgery. The remaining patient died of congestive
heart failure 244 days after the initial procedure. This
patient had already suffered MIs twice before the index
procedure and had severe left ventricular dysfunction.
The overall TVR rate was 7.5% and the incidence of
MACE was 18.0% at 1 year. There were no statistically
significant differences between the SES and the PES
groups. Multivariate predictors of 1-year MACE were
cardiogenic shock (hazard ratio 8.96, 95% CI 2.11-28.66,
P = .0006) and female sex (hazard ratio 2.71, 95% CI
1.06-6.02, P = .02). Mean late loss was 0.12 F 0.58 mm
in 38 patients who were consecutively enrolled in the
first 6 months of our experience and who, for this
reason, underwent mandatory follow-up angiography
(Table IV).
Figures 2-4 are a representative example of a patient
successfully treated with 3 stents (SES) with a total stent
length of 84 mm.
Discussion
In this study, median stented length was 79 mm (range
64-168 mm). The incidence of subacute stent thrombo-
sis was 0.8% (1 patient) and the TVR rate was 7.5% at
1 year. Of the 6 patients who had in-stent restenosis
within 1 year, 5 (83.3%) patients had focal restenosis
easily treated with repeat coronary stenting (mean stent
length 20.0 F 8.9 mm).
In the bare metal stent era, the stented length is
an important predictor of in-stent restenosis. How-
ever, there are no precious reports regarding full
metal jacket. The results of this present study are
promising when compared with published data on
bare metal stents with long stented lengths or
multiple stenting despite significantly longer lengths
in this study (Table V).11-14 A group of 21 consec-
Figure 2
Baseline angiography showing diffuse right coronary artery disease.
Figure 3
The patient was successfully treated with 3 Cypher stents (total length
was 84 mm).
Figure 4
Follow-up angiography (216 days after the index procedure)
documenting the absence of in-stent restenosis.
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utive patients from our institution, treated with at
least 64 mm of continuous bare metal stents (BMS)
in the same vessel from the immediate period
preceding the introduction of DES, is included as a
comparison (unpublished data). The 1-year TVR rate
in the BMS group was approximately 3 times higher
than the DES population from this study.
Concerns have been raised regarding the clinical
impact of high local drug concentration in the tissue
wall caused by long stented lengths and overlapped
stents (eg, the development of coronary aneurysms).15,16
We did not observe aneurysm formation in patients who
underwent follow-up angiography beyond 6 months.
Nor was there any evidence of systemic complications,
related to the use of multiple DES, in our patient cohort
up to 1 year.
A limitation of treating diffuse coronary disease with
long stented lengths in the bare metal stent era was a
high incidence of periprocedural MI; this was docu-
mented in several stent trials that enrolled patients
with long lesions.11,13,17 In the ADVANCE study, 21.4%
had elevated CK-MB, with 7.1% N5 times elevated in
the bail out stenting group.13 The definition of MI after
percutaneous coronary interventions differed among
studies.18-20 Even in case of not long length stenting,
reports in the literatures indicated that 8.5% had
elevated CK-MB (N5 times17 or N3 times21) after stent
implantation. If an MI is defined as a CK-MB of N5
times the upper limit of normal, the incidence of
periprocedural MI was 3.3% in our study. Based on our
results, DES use does not increase the incidence of
periprocedural MI compared with published bare metal
stent data.
SES and PES were used in this study in consecutive
periods. This study is limited by its single-arm design and
moderate sample size, and follow-up angiography was
performed in one third of patients, precluding reporting
of quantitative angiographic variables and our main
purpose was not to compare the clinical effect of
2 different types of DES. Procedural characteristics were
not similar between both groups (in the PES group, the
mean stent diameter was larger and the median stented
length was longer compared with the SES group).
However, we found that despite extremely long stent
lengths, the incidence of TVR was quite low for both SES
and PES. Percutaneous coronary intervention using DES
therefore seems to be a feasible, effective, and safe
option for the treatment of patients with diffuse
coronary disease.
Conclusion
Stented length of z64 mm with DES for de novo
coronary artery lesions was safe. Drug-eluting stents had
similar clinical results with low TVR rates. The use of
DES for the treatment of diffuse coronary lesions is a
feasible percutaneous alternative.
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Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous
Vein Graft Disease With Paclitaxel-Eluting Stents
Keiichi Tsuchida, MD, Andrew T. L. Ong, MBBS, Jiro Aoki, MD,
Carlos A. G. van Mieghem, MD, Gastón A. Rodriguez-Granillo, MD, Marco Valgimigli, MD,
Georgios Sianos, MD, PhD, Evelyn Regar, MD, PhD, Eugène P. McFadden, MD,
Willem J. van Der Giessen, MD, PhD, Pim J. de Feyter, MD, PhD,
Peter P. T. de Jaegere, MD, PhD, Ron T. van Domburg, PhD, and
Patrick W. Serruys, MD, PhD*
The aim of this study was to evaluate the outcome after paclitaxel-eluting stent
implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier
estimates, the probability of major adverse cardiac event-free survival for 1 year was
92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be
feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is
needed to conﬁrm these observations. © 2005 Elsevier Inc. All rights reserved. (Am
J Cardiol 2005;96:395–398)
Trials in native coronary arteries have demonstrated that
sirolimus-eluting stents dramatically reduce restenosis.1,2
More recently, our group reported that sirolimus-eluting
stents result in a low rate of target vessel revascularization
in saphenous vein graft disease.3 Paclitaxel-eluting stents
(PESs), the second commercially available stent coated with
an antiproliferative agent, have also shown excellent results
in reducing restenosis in native vessels.4,5 The aim of this
study was to investigate the immediate and 1-year outcome
of PES implantation in patients with saphenous vein graft
disease.
• • •
Since February 2003, PESs have been used as the device of
choice for every patient treated with percutaneous coronary
intervention at our institution. Between February and De-
cember 2003, coronary intervention was performed in 50
consecutive patients with 62 vein graft lesions. Eight pa-
tients received bare metal stents, because PESs were not
available in diameters 3.5 mm. Two patients presented
with cardiogenic shock subsequent to acute myocardial in-
farction, and, despite the successful deployment of a PES,
they died of refractory left ventricular failure immediately
after the procedure. Thus, a total of 40 consecutive patients
with 52 vein graft lesions underwent elective coronary in-
tervention using PESs, exclusively and constituted the study
population. The stent used in this study was the TAXUS
Express2 PES (Boston Scientiﬁc, Natick, Massachusetts),
with paclitaxel incorporated in a slow-release co-polymer
carrier system.
All of the present cohort were treated with life-long
aspirin therapy and received a loading dose of 300 mg
clopidogrel followed by 75 mg/day for 6 months. During the
procedure, intravenous heparin was administered to main-
tain an activated clotting time of 250 seconds. The use of
glycoprotein IIb/IIIa inhibitors, thrombectomy devices, or
distal protection devices was at the discretion of the oper-
ator. The local ethics committee approved the study proto-
col, and all patients provided written informed consent.
Angiographic variables were assessed before and after
each procedure. Degenerated grafts were deﬁned as grafts
with luminal irregularities or ectasia involving 50% of its
total length.6 A plaque was considered ulcerated if a small
crater consisting of a discrete luminal widening in the area
of the stenotic lesion, not extending beyond the normal
vascular lumen, was seen on angiography.6 A lesion was
classiﬁed as containing thrombus if angiography demon-
strated an intraluminal ﬁlling defect or an abrupt vessel
cutoff.7 Postprocedural remaining stenosis (41% to 50%
diameter stenosis on quantitative coronary angiography)
was also identiﬁed.8 In this study, the term “de novo lesion”
referred to a treatment site without previously implanted
stents. The quantitative analysis was performed using the
computer-based quantitative coronary angiography system
CAAS II (Pie Medical, Maastricht, The Netherlands), as
previously described.9
Patients were followed up prospectively and evaluated
for survival free of major adverse cardiac events (MACEs),
deﬁned as (1) death, (2) myocardial infarction (MI), (3)
target lesion revascularization (TLR), or (4) target vessel
revascularization. MI was deﬁned as the occurrence of an
Department of Interventional Cardiology, Thoraxcenter, Erasmus Med-
ical Center, Rotterdam, The Netherlands. Manuscript received January 26,
2005; revised manuscript received and accepted March 21, 2005.
This study was supported by healthcare funds allotted by Erasmus
Medical Center, Rotterdam, The Netherlands, and by an unrestricted in-
stitutional grant from Boston Scientiﬁc Corporation, Boston, Massachu-
setts.
* Corresponding author: Tel: 31-10-463-5260; fax: 31-10-436-9154.
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elevated creatine kinase-MB fraction 3 times the upper
limit of normal measured during the ﬁrst 24 hours after the
procedure. TLR was deﬁned as surgical or percutaneous
reintervention driven by signiﬁcant (50%) luminal nar-
rowing either within the stent or the borders 5 mm proximal
and distal to the stent that was undertaken in the presence of
either anginal symptoms or objective evidence of ischemia.
Target vessel revascularization was deﬁned as reinterven-
tion in the treated vessel outside the target lesion.
The numeric data are expressed as the mean  SD and
the frequency as percentages for descriptive purposes.
Kaplan-Meier event-free survival curves were constructed.
Table 1 describes the baseline patient demographics of
the total study population and the 2 subgroups designated
according to their previous history. The de novo group
comprised patients without previous stents and the resteno-
sis group comprised patients with previously stented le-
sions. The proportion of men and prevalence of hypercho-
lesterolemia were great. More patients were treated for
unstable angina. The demographics were similar between
the 2 groups.
The procedural characteristics are reported in Table 2.
The mean graft age was 13  5 years. Sequential grafting,
or construction of a venous conduit anastomosed at multiple
vessel sites, was predominant in this population (62%).
Either the PercuSurge GuardWire system (Medtronic, Min-
neapolis, Minnesota) or FilterWire EX (Embolic Protection,
Boston Scientiﬁc) was used as distal protection device.
Lesions located in the body of the vein graft were the
most common. Direct stenting was the strategy preferred
(58%) over predilation followed by stenting. After the pro-
cedure, untreated remote sites with a diameter stenosis of
41% to 50% in the target vein graft were observed in 7
vessels (Table 2). The reference graft vessel diameter was
Table 1
Baseline patient characteristics (n  40)
Variable All Patients
(n  40)
De Novo*
(n  33)
Restenosis†
(n  7)
Age (yrs) (mean  SD) 70  8 70  8 73  6
Men 36 (90%) 30 (91%) 6 (86%)
Previous MI 24 (60%) 19 (58%) 5 (71%)
Diabetes 16 (40%) 15 (46%) 1 (14%)
Hypertension 17 (43%) 13 (39%) 4 (57%)
Hypercholesterolemia‡ 36 (90%) 29 (88%) 7 (100%)
Current smoker 2 (5%) 2 (6%) 0 (0%)
Indication for
revascularization
Stable angina pectoris 16 (40%) 14 (42%) 2 (29%)
Unstable angina pectoris 24 (60%) 19 (58%) 5 (71%)
No. of coronary arteries
narrowed 50%
1 6 (15%) 3 (9%) 3 (43%)
3 34 (85%) 30 (91%) 4 (57%)
Left ventricular ejection
fraction§
Normal (0.55) 19 (48%) 15 (46%) 4 (57%)
Moderate dysfunction
(0.31–0.54)
10 (25%) 9 (27%) 1 (14%)
Poor (0.30) 6 (15%) 5 (15%) 1 (14%)
* Patients with lesions without previous stents.
† Patients treated in previously stented lesions.
‡ Deﬁned as total cholesterol 220 mg/dl or known statin therapy.
§ Left ventriculography was not performed in 5 patients.
Table 2
Procedural characteristics
Baseline graft characteristics (n  42 vessels)
Graft age (yrs) (mean  SD) 13 5
Saphenous vein - coronary anastomosis
LAD 2 (5%)
Left circumﬂex 8 (19%)
Right 6 (14%)
Jump graft (multiple distal anastomoses) 26 (62%)
Jump graft anastomosed at LAD 8/26 (31%)
Degenerated graft 12 (29%)
Multiple treatment site 12 (29%)
Initial TIMI ﬂow 0 or 1 9 (21%)
Use of glycoprotein IIb/IIIa inhibitor 11 (26%)
Use of distal protection device 22 (52%)
Use of transluminal extraction catheter 3 (7%)
Postprocedural graft characteristics (n  42 vessels)
Postprocedural stenoses 41%–50% at unstented sites 7 (17%)
Final TIMI ﬂow
0 1 (2%)
1 0 (0%)
2 4 (10%)
3 37 (88%)
Baseline lesion characteristics (n  52 lesions)
Treatment site
Ostial 7 (14%)
Body 35 (67%)
Distal 10 (19%)
Diffuse (lesion length 20 mm) 15 (29%)
De novo lesion 41 (79%)
Eccentricity 24 (46%)
Ulcer 11 (21%)
Thrombus containing lesion 12 (23%)
Target lesion angulation 45° 3 (6%)
No. of stents per lesion (mean  SD) 1.6  1.1
Total stent length per lesion (mm) (mean  SD) 30  29
Direct stenting 30 (58%)
LAD  left anterior descending; TIMI  Thrombolysis In Myocardial
Infarction.
Table 3
Quantitative coronary angiography
Paclitaxel-eluting Stent
(n  52 lesions)
Value
Baseline
Lesion length (mm) 19.1 23.6
Reference diameter (mm) 2.9 0.5
Minimum lumen diameter (mm) 0.8 0.5
Diameter stenosis (%) 73 16
Postprocedural (in-stent)
Stented segment length (mm) 25.7 22.7
Reference diameter (mm) 3.1 0.6
Minimum lumen diameter (mm) 2.5 0.4
Diameter stenosis (%) 18 9
Data presented as mean  SD.
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3 mm, and the mean lesion length at baseline was 19.1 
23.6 mm (Table 3).
One patient (2.5%) developed a non–Q-wave MI related
to the procedure as an in-hospital MACE. During the 1-year
follow-up (average 472  150 days), no patient died. One
patient (2.5%) underwent TLR, and a second (2.5%) under-
went treatment of a new lesion within the same vessel
(repeat PCI in these 2 cases). The cumulative MACE rate
was 7.5%. The Kaplan-Meier estimate of the 1-year event-
free survival among patients without MACEs was 92.5%.
No MACEs occurred in patients treated for in-stent reste-
nosis (restenosis group).
• • •
The results of this study indicate that the use of PESs for the
treatment of saphenous vein graft narrowing is associated
with low clinical event rates, including death, MI, and the
need for repeat revascularization. This is the ﬁrst study to
evaluate the performance of PESs in vein graft disease.
Coronary intervention in patients with vein graft disease
is still challenging because of the high risk of restenosis.10
Stent implantation has been associated with more favorable
outcomes than balloon angioplasty.11–13 However, the use
of bare metal stents in vein graft disease has not been
proved to decrease morbidity and mortality and is associ-
ated with a high 6-month restenosis rate.11 Pathologic ﬁnd-
ings have identiﬁed a constant inﬂammatory reaction over
the years around bare metal stents implanted in vein
grafts.14 Consequently, stents coated with anti-inﬂammatory
agents such as sirolimus and paclitaxel may exert a preven-
tive effect on persistent inﬂammation.
Our study population had the following characteristics
compared with other studies of bare metal stents11–13,15–18:
(1) complex saphenous vein graft lesions, including acute
coronary syndrome, long lesions, and multiple stenting; (2)
an older graft age; and (3) a smaller reference vessel size.
In the present study, we evaluated consecutive patients
without acute MI, who had more severe complex lesions in
contrast to other studies that had excluded patients with long
lesions, thrombotic lesions, or stenoses at the ostial or anas-
tomotic site11–13,15–18 (Table 4). In addition, nonstaged stent-
ing in multiple lesions was performed in 29% of our pop-
ulation. This population also included 7 patients treated for
in-stent restenosis. The treatment result of the subgroup was
excellent. As is true in native coronary arteries, treatment of
in-stent restenosis lesions in vein grafts is safer than treat-
ment of de novo vein graft lesions.6,19 This subgroup may
have favorably inﬂuenced the global results.
Our patients had older vein grafts (13 years) than those in
other studies11–13,15–18. Plaques in older vein grafts may be
softer and more friable, as well as being larger and more
frequently associated with thrombus formation.20
With regard to the impact of the smaller reference size in
these patients, the larger diseased graft would generally
contain more bulky lesions, which may distally embolize,
with subsequent myocardial damage. In that respect, the
present study population might be somewhat more favor-
able. However, smaller graft vessels have also been reported
to be 1 of the independent predictors for restenosis.17 De-
spite a mean vessel size of 3.0 mm, only 1 patient under-
went TLR.
Our ﬁndings strongly suggest that PESs exert a preven-
tive effect against restenosis, not only in native coronary
artery disease, but also in vein graft lesions.
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Drug-eluting stent implantation for chronic total 
occlusions: comparison between the Sirolimus- 
and Paclitaxel-eluting stent
Abstract
Aims: Long-term results following percutaneous coronary intervention (PCI) with bare metal stents in the
treatment of chronic total occlusions (CTOs) is hindered by a significant rate of restenosis and re-occlu-
sion. Drug-eluting stents have shown dramatically reduced restenosis rates for the treatment of relatively
simple non-occlusive lesions, though there is only limited data as to the efficacy in CTO’s. We evaluated
the long-term results of the sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) for the treatment
of CTOs. 
Methods and results: From April 2002, all patients at our institution were treated with SES as the device of
choice during PCI. During the first quarter of 2003 the default strategy changed to the use of PES. Drug-
eluting stent implantation was carried out in CTOs (defined as >3 months’ duration) in 9% of de novo PCI
procedures. A total of 76 consecutive patients were treated with SES implantation, followed by a consecu-
tive series of 57 patients treated with PES implantation. These patients were compared with a similar group
of patients (n=26) treated with BMS in the 6-month period preceding April 2002. 
At 400 days, the cumulative survival-free of target vessel revascularization was 80.8% in the BMS group
versus 97.4% and 96.4% in the SES and PES groups respectively (p=0.01). 
Conclusions: The use of both the SES and PES in the treatment of chronic total coronary occlusions
reduces the need for target vessel revascularization compared to bare metal stents.
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Introduction
Successful percutaneous therapy of chronic total occlusions (CTOs)
has been shown to improve symptoms of angina and left ventricu-
lar function, and reduce the subsequent need for coronary artery
bypass surgery1-5. In addition, in the long-term, recanalization of a
CTO can reduce mortality compared with those with an unsuccess-
ful attempt at recanalization6. However, the long-term outcome of
percutaneous coronary intervention (PCI) for chronic total coronary
occlusions is subject to an increased risk of restenosis and re-occlu-
sion compared with non-occlusive lesions1,7. The advent of drug-
eluting stents is revolutionising the practice of interventional cardi-
ology. Several randomized trials have demonstrated a dramatic
reduction in restenosis rates compared with bare metal stents when
used for the treatment of relatively simple lesions8-11. In addition,
preliminary data has confirmed the efficacy utilizing the sirolimus-
eluting stent (SES) for the treatment of chronic total occlusions12. In
the present report, we evaluate the use of drug-eluting stent implan-
tation for chronic total occlusions in a consecutive series of patients,
with comparison between the sirolimus- and paclitaxel-eluting
stents.
Methods
The sirolimus-eluting stent (Cypher™, Johnson & Johnson - Cordis
unit) received CE mark approval in April 2002. Since that time, all
patients undergoing percutaneous therapy in our institution have
been treated with drug-eluting stent implantation as the default
strategy. During the first quarter of 2003, our strategy switched from
the sirolimus- to the paclitaxel-eluting stent (Boston Scientific)
enabling a comparison of the two stent types. All consecutive
patients with successful chronic occlusion recanalization were
enrolled. Those patients treated with drug-eluting stent implantation
were compared to all those treated for a CTO in the preceding 
6-months with bare metal stents (BMS), identified from the depart-
ments’ dedicated database. All groups were treated by the same
operators utilizing standard techniques; the only difference being
the type of stent.
During the procedure, heparin was given to maintain an activated
clotting time ≥ 250 seconds. All patients received lifelong aspirin,
and before the procedure were pre-treated with a loading dose of
300mg clopidogrel, additional anti-platelet therapy was given with
clopidogrel for 1 month in the BMS group, and for 6-months in the
drug-eluting stent groups. The use of Glycoprotein IIb/IIIa inhibitor
therapy was at the discretion of the operator and was only given
once wire passage was confirmed as successful. The protocol was
approved by the local ethics committee and is in accordance with
the principles of Good Clinical Practice for Trials of Medicinal
Products in the European Community and the Declaration of
Helsinki. All patients signed a written informed consent
Chronic total occlusion definition
Complete occlusion of a coronary artery on angiography, with no
antegrade filling of the distal vessel other than via collaterals. All
patients included had a native vessel occlusion estimated to be of
at least 3-months’ duration, based on either a history of sudden
chest pain, a previous acute myocardial infarction in the same tar-
get vessel territory, or the time between the diagnosis made on coro-
nary angiography and PCI. 
Length of occlusion
This was measured by quantitative coronary angiography (CAAS II;
Pie Medical Imaging, The Netherlands) either utilizing antegrade fill-
ing via collaterals, or assessment of the retrograde collateral filling
achieved through making a simultaneous injection into both the left
and right coronary arteries to delineate the distance between the site
of occlusion and the most proximal part of the vessel filled retro-
gradely. This length evaluated only the occluded vessel, and did not
therefore include stenosis of the vessel pre- and post- the occlusion. 
Follow-up
Patients were prospectively followed-up for clinical events, and eval-
uated for survival-free of major adverse cardiac events (MACE)
using questionnaires and telephone enquiries. MACE was pre-
defined as: 1) death, 2) non-fatal myocardial infarction (AMI), or 3)
repeat target vessel revascularization (TVR). The diagnosis of AMI
required an elevation of creatine kinase to twice the upper limit of
normal, together with a rise in creatine kinase-MB fraction. TVR was
defined as either surgical or percutaneous reintervention driven by
significant (>50%) luminal narrowing within the treated vessel, and
was undertaken in the presence of either anginal symptoms or
objective evidence of ischemia. Follow-up angiography was under-
taken in all patients in the presence of anginal symptoms at clinical
evaluation; in addition those patients treated during the first 
6-months of DES implantation were invited. 
Statistical analysis
Discrete variables are presented as percentages and compared with
Pearson’s chi-square test. Continuous variables are expressed as
mean ± standard deviation and compared with one-way ANOVA.
Cumulative survival and MACE-free survival were calculated
according to the Kaplan-Meier method. The log-rank test was used
to compare MACE-free survival between the groups. A p value of
<0.05 was considered as significant. 
Results
There were no significant differences between the groups with
respect to baseline patient characteristics (table 1). Procedural
characteristics are presented in table 2. One patient in both the
BMS and PES groups had stent implantation in 2 chronic occlu-
sions. Occlusion length was able to be measured in 74.1%, 84.2%,
and 72.4%of the BMS, SES, and PES groups respectively (p=0.3).
Both drug-eluting stent cohorts were treated with a higher number
of stents resulting in a longer length of stented segment. 
At one year, there was a single death occurring in hospital, 22 days
after successful RCA recanalization and PES implantation. The
patient had been admitted 1 week previously, with no evidence of
a cardiac problem, and the cause of death was related to an inop-
erable glioblastoma. There were 4 patients who had an acute
myocardial infarction, all having been treated with drug-eluting
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stent implantation. The first had SES implantation for a RCA CTO
together with PCI of the LAD. There was a peri-procedural eleva-
tion of creatine kinase (maximum elevation of 854 IU/l) related to
loss of a sizeable septal branch related to the LAD stent (non-
occluded vessel). The second related to subacute thrombosis
occurring 11 days after SES implantation (a 2.5x33mm and a
3.0x33mm) in a LAD occlusion. IVUS suggested that 2.5mm stent
was under-expanded and the patient was treated with a glycopro-
tein IIb/IIIa inhibitor and balloon dilatation. The third had PES
implantation for a RCA CTO together with treatment of the left main
stem. On day 14, he complained of chest pains and had a maxi-
mum CK elevation of 819. Angiography demonstrated an excellent
result in the RCA, but haziness of the ostium of the left circumflex
artery which was subsequently treated with further PCI (culprit
lesion in other vessel). The fourth patient had SES implantation (a
2.5x33mm and a 3.0x33mm) for a LAD CTO. At 6-months, control
angiography demonstrated no evidence of restenosis, but he was
admitted 4 months later to another hospital with a myocardial
infarction that was managed medically. 
Table 1. Baseline patient demographics 
BMS SES PES p value
n=26 n=76 n=57
Mean age (years) 60.3±11.0 61.1±10.6 58.4±10.4 0.3
Male sex (%) 92.3 65.8 80.7 0.3
Current smoker (%) 30.8 18.4 22.8 0.5
Diabetes mellitus (%) 7.7 14.5 19.3 0.4
Hypertension (%) 42.3 42.1 50.9 0.7
Hypercholesterolemia (%) 57.7 67.1 75.4 0.6
Previous myocardial infarction (%) 46.2 51.3 43.9 0.8
Previous CABG (%) 0 3.9 5.3 0.5
Glycoprotein IIb/IIIa inhibitor usage (%) 23.1 18.4 19.3 0.9
PCI in at least one additional (non-occluded) major 26.9 38.2 47.4 0.4
epicardial vessel during the index procedure (%)
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention
Figure 1. Kaplan-Meier estimates of the cumulative survival-free of
target vessel revascularization following stent implantation in a chron-
ic total occlusion for patients treated with sirolimus-eluting (SES),
paclitaxel-eluting (PES), or bare metal stent (BMS) implantation.
Table 2. Baseline procedural characteristics
BMS SES PES p value
Number of CTO lesions treated n=27 n=76 n=58
Target vessel 0.5
LAD (%) 29.6 46.1 22.4
LCX (%) 25.9 19.7 27.6
RCA (%) 44.4 34.2 50.0
Bifurcation stenting (%) 7.4 13.2 13.8 0.7
Mean length of occlusion (mm) 13.0±7.2 10.3±5.9 11.2±6.6 0.2
Mean number of stents in the target vessel 1.8±0.8 2.2±1.2 2.6±1.3 0.03
Mean nominal diameter of stent in the main vessel (mm) 3.0±0.6 2.8±0.3 2.8±0.4 < 0.001
Mean total lengths of stent in the main vessel (mm) 41.5±23.3 48.8±27.4 58.0±32.8 0.04
Post-procedure QCA data
Reference vessel diameter (mm) 2.34±0.43 2.35±0.51 2.60±0.49 0.008
Minimal lumen diameter (mm) 2.12±0.51 2.04±0.43 2.26±0.42 0.02
Diameter stenosis (%) 11.6 12.9 14.1 0.6
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery
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All events in the bare stent group related to the need for target ves-
sel revascularization. At one year, the survival-free of target vessel
revascularization was significantly higher in the SES and PES
groups compared with the BMS group (97.4% and 96.4% versus
80.8% respectively, p=0.01) Figure 1.
Discussion
In the present report we have demonstrated the efficacy of drug-
eluting stent implantation for the percutaneous treatment of chron-
ic total occlusions when compared to bare metal stents. In addition,
we have shown that both the sirolimus- and paclitaxel-eluting stent
are associated with a low rate of target vessel revascularization at
6 months.
There have been several randomized trials that have demonstrated
the efficacy of stent implantation over balloon-only angioplasty for
the percutaneous treatment of CTOs, reducing the 6-month
restenosis rate from 68-74% to 32-55%13-17. Initial randomized
studies of drug-eluting stent implantation, demonstrated efficacy in
reducing restenosis compared to conventional stent implantation,
but excluded patients with CTOs8-11. However, recent preliminary
data from our own group have shown that the efficacy of the SES is
applicable in the treatment of CTOs (defined as >1 months’ dura-
tion), with a one year cumulative survival-free of major adverse car-
diac events of 96.4%12. In the present study, we evaluate a larger
series of consecutive patients treated for a truly chronic total occlu-
sion (>3 months in duration) with drug-eluting stent implantation.
We have shown that both the SES and PES significantly reduce the
need for TVR, with a cumulative survival-free of TVR of 80.8% in the
BMS group versus 97.4% and 96.4% in the SES and PES groups
respectively (p=0.01) Figure 1. 
Importantly, there were no significant differences in baseline demo-
graphics between the groups, and all procedures were carried out
in the same centre by the same operators. Restenosis following
BMS implantation is known to be inversely related to the post-pro-
cedural MLD and the number of stents utilized18. In the current
study, the mean nominal diameter of stent used was significantly
greater in the BMS cohort, related to a maximum available SES and
PES diameter of 3.0mm and 3.5mm respectively. In addition,
despite utilizing a greater number of stents, both the SES and PES
demonstrated efficacy over the BMS. Furthermore, the beneficial
effect of the SES occurred despite a smaller post-procedural MLD. 
All major adverse cardiac events in the BMS group related to the
need for TVR, including 1 patient who required coronary artery
bypass surgery. Within the drug-eluting stent groups there were
5 additional non-TVR events. One patient had a subacute thrombo-
sis, but this might have been avoidable with evidence from IVUS
demonstrating a possible underlying mechanism of inadequate
stent expansion. In addition, there is good evidence in a further 3 of
these cases that the event was unrelated to treatment of the occlud-
ed vessel. One patient died of non-cardiac causes, and 2 of the
myocardial infarctions were thought to be related to intervention
carried out in another (non-occluded) vessel. The fifth patient pre-
sented with an AMI in the territory of the target vessel, 4 months
after control angiography demonstrated patent stents. Clopidogrel
medication had been stopped at the time of the follow-up
angiogram, such that the patient was on aspirin therapy alone. The
duration of dual anti-platelet therapy needed to reduce / abolish the
risk of late stent thrombosis in patients treated with DES, particular-
ly for complex disease, is still unclear. Recently, Ong et al. reported
on late (>30 days) stent thrombosis following DES implantation in a
consecutive cohort of >2000 patients, they found a low incidence of
0.35% (95% confidence limits 0.17% to 0.72%)19. Importantly,
there were no episodes in patients continuing on dual anti-platelet
therapy. However, whether there is a true benefit in continuing
clopidogrel in addition to aspirin, over and above the possible dis-
advantages, requires further large scale evaluation.
In patients with significant coronary artery disease, although a CTO
is found in at least one third, the majority are treated with either
medical therapy or are referred for coronary artery bypass surgery,
with percutaneous treatment of CTOs accounting for only 10-15%
PCI procedures20. The major limitation of PCI for CTOs is the inabil-
ity to cross the lesion with a wire, however great advancements have
been made in the manufacture of specialized wires, and there are
additionally, promising novel technologies such as the Intraluminal™
wire and Frontrunner catheter21-23. The current report has demon-
strated the efficacy of drug-eluting stent implantation in CTOs and,
together with improvements in recanalization rates, a strategy of
percutaneous therapy of CTOs will become more widely applicable.
Study limitations
The study was not randomized, and angiographic follow-up data
was not routinely obtained in all patients, so additional events such
as silent re-occlusion cannot be excluded. However, clinical follow-
up was obtained in >99% patients (all but one patient), and assess-
ment of symptomatic status in those that did not require re-inter-
vention, showed that all were symptomatically well at follow-up. The
study was not randomized, and used a retrospective comparative
population; however the same operators and interventional tech-
niques were utilised.
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Short- and Long-Term Clinical Outcome After Drug-Eluting
Stent Implantation for the Percutaneous Treatment of Left
Main Coronary Artery Disease
Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At
Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH)
Marco Valgimigli, MD; Carlos A.G. van Mieghem, MD; Andrew T.L. Ong, MBBS, FRACP;
Jiro Aoki, MD; Gaston A. Rodriguez Granillo, MD; Eugene P. McFadden, MD, FRCPI;
Arie Pieter Kappetein, MD, PhD; Pim J. de Feyter, MD, PhD; Pieter C. Smits, MD, PhD;
Evelyn Regar, MD, PhD; Willem J. Van der Giessen, MD, PhD; George Sianos, MD, PhD;
Peter de Jaegere, MD, PhD; Ron T. Van Domburg, PhD; Patrick W. Serruys, MD, PhD
Background—The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular
events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown.
Methods and Results—From April 2001 to December 2003, 181 patients underwent percutaneous coronary intervention
for LM stenosis at our institution. The first cohort consisted of 86 patients (19 protected LM) treated with bare metal
stents (pre-DES group); the second cohort comprised 95 patients (15 protected LM) treated exclusively with DES. The
2 cohorts were well balanced for all baseline characteristics. At a median follow-up of 503 days (range, 331 to 873 days),
the cumulative incidence of major adverse cardiovascular events was lower in the DES cohort than in patients in the
pre-DES group (24% versus 45%, respectively; hazard ratio [HR], 0.52 [95% CI, 0.31 to 0.88]; P0.01). Total mortality
did not differ between cohorts; however, there were significantly lower rates of both myocardial infarction (4% versus
12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P0.006) and target vessel revascularization (6% versus 23%,
respectively; HR, 0.26 [95% CI, 0.10 to 0.65]; P0.004) in the DES group. On multivariate analysis, use of DES,
Parsonnet classification, troponin elevation at entry, distal LM location, and reference vessel diameter were independent
predictors of major adverse cardiovascular events.
Conclusions—When percutaneous coronary intervention is undertaken at LM lesions, routine DES implantation, which
reduces the cumulative incidence of myocardial infarction and the need for target vessel revascularization compared
with bare metal stents, should currently be the preferred strategy. (Circulation. 2005;111:1383-1389.)
Key Words: stents  angioplasty  arteries
Despite the recognition that coronary revascularization,in selected patients with multivessel disease, can
presently be accomplished by either a surgical or a
percutaneous approach with no significant difference in
long-term mortality,1,2 coronary artery bypass grafting
(CABG) is still considered the treatment of choice in
patients with left main (LM) disease.3 Several trials have
reported on the safety and feasibility of stent implantation
to treat LM stenosis.4,5 However, particularly in this subset
of patients, restenosis remains a major, and potentially
fatal, complication, precluding more widespread use of
percutaneous coronary intervention (PCI).4,6 In the first
observational report of patients treated with a sirolimus-
eluting stent (SES) for LM disease, a low rate of binary
restenosis and a favorable clinical outcome were reported.7
However, the benefit of drug-eluting stents (DES) on the
short- and long-term incidence of major adverse cardio-
vascular events in this setting, compared with bare metal
stents (BMS), remains largely unknown.
The purpose of the present study was to investigate, in this
subset of patients undergoing revascularization in a tertiary
referral center, the differential impact of DES as opposed to
conventional BMS on the occurrence of short- and long-term
major cardiovascular events.
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Methods
Study Design and Patient Population
Since April 16, 2002, SES (Cypher, Johnson & Johnson, Cordis unit)
have been used as a default strategy for every PCI at our institution
as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry. From the first quarter of
2003, paclitaxel-eluting stents (PES) (Taxus, Boston Scientific
Corporation) became commercially available, replacing SES as the
strategy of choice in every PCI because of cost-effectiveness
considerations, as part of the Taxus Stent Evaluated At Rotterdam
Cardiology Hospital (T-SEARCH) registry. As a policy, all elective
patients presenting with significant (50% by visual estimation) LM
disease, referred to our institution for coronary revascularization, are
evaluated by both interventional cardiologists and cardiac surgeons,
and the decision to opt for PCI or surgery is reached by consensus on
the basis of a comprehensive evaluation of the following items:
suitable anatomy and lesion characteristics for stenting and size and
quality of vessels distal to the disease and of arterial and/or venous
conduits for grafting. Finally, patient and/or referring physician
preferences for a percutaneous approach, with both aware of the
procedural risks and contraindications to surgery on the basis of the
presence of comorbidity as evaluated by a cardiac surgeon, are also
considered.
From April 16, 2002, to December 31, 2003, a total of 95
consecutive patients were treated exclusively with 1 DES in the
LM as part of an elective or nonelective revascularization procedure
and constitute the DES group of the present report. Fifty-two patients
in the first cohort (of whom procedural details and medium-term
follow-up were previously reported for 317), received SES exclu-
sively (available, at that time, in diameters from 2.25 to 3.00 mm),
whereas in the following group of 43 patients, PES (available in
diameters from 2.25 to 3.5 mm) were implanted. A control group for
comparison was composed of 86 consecutive patients who received
conventional BMS (available in diameters from 2.5 to 5.00 mm) for
LM treatment in the period immediately before the introduction of
SES. The following BMS were used: BX Sonic or BX Velocity in
35% (Cordis, Johnson & Johnson Company), R-Stent in 29% (Orbus
Medical Technologies), Multi-Link Penta in 28% (Guidant Corp),
Multi-Link Tetra in 8% (Guidant Corp), and other stents in 4%.
Therefore, the total study population comprised all 181 consecutive
patients who underwent percutaneous LM treatment from April 2001
to December 2003 with either BMS or DES in the 2 study phases,
respectively. To stratify the study population into high– and low–
surgical risk groups, the Parsonnet surgical risk score was calculated
for each patient.8 A score 15 was used to identify patients at high
risk, as previously suggested.6,9 Protected LM segment was defined
as the presence of at least 1 patent arterial or venous conduit to at
least 1 left coronary segment. Nonelective treatment was defined as
a procedure performed on referral before the beginning of the next
working day.10
This protocol was approved by the hospital ethics committee and
is in accordance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
Procedures and Postintervention Medications
All interventions were performed according to current standard
guidelines, and the final interventional strategy, including the use of
glycoprotein IIb/IIIa inhibitors, was left entirely to the discretion of
the operator, except for the stent utilization. Angiographic success
was defined as residual stenosis 30% by visual analysis in the
presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow
grade. All patients were advised to maintain the use of aspirin
lifelong. One-month clopidogrel treatment (75 mg/d) was recom-
mended for patients treated in the pre-DES phase. For patients
treated with either SES or PES, clopidogrel was prescribed for 6
months.
End Point Definitions and Clinical Follow-Up
The primary outcome was the occurrence of major adverse cardiac
events, defined as (1) death, (2) nonfatal myocardial infarction (MI),
or (3) target vessel revascularization. Patients with 1 event have
been assigned the highest ranked event, according to the previous
list. All deaths were considered to be of cardiac origin unless a
noncardiac origin was established clinically or at autopsy. MI was
diagnosed by a rise in the creatine kinase level to more than twice the
upper normal limit with an increased creatine kinase-MB fraction.
Target vessel revascularization was defined as a repeated interven-
tion (surgical or percutaneous) to treat a luminal stenosis within the
stent or in the 5-mm distal or proximal segments adjacent to the
stent, including the ostium of the left anterior descending artery
(LAD) and/or circumflex artery. Information about in-hospital out-
comes was obtained from an electronic clinical database for patients
maintained at our institution and by review of hospital records for
those discharged to referring hospitals (patients were referred from a
total of 14 local hospitals). Postdischarge survival status was
obtained from the Municipal Civil Registries. Information on occur-
rence of MI or repeated interventions at follow-up was collected by
consulting our institutional electronic database and by contacting
referring physicians and institutions and all living patients.
Statistical Analysis
Continuous variables are shown as meanSD and were compared by
Student unpaired t test. Categorical variables are presented as counts
and percentages and were compared with the Fisher exact test.
Survival curves were generated by the Kaplan-Meier method, and
survival among groups was compared with the log-rank test. Cox
proportional hazards models were used to assess risk reduction of
adverse events. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were censored.
Univariate analysis was performed with the consideration of all
variables reported in Tables 1 and 2. Multivariate analyses, with
consideration of all variables with a value of P0.10, were per-
formed to identify independent predictors of adverse events. Proba-
bility was significant at a level of 0.05. All statistical tests were
2-tailed. Statistical analysis was performed with the use of Statistica
6.1 (Statsoft Inc).
Results
Baseline and Procedural Characteristics
Baseline and procedural characteristics are shown in Table 1
and Table 2. The 2 groups were well matched for all baseline
characteristics, including comorbidities. Overall, the average
left ventricular ejection fraction was slightly 40%, and
approximately half of the patients in both groups were
admitted with acute coronary syndromes. Acute MI was the
indication to the procedure in 19%; 10% of the patients
presented with severe hemodynamic compromise at entry.
The distal LM was involved in two thirds of cases in both
groups, whereas patients treated with DES had significantly
more 3-vessel disease, more bifurcation stenting, a higher
number of stents, and greater total stent length per patients.
The nominal stent diameter, as a result of limited size
availability, was on average smaller in the DES group, which
explains the more common practice of postdilatation in this
group of patients. Procedural success was 99% in patients
receiving DES: in 1 patient who presented with acute MI and
shock, a final TIMI 1 flow grade was obtained, and the patient
died 3 hours after the procedure. The procedural success was
98% in patients treated in the pre-DES phase: in 2 patients
with acute MI and TIMI 0 flow grade in the left coronary
artery, the LM and proximal LAD were stented, and subse-
quently CABG was performed because of residual critical
stenosis in the left circumflex artery.
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Thirty-Day Outcomes
There were no significant differences between the DES and
the pre-DES groups in the incidence of major adverse
cardiovascular events during the first 30 days (Table 3). In the
DES group, all deaths except 3 occurred in patients pres-
enting with ST-segment elevation acute MI and cardiogenic
shock at entry. In all these patients except 4 with severe
peripheral artery disease, an intra-aortic balloon was placed
during PCI. In the elective population, a total of 2 deaths
occurred; both patients presented with unstable angina with
mild troponin elevation and were refused by surgeons be-
cause of old age (84 years), low left ventricular ejection
fraction (30%), and diabetic chronic renal insufficiency in 1
patient and diffuse 3-vessel disease associated with small-
caliber vessels in the second. In this second patient the right
coronary artery was occluded. The reason for death was
pulmonary infection, which developed 19 days after the
procedure in the first patient, and cardiogenic shock, which
developed during the intervention, resistant to hemodynamic
support (left ventricular assist device) in the other patient. In
the pre-DES group, all 6 deaths occurred in patients with
ST-segment elevation acute MI, of whom 4 were in cardio-
genic shock at entry. No documented thrombotic stent occlu-
sion occurred in the first 30 days or thereafter.
Long-Term Outcome
After a median follow-up of 503 days (range, 331 to 873
days), the cumulative incidence of major adverse cardiovas-
cular events (death, MI, or target vessel revascularization)
was significantly lower in the DES patients than in the
pre-DES patients (24% versus 45%, respectively; hazard ratio
TABLE 1. Baseline Characteristics of the Study Population
Variables
Pre-DES Group
(n86)
DES Group
(n95) P
Age, y * 6610 6412 0.18
Men, %* 62 66 0.53
Body mass index, kg/m2* 264 274 0.31
Diabetes, %* 22 30 0.23
Non–insulin-dependent, % 17 20 0.71
Insulin-dependent, % 5 10 0.17
Hypertension, %* 57 53 0.65
Hypercholesterolemia, % 55 56 0.88
Current smoking, % 19 18 0.8
Creatinine, mol/L* 10280 9531 0.36
LVEF, %* 4213 4114 0.85
Medical history, %
Protected LM 22 16 0.17
PCI 35 28 0.42
MI 41 38 0.58
Transient ischemic attack/stroke 8 11 0.81
Heart failure* 16 20 0.36
Severe COPD*† 5 8 0.38
Peripheral arterial disease* 24 22 0.86
Carotid artery disease* 6 6 0.98
Clinical presentation, %
Stable angina 50 48 0.8
Unstable angina 33 33 1
Acute MI* 17 20 0.70
Cardiogenic shock at entry* 9 12 0.66
Parsonnet score 1611 1912 0.17
LVEF indicates left ventricular ejection fraction; COPD, chronic obstructive
pulmonary disease.
*Parameters included in the Parsonnet classification.
†Resulting in functional disability or hospitalization, requiring chronic
bronchodilator therapy, or forced expiratory volume in 1 second 75% of
predicted.8
TABLE 2. Angiographic and Procedural Characteristics of the
Study Population
Variables
Pre-DES
Group
(n86)
DES Group
(n95) P
Lesion location, %
Ostium 18 27 0.20
Body 40 37 0.31
Distal 66 65 0.9
Pure LM disease, % 2 3 1
LM plus 1-vessel disease, % 29 17 0.4
LM plus 2-vessel disease, % 42 21 0.001
LM plus 3-vessel disease, % 27 59 0.003
Right coronary artery 70%
stenosis, %
27 53 0.02
Right coronary artery occlusion, % 13 19 0.43
No. of implanted stents 1.20.5 1.40.6 0.01
Nominal stent diameter, mm 3.60.5 3.10.32 0.001
Total stent length per patient, mm 209 2413 0.02
Predilatation, % 67 71 0.62
Cutting balloon, % 5 6 0.94
Rotational atherectomy, % 1 3 0.8
Directional atherectomy, % 6 0 0.007
Postdilatation, % 58 80 0.01
Larger balloon inflated, mm 40.6 3.90.4 0.07
Maximal pressure, atm 172 173 0.85
Bifurcation stenting, % 10 26 0.02
Culotte* 11 36 0.4
T technique* 88 44 0.35
Crush* 0 12 0.56
Kissing technique* 0 8 0.91
Intravascular ultrasonography, % 23 27 0.36
Glycoprotein IIb/IIIa inhibitors, % 26 28 0.83
Intra-aortic balloon pump, % 16 15 0.88
Left ventricular assist device, % 0 2 0.52
Minimal lumen diameter, mm,
preintervention
1.050.59 1.090.44 0.58
Minimal lumen diameter, mm,
postintervention
2.970.6 2.830.49 0.09
Reference vessel diameter, mm,
postintervention
3.370.6 3.250.5 0.2
*Relative to patients with bifurcation stenting.
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[HR], 0.52 [95% CI, 0.31 to 0.88]; P0.01) (Figure, A).
Mortality was similar in the DES (14%) and pre-DES cohort
(16%; HR, 0.79 [95% CI, 0.38 to 1.66]; P0.54) (Figure, B),
whereas there was a significant reduction in both the rate of
MI (4% versus 12%, respectively; HR, 0.22 [95% CI, 0.07 to
0.65]; P0.006) and composite death/MI (Figure, C) as well
as in the need for target vessel revascularization (6% versus
23%, respectively; HR, 0.26 [95% CI, 0.10 to 0.65];
P0.004) (Figure, D) in the DES group. Seventy-four per-
cent of the deaths were cardiac, whereas 3 of 13 in the DES
group and 4 of 14 in the pre-DES phase were attributed to
extracardiac reasons. In Table 4, the baseline and procedural
characteristics of those patients in the DES group who
underwent target vessel revascularization during follow-up
are reported. In all cases, the lesion was located in the distal
LM, in 50% of cases diabetes was present, and all except 1
were women. In 3 cases, in-stent restenosis occurred; in 2
patients intimal hyperplasia developed at the distal edge of
the stent, whereas in 1 patient severe ostial side branch
restenosis (circumflex artery) necessitated reintervention. In
all cases, restenosis was focal (10 mm in length) and was
successfully treated with repeated PCI. In the pre-DES group,
13 cases of pure in-stent restenosis, of which 3 were focal,
were treated with PCI (9 patients) or CABG (4 patients). In 2
patients, diffuse intimal hyperplasia associated with progres-
sion of atherosclerotic disease in other vessels was treated
with CABG, and in 5 patients (3 with ST-segment elevation
acute MI as the indication for LM intervention), staged
reintervention with CABG (in 4 patients) and PCI (in 1
patient) was performed because revascularization remained
incomplete at the time of the index procedure.
One-year adverse events in patients treated with BMS before the introduction of DES (pre-DES group) and in patients treated exclusively with
DES implantation (DES group). Cumulative risk of major adverse cardiovascular events (MACE) (A), death (B), death or MI (C), and target ves-
sel revascularization (TVR) (D) is shown.
TABLE 3. Thirty-Day Outcomes
Variables
Pre-DES Group
(n86)
DES Group
(n95) P*
Death, n (%) 6 (7) 10 (11) 0.60
Nonfatal MI, n (%) 8 (9) 4 (4) 0.24
Death or nonfatal MI, n (%) 14 (16) 14 (15) 0.84
Target vessel revascularization, n (%) 2 (2) 0 (0) 0.22
Repeated PCI 1 (1) 0 (0)
CABG 1 (1) 0 (0)
Any event, n (%) 16 (19) 14 (15) 0.56
Stent thrombosis, n (%)† 0 (0) 0 (0) 1
*By Fisher exact test.
†Angiographically documented.
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Predictors of Adverse Events
The Parsonnet score, ranging from 2.5 to 55.5 (mean value,
182; interquartile range, 16.5) was 1611 and 1912 in
the pre-DES and DES groups, respectively (P0.17) (Table
1), with a trend toward a higher rate of patients considered at
high surgical risk (58% versus 46%, respectively; P0.13) in
the DES compared with the pre-DES cohort.
On univariate analysis, Parsonnet classification, use of
intra-aortic balloon pump, presence of shock at entry,
lesion located in the distal LM, nonelective PCI, troponin
elevation at entry, TIMI flow grade before and after PCI,
reference vessel diameter, left ventricular ejection fraction,
and the use of DES were identified as significant predic-
tors of adverse events. On multivariate analysis, Parsonnet
classification, troponin elevation at entry, lesions located
at distal site, reference vessel diameter, and the use of DES
were independent predictors of major adverse cardiovas-
cular events (Table 5).
Discussion
Despite the feasibility and the high procedural success rate of
percutaneous LM intervention, the long-term incidence of
adverse events in the pre-DES “era” was often reported to be
unacceptably high in this subset of patients.4,6 This reflected
the inclusion of high-risk patients, such as those not consid-
ered “good surgical candidates,” as well as the dramatic
impact of treated vessel failure in this specific anatomic
context. In consecutive patients receiving elective BMS for
unprotected LM treatment, the 3-year cumulative incidence
of death was recently reported to be 16%.6 In that series,
28% of the population was at high surgical risk. More than
50% of our study population was at high surgical risk
according to the Parsonnet classification, thus explaining the
relatively high rate of adverse events we observed. In this
setting, when patients treated with DES were compared with
those treated with BMS, a marked benefit with respect to the
rate of major adverse cardiac events, as evidenced by a 47%
relative risk reduction, emerged in the former. This was
mainly due to the difference in the incidence of MI (67%
relative risk reduction) and target vessel revascularization
(65% relative risk reduction), with no effect on mortality. The
higher prevalence of 3-vessel disease and bifurcation stenting
in the DES group makes the observed benefit even more
convincing. The difference in the incidence of events between
TABLE 4. Characteristics of Patients in the DES Group Who Underwent Target
Vessel Revascularization During Follow-Up
Patient No.
1 2 3 4 5 6
Age, y 66 77 36 70 52 56
Gender F F F M F F
Diabetes Yes No No Yes No Yes
Lesion location Distal Distal Distal Distal Distal Distal
Severe calcification Yes No No No No No
Stent type SES SES PES PES PES PES
Stent No. 2 2 1 2 1 2
Total stent length, mm 16 36 20 48 16 36
Bifurcation stenting No Yes No Yes No Yes
Technique    Crush    Culotte    Culotte
Postdilatation Yes Yes Yes Yes Yes Yes
Final kissing No No No Yes No No
Gap between stents No No No No No No
Stent underexpansion Yes No No No No No
Restenosis location In-stent In-stent* RS In-stent DER DER*
Revascularization type PCI PCI PCI PCI PCI PCI
QCA after PCI
Reference vessel diameter, mm 3.74 3.27 3.53 2.65 2.44 2.76
Minimal lumen diameter, mm 2.12 1.06 3.34 2.49 1.94 2.32
Lesion length, mm 13.4 19.7 13.5 21.3 8.9 18.9
QCA at follow-up
Reference vessel diameter, mm 3.87 3.43 3.21 2.32 1.82 2.36
Minimal lumen diameter, mm 1.23 0.57 0.98 0.99 0.6 0.71
Restenosis length, mm 5.8 9.06 3.6 5.48 7.72 9.5
QCA indicates quantitative coronary angiography; In-stent, restenosis located within the stent
margins; RS, restenosis located in the side branch (the ostium of the circumflex artery); and DER,
distal edge restenosis located within the 5-mm segment distal to the stent.
*More than 1 focal site.
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the 2 groups emerged slowly after the procedure, with no
clear advantage at 30 days, possibly reflecting the specific
mechanism of action of DES on intimal hyperplasia.
The overall advantage of DES remained significant after
adjustment for the Parsonnet score, the anatomic site of
obstruction, and troponin status at entry. Therefore, our data
suggest that when percutaneous treatment of LM coronary
artery disease is undertaken, DES should be used as the
default strategy.
The LM bifurcation was frequently involved (60%) in
our series, and even when the obstruction was more proxi-
mally located and did not directly involve the LAD or left
circumflex artery ostia, its treatment often required the
management of LM bifurcation. To date, the results of SES
implantation to treat bifurcated lesions have been relatively
disappointing, with high rates of restenosis in the side
branch.11 Our present findings are in keeping with these
previous observations, confirming that in the DES era distal
LM location is an independent predictor of adverse events at
follow-up. Furthermore, because the strategy and technical
aspects of bifurcation management were left entirely to the
preference of treating physicians, no clear conclusions can be
drawn in this regard.
Inconsistent findings have been reported thus far with
regard to the effect of DES on long-term cumulative
incidence of MI. In the first randomized clinical trials
comparing SES or PES with BMS, no difference in the
incidence of MI was observed.12,13 Second-generation
randomized trials assessing the benefit of DES in patients
selected to be at intermediate risk for in-stent restenosis or
all-inclusive registries reported trends toward MI reduction
in the DES group, but none of them reached statistical
significance.14,15 Recently, a clear reduction in the cumu-
lative incidence of MI in the DES group was reported in
the SES-SMART trial, in which a selected group of
high-risk patients has been evaluated.16 Similarly, in our
patient population, a reduced incidence of MI was ob-
served in the DES group. Of note, 2 and 1 cases of MI in
the pre-DES phase were related to target vessel revascu-
larization and not related to target vessel revascularization,
respectively. Whether this difference between studies is
the reflection of a type II error in studies enrolling patients
at low or intermediate risk remains unclear, but when the
retrospective nature of our investigation is considered, data
from prospective studies are needed to confirm our
findings.
Limitations of the Study
The present study is a single-center experience from a tertiary
referral center and lacks the clear advantages of a multicenter
randomized study. In keeping with the aim of our investiga-
tion, an “all-comers” population has been enrolled, clearly
resulting in a heterogeneous group of patients. Further stud-
ies, with larger sample sizes, are required to investigate the
differential impact of DES versus BMS in prespecified
subgroups, stratified according to clinical presentation (stable
versus unstable) or protected versus unprotected type of
treatment.
Despite the fact that the study was conducted over a relatively
short period, we cannot exclude the possibility that improve-
ments in technique or differences in drug prescription could have
partially accounted for the difference observed in terms of major
adverse cardiovascular events between groups. However, con-
ducting randomized trials that seek to assess the efficacy of DES
versus BMS in this specific subset of patients seems unlikely,
and our understanding of the benefit of drug-coated stents to
treat this group of patients will probably also rely in the near
future on well-conducted registries that are able to record and
monitor our daily clinical practice.
Conclusions
The use of DES as a default strategy to treat LM disease was
associated with a significant reduction in adverse events. The
effectiveness of DES persisted even after adjustment for
clinical and procedural variables, including the Parsonnet
TABLE 5. Univariate and Multivariate Cox Proportional
Hazards Analysis
Variables P
Hazard Ratio
(95% CI) 2
Univariate analysis
Distal LM disease 0.003 2.7 (4.8–1.53) 13.3
DES use 0.019 0.54 (0.9–0.32) 5.48
Nonelective PCI 0.0047 2.1 (3.5–1.3) 8
Intra-aortic balloon pump
use
0.0002 2.9 (4.9–1.7) 14
LVEF, % 0.00001 0.95 (0.97–0.93) 20
Parsonnet score 0.00001 1.07 (1.09–1.05) 44
Reference vessel diameter 0.00001 0.36 (0.58–0.32) 19
Shock at entry 0.00001 4.48 (7.9–2.5) 21
TIMI flow before PCI 0.03 0.75 (0.96–0.58) 4.3
TIMI flow after PCI 0.03 0.58 (0.85–0.39) 4.7
Troponin T 0.02 g/L
at entry
0.0002 3.15 (5.26–1.9) 18
Multivariate analysis 1
Distal LM disease 0.0007 2.94 (5.5–1.57) 76
DES use 0.00009 0.33 (0.57–0.19)
LVEF, % 0.09 0.98 (1.001–0.95)
Parsonnet score 0.0009 1.04 (1.07–1.01)
Reference vessel diameter 0.005 0.51 (0.79–0.33)
Troponin T 0.02 g/L at
entry
0.02 2.3 (4.4–1.2)
Multivariate analysis 2
Distal LM disease 0.00017 3.3 (6.1–1.7) 68
DES use 0.00018 0.35 (0.6–0.20)
LVEF, % 0.00013 0.95 (0.98–0.94)
Reference vessel diameter 0.0011 0.48 (0.74–0.30)
Shock at entry 0.006 3.49 (8.6–1.4)
Troponin T 0.02 g/L at
entry
0.016 2.27 (4.2–1.17)
Multivariate analysis model 1 was performed with all major adverse
cardiovascular event predictors on univariate analysis; in multivariate analysis
model 2, the Parsonnet score was removed because of colinearity between the
variables included in the model and those used in the calculation of the score,
such as left ventricular ejection fraction (LVEF), use of intra-aortic balloon
pump, and presence of shock.
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surgical risk score. Our findings apply to a selected group of
patients referred for percutaneous LM treatment and suggest
that in this setting routine DES implantation, by reducing the
cumulative incidence of major adverse cardiovascular events,
should be currently regarded as the strategy of choice. Until
new evidence is provided by randomized clinical trials
directly comparing the surgical and percutaneous approaches,
CABG should remain the preferred revascularization treat-
ment in good surgical candidates presenting with LM coro-
nary artery disease.
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Treatment of de novo bifurcation lesions: 
comparison of Sirolimus- and Paclitaxel-eluting stents 
Abstract
Objective: Both the sirolimus-(SES) and paclitaxel-eluting (PES) stents have been shown to reduce resteno-
sis rates when used in relatively simple lesions. This study aimed to evaluate the results of a consecutive
series of patients treated with drug-eluting stent implantation for de novo bifurcation lesions, and compared
outcomes with respect to stenting strategy and stent type.
Patients: From April 2002 to September 2003, all patients at our institution were treated with drug-eluting
stent implantation. A consecutive series of 144 patients were treated for 167 de novo bifurcation lesions
with SES, followed by 104 patients treated with PES for 113 lesions. 
Results: Clinical follow-up at 6 months was obtained in 99% patients with survival-free of major adverse
cardiac events (MACE) of 93.7% for SES versus 85.8% for PES, p=0.05. By multivariate analysis, factors
predictive for MACE were age, diabetes mellitus, previous CABG, multivessel disease, treatment for acute
myocardial infarction, and treatment with PES. Survival-free of target lesion revascularization (TLR) was
95.7% for SES versus 86.8% for PES, p=0.01, with stent type being the only independent predictor.
Technique of stenting was not a predictor of either MACE or TLR. 
Conclusions: MACE rates for both the SES and PES are low compared with historical data of bare metal
stents. The most effective techniques for bifurcation stenting remain undefined. Our data suggests a high-
er need for TLR for the PES compared with the SES, however further randomized studies are needed to
fully evaluate both stenting strategy, and any difference between the stents.
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Introduction
The outcome of percutaneous therapy (PCI) of bifurcation lesions
with bare metal stents is hindered by an increased rate of procedural
complications1, and a high rate of restenosis particularly when both
the main vessel and side branch are stented2,3,4,5,6. The advent of
drug-eluting stents is revolutionising the practice of interventional
cardiology by demonstrating a reduction in the subsequent rate of
restenosis. There is evidence of efficacy in randomized trials for
both the sirolimus- (SES) and paclitaxel-eluting (PES) stents for the
treatment of relatively simple lesions7,8. In addition, the sirolimus-
eluting stent for the treatment of bifurcation lesions has demonstrat-
ed a low rate of adverse cardiac events compared with historical
data utilizing bare metal stents9,10. However, the most effective tech-
nique of stenting for bifurcation lesions with drug-eluting stents is
currently unknown. In the present report we evaluate the rate of
major adverse cardiac events following PCI for bifurcation lesions
treated with either SESs or PESs in a consecutive series of patients.
In addition, outcomes were assessed with respect to the baseline
bifurcation anatomy and type of stenting strategy employed. 
Methods
Bifurcation classification: All lesions were classified on baseline
angiography according to the Duke classification (figure 1). 
Procedure: The sirolimus-eluting stent (Cypher™, Johnson &
Johnson - Cordis unit) received CE mark approval in April 2002.
Since that time, all patients undergoing percutaneous therapy in our
institution have been treated with drug-eluting stent implantation as
the default strategy. During the first quarter of 2003, our strategy
switched from the sirolimus- to the paclitaxel-eluting stent (Boston
Scientific) enabling a comparison of the two stent types. All consec-
utive patients were enrolled irrespective of clinical presentation and
lesion characteristics, and the incidence of major adverse cardiac
events (MACE) was prospectively evaluated during the follow-up. 
All procedures were performed with standard interventional tech-
niques. The strategy of bifurcation stenting employed, and the use
of kissing balloon dilatation post-procedure were at the operators’
discretion. One of 6 methods of stenting was used: stenting of the
main vessel with balloon-only angioplasty of the side branch; type A
T-stenting (stenting first of the side branch, followed by stenting of
the main vessel); type B T-stenting (stenting of the main vessel fol-
lowed by stenting of the side branch because of a sub-optimal
result)2; the ‘crush’ technique11; culotte stenting12; or kissing stents
(simultaneous implantation in the main vessel and side branch with
the proximal edges of the stents side by side). SESs were available
in diameters from 2.25 mm to 3.00 mm and lengths from 8 mm to
33 mm. PESs were available in diameters from 2.25 mm to 3.5 mm
and lengths from 8mm to 32mm. During the procedure, intra-
venous heparin was given to maintain an activated clotting time
≥250 seconds. Patients were preloaded with 300 mg clopidogrel,
and received life-long aspirin together with 75 mg clopidogrel per
day for 6-months. The use of glycoprotein IIb/IIIa inhibitors was at
the discretion of the operator. The protocol was approved by the
Institutional ethics committee and is in accordance with the princi-
ples of Good Clinical Practice for Trials of Medicinal Products in the
F I G U R E 1 .
Fig. 1: The Duke classification of bifurcation lesions.
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European Community and the Declaration of Helsinki. All patients
signed a written informed consent
Follow-up: Clinical follow-up was obtained using telephone calls and
questionnaires, and evaluated the rate of major adverse cardiac
events (MACE) which were pre-defined as death, acute myocardial
infarction (AMI), or target vessel revascularization (TVR). The diag-
nosis of AMI required an elevation of creatine kinase levels to twice
the upper limit of normal, together with a rise in creatine kinase-MB
fraction. Target lesion revascularization was defined as either surgi-
cal or percutaneous reintervention driven by significant (>50%)
luminal diameter narrowing either within the stent or the 5mm bor-
ders proximal and distal to the stent, and was undertaken in the
presence of either anginal symptoms or objective evidence of
ischemia. Target vessel revascularization was defined as revascular-
ization within the target vessel including encompassing the target
lesion. The definition of stent thrombosis was the presence of intra-
stent thrombosis, with or without stent occlusion, documented on
angiography, and was categorized as acute if occurring within
24 hours or subacute if within 30 days after stent implantation.
Statistical analysis: Discrete variables are presented as percentages
and compared with Fisher exact test. Continuous variables are
expressed as mean ± standard deviation and compared with
Student’s t test. Cumulative survival and MACE-free survival were
calculated according to the Kaplan-Meier method. The log-rank test
was used to compare MACE-free survival between the two groups.
All tests were two-tailed, and a p value of <0.05 was considered as
significant. Logistic regression models were established to investi-
gate independent predictors of MACE (death, AMI, or TVR), and tar-
get lesion revascularization. Variables entered were age, gender,
diabetes mellitus, hypertension, hypercholesterolemia, smoking,
multivessel disease, prior AMI, prior CABG, clinical presentation,
use of a glycoprotein IIb/IIIa inhibitor, target vessel, bifurcation
anatomy, stent type, stenting technique, diameter of stent, total
length of stents, and use of kissing balloon post-dilatation. Odds
ratio with corresponding 95% confidence intervals are reported.
Results
The baseline patient and procedural characteristics for the SES and
PES cohorts are presented in tables 1 and 2 respectively. There
were no significant differences between the 2 groups with respect
to baseline patient characteristics, though there was a trend
towards an increased usage of glycoprotein IIb/IIIa inhibitors in the
PES group (38.5% versus 27.8% in the SES group, p=0.07). There
was no significant difference in the number of stents used, howev-
er, the mean nominal diameter of stent used in the main vessel was
greater with the PES (2.93 ± 0.34mm versus 2.85 ± 0.23 for the
SES, p=0.007). For those patients treated with stent implantation in
the side branch, though there was no significant difference in the
number of stents used, the total length of stented segment in the
side branch was longer for the PES-treated patients (18.8 ±
10.5mm versus 14.1 ± 7.6mm, p=0.0001). The choice of stenting
strategy during the 2 treatment periods is presented in figure 2. 
The total number of lesions treated with each stenting technique
was single stent utilization in 55 (19.6%), type A T-stenting in 
47 (16.8%), type B T-stenting in 46 (16.4%), crush stenting in 
88 (31.4%), culotte stenting in 24 (8.6%), and kissing stents in 
20 (7.1%). There was no difference with respect to the use of kiss-
ing balloon post-dilatation between the SES and PES cohorts.
Clinical follow-up was obtained in 99.2% patients. Angiographically
documented stent thrombosis occurred in 2 patients treated with
SES (1.4%) and 3 patients treated with PES (2.9%), p=0.4 (Table 3).
All episodes of stent thrombosis were subacute (within 30 days fol-
lowing stent implantation), and were treated percutaneously, all
patients survived. The cumulative incidence of major adverse car-
diac events at 6-months for the SES and PES groups are presented
in Table 4, and the survival-free of MACE at 6-months is illustrated
in figure 3. The independent predictors for MACE and TLR by mul-
tivariate analysis are shown in Table 5. The only factor found to be
predictive for TLR was stent type. Neither the baseline bifurcation
anatomy, nor the type of stenting strategy utilized, were predictive of
events. 
At 6-months, survival-free of TLR was 95.7% for SES versus 86.8%
for PES, p=0.01 (figure 4). TLR was for subacute thrombosis in
5 patients (see above), was for restenosis of the main vessel in
4 lesions treated with SES (2.4%) and 6 lesions treated with PES
(5.3%), for restenosis of the side branch in 3 lesions treated with
SES (1.8%) and 3 treated with PES (2.7%), and for restenosis of
both branches in 2 lesions treated with SES (1.2%) and 2 treated
with PES (1.8%). 
Discussion
In the present report we have demonstrated low rates of major
adverse cardiac events at 6-months for both the sirolimus- and
paclitaxel-eluting stents when used for the treatment of de novo
bifurcation lesions. Independent predictors for MACE were age, dia-
betes mellitus, multivessel disease, previous CABG, treatment in the
setting of acute myocardial infarction, and therapy with PES. Target
lesion revascularization (TLR) at 6-months was higher in the PES
group than the SES group, with a survival-free of TLR of 86.8% ver-
sus 95.7% respectively, p=0.01. By multivariate analysis, the use of
PES was the only factor predictive for TLR.
The most effective strategy for the treatment of bifurcation lesions
with drug-eluting stents is currently unknown. In the present study,
the choice of stenting strategy was at the operators’ discretion.
Previous data from our group following bifurcation stenting with the
SES, demonstrated an overall restenosis rate of 23%9. The majority
of restenoses of the side branch occurred at the ostium following 
T-stenting. Indeed, the restenosis rate in the side branch following
T-stenting was 16.7% whilst that following other stenting techniques
was 7.1%. We hypothesised that these restenoses might relate to
inadequate / incomplete coverage of the ostium of the side branch
thereby reducing the efficacy of the drug-eluting stent. This led to a
shift away from a strategy of T-stenting, towards methods which
ensure complete coverage - the crush and culotte techniques of
stenting (figure 2). One potential disadvantage of these strategies
however, is that they lead to an area of double or triple layer of stent
struts raising theoretical concerns that the increased dosage of drug
at this site might induce endothelial dysfunction and potentiate the
risk of thrombosis. Despite the change in stenting technique in the
present study, the choice of strategy was not an independent pre-
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Table 1. Baseline patient demographics 
SES PES p value
n=144 n=104
Mean age (years) 62.4 ± 10.5 60.3 ± 11.8 0.1
Male sex (%) 74.3 73.1 1
Current smoker (%) 27.1 27.9 1
Diabetes mellitus (%) 18.8 17.3 1
Hypertension (%) 43.1 46.2 0.7
Hypercholesterolemia (%) 56.9 62.5 0.3
Previous myocardial infarction (%) 35.4 38.5 0.2
Previous CABG (%) 4.9 3.8 0.9
Clinical presentation 0.4
Stable angina (%) 65.3 67.3
Unstable angina (%) 21.5 17.3
Acute ST-elevation myocardial infarction (%) 13.2 16.3
Glycoprotein IIb/IIIa inhibitor usage (%) 27.8 38.5 0.07
PCI in at least one additional major epicardial vessel 
during the index procedure (%) 40.3 39.4 1
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention.
Table 2. Baseline procedural characteristics
SES PES p value
Total number of bifurcation lesions treated 167 113
Target vessel 0.3
LAD / diagonal (%) 61.1 56.6
LCX / obtuse marginal (%) 19.2 17.7
RCA bifurcation (%) 9.6 8.0
LMS (%) 10.2 17.7
Bifurcation classification 0.4
A (%) 4.8 3.5
B (%) 7.2 5.3
C (%) 8.4 6.2
D (%) 17.5 20.4
E (%) 8.4 3.5
F (%) 44.0 50.4
Total occlusion (TIMI 0 flow) (%) 9.6 10.6
Pre-dilatation of main vessel (%) 59.3 54.0 0.4
Pre-dilatation of the side branch (%) 42.5 31.9 0.07
Pre-dilatation with kissing balloons (%) 15.0 13.3 0.9
Mean number of stents in the main vessel 1.56 ± 0.84 1.48 ± 0.67 0.4
Mean nominal diameter of stent in the main vessel (mm) 2.85 ± 0.23 2.93 ± 0.34 0.007
Mean total lengths of stent in the main vessel (mm) 30.4 ± 17.7 30.3 ± 17.8 1.0
Mean number of stents in side branch 1.11 ± 0.36 1.13 ± 0.39 0.8
Mean nominal diameter of stent in the side branch (mm) 2.53 ± 0.29 2.60 ± 0.35 0.06
Mean total lengths of stent in the side branch (mm) 14.1 ± 7.6 18.8 ± 10.5 0.0001
Nominal diameter of balloon in side branch for POBA 2.28 ± 0.44 2.19 ± 0.49 0.5
Post-dilatation with kissing balloons (%) 47.3 45.1 0.9
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery,
LMS: left main stem, POBA: plain old balloon angioplasty.
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Table 4. Cumulative incidence of major adverse cardiac events at
6-months for the Sirolimus- and Paclitaxel-eluting stents 
SES PES p value 
n=144 n=104 (log rank)
Death (%) 1.4 3.2 0.4
Death or AMI (%) 4.9 7.1 0.5
Death, AMI, or TLR (%) 6.3 13.2 0.08
Death, AMI, or TVR (%) 6.3 14.2 0.05
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, 
AMI: acute myocardial infarction, TLR: target lesion revascularization,
TVR: target vessel revascularization.
Table 5. Independent predictors of major adverse cardiac events
and target lesion revascularization at 6 months
Odds ratio 95% confidence 
intervals
MACE
Age 1.02 1.01 to 1.05
Prior CABG 2.75 1.1 to 7.2
Diabetes mellitus 2.15 1.2 to 4.0
Multivessel disease 1.36 1.0 to 1.9
Presentation with acute 
myocardial infarction 2.35 1.1 to 5.0
Therapy with Sirolimus-eluting stent 0.71 0.4 to 1.0
TLR
Therapy with Sirolimus-eluting stent 0.45 0.19 to 0.95
MACE: major adverse cardiac event; CABG: coronory artery bypass graft
surgery; TLR: target lesion revascularization
F I G U R E 4 .
Fig. 4: Kaplan-Meier curves for survival-free of target lesion revascu-
larization (TLR) for the Sirolimus-eluting (SES) and Paclitaxel-eluting
stent (PES).
F I G U R E 2 .
Fig. 2: The type of stenting strategy employed for the Sirolimus-
eluting (SES) and Paclitaxel-eluting stent (PES).
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Fig. 3: Kaplan-Meier curves for survival-free of major adverse cardiac
events (MACE) for the Sirolimus-eluting (SES) and Paclitaxel-eluting
stent (PES).
Table 3. Demographic of the 5 patients angiographically documented stent thrombosis 
Age, Stent Target Time to Diabetes Use of Clinical Stenting Kissing
sex type vessel thrombosis, mellitus GP IIb/IIIa presentation strategy balloon
days inhibitor at index post-dilatation
74yr F SES LAD 1 N N SA Crush Y
57yr M SES LAD 18 Y Y AMI Type B “T” N
66yr M PES LCx 7 N N UA Crush N
46yr F PES LAD 6 N N AMI Crush N
51yr F PES LCx 4 N Y AMI Type B “T” Y
SES: Sirolimus-eluting stent; PES: Paclitaxel-eluting stent; LAD: left anterior descending; LCx: left circumflex; SA: stable angina; AMI: acute myocar-
dial infarction; UA: unstable angina.
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dictor for either MACE or the need for TLR. The current study is lim-
ited by the lack of angiographic follow up, so cannot fully evaluate
restenosis which, particularly when occurring in the side branch,
may be clinically silent. 
Currently, there is only one published randomized evaluation of
drug-eluting stents for bifurcation lesions10. This randomized
85 patients to a single SES with balloon-angioplasty of the side
branch, versus implantation of 2 SESs. The overall rate of resteno-
sis at 6 months was 26% (19% in the single stent group versus
28% in the double stent group, p=NS). However, the study was lim-
ited by the high crossover rate with 51% of the patients in the sin-
gle stent group crossing to the double stent group because of a sub-
optimal result in the side branch. In addition, the approach to stent-
ing technique was not uniform. However, both this randomized
study, and the registry data from our group demonstrate an
improvement in the restenosis rates compared with historical data
of bare metal stenting. 
Restenosis following bare stent implantation is related to the length
of stent, and inversely related to the diameter13. The majority of
TLRs were for restenosis within the main vessel stent, yet the nom-
inal stent diameter was actually bigger for the PES. This probably
related to a larger available diameter of PES (3.5mm versus 3.0mm
for the SES), and throughout the study, post-dilatation was carried
out whenever necessary. The mean total length of stent used in the
side branch of the PES group was significantly longer than the SES
group. However, neither stent diameter nor length was an inde-
pendent predictor for subsequent MACE or need for TLR. 
Previous data of bare metal stent implantation in bifurcation
lesions, demonstrate rates of target lesion revascularization of
between 16% and 38%2,3,4,5,6. Compared with this historical data,
in the current study, TLR was certainly lower for the SES (survival-
free of TLR of 95.7% at 6 months). However, multivariate analysis
demonstrated a significantly higher need for TLR following stenting
with the PES compared with the SES, with the majority of TLRs in
the main vessel. This might reflect a difference in the efficacy of
the 2 drugs, at least at the current dosages, or relate to differences
in stent design14. The SES is a closed-design stent whereby each
cell is bound on all sides with the junction of each strut pair joined
to another strut pair junction. The PES however, is an open-cell
design meaning that some of the junction nodes are unattached
within the stent structure. A previous of 54 patients undergoing
elective stenting showed that platelet activation was lower in those
receiving a closed versus open-cell designed stent15. In the pres-
ent study, though not significantly different between the 2 groups,
subacute thrombosis did occur in a higher percentage of the PES
patients (2.9% versus 1.4%, p=0.4). The same authors15 exam-
ined stent implantation in the pig model and found that more tis-
sue prolapse occurred following implantation of a stent with an
open cell design. Both the SES and PES have been evaluated in
large randomized studies and compared with their respective bare
stents (Bx Velocity™ and Express™)16,17. Though the inclusion cri-
teria in these studies were not absolutely identical, both studies
were very similar and included patients with stable or unstable
angina and single de novo lesions; bifurcation lesions were exclud-
ed. Both the mean lesion length, and reference vessel diameter
were similar. Evaluation of the angiographic follow-up of those
treated with bare stents, showed a mean in-stent lumen loss of
1.00 ± 0.70mm in SIRIUS (Bx Velocity™), and 0.92 ± 0.58mm in
TAXUS-IV (Express™). The higher late lumen loss in the Bx
Velocity™ stent conflicts with the suggestion that the lower TLR
rate with SES in the present study might relate to the difference in
stent design. Both the SES and PES are covered by polymer coat-
ings to facilitate drug-elution. Previous evaluation of other polymers
has suggested that these can in themselves promote varying
degrees of an inflammatory response and restenosis18. In the same
randomized studies, evaluation of the drug-eluting stent cohorts
showed a mean in-stent late loss of 0.17 ± 0.45mm in SIRIUS, and
0.39 ± 0.50mm in TAXUS-IV, perhaps suggesting the SES is more
efficacious at inhibiting the development of neointimal hyperplasia
than the PES. 
Interpretation of the results of the present study with respect to stent
type is limited by the lack of randomization. The REALITY study is a
multicenter evaluation of more than 1300 patients with multivessel
disease, randomized to either SES or PES implantation. Initial results
were recently presented at the American College of Cardiology meet-
ing in 200519. There was no significant difference with respect to the
overall rates of MACE between the stent types (9.2% for SES versus
10.6% for PES, p=0.41). However, in keeping with the difference in
the degree of platelet activation related to stent design15, the rate of
stent thrombosis was higher for the PES group (1.8% versus 0.4%,
p=0.0196). Furthermore, all angiographic parameters with respect
to efficacy of suppression of neointimal growth were better following
SES implantation. The in-stent late loss was 0.09 ± 0.43mm for the
SES, versus 0.31 ± 0.44mm for the PES, p<0.001. Such a difference
may potentially be clinically relevant when treating complex lesions
such as bifurcations, particularly when vessels with a small diameter
are stented. Patients with bifurcation lesions were not excluded from
this study, and a more detailed analysis of subgroups such as those
treated for a bifurcation lesion is awaited.
The most effective strategy for percutaneous therapy of bifurcation
lesions with drug-eluting stents needs to be carefully evaluated in
future studies. Interpretation of future randomized studies should
take into account baseline anatomical differences of bifurcation
lesions as the best strategy for a true bifurcation lesion (involving
both the main vessel and side branch) may not necessarily be the
same as that for lesions affecting only one of the branches. In addi-
tion, restenosis particularly at the side branch may not always lead
to a recurrence in symptoms and follow-up angiography should be
carried out to fully evaluate the results. 
Study limitations
The major limitations of this study are that it is a single centre reg-
istry and is non-randomized, with the choice of stenting strategy left
entirely at the operators’ discretion. In addition, routine angiograph-
ic follow-up data was not obtained, and additional restenoses giving
rise to minimal / no symptoms, particularly at the ostium of the side
branch, cannot be excluded. However, clinical follow-up data was
available for >99% providing an accurate reflection of the rate of
clinically important adverse events following therapy of bifurcation
lesions in a consecutive series of patients without exclusion.
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Conclusions
The use of both the sirolimus- and paclitaxel-eluting stents for the
treatment of de novo bifurcation lesions appears feasible and safe,
both demonstrating low rates of major adverse cardiac events at 
6-months. The increased rate of target lesion revascularization fol-
lowing PES implantation needs to be further evaluated in a random-
ized fashion, and at present, the most appropriate technique for
bifurcation stenting with drug-eluting stents remains unclear.
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Thirty-Day Incidence and Six-Month Clinical
Outcome of Thrombotic Stent Occlusion After
Bare-Metal, Sirolimus, or Paclitaxel Stent Implantation
Andrew T. L. Ong, MBBS, FRACP, Angela Hoye, MBCHB, MRCP, Jiro Aoki, MD,
Carlos A. G. van Mieghem, MD, Gaston A. Rodriguez Granillo, MD, Karel Sonnenschein,
Evelyn Regar, MD, PHD, Eugene P. McFadden, MBCHB, MD, FRCPI, FACC,
Georgios Sianos, MD, PHD, Willem J. van der Giessen, MD, PHD, Peter P. T. de Jaegere, MD, PHD,
Pim de Feyter, MD, PHD, FACC, Ron T. van Domburg, PHD, Patrick W. Serruys, MD, PHD, FACC
Rotterdam, The Netherlands
OBJECTIVES We sought to determine the real-world incidence of angiographically conﬁrmed and possible
stent thrombosis (ST) in an unrestricted population during the ﬁrst 30 days after bare-metal
stent (BMS), sirolimus-eluting stent (SES), and paclitaxel-eluting stent (PES) implantation.
BACKGROUND Current data on ST in drug-eluting stents (DES) have come from randomized trials with
strict entry criteria, which limits their generalizability to daily practice.
METHODS The study population comprised three sequential cohorts of 506 consecutive patients with
BMS, 1,017 consecutive patients with SES, and 989 consecutive patients treated with PES.
RESULTS In the ﬁrst 30 days after stent implantation, 6 BMS (1.2%, 95% conﬁdence interval [CI] 0.5%
to 2.6%; p  0.9), 10 SES (1.0%, 95% CI 0.5% to 1.8%), and 10 PES (1.0%, 95% CI 0.6%
to 1.9%) patients developed angiographically proven ST. Multiple potential risk factors were
identiﬁed in most patients with ST. Bifurcation stenting in the setting of acute myocardial
infarction was an independent risk factor for angiographic ST in the entire population (odds
ratio [OR] 12.9, 95% CI 4.7 to 35.8, p 0.001). In patients with DES who had angiographic
ST, 30-day mortality was 15%, whereas another 60% suffered a nonfatal myocardial
infarction; no further deaths occurred during six months of follow-up. Including possible
cases, 7 BMS (1.4%, 95% CI 0.7% to 2.8%), 15 SES (1.5%, 95% CI 0.9% to 2.4%), and 16
PES (1.6%, 95% CI 1.0% to 2.6%) patients had ST.
CONCLUSIONS The unrestricted use of SES or PES is associated with ST rates in the range expected for
BMS. Stent thrombosis was associated with a high morbidity and mortality. Bifurcation
stenting, when performed in patients with acute myocardial infarction, was associated with an
increased risk of ST. (J Am Coll Cardiol 2005;45:947–53) © 2005 by the American
College of Cardiology Foundation
Drug-eluting stents (DES) reduce clinical events related to
restenosis. Concerns have been raised regarding the inci-
dence of stent thrombosis (ST) with the unrestricted use of
these stents. Data from the bare-metal stent (BMS) era
report a high morbidity and mortality with ST (1,2).
Evidence for ST in DES has come from randomized
controlled trials with strict entry criteria for the treatment of
single lesions, limiting conclusions that are applicable to the
real-world setting (3–6). Other information has come from
electronic registries with inherent biases that preclude gen-
eralization of the ﬁndings. A single-center registry recently
reported its results with sirolimus-eluting stents (SES) (7).
The aim of this present study is to describe the incidence of
ST (both angiographically proven and including possible
cases) in three consecutive populations while analyzing the
unrestricted use of a control BMS group, SES, and
paclitaxel-eluting stents (PES).
METHODS
Study design and patient population. Since April 2002,
SES (Cypher; Cordis Corp., Miami Lakes, Florida, a
Johnson & Johnson Company) have been the stents of
choice for all percutaneous coronary interventions irrespec-
tive of their clinical presentation or clinical outcome (8). In
the ﬁrst quarter of 2003, PES (Taxus; Boston Scientiﬁc
Corp., Natick, Massachusetts) replaced SES as the default
stent.
This present study comprises three sequential cohorts: a
control group of the last 506 consecutive patients treated
with BMS before April 2002; 1,017 consecutive patients
with SES treated between April 2002 and February 2003;
and 989 consecutive patients with PES treated between
February 2003 and December 2003.
Procedure and antiplatelet management. All interven-
tions were performed according to current standard guide-
lines, and the ﬁnal interventional strategy including peripro-
cedural glycoprotein IIb/IIIa and intravascular ultrasound
use, was left to the discretion of the operator. Patients were
pretreated with aspirin and a loading dose of 300 mg of
clopidogrel. After their procedure, all patients were pre-
scribed a lifelong aspirin regimen. Clopidogrel was pre-
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scribed for at least one month in the BMS group, for at least
three months in the SES group (8), and for at least six
months in the PES group.
Follow-up. As part of the national health system, our
institution as a tertiary referral center is the only interven-
tional facility within our catchment area. The survival status
of our patients at one and six months after discharge was
obtained from the Municipal Civil Registries. Details of all
repeat interventions (surgical and percutaneous) were col-
lected prospectively during follow-up. Referring physicians
and institutions were contacted whenever necessary for
additional information. This protocol was approved by the
Hospital Ethics Committee, and written, informed consent
was obtained from every patient.
Deﬁnitions. Stent thrombosis was considered to have oc-
curred when conﬁrmed angiographically: either Thrombol-
ysis In Myocardial Infarction (TIMI) ﬂow grade 0 or 1 or
the presence of ﬂow-limiting thrombus (TIMI ﬂow grade 1
or 2) occurring in an acute (within 24 h of stent implanta-
tion) or subacute (between 1 and 30 days) time period after
stent implantation (9). In addition, a clinical deﬁnition of
“possible stent thrombosis” was used for patients who
within the ﬁrst 30 days experienced sudden death, who
suffered a fatal out-of-hospital cardiac arrest, or who suf-
fered a myocardial infarction (MI) that was not clearly
attributable to another coronary lesion and who did not
undergo repeat angiography. All deaths and MIs were
reviewed independently by two interventional cardiologists
(A.O., E.Mc.F) for “possible stent thrombosis.”
Statistical analysis. Categorical variables were compared
using the Fisher exact test and continuous variables with the
Student t test or one-way analysis of variance where appro-
priate. Univariate and forward stepwise (entry criteria of
0.05 and exit criteria of 0.10) multivariate logistic regression
analysis were performed to identify characteristics or vari-
ables independently associated with stent thrombosis. From
the univariate analysis, the following baseline, clinical,
angiographic and procedural variables were entered into the
multivariate model: bifurcation stenting, diabetes, smallest
stent diameter, multilesion stenting, and acute myocardial
infarction (AMI) as the indication. All probability values are
Table 1. Baseline and Procedural Characteristics
BMS
(n  506)
SES
(n  1,017)
PES
(n  989) p Value
Baseline characteristics
Age, yrs, mean  SD 61.0  11.4 61.9  11.3 61.7  11.4 0.3
Male, % 73 70 74 0.1
Diabetes, % 16 18 17 0.6
Hypercholesterolemia, % 52 55 60 0.01
Current smoker, % 35 28 28 0.01
Hypertension, % 40 41 41 0.9
Previous MI, % 43 32 35 0.01
Previous PCI, % 22 25 26 0.2
Previous CABG, % 11 9 8 0.2
Multivessel disease, % 54 57 56 0.4
Indication for index procedure 0.01
Stable angina, % 42 43 41
Unstable angina, % 35 36 30
Acute MI, % 20 19 26
Silent ischemia, % 3 2 3
Number of vessels treated, mean  SD 1.4  0.6 1.4  0.6 1.4  0.6 0.8
LAD, n 281 594 540
LCx, n 164 332 333
RCA, n 194 398 384
Others, n 29 75 90
Total stent length, mm (mean  SD) 31.9  22.1 42.5  29.6 44.2  29.4 0.01
Stents implanted, mm (mean  SD) 1.9  1.1 2.3  1.5 2.2  1.4 0.01
At least one 2.5 mm stent implanted (%) 23 38 38 0.01
Bifurcations stented, % 5 18 17 0.01
Glycoprotein IIb/IIIa use (%) 37 21 28 0.01
BMS  bare metal stent; CABG  coronary artery bypass grafting; LAD  left anterior descending; LCx  left circumﬂex;
MI myocardial infarction; PCI percutaneous coronary intervention; PES paclitaxel-eluting stent; RCA right coronary
artery; SES  sirolimus-eluting stent.
Abbreviations and Acronyms
AMI  acute myocardial infarction
BMS  bare-metal stents
CI  conﬁdence interval
DES  drug-eluting stents
MI  myocardial infarction
OR  odds ratio
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
ST  stent thrombosis
TIMI Thrombolysis In Myocardial Infarction
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two-sided, and statistical signiﬁcance was set at the 0.05
level. A cumulative event graph consisting of patients with
angiographic stent thrombosis was generated plotting the
proportion of patients with stent thrombosis (Y-axis)
against time (X-axis) stratiﬁed by stent type. Incidences of
stent thrombosis are reported as a percentage with associ-
ated 95% conﬁdence intervals (CIs).
RESULTS
Baseline and procedural characteristics. The patients in
our cohort were at high risk, with unstable angina or AMI
being the indication in more than one-half of the cases
(Table 1). Multivessel disease was present in more than
one-half of the population. One-third of the population had
a previous AMI, whereas one-quarter had previous coronary
interventions. Glycoprotein IIb/IIIa use was lower in the
SES and PES groups compared with the BMS group.
Clinical outcome. Angiographic ST was documented in
26 of 2,512 patients (Table 2). Six cases occurred in the
BMS group (1.2%, 95% CI 0.5% to 2.6%), 10 cases
occurred in the SES group (1.0%, 95% CI 0.5% to 1.8%),
and 10 cases occurred in the PES group (1.0%, 95% CI
0.6% to 1.9%). The ﬁrst two SES patients with ST have
been reported previously (10). Most stent thromboses oc-
curred in the ﬁrst 11 days, regardless of stent type, with a
mean time to event of 5.8  5.4 days (Fig. 1).
In the BMS population, there were two acute stent
thromboses and four subacute stent thromboses. Among the
six patients, ST presented as AMI in ﬁve patients. None
died during the six months of follow-up (Table 2). In the
combined group of SES and PES (2,006 patients), there
were 2 cases of acute ST and 18 cases of subacute ST (Fig.
1). A detailed description of these patients is given in Table
3. Analysis via intravascular ultrasonography was performed
in four patients. In most patients, at least one recognized
risk factor for ST (i.e., long stented length, use of small
stents, use of multiple stents, and residual dissection after
stent implantation) was present. Importantly, 2 of the 20
patients had not taken clopidogrel.
Mortality and morbidity. Overall, 20 of 26 patients (77%)
re-presented with an AMI, whereas the other 6 re-
presented with angina pectoris (Table 2). Of these 26
patients, 3 (Patients #12, #18, and #20 from Table 3—all in
the DES population) died at days 11, 5, and 3, respectively.
Two patients died during reintervention from intractable
ventricular ﬁbrillation, whereas the third underwent emer-
gency surgery after a suboptimal reintervention and could
not be weaned from bypass. The incidence of death at 30
days was 12%, whereas another 65% suffered a nonfatal MI.
Among the survivors of ST, there were no further deaths in
the six months after reintervention.
Possible ST. Thirty-day survival data was complete for
98% of patients (Table 4). There were 12 patients who were
judged with “possible stent thrombosis,” of which 9 died
and 3 had nonfatal MIs. Of the nine deaths, four were
out-of-hospital sudden deaths, three occurred in hospital
with ventricular tachycardia as the initiating preterminal
rhythm, and two had ST-segment elevation and died before
they could undergo reangiography. Among those with MIs,
one patient developed a postprocedural enzyme leak, and
another developed ventricular ﬁbrillation requiring multiple
cardioversions the day after the procedure. Repeat coronary
angiography six months later demonstrated occluded stents
in both of these patients; whereas a third underwent
coronary angiography 14 days after stent implantation
because of an increase in cardiac enzyme levels, which
demonstrated an in-stent ﬁlling defect which was treated
Figure 1. Cumulative incidence of angiographic stent thrombosis stratiﬁed
by groups against time. Vertical line  day 11 on horizontal axis. BMS 
bare-metal stents; PES  paclitaxel-eluting stents; SES  sirolimus-
eluting stents.
Table 2. Outcome Following Angiographic Stent Thrombosis
BMS SES PES p Value
Angiographic stent thrombosis, n (%) 6 (1.2%) 10 (1.0%) 10 (1.0%) 0.9
Clinical presentation
Acute MI, n 5 7 8
Angina, n 1 3 2
Maximum total CK, mean  SD 4,983  2,570 1,268  476 3,361  1,404 0.01
Maximum CK-MB, mean  SD 397  186 171  80 322  166 0.01
Outcome
30-day mortality, n 0 0 3
6-month mortality, n 0 0 3
CK  creatine kinase; other abbreviations as in Table 1.
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with abciximab, and subsequently underwent repeat percu-
taneous coronary intervention two weeks later. Including
the suspected cases, the combined incidence of angiographic
and possible ST was 1.4% (95% CI 0.7% to 2.8%) in the
BMS control group, 1.5% (95% CI 0.9% to 2.4%) in the
SES group, and 1.6% (95% CI 1.0% to 2.6%) in the PES
group. In the combined total of 38 documented and possible
ST, there were 12 deaths (32%) and 20 nonfatal MIs (53%)
in the ﬁrst 30 days.
Multivariate analysis. By univariate analysis, bifurcation
stenting was the only signiﬁcant factor (p  0.01). Multi-
variate analysis was performed with the following covariates
based on their signiﬁcance on univariate analysis as well as
their potential clinical impact: diabetes (p  0.07), smallest
stent diameter (p  0.13), multilesion stenting (p  0.17),
AMI as the indication (p  0.3), and bifurcation stenting.
By multivariate analysis, bifurcation stenting was the only
independent predictor of ST (odds ratio [OR] 3.0, 95% CI
1.3 to 6.8, p  0.01). When the interaction of bifurcation
stenting by AMI was entered as a covariate, it was highly
signiﬁcant (OR 12.9, 95% CI 4.7 to 35.8, p  0.001), and
bifurcation stenting as a covariate was no longer signiﬁcant.
DISCUSSION
The main ﬁndings in this study can be summarized as
follows: 1) the incidence of angiographic ST in an un-
selected, complex DES population was low (1.0%), within
the same range as the corresponding BMS population and
concordant with previously published results from the BMS
Table 3. Detailed Description of Drug-Eluting Stent Patients With Angiographic Stent Thrombosis
Patient 1 2 3 4 5 6 7 8 9 10
Type of DES SES SES SES SES SES SES SES SES SES SES
Time to Thrombosis (days) 0.125 11 7 10 1.08 6 3 7 17 3
Baseline characteristics
Age (yrs) 72 61 86 57 75 55 53 58 58 74
Gender F F F M F F M M M M
Diabetes   	  	 	  	  	
Current smoker 	 	 	  	 	 	 	 	 	
Previous MI 	  	  	 	  	  
Previous intervention 	 	 	  	   	 	 	
Index procedure
Indication for procedure UAP AP UAP AMI, ST AP AP, ISR UAP post-AMI AP AMI UAP post-AMI
Glycoprotein IIb/IIIa use 	 	 	 Y 	 	 	 Y Y 	
Angiographic features of index procedure
Culprit vessel LAD LAD LAD LAD LAD/DIAG LAD/DIAG RCA LAD DIAG LAD
Lesion type (AHA) B1 C C C B2 C B2 B2 B2 B2
Bifurcation technique (where
performed)
	 	 	 	 crush t-stent 	 	 t-stent 	
Final kissing balloons in bifurcation
stenting
	 	 	 	 Y N N
Minimum stent diameter (mm) 2.25 2.5 3 3 3 2.5 3 2.75 3 2.75
Total stent length (mm) 26 66 41 26 36 41 41 18 31 36
Total stents implanted 2 2 3 2 2 2 2 1 2 2
Reintervention
Clinical presentation AMI AP AMI AP AMI AMI AMI AP AMI AMI
Additional stent implanted Y 	 Y Y 	 	 Y 	 	
IVUS ﬁndings (where performed) RD UD 	 RD 	 	 	 	 UD
Site of thrombosis in bifurcation lesions 	 	 	 	 MBSB SB 	 	 SB 	
Incomplete oral anti-platelet therapy 	 	 	 	 	 	 	 	 Y 	
Successful procedural outcome Y Y Y Y Y Y Y Y Y Y
AMI acute myocardial infarction; AP angina pectoris; DIAG diagonal branch; IM intermediate branch; LAD left anterior descending artery; LCx left circumﬂex
artery; MB  mainbranch; N  no; OMCx  obtuse marginal branch; RCA  right coronary artery; RD  residual dissection; SB  sidebranch; ST  stent thrombosis; UAP
 unstable angina pectoris; UD  underdeployment; Y  yes; other abbreviations as in Table 1.
Table 4. Incidence of Stent Thrombosis Classiﬁed by Deﬁnition
Stent Type
Number of
Patients
Angiographically Proven
Stent Thrombosis
n (% [95% CI])
Possible Stent
Thrombosis
n (% [95% CI])
All Stent Thrombosis
n (% [95% CI])
BMS 506 6 1 7
(1.2% [0.5%–2.6%]) (0.2% [0.0%–1.1%]) (1.4% [0.7%–2.8%])
SES 1,017 10 5 15
(1.0% [0.5%–1.8%]) (0.5% [0.2%–1.1%]) (1.5% [0.9%–2.4%])
PES 989 10 6 16
(1.0% [0.6%–1.9%]) (0.6% [0.3%–1.3%]) (1.6% [1.0%–2.6%])
CI  conﬁdence interval; other abbreviations as in Table 1.
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era; 2) the inclusion of possible ST increases the overall
incidence of ST to 1.5%; 3) angiographically proven ST
was associated with a high mortality and morbidity; 4)
patients who developed ST often had multiple high-risk
features, regardless of stent type; and 5) the association of
bifurcation stenting for AMI was a highly signiﬁcant
independent risk factor for ST.
The availability of DES as the default stent at our
institution has allowed us to analyze this new technology in
an unrestricted population (8), a population that would
have comprised any BMS population in the pre-DES
era. Therefore, this availability allows us to analyze inci-
dences in an “all-comers” population because patients were
enrolled irrespective of clinical presentation or outcome. In
this population sample, angiographic ST rates in the ﬁrst 30
days for both DES, i.e., SES and PES, occurred within the
range as that reported in the BMS era (1,2,11,12).
The angiographic deﬁnition used is the most accurate for
diagnosis but may underestimate the true incidence of ST
because some patients who have a presumed ST may die
before receiving medical attention. Conversely, the use of
major adverse cardiac events (i.e., death and MI in addition
to the angiographic ﬁndings) to deﬁne ST overestimates the
true incidence because not all patients who die suddenly or
suffer a MI do so because of ST (13). This consideration is
important in our heterogeneous unrestricted population
with multivessel disease, previous MI, and previous revas-
cularization. Furthermore, not all patients who die will
Table 3 Continued
11 12 13 14 15 16 17 18 19 20 Mean  SD, %
PES PES PES PES PES PES PES PES PES PES
0.04 4 7 6 3 4 24 5 5 3 6.3  5.7
59 50 67 47 61 52 60 54 65 31 59.7  11.9
M M M F M F M M M M 13 M:7 F
	 	 	 	  	 	 	 	 	 30%
	 	 	    	  	  30%
	 	  	  	  	  	 45%
	 	  	 	 	 	 	 	  25%
AMI AMI AP AMI AP AMI AP AMI AP AP
	 	 	 Y 	 	 	 Y Y 	 30%
RCA LAD OMCX LAD/DIAG LCx LCx/OMCx LCx LAD/Diag LAD/IM/LCx LAD
B2 B2 C C B2 C C C C B2
	 	 crush crush 	 t-stent 	 crush culotte crush 	 40%
	 	 N N 	 N 	 N Y 	
3 3.5 2.5 2.5 2.5 2.25 2.25 2.75 2.25 3 2.7  0.3
28 24 32 36 20 44 32 36 140 84 41.2  27.8
1 1 2 2 1 2 2 2 8 4 2.2  1.5
AMI AMI AMI AMI AMI UAP UAP AMI AMI AMI AMI  75%
	 	 Y 	 Y 	 Y 	 	 	 Yes  35%
	 	 	 	 	 	 	 	 	 	
	 	 SB SB 	 SB MBSB SB MBSB 	
	 	 	 	 Y 	 	 	 	 	 10%
Y Died Y Y Y Y Y Y Died Died Death  15%
Table 5. Clinical Trials on Drug-Eluting Stents
Trial Name
Number of Patients
in Drug-Eluting Arm
Total Stent
Length mm
(Mean  SD)
Incidence of Stent
Thrombosis in the
First 30 Days (%)
SIRIUS (3) 533 23.0  8.6 0.2*
E-SIRIUS (6) 157 21.5  6.7 1.1*
C-SIRIUS (5) 50 23.8  8.4 2.0*
TAXUS-IV (4) 662 21.9  8.1 0.3†
SES group 1,017 42.5  29.6 ‡1.0–1.5§
PES group 989 44.2  29.4 ‡1.0–1.6§
*Deﬁnition of stent thrombosis was not stated. †Stent thrombosis deﬁned as angiographically proven, or cardiac death or
myocardial infarction in the ﬁrst 30 days. ‡Stent thrombosis deﬁned as angiographically proven. §Stent thrombosis deﬁned as
angiographically proven, or adjudicated death or myocardial infarction in the ﬁrst 30 days.
Abbreviations as in Table 1.
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undergo autopsy studies to determine the cause of death. To
attenuate this overestimation and to provide an accurate
ﬁgure, we have adjudicated all deaths and noncatheterized,
nonfatal MIs within the ﬁrst 30 days in the three groups and
included them with the angiographically proven patients to
provide an overall incidence for each group.
The incidences of ST for both groups of DES are within
the range reported in the larger randomized clinical trials of
DES (3–6) despite longer total stent length, multivessel
treatment, and a heterogeneous population (Table 5). This
incidence complements information already available from
the randomized trials regarding the safety of these new
devices.
Angiographic ST was associated with a high mortality
and morbidity in our study. Within the DES population, 15
patients (75%) experienced a MI as their diagnosis at the
second presentation, and 3 (15%) died during the reinter-
vention procedure. The inclusion of possible ST patients
increased the mortality to 32%. Given the small number of
events, the fact that no deaths occurred in the BMS group
was most likely due to chance. These results are in concor-
dance with the results of a large BMS registry (2).
Previous studies have demonstrated that residual dissec-
tion (1,11), long stents (1), small ﬁnal lumen diameter (1),
and use of multiple stents (2) are risk factors for the
development of ST. In our series, multiple risk factors were
identiﬁed in most patients who developed ST. Patients with
ST had more multiple lesions treated, smaller minimum
stent diameters, and longer stent lengths compared with
those without ST; however, these factors were not signiﬁ-
cant on univariate analysis. What did emerge and which has
not been previously reported is that patients undergoing
bifurcation stenting had a higher incidence of ST compared
with those without bifurcation stenting. A recent study on
bifurcations reported a 3.5% incidence of ST, which is
higher than the overall incidence in this population (14).
Although stent implantation for AMI was not signiﬁcant
on univariate analysis, the interaction of AMI and bifurca-
tion stenting when entered as a covariate for ST on
multivariate analysis emerged as a highly signiﬁcant inde-
pendent predictor, and bifurcation stenting as a covariate
was no longer signiﬁcant. This result conﬁrms a clinical
suspicion in our department regarding the increased risk of
ST in patients treated with bifurcation stenting in the
setting of AMI.
Mechanical reasons that predispose to ST can be modi-
ﬁed by interventional technique. Optimizing stent place-
ment including, if necessary, intravascular ultrasound-
guided postdilation, kissing balloon postdilation with
bifurcation stenting, and careful inspection for residual
dissection after stent implantation, may further reduce the
incidence of ST.
Pharmacologic reasons for ST, i.e., inadequate antiplate-
let therapy, are patient-speciﬁc factors. Recent research
literature has focused on “resistance” to either aspirin (15) or
to clopidogrel (16). Currently, most laboratories do not
routinely test for antiplatelet resistance. In our series, two
patients who had not taken their prescribed clopidogrel after
the procedure developed ST.
This report covers ST occurring in the ﬁrst 30 days after
stent implantation only, during which all patients received
dual antiplatelet therapy. The duration of clopidogrel ther-
apy differed among the three groups; in part, it reﬂects
uncertainty with regards to re-endothelialization after DES
implantation. Late ST has been reported to occur with
BMS (17) and with DES (18), including a reported fatality
(19) after clopidogrel discontinuation. At this stage, the
incidence of late ST in the DES era is unknown, and further
studies are required to clarify this potential late complica-
tion.
Comment on sample size and statistical comparisons.
Because ST occurs at a low incidence (1.0 to 1.5%), a
small sample size may underestimate or overestimate the
true incidence. In a previously published report from our
institution, we reported an angiographic incidence of 0.4%
in 508 patients (8). In the present study we extended the
population to incorporate the entire period of DES used to
date at our institution (n  2,006) to allow a more accurate
analysis of the true incidence of ST in the DES population.
Despite having 2,512 patients, the low and small/negligible
absolute difference in incidence precludes formal statistical
comparisons of ST rates among the three groups because it
lacks sufﬁcient statistical power. To achieve adequate power
would require sample sizes in the order of 100,000
patients. To date, this study is the largest series of patients
reported on in the DES era.
Study limitations. These single-center registry data com-
plement available randomized data, as they reﬂect the results
of unrestricted DES use.
Conclusions. Despite having a more complex cohort with
high-risk inclusion criteria, longer stent lengths, and more
complex procedural features, the incidence of ST with DES
are in the same range as the BMS population observed in
our present study. They also are in agreement with previ-
ously reported data by others from the BMS era and with
those results reported on in the earlier randomized DES
trials. Furthermore, the two groups of DES, i.e., SES and
PES, share an incidence of 1.0% to 1.5%. Stent throm-
bosis is associated with a high morbidity and mortality.
As extensively documented in previous reports with BMS,
mechanical reasons were observed to be frequent associations
for ST with DES. In this study, bifurcation stenting in the
setting of AMI was a highly signiﬁcant independent predictor
for angiographic ST.
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Metallic coronary stents are implanted in more than
1·5 million patients per year. Polymer-based coronary
stents eluting sirolimus or paclitaxel substantially reduce
the need for repeat percutaneous intervention compared
with bare-metal stents, and drug-eluting stents are
rapidly replacing bare-metal stents. A meta-analysis1 of
11 randomised trials (5013 patients) showed no evidence
that the short-to-medium-term safety proﬁles of
sirolimus-eluting or paclitaxel-eluting stents differed
from those of bare-metal stents. However, these trials
were not powered to detect or exclude an effect of drug-
eluting stents on rare events such as stent thrombosis.
Stent thrombosis usually results in ST-segment
elevation myocardial infarction or death. Angio-
graphically documented late (>6 months) stent throm-
bosis is extremely rare with bare-metal stents except
after intracoronary irradiation, which delays vascular
healing. There is concern that drug-eluting stents might
also be susceptible to late thrombosis related to delayed
endothelialisation of the stent struts.2 We report
four cases of late stent thrombosis when antiplatelet
therapy was interrupted after elective implantation of
drug-eluting stents. 
In March, 2003, a 63-year-old man presented with
unstable angina and angiographically signiﬁcant lesions
(>50% diameter stenosis) in the left anterior descending
artery and a non-dominant right coronary artery. He
underwent percutaneous intervention of the left anterior
descending artery in June, 2003, with one paclitaxel-
eluting stent (3 mm diameter, 16 mm long; Taxus
Express 2, Boston Scientiﬁc, Natick, MA, USA) and had
no further angina. Aspirin was stopped in May, 2004,
before elective resection of bladder polyps. 5 days later,
343 days after stenting, the patient presented with an
anterior myocardial infarction. Angiography showed
stent occlusion. Percutaneous intervention restored
vessel patency; peak concentration of creatine kinase was
6500 IU/L.
A 73-year-old man sustained an aborted out-of-hospital
cardiac arrest with documented ventricular ﬁbrillation.
In the preceding weeks, he had atypical chest pain. The
admission electrocardiogram was normal. Coronary
angiography showed an isolated proximal lesion of the
left anterior descending artery (ﬁgure 1A).
Electrophysiological investigations were negative. The
patient underwent percutaneous intervention with one
paclitaxel-eluting stent (3·5 mm diameter, 16 mm long;
Taxus Express 2), in April, 2003 (ﬁgure 1B and 1C) and
was subsequently asymptomatic. In June, 2004, aspirin
was discontinued before resection of a newly diagnosed
colon carcinoma. 1 week later, on the evening of surgery,
442 days after stenting, the patient developed anterior
myocardial infarction. Angiography showed stent
occlusion (ﬁgure 1D) and extensive thrombus after
guidewire passage (ﬁgure 1E). Percutaneous intervention
restored vessel patency; peak concentration of creatine
kinase was 3500 IU/L. 
A 42-year-old man admitted to hospital with chest pain
in May, 2003, developed ventricular ﬁbrillation. After
successful cardioversion, angiography showed
signiﬁcant lesions in the left anterior descending artery
(the culprit lesion) and left circumﬂex artery. Two bare-
metal stents (3·0 mm diameter, 18 mm long; Vision,
Guidant Santa Clara, CA, USA) were placed in the left
anterior descending artery. 2 days later, the patient
underwent elective stenting of the left circumﬂex artery
with one sirolimus-eluting stent (3 mm diameter, 33 mm
long; Cordis, Miami Lakes, FL, USA) in a second obtuse
marginal branch, and was subsequently asymptomatic.
In November, 2003, after negative nuclear stress testing,
clopidogrel was discontinued. In May, 2004, the patient
stopped taking aspirin. 2 weeks later, 375 days after
stenting, he presented with chest pain. Angiography
showed patent bare-metal stents (ﬁgure 2A) but the
sirolimus-eluting stent was occluded (not shown).
Intravascular ultrasonography after thrombectomy ruled
out both malapposition (ﬁgure 2B) and edge restenosis.
Percutaneous intervention was successful.
A 62-year-old man with stable angina and two-vessel
coronary disease underwent successful percutaneous
intervention with one sirolimus-eluting stent (3 mm
diameter, 18 mm long; Cordis) in the left anterior
descending artery, and one bare-metal stent (3 mm
diameter, 18 mm long; Vision) in an obtuse marginal
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Late thrombosis in drug-eluting coronary stents after
discontinuation of antiplatelet therapy
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Although the safety proﬁles of coronary stents eluting sirolimus or paclitaxel do not seem to differ from those of bare
metal stents in the short-to-medium term, concern has arisen about the potential for late stent thromboses related to
delayed endothelialisation of the stent struts. We report four cases of angiographically-conﬁrmed stent thrombosis
that occurred late after elective implantation of polymer-based paxlitaxel-eluting (343 and 442 days) or sirolimus-
eluting (335 and 375 days) stents, and resulted in myocardial infarction. All cases arose soon after antiplatelet
therapy was interrupted. If conﬁrmed in systematic long-term follow-up studies, our ﬁndings have potentially
serious clinical implications. 
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branch in July, 2003. In June, 2004, the patient stopped
clopidogrel and aspirin before colonoscopy and
polypectomy. 4 days later, 335 days after stenting, he
presented with an anterior myocardial infarction.
Angiography showed occlusion of the sirolimus-eluting
stent, whereas the bare-metal stent was patent.
Percutaneous intervention was successful.
Late thrombosis after bare-metal stenting is a well
documented, albeit rare, complication when intra-
coronary irradiation is used as an adjunct to stent
placement to reduce restenosis after percutaneous
intervention. This problem has been attributed to
delayed vascular healing that renders the surface of the
stent prothrombotic, and, in the presence of an
appropriate physiological stimulus, can result in
thrombotic occlusion.
Studies in animals have generated concern that drug-
eluting stents could also be prone to late stent
thrombosis, although extrapolation of such ﬁndings to
human beings might be unreliable.2 Evidence from
animal models suggests that the Cypher sirolimus-
eluting stent does not impede endothelialisation.3 By
contrast, animal studies with paclitaxel-eluting stents
A
B
Figure 1: Coronary angiography showing implantation of a paclitaxel-eluting
stent and subsequent thrombosis 
Concentric lesion in the mid left anterior descending artery at baseline (A),
during (B) and after (C) implantation of a paclitaxel-eluting stent. (D) Occlusion
at the proximal margin of the stent. (E) Angiogram after passage of guidewire
showing large thrombus in the stent.
Figure 2: Angiographic and intravascular ultrasound images on presentation
with stent thrombosis in a patient previously treated with sirolimus-eluting
and bare-metal stents
(A) Left coronary angiogram, after mechanical thrombectomy, showing the
widely patent bare-metal stent in the left anterior descending coronary artery
(left) with residual thrombotic material (white arrow) in the sirolimus-eluting
stent (right). There was no “edge” restenosis. (B) Intravascular ultrasound
images within the stent (white lines), after mechanical thrombectomy, showing
optimal stent apposition. 
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clearly show delayed re-endothelialisation.4 However,
these studies were done with stents in which the
polymer coating, design, and drug-release kinetics
differed substantially from those of the Taxus paclitaxel-
eluting stents; to our knowledge, no reports have been
published about the effects of Taxus stents on re-
endothelialisation. There are also differences between
the drug-release kinetics of Cypher and Taxus stents.
With the Taxus stent, about 10% of the paclitaxel is
released by 10 days; the rest remains in the polymer
indeﬁnitely. With the Cypher stent, almost all the
sirolimus has eluted by 6 weeks, leaving a polymer-
coated bare-metal stent. It is unclear whether this
difference is of any clinical importance, in terms of the
potential for long-term adverse events. 
Based on the design of the pivotal clinical trials that led
to approval of such stents, dual antiplatelet therapy is
prescribed on an empirical basis, for 2–3 months after
implantation of sirolimus-eluting stents, and for
6 months after implantation of paclitaxel-eluting stents,
with life-long aspirin. Our report shows that thrombosis
can arise very late after uncomplicated placement of a
single drug-eluting stent, in a large vessel, when
antiplatelet therapy is discontinued. In two of four
patients, a bare-metal stent implanted in a different
vessel, at or around the same time, remained patent
when the drug-eluting stent occluded. 
Three of these late occlusions happened when
antiplatelet therapy was discontinued for non-cardiac
surgery. In the bare-metal stent era, an initial report
showed that non-cardiac surgery more than 2 weeks
after stent placement was associated with a prohibitive
rate of adverse events (32% mortality).5 Findings from a
subsequent larger series suggested that discontinuation
of antiplatelet therapy, later than 6 weeks after
placement of a bare-metal stent, for non-cardiac surgery
was relatively safe.6 The time window of the occlusions
we encountered far exceeds that reported for bare-metal
stents. 
Our report has limitations. Intravascular ultrasound
deﬁnitively excluded restenosis as a contributing factor
to late thrombosis in only one patient. The others were
haemodynamically unstable, precluding intravascular
ultrasound. However the absence of symptoms after
stenting, coupled with the acute presentation and the
angiographic ﬁndings, suggest that the mechanism
was purely thrombotic. Second, we only report
angiographically-conﬁrmed cases; highly suspect
presumed cases have been reported; thus, the true rate
might be higher.7
We report these cases to draw attention to a problem,
with serious clinical implications, that might be under-
reported. We suggest that the potential risk of stent
occlusion should be considered when discontinuation of
antiplatelet therapy is contemplated in patients with
drug-eluting stents. Finally, as the use of drug-eluting
stents becomes widespread, careful long-term follow-up
of patients with such stents is needed to assess the true
rate of late thrombosis. 
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Late Angiographic Stent Thrombosis
(LAST) Events With Drug-Eluting Stents
Andrew T. L. Ong, MBBS, FRACP, Eugène P. McFadden, MD, FRCPI, FACC,
Evelyn Regar, MD, PHD, Peter P. T. de Jaegere, MD, PHD, Ron T. van Domburg, PHD,
Patrick W. Serruys, MD, PHD, FACC
Rotterdam, the Netherlands
OBJECTIVES We sought to describe the incidence of late angiographic stent thrombosis (LAST) events in
an unselected drug-eluting stent (DES) population.
BACKGROUND Concerns have been raised that LAST may be a potential limitation of DES.
METHODS We have previously reported the angiographic incidence of early stent thrombosis (1.0%) in
this prospective cohort of 2,006 patients treated with either sirolimus-eluting stents (SES) (n
 1,017) or paclitaxel-eluting stents (PES) (n  989). We continued long-term follow-up to
determine the incidence of LAST events, deﬁned as angiographically proven stent thrombosis
associated with acute symptoms more than 30 days after DES implantation. All patients had
at least 1 year of follow-up, mean duration 1.5 years.
RESULTS There were eight angiographically conﬁrmed LAST events in seven patients: three with SES
(at 2, 25, and 26 months) and ﬁve with PES (at 6, 7, 8, 11, and 14.5 months). Three cases
were related to complete cessation of antiplatelet therapy, two cases occurred while patients
were on aspirin therapy within one month of cessation of clopidogrel, and three cases occurred
at a time when patients were apparently clinically stable on aspirin monotherapy. We
observed no cases of LAST in patients who were on dual antiplatelet therapy. Two deaths
occurred directly as a result of LAST.
CONCLUSIONS Angiographically proven late stent thrombosis occurs with an incidence of at least 0.35%
(95% conﬁdence limits 0.17% to 0.72%) in patients treated with DES. Importantly, it may
also occur when patients are stable on antiplatelet monotherapy. (J Am Coll Cardiol 2005;
45:2088–92) © 2005 by the American College of Cardiology Foundation
Drug-eluting stents (DES) have revolutionized the practice
of interventional cardiology with their proven efﬁcacy in
reducing restenosis rates. In the U.S., up to 80% of stent
implantations currently are with DES. A meta-analysis of
11 randomized trials conﬁrmed the efﬁcacy and safety
proﬁle of these stents, but these trials were not powered to
detect or exclude an effect of DES on rare events such as
stent thrombosis (1). Since April 2002, we have adopted a
policy of universal DES implantation for all patients irre-
spective of clinical presentation or angiographic features, the
“all-comers” approach. Based on this approach, we were
able to deﬁne the incidence of early stent thrombosis (30
days) in a DES population of 2,006 patients (2).
Our institution has been confronted with patients pre-
senting with late angiographic stent thrombosis (LAST)
events, an unexpected occurrence given the long period of
dual antiplatelet therapy prescribed in comparison to bare
stents (3). Late angiographic stent thrombosis events were
uncommon with bare stents except after brachytherapy (4),
and subsequent to that report, dual antiplatelet therapy was
prolonged for that population. Furthermore, in animal
models, DES may delay or cause incomplete healing to a
greater degree than with bare-metal stents (5). Therefore,
we sought to investigate the incidence of LAST events in
the DES population.
METHODS
Study design and patient population. Brieﬂy, since April
2002, we have adopted a policy of universal DES implan-
tation for all patients irrespective of clinical presentation or
angiographic characteristics, known as an “all-comers pop-
ulation.” We have previously reported on the incidence of
early stent thrombosis (deﬁned as stent thrombosis occur-
ring within the ﬁrst 30 days following stent implantation) in
2,006 consecutive patients after DES implantation (2). This
study population thus comprises 1,017 patients treated with
sirolimus-eluting stents (SES) from April 2002 to February
2003, and 989 patients treated with paclitaxel-eluting stents
(PES) from February 2003 to December 2003. We contin-
ued a long-term (minimum one year) follow-up on this
cohort of patients to determine the incidence of LAST.
Follow-up. Post-discharge survival status was obtained
from the Municipal Civil Registries. A health questionnaire
was sent to all living patients with speciﬁc questions on
re-hospitalization and adverse events. As the principal
referral center within the region, repeat procedures are
normally performed at our institution and recorded prospec-
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tively in our database. For patients who suffered an adverse
event at another center, medical records or discharge summa-
ries from the other institutions were systematically reviewed.
General practitioners, referring cardiologists, and patients were
contacted as necessary for additional information.
Procedure and antiplatelet management. All interven-
tions were performed according to current standard guide-
lines, with the interventional strategy including periproce-
dural glycoprotein IIb/IIIa inhibitor and intravascular
ultrasound (IVUS) use left to the discretion of the operator.
Patients were pretreated with aspirin and a loading dose of
300 mg clopidogrel.
Duration of clopidogrel therapy. Upon completion of the
index procedure, patients are advised to maintain lifelong
aspirin therapy. Patients who received SES were prescribed
clopidogrel for three or six months depending on the
complexity of the procedure, whereas patients treated with
PES were given a six-month prescription. In the Nether-
lands, clopidogrel after stenting is not reimbursed by med-
ical insurance companies and our department has covered
the cost for patients treated here. As a tertiary referral
center, most of our patients are referred from other institu-
tions and after discharge from our institution, are managed
by referring physicians at peripheral centers. Late decisions
regarding antiplatelet therapy are at their discretion.
Deﬁnition of LAST. Late angiographic stent thrombosis
is deﬁned as late—occurring at least one month after DES
implantation with acute symptoms; angiographic—stent
thrombosis conﬁrmed angiographically; stent thrombosis—
deﬁned as Thrombolysis In Myocardial Infarction (TIMI)
ﬂow 0 or 1 or the presence of ﬂow-limiting thrombus
(TIMI ﬂow 1 or 2).
RESULTS
Baseline and procedural characteristics. The average age
of our patients was 62 years, with 72% being male (Table 1).
Over half had multivessel disease on angiography, one-third
presented with unstable angina, and 22% with an acute
myocardial infarction (MI) as the indication for treatment.
Stent type was approximately equally distributed as was the
enrolment period. On average, 1.9 lesions in 1.4 vessels were
treated with 2.3 stents implanted, totaling 43 mm/patient.
Findings. Follow-up was complete for 98% of the popula-
tion. Mean follow-up was 1.5 0.5 years. There were eight
LAST events in seven patients, three with SES and ﬁve
with PES (Tables 2 and 3), with an overall incidence of
0.35% (95% conﬁdence limits 0.17% to 0.72%). All patients
were male, and all presented at the time of LAST with an
acute ST-segment elevation MI. Figure 1 is a representative
example of LAST. No differences in patient characteristics
(Table 1) were noted between patients with and without
LAST. None of the 20 patients described in the previous
report with early stent thrombosis (2) developed LAST.
There were two deaths in the seven patients with LAST.
One death (Patient #6) occurred in a patient who received
a SES to the left anterior descending coronary artery
(LAD). Late angiographic stent thrombosis 25 months later
resulted in a large anterior MI with cardiogenic shock and
the patient died from refractory left ventricular failure two
days later. The second death occurred in a patient (Patient
#7) who had a pre-existing occlusion of the right coronary
artery that received collaterals from the LAD. A single SES
was implanted at a proximal LAD lesion. Late angiographic
stent thrombosis 26 months later resulted in a large acute
anterior MI with cardiogenic shock and the patient died on
the catheterization table. Of note, in both these patients,
initial attempts to pass a wire through the previous stent
were unsuccessful because the wires, on each occasion,
appeared to pass between the outside of the stent and the
Table 1. Baseline and Procedural Characteristics of
Drug-Eluting Population
Drug-Eluting Stents
(n  2,006)
Baseline characteristics
Age, yrs, mean  SD 61.9  11.3
Male, % 72
Diabetes, % 17
Hypercholesterolemia, % 58
Current smoker, % 28
Hypertension, % 41
Previous myocardial infarction, % 33
Previous PCI, % 25
Previous CABG, % 9
Multivessel disease, % 57
Indication for index procedure
Stable angina, % 42
Unstable angina, % 33
Acute myocardial infarction, % 22
Silent ischemia, % 3
Procedural characteristics
Number of lesions treated, mean  SD 1.9  1.0
Number of vessels treated, mean  SD 1.4  0.6
LAD, n 1,135
LCx, n 665
RCA, n 784
Others, n 163
Patients treated with SES, n 1,017
Patients treated with PES, n 989
Total stented length, mm (mean  SD) 43  31
Number of stents implanted, n (mean  SD) 2.3  1.5
At least one 2.50 mm stent implanted (%) 38
Bifurcations stented, % 18
Glycoprotein IIb/IIIa use (%) 25
CABG  coronary artery bypass grafting; LAD  left anterior descending; LCx 
left circumﬂex; PCI  percutaneous coronary intervention; PES  paclitaxel-eluting
stent; RCA  right coronary artery; SES  sirolimus-eluting stent.
Abbreviations and Acronyms
DES  drug-eluting stents
IVUS  intravascular ultrasound
LAST  late angiographic stent thrombosis
MI  myocardial infarction
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
TIMI  Thrombolysis In Myocardial Infarction
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vessel wall. This is highly suggestive of acquired aneurysm
formation at the stented site because on review, the initial
procedural result was optimal. Due to hemodynamic insta-
bility, IVUS was not attempted. Autopsy was refused in
both cases.
One patient (Patient #3) treated with a PES to the LAD
developed two LAST events. The ﬁrst occurred 11 months
after the index procedure and re-presented with an anterior
ST-segment elevation MI. He was treated with a new PES
inside the original PES stent and lifelong clopidogrel was
recommended; before discharge he was given his ﬁrst
prescription of six months worth of clopidogrel. He com-
pleted the prescribed six-month course of dual antiplatelet
therapy and did not renew the prescription of clopidogrel.
Twenty-one days later, he re-presented with lateral ST-
segment elevation. Three new PES were used to re-canalize
a diagonal branch occluded with thrombus. Intravascular
ultrasound study did not reveal a speciﬁc contributory
factor, in particular, there was no evidence of incomplete
stent apposition.
With regard to antiplatelet therapy, three events occurred
when patients had stopped all antiplatelet therapy (two were
for non-cardiac surgery, and one due to non-compliance).
Five events occurred in patients on aspirin monotherapy
who had completed their prescribed course of clopidogrel.
Two of these events occurred soon after (21 and 28 days)
clopidogrel was stopped.
Treatment. Balloon angioplasty was performed in all pa-
tients, followed by new DES implantation in seven of eight
(Table 3). Glycoprotein IIb/IIIa inhibitors were used in ﬁve
cases. Intravascular ultrasound was performed in two pa-
tients with no evidence of incomplete stent apposition
noted. A thrombectomy device was used in two cases. After
an episode of late stent thrombosis, prolonged clopidogrel
therapy was empirically recommended.
DISCUSSION
The purpose of this report is to highlight that LAST occurs
with an incidence of at least 0.35% and possibly up to 0.72%
after DES implantation. Furthermore, we have now ob-
served that LAST may also occur not only in temporal
relation to complete cessation of antiplatelet therapy (3), but
may also occur shortly after clopidogrel is stopped but
aspirin continued, and unexpectedly remote from clopi-
dogrel cessation when patients were clinically stable on
long-term aspirin therapy. We observed no episodes of
LAST while patients were on dual antiplatelet therapy.
In the randomized trials of DES, late stent thrombosis
has been reported. Two presumed late stent thromboses
related to clopidogrel discontinuation were reported in the
TAXUS-II trial (6). With SES, there has been one pub-
lished report of LAST from the European multicenter,
randomized, double-blind study of the SIRolImUS-coated
Bx velocity balloon-expandable stent in the treatment of
patients with de novo coronary artery lesions (E-SIRIUS)Ta
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trial, with accompanying histological ﬁndings showing ac-
quired aneurysm formation with eosinophilic inﬁltrates; the
investigators concluded that LAST was due to a hypersen-
sitive reaction to the polymer coating of the stent (7). Two
of the LAST events we report occurred more than two years
after SES implantation and both patients died. The timing
of the events and the intraprocedural difﬁculty in wiring the
lesion in both patients are potentially compatible with a
similar etiology of LAST.
Late stent thrombosis was a major problem with the now
discontinued QP2 stent program (8). The ongoing occur-
rence of stent thrombosis (3.2%, 7.1%, and 10.3% at 1, 6,
and 12 months) in the Study to COmpare REstenosis Rate
between QueST and QuaDDS-QP2 (SCORE) trial was
attributed to the long duration of high-dose drug release
and proinﬂammatory nature of the polymer sleeves.
Several mechanisms of LAST have been postulated: a
local drug effect delaying endothelialization or results in the
formation of a dysfunctional endothelium, a hypersensitiv-
ity, or inﬂammatory reaction to the polymer, or the devel-
opment of neointimal hyperplasia with occlusive thrombus
formation as the acute event. Furthermore, it is known that
previous treatment with brachytherapy is associated with an
increased risk of late stent thrombosis when on mono-
antiplatelet therapy (4); however, no patient in this report
had previous brachytherapy in the stented segment. The use
of IVUS, if clinically feasible at the time of stent thrombo-
sis, may help facilitate the elucidation of its etiology.
However, their clinical condition often precludes a pre-
intervention IVUS.
In patients with documented LAST, we empirically
prescribe long-term dual antiplatelet therapy in an attempt
to reduce recurrence. The use of long-term dual antiplatelet
therapy for the primary prevention of LAST is more
problematic. Although it would seem intuitive to do so,
there is debate in published literature. There are data from
the pre-DES era to suggest that in selected patients,
prolonged dual antiplatelet therapy is associated with a
reduction in major adverse cardiac events (9,10); however,
such potent inhibition of platelet function is associated with
an increased risk of major bleeding complications (11,12).
It is difﬁcult to compare the incidence we have reported
with that from the bare stent era due to the paucity of
reports; a single center registry reported a late stent throm-
bosis incidence (deﬁned as 30 days) of 0.76%, a ﬁgure not
dissimilar to this report (13).
The results of this preliminary report expand our previous
observations that LAST occurs with DES, demonstrate that
it may occur when patients are receiving antiplatelet mono-
therapy, and provide an estimate of the expected rate in an
unselected DES population. Its incidence is low, but po-
tentially problematic given the rapid uptake of such stents.
It is imperative that cardiologists and other doctors who
treat these patients are aware of this potential late compli-
cation, and any decision to stop antiplatelet therapy for
whatever reason must take this into account.
Table 3. Treatment of Patients With LAST
Pt.
No. Age, Gender IVUS
Glycoprotein
IIb/IIIa Use Treatment
Post-LAST Clopidogrel
Recommendation
1 74, Male No Abciximab Balloon angioplasty, SES 2.75*18 mm Lifelong
2 57, Male Yes Abciximab Thrombectomy, balloon angioplasty, PES 3.5*20 mm 1 year
3a 64, Male* Yes Abicixmab Balloon angioplasty, PES 2.25*8mm, 3.5*8 mm, 3.5*8 mm Lifelong
3b 64, Male* No Abciximab Balloon angioplasty, PES 3*32 mm Lifelong
4 74, Male No No Thrombectomy, balloon angioplasty, PES 3.5*12 mm Not stated
5 39, Male No No Balloon angioplasty, inotropes, atropine Not stated
6 63, Male No Integrellin Balloon angioplasty, PES 2.5*24 mm, intra-aortic balloon pump,
inotropes
—
7 71, Male No No Balloon angioplasty, PES 3*20 mm, 3*8 mm, 3*12 mm, intra-
aortic balloon pump, inotropes
—
*This patient had two separate episodes of late stent thrombosis.
IVUS  intravascular ultrasound; other abbreviations as in Tables 1 and 2.
Figure 1. Representative ﬁlm of late angiographic stent thrombosis (LAST). (A) Index procedure, post-stent implantation, right coronary artery. (B) Late
angiographic stent thrombosis with ST-segment elevation. (C) After wire passage, LAST demonstrating large thrombus burden.
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Study limitations. This report is conﬁned to patients who
presented with acute symptoms and angiographically proven
late stent thrombosis. The low frequency of postmortem
studies performed in the Netherlands, which would have
accurately determined the cause of death, precluded an
accurate assessment of the overall rate of late stent
thrombosis.
Reprint requests and correspondence: Prof. Patrick W. Serruys,
Thoraxcenter, Ba-583, Dr. Molewaterplein 40, 3015-GD Rotter-
dam, the Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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Cost-effectiveness of the unrestricted use of
sirolimus-eluting stents vs. bare metal stents at 1 and
2-year follow-up: results from the RESEARCH Registry{
Andrew T.L. Ong, Joost Daemen, Ben A. van Hout, Pedro A. Lemos, Johanna L. Bosch,
Ron T. van Domburg, and Patrick W. Serruys*
Thoraxcenter, Erasmus Medical Center, Ba-583, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
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Aims To assess the cost-effectiveness of sirolimus-eluting stents (SESs) compared with bare metal stents
(BMSs) as the default strategy in unselected patients treated in the Rapamycin Eluting Stent Evaluated
At Rotterdam Cardiology Hospital (RESEARCH) Registry at 1 and 2-years following the procedure.
Methods and results A total of 508 consecutive patients with de novo lesions exclusively treated with
SES were compared with 450 patients treated with BMS from the immediate preceding period. Resource
use and costs of the index procedure, and clinical outcomes were prospectively recorded over a 2-year
follow-up period. Follow-up costs were measured as unit costs per patient based on the incidence of
clinically driven target vessel revascularization (TVR), to obtain cumulative costs at 1 and 2-years. Cost-
effectiveness was measured as the incremental cost-effectiveness ratio (ICER) per TVR avoided.
The use of SES cost E3036 more per patient at the index procedure, driven by the price of SES.
Follow-up costs after 1-year were E1,089 less with SES when compared with BMS, due to less TVR,
resulting in a net excess cost of E1968 per patient in the SES group, and reduced by a further E100
per patient in the second year. The incidence of death or myocardial infarction between groups was
similar at 1 and 2 years. Rates of TVR in the SES and BMS groups were 3.7% vs. 10.4%, P, 0.01 at
1 year, respectively; and 6.4% vs. 14.7%, P, 0.001 at 2 years. The ICER per TVR avoided was
E29 373 at 1 year, and E22 267 at 2 years.
Conclusion The use of SES, while signiﬁcantly beneﬁcial in reducing the need for repeat revasculariza-
tion, was more expensive and not cost-effective in the RESEARCH registry at either 1 or 2-years when
compared with BMS. On the basis of these results, in an unselected population with 1 year of follow-up,
the unit price of SES would have to be E1023 in order to be cost-neutral.
KEYWORDS
Cost-effectiveness;
Drug-eluting stents;
Sirolimus;
Real-world;
Registry
Introduction
Drug-eluting stents have revolutionized the treatment of
coronary artery stenosis by systemically reducing the need
for re-intervention following stent implantation.1 The
pivotal European randomized trial comparing
sirolimus-eluting stents (SESs) with bare metal stents
(BMSs), RAVEL,2 paved the way for the deﬁnitive trial,
SIRIUS,3 conducted in the United States. These respective
trials led to its commercialization in Europe in 2002 and in
the United States in 2003. Conﬁrmation of the efﬁcacy of
SES over BMSs in a diverse unselected population was
made in the Rapamycin Eluting Stent Evaluated At Rotter-
dam Cardiology Hospital (RESEARCH) Registry with 14 and
2-year follow-up.5 More recently, the randomized BASKET
trial with 6 months follow-up concurred with the results of
RESEARCH.6
The market price of drug-eluting stents has almost unan-
imously been perceived as the major limitation for a more
widespread use of SES worldwide.7 On the other hand, the
striking decrease in the incidence of cardiac events with
the use of SES is theoretically associated with a reduction
in resource utilization, and therefore costs, during
follow-up. In the RAVEL trial, the treatment of a single
native de novo coronary lesion with SES was associated
with an increased procedural cost of E1286 over BMS,
which was reduced to an additional cost of E54 after
1 year of follow-up, mainly because of the lower frequency
of repeat revascularizations among SES-treated patients.8
Correspondingly, in the SIRIUS randomized trial, patients
treated with SES cost US$2881 more than BMS patients. At
1 year, aggregate costs narrowed but were still US$ 309
higher in SES patients.9 The incremental cost-effectiveness
ratio (ICER) for SES was US$1650 per repeat revasculariza-
tion avoided.
* Corresponding author. Tel: þ31 10 463 5260; fax: þ31 10 436 9154.
E-mail address: p.w.j.c.serruys@erasmusmc.nl
{ The results reported in this manuscript have been presented in part at the
EuroPCR 2005 Meeting, May 2005, Paris, France.
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Although the cost-effectiveness proﬁle of SES has been
assessed in the context of randomized trials,8,9 there is
limited information on the balance between costs and
effects of SES in the real world. In the present study, we per-
formed a prospective resource utilization and economic
evaluation during a 2-year follow-up period of the patients
treated in the RESEARCH registry.
Methods
Patient population and treatment strategy
The RESEARCH registry is a single-centre registry conducted with
the main purpose of evaluating the safety and efﬁcacy of SES
implantation for patients treated in daily practice. Its study
design has been previously published.10 Brieﬂy, since 16 April
2002, our institution has adopted a policy of using SES (Cypher;
Johnson & Johnson-Cordis unit, Cordis Europa, NV, USA) as the
default stent for every percutaneous coronary intervention. In the
ﬁrst 6 months of enrolment, 508 patients with de novo lesions
were treated exclusively with SES (SES group) and compared with
a group of 450 consecutive patients treated with BMS for de novo
lesions in the preceding 6 months (pre-SES group). The total study
population thus comprised 958 patients divided into two sequential
cohorts, primarily distinguished by the interventional strategy
applied (BMS or SES implantation, respectively). This protocol was
approved by the hospital Ethics Committee and is in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from every patient.
All interventions were performed according to current standard
guidelines with the ﬁnal interventional strategy (including use of
periprocedural glycoprotein IIb/IIIa inhibitors) at the operator’s dis-
cretion. All patients were advised to maintain lifelong aspirin. At
least 1-month clopidogrel treatment (75 mg/d) was recommended
for patients treated in the pre-SES phase. For patients treated
with SES, clopidogrel was prescribed for at least 3 months, unless
one of the following was present (in which case clopidogrel was
maintained for at least 6 months): multiple SES implantation (.3
stents), total stented length .36 mm, chronic total occlusion, and
bifurcations.
Determination of costs
For each index procedure, detailed resource use and costs were
recorded on a dedicated electronic database, together with the
actual costs for 2001 and 2002 and calculated on the basis of
equipment opened during the angioplasty, irrespective of its
actual use in the patient. With respect to costs, the analysis was
limited to direct medical costs. The actual price paid for per SES
was E1929 euros, while the average weighted price of a bare
stent in the study period was E692. Medication costs were
obtained for glycoprotein IIb/IIIa inhibitors and contrast, while
for the others, a reasonable assumption of E150 per patient was
made to cover the costs of other intra-procedural medications
(e.g. heparin, nitrates, saline, beta-blockers, etc.). The cost of
post-procedural clopidogrel in both groups was calculated on the
basis of duration of prescription determined at the completion of
the index procedure.
Lengths of hospital stay were calculated by querying the hospi-
tal’s admission and discharge database, which records the date of
admission and discharge, into and out of individual wards.
Consequently, admissions to a particular type of ward are con-
sidered on a per day basis. As this hospital is a tertiary referral
centre, the majority of discharges are to referring or peripheral hos-
pitals. Length of stay was calculated from the time of the procedure
up to the point of discharge from this hospital. Unit costs were esti-
mated on the basis of detailed information from our institution
following an approach similar to that reported previously.8
Follow-up costs were estimated according to the need for repeat
revascularization. As the incidence of death and myocardial infarc-
tion (MI) between both groups did not differ, they were not
costed.4,5 A re-intervention was deﬁned as any target-vessel revas-
cularization (TVR) (percutaneous or surgical). Costs of
re-intervention were estimated as the product of the event multi-
plied by the cost per event taken from the RAVEL study, adjusted
for inﬂation.11 The costs of outpatient visits, related work-up, and
other ongoing medications were not tracked.
Determination of effectiveness and
cost-effectiveness analysis
Major adverse cardiac events were deﬁned as (1) death, (2) non-
fatal MI, or (3) TVR. An MI was diagnosed by a rise in the creatine
kinase-MB fraction of more than three times the upper limit of
normal. A TVR was deﬁned as a repeat intervention (surgical or per-
cutaneous) driven by any lesion located in the same epicardial
vessel(s) as the treated lesion(s). The results of both the 1 and
2-year clinical follow-up have been published.4,5
For the purposes of the cost-effectiveness analysis, the following
assumptions were required. The incidence of repeat revasculariza-
tion is given as whole numbers and the proportion estimated
according to the Kaplan–Meier method. There were a dispropor-
tionate number of post-procedural coronary angiograms performed
in the SES period, due to the repeat angiography mandated in
‘complex’ patients, typically with SES implanted in bifurcations,
left main coronary, chronic total occlusions, very small vessels,
long stented length (.36 mm), and acute MI.4 Because of the well-
known effect of angiographic re-evaluation in increasing the inci-
dence of repeat revascularization,12 all re-interventions in the
ﬁrst year were retrospectively adjudicated and classiﬁed as clini-
cally driven or non-clinically driven by a group of clinicians not
involved in the treatment of the particular patient analysed.4
Clinically driven repeat revascularizations were deﬁned as any
intervention motivated by a signiﬁcant luminal stenosis (.50%
diameter stenosis) in the presence of anginal symptoms and/or
proven myocardial ischaemia in the target-vessel territory by
non-invasive testing. No mandated angiographic re-study was
performed in the pre-SES group.
In order to correct for the excess additional costs related to the
mandatory angiographic studies in the SES group, it was assumed
that the actual number of clinically driven restudies would be pro-
portionate to the number of clinically driven re-interventions.
Therefore, the number of patients that would have had clinically
driven angiography could be calculated from the ﬁgures found in
the pre-SES phase. As clinically driven re-interventions in the SES
phase were less frequent than in the pre-SES by a factor of 0.356,
the number of patients who would have undergone clinically
driven re-study in the absence of mandatory angiographic follow-up
was calculated as 0.356 proportion of patients in pre-SES group
with angiography  number of patients in SES group. From this, it
was estimated that 24 patients would have had a re-study in the
SES group.
Statistical analysis
Continuous variables are presented as mean+ SD and were com-
pared by means of the Student unpaired t-test. Categorical vari-
ables are presented as counts and percentages and compared by
means of the Fisher exact test. Resource use is reported on a per
patient basis. Cost data are reported as both mean and median
values and compared by t-tests. All statistical and cost-
effectiveness analysis were performed on an intention-to-treat prin-
ciple. All statistical tests were two-tailed.
The uncertainty surrounding the differences in costs and effects
were estimated using the bootstrapping technique. With bootstrap-
ping, average costs and effects were repeated 1000 times. Each
bootstrap provides a new estimate of average costs and average
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effects with the resulting 1000 estimates summarized in terms of a
distribution. Truncating the upper and lower 2.5% of the distribution
provides the 95% conﬁdence intervals which are then demonstrated
visually. This is a useful method when the distribution cannot be
obtained in a classic way.13 Furthermore, additional graphical rep-
resentation of the bootstrapping results are presented with 5%,
50%, and 95% probability ellipses, to describe their degree of
uncertainty.
Cost-effectiveness was measured as the ICER per repeat revascu-
larization avoided. It is obtained by dividing the difference in
medical costs expended by our institution at the end of one and
2 years for the two treatment groups by the difference in repeat
revascularization rates over the same time frames.9
Results
Baseline and procedural characteristics
The RESEARCH registry was a real-world study into
drug-eluting stent use, and enrolled all-comers. The base-
line and procedural characteristics in Table 1 reﬂect the
complex patient demographics typically seen in a tertiary
referral centre for PCI. Both groups were reasonably well
matched for baseline characteristics, with the exception
of previous MI being more common in the pre-SES group.
Over half of the patients presented with an acute coronary
syndrome, and an acute MI was the reason for intervention
in 18% of patients.
Major adverse cardiac events
The 1 and 2-year results of the RESEARCH registry have been
published.4,5 Brieﬂy, the combined outcome of death or MI
was similar and the difference in major adverse cardiac
events was driven by the reduction in the need for repeat
revascularization, deﬁned as TVR in the SES group.
Similarly, at 2 years, the reduction in major adverse
cardiac events was again due to the reduction in TVR in
the SES group.
At the end of 1 year, less patients underwent a re-
intervention procedure in the SES group (3.65% in the SES
group as compared with 10.4% in the pre-SES group,
P , 0.001; Table 4, Figure 1). During the ﬁrst year of
follow-up, because of mandated angiographic re-study, sig-
niﬁcantly more patients underwent coronary angiography
in the SES period compared with the BMS period, 175 vs.
59, P, 0.001). At 2 years, the difference in re-intervention
Table 1 Baseline and procedural characteristics
Pre-SES group (n ¼ 450) SES group (n ¼ 508) P-value
Male, n (%) 317 (72) 345 (68) 0.4
Age, years+ SD 61+ 11 61+ 11 0.7
Diabetes, n (%) 67 (15) 90 (18) 0.3
Non-insulin-dependent, n (%) 49 (11) 60 (12) 0.7
Insulin-dependent, n (%) 18 (4) 30 (6) 0.2
Hypertension, n (%) 169 (48) 210 (41) 0.2
Hypercholesterolaemia, n (%) 249 (55) 282 (56) 1.0
Current smoking, n (%) 153 (34) 156 (31) 0.3
Previous MI, n (%) 176 (40) 152 (30) 0.002
Previous angioplasty, n (%) 81 (18) 95 (19) 0.8
Previous coronary bypass surgery, n (%) 36 (8) 47 (9) 0.5
Single-vessel disease, n (%) 235 (52) 232 (46) 0.05
Multivessel disease, n (%) 215 (48) 275 (54) 0.05
Clinical presentation — — 0.8
Stable angina, n (%) 214 (48) 227 (45) —
Unstable angina, n (%) 156 (35) 189 (37) —
Acute MI, n (%) 80 (18) 92 (18) —
Cardiogenic shock, n (%)a 9 (12) 9 (10) 0.7
Treated vessel
Left anterior descending, n (%) 267 (59) 298 (59) 0.8
Left circumﬂex, n (%) 149 (33) 161 (32) 0.7
Right coronary artery, n (%) 153 (34) 196 (39) 0.2
Left main coronary, n (%) 10 (2) 15 (3) 0.6
Bypass graft, n (%) 9 (2) 17 (3) 0.2
Lesion type
Type A, n (%) 88 (20) 111 (22) 0.4
Type B1, n (%) 143 (32) 156 (31) 0.7
Type B2, n (%) 223 (50) 247 (49) 0.8
Type C, n (%) 134 (30) 216 (43) 0.000
Bifurcation stenting, n (%) 35 (8) 80 (16) 0.000
Number of stented segments+ SD 1.8+ 0.9 2.0+ 1.0 0.000
Individual stent length 33 mm, n (%) 44 (10) 178 (35) 0.000
Total stented length per patient, mm+ SD 30.1+ 19.6 38.7+ 28.7 0.000
Nominal stent diameter 2.5 mm, n (%) 102 (23) 183 (36) 0.000
Post-dilatation with a balloon 0.5 mm larger, n (%) 85 (19) 249 (49) 0.000
Angiographic success of all lesions, n (%) 438 (97) 494 (97) 1.0
aRelative to acute MI.
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rates widened from 6.75 to 8.3%. (a cumulative incidence of
6.4 vs. 14.7% respectively, P, 0.001).
Resource use at index procedure
The procedural equipment use is listed in Table 2 with the
results expressed as mean number of items consumed per
patient. On a per patient basis, signiﬁcantly more guiding
catheters, coronary wires, balloons, and contrast were
used, and more stents were implanted resulting in a
longer procedural time in the SES phase compared with
the pre-SES phase. This reﬂects the increased complexity
of cases seen in the SES phase. Post-procedurally, total
in-hospital stay at our institution was similar, 2.6 days in
the pre-SES phase and 2.0 days in the SES group, P ¼ 0.15.
Costs of index procedure
The overall average per patient cost of the index procedure
was E6887 in the pre-SES group and E9924 in the SES group,
an excess of E3036 in the SES group (Table 3), driven by the
difference of E2925 due to the price premium of SES.
Costs at follow-up
At 1-year follow-up, the difference in costs had narrowed
from E3036 to E1968 due to the reduction in
re-interventions (Table 4). At the end of 2 years following
the index procedure, this difference further narrowed to
E1869, due to a non-signiﬁcantly fewer number of events
in the SES group in the second year of follow-up.
Cost effectiveness
Figures 2 and 3 depict the estimated differences in costs and
effectiveness of SES vs. BMS, at 1 and 2 years. All estimates
lie in the right-upper quadrant, indicating that SES are
clearly more effective but also more costly than BMS. Note
that the ellipse in Figure 4 is shifted downwards and out-
wards in the 2-year follow-up, as compared with the
1-year follow-up, although not signiﬁcantly.
On the basis of costs and results obtained from the
RESEARCH registry, the ICER was then calculated. In the
1-year analysis, the ICER for SES was calculated at E29 373
per repeat revascularization avoided; while at the end of
2 years, this number had decreased to E22 627 per repeat
revascularization avoided (Table 4).
From this ratio, a straight-line relationship exists between
the unit price of a new device vs. the ICER at a given unit
price of the old device (Figure 4). Thus, at a price of E692
per bare stent for the bare stent group (the actual
average weighted price of BMSs in this registry), the calcu-
lated cost neutral price for the DES would be E1023 with
the 1-year result of this registry, while at the maximum
acceptable threshold of E10 000 per repeat revasculariza-
tion avoided,9 the highest price would be E1336 per DES.
At 2 years, the cost neutral price and the cost at the
E10 000 threshold declined slightly (E1069 and E1452,
respectively) due to the non-signiﬁcant reduction in events
in the second year.
Discussion
The primary ﬁnding of this analysis of the RESEARCH registry
is that based on the price of E1929 per SES paid by our insti-
tution in April 2002, the unrestricted use of SES was not
cost-effective to our institution, at either 1 or 2 years,
using the acceptable maximum threshold of E10 000 per
repeat revascularization avoided. Using 1-year costs and
effects, the calculated cost-neutral price for SES was
E1023; while at the acceptable threshold of E10 000 per
repeat revascularization avoided, the calculated price was
E1336 per SES. With the inclusion of second year costs, in
association with a further non-signiﬁcant reduction in
events in the second year, the cost neutral price was
E1069 or E1452 at the E10 000 threshold.
Speciﬁc features of this study
As a tertiary referral centre with a feeder population of 14
peripheral hospitals, our institution has a policy of returning
stable patients to their referral hospital or to the hospital in
their catchment area. Unstable patients and patients from
our catchment area are treated at our institution until
such time that they are suitable for discharge home or dis-
charge to their local hospital. In the combined population,
only 4.1% of patients were admitted for longer than 10
days at our institution.
The introduction of SES in the second period of the
RESEARCH registry created a real-world imbalance. Despite
similar presenting symptoms and clinical characteristics,
more segments were treated, resulting in longer stented
lengths and the use of more stents. Although this resulted
in higher costs to the SES group, it reﬂects daily practice
outside of clinical trials, where the introduction of DES has
resulted in the implantation of more stents. Furthermore,
the ongoing use of DES at our institution resulted in the treat-
ment of more complex patients, with even longer stented
lengths implanted in the following year.14
Costs outside randomized trials
Cost-effectiveness studies from the randomized RAVEL and
SIRIUS trials have been published. In both these studies,
use of SES resulted in additional 1-year costs of E166 and
US$309 in the SES groups, respectively (NB E1  US$1.30
April 2005). The additional cost of DES was effectively
negated by the decreased follow-up costs resulting from a
decrease in the need for repeat intervention. In this
present study, the reduction in follow-up costs were insufﬁ-
cient to compensate for the elevated index cost, when
Figure 1 Clinically driven re-intervention (TVR) in the RESEARCH Registry
at 2-year follow-up.
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measured at the end of either 1 or 2 years. The respective
excess cost in the SES group were E1968 and E1869,
respectively, much higher than that reported from the ran-
domized trials. This reﬂects the results of DES use outside
of trials.
Acceptable cost of DES outside randomized trials
The results of RAVEL and SIRIUS would suggest that the
prices of DES of E2000 and US$2900 are reasonably cost-
effective. At the time this registry was conducted, the
price of DES paid for by our institution was E1929 while
the price of bare stents was E692, reﬂecting the prices of
April 2002. Since that time, paclitaxel-eluting stents
(Boston Scientiﬁc Corporation) have been introduced, and
zotarolimus-eluting stents (Medtronic Corporation) have
recently received CE mark certiﬁcation. This increased com-
petition, together with an increasing market share of DES,
will serve to bring down prices of DES to that judged as cost-
effective in our model. Correspondingly, as the market share
of BMSs shrink, their prices will also fall, thus necessitating
that the price of DES fall even further than that predicted.
Given a not unreasonable bare stent price of E400 today, a
DES would have to fall to E779 to be cost-neutral within the
framework of the model presented here.
Comparison with other ‘real-world’ trials
The BASKET ‘real-world’ randomized study demonstrated
that at 6 months, DES were on average, E905 more
Table 2 Resource use at index procedure
Index procedure BMS (n ¼ 450) SES (n ¼ 508) Difference (95% CI) P-value
Equipment use during the index
procedure, expressed as units used
per patient unless stated otherwise
Basic diagnostic packet (includes 0.035 in. wire) 1.00 1.01 0.00 (20.01; 0.01) 0.5
Diagnostic catheter, n 0.63 0.50 0.13 (0.01; 0.25) 0.03
Guiding catheter, n 1.43 1.59 20.16 (20.27; 20.05) 0.003
Additional 0.035 in. wire, n 0.16 0.19 20.03 (20.09; 0.03) 0.3
0.014 in. coronary wire, n 1.62 2.07 20.45 (20.63; 20.28) ,0.001
Coronary balloon, n 1.30 1.81 20.50 (20.68; 20.32) ,0.001
Multifunctional probing catheter, n 0.08 0.06 0.02 (20.01; 0.05) 0.3
Pressure/Flow/Doppler wire, n 0.08 0.07 0.10 (20.03; 0.05) 0.6
IVUS catheter, n 0.15 0.18 20.02 (20.08; 0.03) 0.4
Atherectomy catheter, n 0.01 0.01 0.00 (20.01; 0.01) 0.9
Cutting balloon, n 0.03 0.02 0.01 (20.01; 0.03) 0.3
Thrombectomy catheter, n 0.00 0.01 20.01 (20.02; 0.01) 0.4
Distal protection device, n 0.01 0.01 0.00 (20.02; 0.01) 0.5
Swan Ganz catheter, n 0.02 0.04 20.01 (20.03; 0.01) 0.3
Temporary pacing wire, n 0.02 0.02 20.01 (20.02; 0.01) 0.5
Intra-aortic balloon pump, n 0.02 0.02 0.01 (20.01; 0.02) 0.5
Femoral artery closure device, n 0.47 0.53 20.06 (20.13; 0.01) 0.08
Bare stent, n 1.81 —
Covered stent, n 0.01 —
Drug-eluting stent, n — 2.16
Contrast volume, mL+ SD 253+ 118 284+ 137 231 (249; 212) 0.001
Abciximab use, % 33 19 14 (8; 20) ,0.001
Clopidogrel prescription, months+SD 2.9+ 2.0 4.0+ 2.0 21.1 (21.4; 1.0) ,0.01
Procedure time, mins+ SD 92+ 43 107+ 48 215 (221;2 9) ,0.001
Post-procedural hospital stay
ICU, days 0.06+ 0.75 0.01+ 0.11 0.05 (20.01;0.12) 0.12
CCU, days 0.56+ 1.87 0.54+ 2.14 0.02 (20.24;0.28) 0.9
General ward, days 2.27+ 4.76 1.56+ 4.1 0.71 (0.15;1.27) 0.01
Table 3 Costs at index procedure, expressed on a per patient basis
Index procedure BMS SES Difference (95% CI of the difference) P-value
Cost of stents, E+ SD 1266+ 771 4192+ 2791 22925 (23192; 22659) 0.000
Cost of consumables (excluding stents),
E+ SD
1575+ 772 1819+ 938 2244 (2353; 2134) 0.000
Medication, E+ SD 765+ 529 685+ 473 79 (15; 143) 0.015
Laboratory cost, E+ SD 1790+ 841 2078+ 937 2288 (2401; 2174) 0.000
Post-procedural hospital stay, E+ SD 1491+ 3323 1150+ 3350 341 (283; 2765) 0.11
Total cost at index, E+ SD 6887+ 3962 9924+ 5734 23036 (23669; 22403) 0.000
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expensive per patient when compared with BMS. In that
study, the price difference between DES and BMS were con-
siderably less than in this study, resulting in a calculated
ICER of less than E20 000 per major event avoided, as
opposed to the E29 373 at 1 year, and E22 627 at 2 years
per repeat revascularization avoided in our series. Despite
the smaller difference, the results of the present study are
in concordance with their ﬁndings, and has the advantage
of extended follow-up out to 2 years.
Implications of prolonged follow-up
A speciﬁc feature of this report is the prolonged follow-up
out to 2 years. The non-signiﬁcant widening of the treat-
ment effect from the ﬁrst to the second year resulted in low-
ering of the ICER by almost E7000, but not sufﬁcient to
make the ﬁnding cost-effective. It remains to be seen if pro-
longed follow-up out to 5 years will equalize the groups,
however, most cost-effectiveness studies are generally
limited to short-term follow-ups of 1 year.
Applicability to other drug-eluting stent systems
and to newer bare-stent systems
This study was a speciﬁc comparison between SES and BMS,
and since both pricing and efﬁcacy of the different DES
systems in the market today vary, the results of this study
may not be totally generalizable to other systems.
However, given the ongoing price premium and better out-
comes of DES, this study may therefore be used as a guide.
Similarly, there are now newer generation BMS, such as
those incorporating non-drug-eluting coatings (e.g. carbon-,
titanium oxide-, and CD34 antibody-coated stents),15,16
which have demonstrated better restenosis rates than con-
ventional BMS used in this study and consequently, the possi-
bility exists that the differential beneﬁt of DES may be
reduced when compared against these newer BMS devices.
Limitations
By design, the costs in this study speciﬁcally reﬂect pro-
cedural and follow-up costs directly impacting on our insti-
tution. It is therefore an institutional as opposed to a
Figure 2 Estimates of differences in cost and effects after bootstrapping
analysis based on the normal distributions surrounding the estimates of the
relative risks at one (top panel) and 2 years (bottom panel), respectively.
All points reside in the top-right quadrant, signifying that SESs are more
effective, but more expensive than BMSs, both at 1 and at 2 years following
implantation.
Table 4 Costs, effectiveness, differences in costs and effectiveness at the end of 1 and 2 years, expressed on a per patient basis
Follow-up events BMS
events, n
BMS
events, %
BMS
cost, E
SES
events, n
SES
events, %
SES
cost, E
Difference,
(95% CI)a
First year of follow-up
Clinically driven
repeat revascularization
45 10.4b 18 3.65b 6.75 (3.0;9.4)
Re-PCI 35 8.1 695 16 3.3 279
CABG 10 2.3 393 2 0.4 69
Total coronary angiography 59 13.1 506 175 3.45 177
Total follow-up cost 1594 525c
Total cost at 1 year 8481 10 449 2E1968 (2E2854;
2E1212) ICER ¼ 29 373
(14 659; 83 884)
Second year of follow-up
Repeat revascularization 18 4.3 13 2.75 8.3 (3.8;11.4)
Re-PCI 16 3.8 331 11 2.3 203
CABG 2 0.5 82 2 0.4 73
Coronary angiography 17 3.8 148 24 4.7 185
Total follow-up cost 561 461
Total cost at 2 years 9042 10 911 2E1869 (E2796;
E1080) ICER ¼ 22 627
(10 737; 65 978)
a95% conﬁdence intervals calculated using the bootstrap method. The comparison of costs and effectiveness are presented in Figures 3 and 4.
bEvent rate derived from Kaplan–Meier estimates.
cCorrection factor of 0.35 applied to coronary angiograms in the SES phase relative to the BMS phase.
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societal analysis, and therefore underestimates the true
overall societal cost by not accounting for total length of
stay in other hospitals nor costs associated with follow-up
visits and work-up for recurrent symptoms. This was a
necessary limitation, given the tertiary referral nature of
our practice and the multiple complex co-morbidities seen
in this ‘real-world’ population.
Conclusion
The lower differential effect in real-world outcomes,
together with increased material use compared with ran-
domized trials combine to reduce the cost-effectiveness of
SESs compared with BMSs. On the basis of our ﬁndings,
prices of SES need to be further reduced in order to
become cost-effective.
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OBJECTIVES The long-term (ﬁve-year) comparative results of treatment of multivessel coronary artery
disease with stenting or coronary artery bypass grafting (CABG) is at present unknown.
BACKGROUND The Arterial Revascularization Therapies Study (ARTS) was designed to compare CABG
and stenting in patients with multivessel disease.
METHODS A total of 1,205 patients with the potential for equivalent revascularization were randomly
assigned to CABG (n 605) or stent implantation (n 600). The primary clinical end point
was freedom from major adverse cardiac and cerebrovascular events (MACCE) at one year;
MACCE at ﬁve-year follow-up constituted the ﬁnal secondary end point.
RESULTS At ﬁve years, there were 48 and 46 deaths in the stent and CABG groups, respectively (8.0%
vs. 7.6%; p  0.83; relative risk [RR], 1.05; 95% conﬁdence interval [CI], 0.71 to 1.55).
Among 208 diabetic patients, mortality was 13.4% in the stent group and 8.3% in the CABG
group (p  0.27; RR, 1.61; 95% CI, 0.71 to 3.63). Overall freedom from death, stroke, or
myocardial infarction was not signiﬁcantly different between groups (18.2% in the stent group
vs. 14.9% in the surgical group; p  0.14; RR, 1.22; 95% CI, 0.95 to 1.58). The incidence
of repeat revascularization was signiﬁcantly higher in the stent group (30.3%) than in the
CABG group (8.8%; p  0.001; RR, 3.46;95% CI, 2.61 to 4.60). The composite event-free
survival rate was 58.3% in the stent group and 78.2% in the CABG group (p  0.0001; RR,
1.91;95% CI, 1.60 to 2.28).
CONCLUSIONS At ﬁve years there was no difference in mortality between stenting and surgery for multivessel
disease. Furthermore, the incidence of stroke or myocardial infarction was not signiﬁcantly
different between the two groups. However, overall MACCE was higher in the stent group,
driven by the increased need for repeat revascularization. (J Am Coll Cardiol 2005;46:
575–81) © 2005 by the American College of Cardiology Foundation
A meta-analysis including nine trials of multivessel coronary
artery disease treated by percutaneous balloon angioplasty
alone or coronary artery bypass grafting (CABG) showed a
statistically signiﬁcant beneﬁt in terms of survival in favor of
surgery at ﬁve and eight years (1). However, these survival
data were from early studies that did not use stents in the
initial revascularization procedure. The Stent or Surgery
Trial (SoS), which involved the use of stents, reported
similar ﬁndings after a median follow-up of two years (2).
However, the Argentine Randomized Trial: Coronary An-
gioplasty with Stenting versus Coronary Bypass Surgery
With Multivessel Disease (ERACI-II) suggested that the
trend in favor of CABG for survival at 2.5 years was no
longer present in the stent era (3).
There are currently no data available on the comparative
survival after multivessel stenting or CABG beyond three
years. The present study reports on the ﬁve-year survival and
event-free survival of the patients enrolled in the Arterial
Revascularization Therapies Study (ARTS) trial (4).
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METHODS
The study protocol, summarized here, has been previously
published (4,5).
Population. Between April 1997 and June 1998, 1,205
patients from 67 participating centers were randomized to
either stent implantation (n  600) or CABG (n  605).
The study population included 208 diabetic patients. The
indications for revascularization included silent ischemia,
stable or unstable angina pectoris, and the presence of at
least two de novo lesions located in different major epicar-
dial coronary arteries, potentially amenable to stent implan-
tation. For each patient, entry into the study required
agreement from both surgeon and interventional cardiolo-
gist that an equivalent degree of revascularization could
potentially be obtained using either approach.
Speciﬁc exclusion criteria from the randomized trial may
be summarized as follows: left ventricular ejection fraction
30%, left main stenosis, history of a cerebrovascular
accident, transmural myocardial infarction within the pre-
ceding week, and severe hepatic or renal disease and need
for concomitant major surgery. All patients gave written
informed consent.
Five-year clinical follow-up. The study protocol required
all patients to have follow-up clinic visits with an electro-
cardiogram at one, two, and three years. In addition, at the
ﬁve-year clinical follow-up, anginal status and use of med-
ications were assessed. Additional information was obtained
by telephone interview or via the referring physician when
needed. An independent committee adjudicated clinical
events and electrocardiograms.
Subgroup analysis. Pre-speciﬁed analyses were performed
on diabetics versus non-diabetics and two- versus three-
vessel disease. In addition, post-hoc analyses were per-
formed on the following subgroups: proximal left anterior
descending versus non-proximal left anterior descending
lesions, renal status, gender, and age.
Clinical end points and effectiveness. The primary end
point was deﬁned as the absence of any of the following
major adverse cardiac and cerebral events (MACCE) within
12 months after randomization: death (all-cause mortality),
cerebrovascular accident, documented non-fatal myocardial
infarction adjudicated by either new abnormal Q-wave or
predeﬁned enzymatic changes, or repeat revascularization by
coronary stenting or CABG (4,5).
Secondary objectives of the study were to compare both
strategies at three and ﬁve years. The MACCE were
counted from the time of randomization, whereas the
clinical status and medications were assessed at predeter-
mined times of one, two, three, and ﬁve years post-procedure.
Of 1,205 patients enrolled in the trial, complete follow-up was
available at ﬁve years in 590 of 600 (98.3%) stent patients and
584 of 605 (96.6%) CABG patients (Fig. 1).
Statistical analysis. Statistical analysis was performed with
SAS 6.12 software (SAS Institute Inc., Chicago, Illinois).
Binary outcome variables are reported as frequencies and
percentages and were compared in terms of relative risk with
95% conﬁdence intervals calculated by the formula of
Greenland and Robins (6). The Fisher exact test was used
for categorical variables. All analyses were based on the
intention-to-treat principle, and statistical tests were two-
tailed. Event-free survival was estimated using the Kaplan-
Meier method, and differences were assessed using the
log-rank test. The sample size calculation to achieve ade-
quate power for an inferiority study was based on the
difference in event-free survival at one year (4). For this
ﬁve-year report on late outcomes, no new calculations were
performed.
RESULTS
Table 1 shows the baseline and procedural characteristics of
the ARTS trial’s randomized patients. The randomized
groups were similar with respect to their demographic and
anatomic characteristics. Five patients, one assigned to
stenting and four assigned to surgery, did not undergo
coronary revascularization and instead continued to receive
only medical therapy (4). The average interval between
randomization and treatment was 27  39 days (range, 0 to
362 days) for patients in the surgery group and 11 16 days
(range, 0 to 173 days) for patients in the stenting group.
Three patients died while waiting for surgery, 6 patients
randomly assigned to stent implantation were instead
treated surgically, and 19 patients randomly assigned to
bypass surgery were instead treated with stent implantation.
A total of 99% of patients in the stenting group (593
patients) and 93% in the surgery group (579 patients)
received the assigned treatment. An equivalent anatomical
degree of revascularization was achieved in each group.
During the initial hospital stay, after complicated or
unsatisfactory angioplasty procedures, 14 patients assigned
to stent implantation underwent bypass surgery, 3 urgently
and 11 electively. Conversely, two patients underwent an
angioplasty procedure after surgical revascularization during
their initial hospital stay (Fig. 1).
Five-year clinical outcome. At ﬁve years, there were 48
deaths in the stent group and 46 deaths in the surgical
group, which represents 8.0% and 7.6% of the respective
cohorts (p  0.83; relative risk [RR], 1.05; 95% conﬁdence
interval [CI], 0.71 to 1.55) (Table 2, Fig. 2). The incidence
of cardiac death was not signiﬁcantly different between the
groups (Table 3). Of the 94 deaths, 6 occurred within 30
days after a repeat revascularization procedure.
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapies Study
CABG  coronary artery bypass grafting
CI  conﬁdence interval
MACCE  major adverse cardiac and cerebral event
PCI  percutaneous coronary intervention
RR  relative risk
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The incidence of death, stroke, or myocardial infarction
was not signiﬁcantly different among the groups (18.2% in
the stent group vs. 14.9% in the surgical group; p  0.14;
RR, 1.22; 95% CI, 0.95 to 1.58).
The incidence of repeat revascularization was signiﬁ-
cantly higher in the stent group (30.3%) than in the CABG
group (8.8%; p  0.001; RR, 3.46; 95% CI, 2.61 to 4.60).
At the end of ﬁve years, 10.5% of patients originally
assigned to stenting required CABG and 23.2% underwent
a second percutaneous coronary intervention (PCI). Con-
versely, 1.2% of patients assigned to CABG required re-
operation and 8.3% required revascularization with PCI. In
the stent group, the majority of re-interventions (69%) took
place within the ﬁrst year, whereas in the CABG group, the
majority of the re-interventions (57%) occurred after the
ﬁrst year. The overall MACCE-free survival at ﬁve years
was 58.3% in the stent group and 78.2% in the CABG
group (p  0.0001).
At ﬁve years, there was a signiﬁcant difference in the
presence of anginal symptoms between the two treatment
groups (21.2% of the stent patients vs. 15.5% of the CABG
patients, p  0.05). More of the stent patients were on
short-acting nitrates (6.1% vs. 2.4%, p  0.003), long-
acting nitrates (19.6% vs. 11.6%, p  0.001), beta-blocker
therapy (53.9% vs. 46.5%, p  0.016), and calcium-channel
antagonists (29.1% vs. 18.9%, p  0.001).
Figure 1. Flow chart. CABG  coronary artery bypass grafting.
Table 1. Baseline and Procedural Characteristics of
ARTS Population
Stent
(n  600)
CABG
(n  605)
No. of patients not revascularized 1 7*
No. of cross-overs 6 19
Age (yrs),  SD 61  10 61  9
Male gender (%) 77 76
Body mass index (kg/m2),  SD† 27.2  3.7 27.4  3.7
Diabetes (%)‡ 19 16
Hypertension (%)§ 45 45
Hypercholesterolemia (%) 58 58
Current smoker (%) 28 26
Previous myocardial infarction 44 42
Unstable angina (%) 37 35
Ejection fraction (%) 61  12 60  13
No. of diseased vessels (% of patients)
1 2 0
2 68 67
3 30 33
No. of lesions with stenosis 50% 2.83  1.02 2.80  1.04
No. of lesions treated 2.60  1.10 2.60  1.00
Lesions treated with stent (%) 89 –
Patients with arterial conduit (%) – 93
*Includes three patients who died while waiting for surgery. †The body mass index is
determined as the weight in kilograms divided by the square of the height in meters.
‡Diabetes was deﬁned as a patient whose condition was controlled by diet, oral
hypoglycemics, or insulin. §Hypertension was deﬁned as a blood pressure of 160/95
mm Hg in repeated measurements or patients on anti-hypertensive medication and/or
requiring medical treatment. Hypercholesterolemia was deﬁned as a total cholesterol
6.5 mmol/l or patients on anti-hypercholesterolemic therapy.
CABG  coronary artery bypass graft; SD  standard deviation.
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Patients with diabetes. In patients with diabetes, those
who underwent stenting had a mortality rate of 13.4%,
versus 8.3% in those who underwent CABG (p 0.27; RR,
1.61; 95% CI, 0.71 to 3.63) (Tables 4 and 5). Within the
stent group, diabetic patients had a signiﬁcantly higher
mortality rate than non-diabetic patients (13.4% vs. 6.8%; p
 0.03; RR, 1.98; 95% CI, 1.11 to 3.52). In stent diabetic
patients, death was attributed to a cardiac cause in 50% of
cases versus 38% (p 0.43; RR, 1.32; 95% CI, 0.68 to 2.58)
in non-diabetic stent patients. There was no signiﬁcant
mortality difference between the diabetic and non-diabetic
patients within the CABG group (8.3% vs. 7.5%; p  0.8;
RR, 1.12; 95% CI, 0.54 to 2.32).
Diabetic patients treated with stenting also had a lower
event-free survival at ﬁve years than non-diabetic pa-
tients. The MACCE rate at ﬁve years in diabetic patients
treated with stents was 54.5%, versus 38.7% in non-
diabetics (p  0.003). Conversely, there was no signiﬁ-
cant difference in the ﬁve-year MACCE rate between
diabetic and non-diabetic patients treated with CABG
(25.0% vs. 21.2%, p  0.42). The difference in MACCE
rate between diabetic and non-diabetic patients treated
with stenting is largely attributable to the higher rate of
repeat revascularization in diabetic patients (42.9% vs.
27.5%, p  0.002).
Two- versus three-vessel treatment. There was no signif-
icant difference in event-free survival rate between patients
with two or three vessels treated with stenting (56.7% vs.
60.1%) or CABG (79.4% vs. 75.7%), respectively. However,
the event-free survival rate was signiﬁcantly higher for
patients treated with CABG than with stenting for both two
and three vessels (p  0.001 and p  0.001, respectively).
Other subgroup analyses. There were also no signiﬁcant
differences in event-free survival within the respective treat-
Table 2. Total Number of Patients With Major Clinical Events Within Interval of Time
(Randomization to 1, 3, and 5 Years)
Stent CABG
Relative Risk
(95% CI) p Value†Event n* %* n* %*
Death
0–1 yr 15 2.5 17 2.8 0.89 (0.45–1.77) 0.86
0–3 yrs 22 3.7 28 4.6 0.79 (0.46–1.37) 0.47
0–5 yrs 48 8.0 46 7.6 1.05 (0.71–1.55) 0.83
CVA
0–1 yr 12 2.0 13 2.1 0.93 (0.43–2.02) 1.00
0–3 yrs 20 3.3 20 3.3 1.01 (0.55–1.86) 1.00
0–5 yrs 23 3.8 21 3.5 1.10 (0.62–1.97) 0.76
Q-wave MI
0–1 yr 32 5.3 26 4.3 1.24 (0.75–2.06) 0.42
0–3 yrs 36 6.0 30 5.0 1.21 (0.76–1.94) 0.45
0–5 yrs 40 6.7 34 5.6 1.19 (0.76–1.85) 0.47
Non–Q-wave MI
0–1 yr 4 0.7 2 0.3 2.02 (0.37–10.97) 0.45
0–3 yrs 8 1.3 4 0.7 2.02 (0.61–6.67) 0.26
0–5 yrs 11 1.8 5 0.8 2.22 (0.78–6.35) 0.14
Composite death/CVA/MI
0–1 yr 57 9.5 52 8.6 1.11 (0.77–1.58) 0.62
0–3 yrs 79 13.2 70 11.6 1.14 (0.84–1.54) 0.43
0–5 yrs 109 18.2 90 14.9 1.22 (0.95–1.58) 0.14
CABG
0–1 yr 40 6.7 4 0.7 10.0 (3.63–28.0)  0.001
0–3 yrs 55 9.2 7 1.2 7.92 (3.64–17.3)  0.001
0–5 yrs 63 10.5 7 1.2 9.08 (4.19–19.7)  0.001
Repeat PCI
0–1 yr 94 15.7 20 3.3 4.74 (2.96–7.58)  0.001
0–3 yrs 120 20.0 37 6.1 3.27 (2.30–4.65)  0.001
0–5 yrs 139 23.2 50 8.3 2.80 (2.07–3.80)  0.001
Any revascularization
0–1 yr 126 21.0 23 3.8 5.52 (3.59–8.49)  0.001
0–3 yrs 160 26.7 40 6.6 4.03 (2.91–5.60)  0.001
0–5 yrs 182 30.3 53 8.8 3.46 (2.61–4.60)  0.001
Any event
0–1 yr 159 26.5 73 12.1 2.20 (1.71–2.83)  0.001
0–3 yrs 205 34.2 103 17.0 2.01 (1.63–2.47)  0.001
0–5 yrs 250 41.7 132 21.8 1.91 (1.60–2.28)  0.001
*Number of patients and percentage of patients with at least one occurrence of the speciﬁed clinical event during the time interval
indicated in the table. †p value calculated by the Fisher Exact test.
CABG  coronary artery bypass grafting; CI  conﬁdence interval; CVA  cerebrovascular accident; MI  myocardial
infarction; PCI  percutaneous coronary intervention.
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ment groups based on renal function, gender, age, or
hypercholesterolemia at the time of randomization. At ﬁve
years, 65.9% in the stent group and 61.5% in the CABG
group were on lipid-lowering agents. Outcomes in patients
who were treated for proximal left anterior descending
lesions or otherwise were not signiﬁcantly different stratiﬁed
by treatment group.
DISCUSSION
This is the ﬁrst randomized trial to report on ﬁve-year
outcomes of patients with multivessel coronary artery dis-
ease treated with bare metal stenting versus CABG. Al-
though this study was not speciﬁcally powered to detect a
difference in ﬁve-year mortality, there was no clinically
relevant difference (p  0.83) with these two forms of
treatment. This contemporary ﬁnding differs from the
meta-analysis of previous randomized trials of balloon
angioplasty alone versus CABG conducted in patients with
multivessel disease, which showed a signiﬁcantly higher
mortality rate with percutaneous treatment at ﬁve years (risk
difference, 2.3%; 95% CI, 0.29 to 4.3%; p  0.025) (1).
In this study, mortality in the CABG arm was 7.6% at
ﬁve years, lower than the composite death rate of 8.9% seen
in the CABG patients from the meta-analysis (1), evidence
that improved peri-operative management and intra-
operative techniques over time have resulted in a reduction
in mortality. Similarly, mortality in the stent arm was 8.0%,
a risk difference of 0.4% (95% CI, 1.1% to 1.9%; p  0.83).
From one to ﬁve years, the risk difference changes from
0.3% in favor of stenting at one year, to 0.9% in favor of
Table 3. Listing of Deaths and Causes of Death
Randomized to
PCI
n  600
CABG
n  605
Total deaths 48 46
Unknown 2 1
Non-cardiac 25 28
Cardiac 21 17
Related to repeat revascularization* 5 1
Repeat revascularization within 30
days of index procedure
4† 0
Repeat revascularization 30 days
of index procedure
1 1
*Cardiac death related to repeat revascularization was deﬁned as death within 30 days
of repeat procedure. †Three died within 30 days of the index procedure as a result of
subacute stent thrombosis, one died of a myocardial tear after CABG for a failed PCI
on day 12.
Abbreviations as in Table 2.
Figure 2. (A) Kaplan-Meier curves showing freedom from death. (B) Kaplan-Meier curves showing freedom from death/cerebrovascular accident/
myocardial infarction or revascularization. (C) Kaplan-Meier curves showing freedom from death/cerebrovascular accident/myocardial infarction or
revascularization. (D) Kaplan-Meier curves showing freedom from revascularization. CABG  coronary artery bypass grafting.
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stenting at three years, to 0.4% in favor of CABG at ﬁve
years (all not signiﬁcant), indicating a strong effect of
chance. Furthermore, this difference is not clinically relevant
and is much lower than the 2.3% of the meta-analysis.
There was a 3.3% absolute difference in the composite
end point of death, stroke, and myocardial infarction in
favor of CABG, primarily driven by a higher incidence of
myocardial infarctions in the stent arm. Although sugges-
tive, this study was underpowered to detect a signiﬁcant
difference in the end point. Based on this difference, a
population of 4,000 patients would be required for statistical
signiﬁcance.
The risk difference for revascularization at ﬁve years, as
reported in this same meta-analysis, was 38% (95% CI, 30%
to 47%). Speciﬁcally, the risk difference for subsequent
CABG was 24% and for subsequent percutaneous translu-
minal coronary angioplasty was 23%. The current observed
differences in the ARTS trial for any revascularization at ﬁve
years is 21.5%, for subsequent CABG is 9.3%, and for
subsequent PCI is 14.9%. It is worth noting that almost
90% of patients initially treated with stenting did not
require CABG over the succeeding ﬁve years. The differ-
ence in the rate of repeat revascularization between the two
groups increases over time from 17.2% at 1 year to 21.5% at
ﬁve years without a concomitant difference in mortality over
this time period. Despite the additional risk of repeat
revascularization in the stent group compared with the
CABG group, this did not translate into an increase in
mortality (Table 3).
In this study, four-ﬁfths of all patients in both groups were
free of anginal complaints at ﬁve years. Although signiﬁcantly
different, this high proportion of patients free of symptoms is
encouraging in this population of patients with chronic mul-
tivessel coronary artery disease. Correspondingly, more stent
patients than CABG patients were on anti-anginal medica-
tions (p  0.001) at ﬁve-year follow-up.
In diabetic patients from three trials comparing balloon
angioplasty with surgery, the risk difference for all death was
8.6% in favor of CABG (p  0.01; 95% CI, 2.2% to 15%)
(n  537 patients) at four years (1). In the present study
involving 208 diabetic patients, mortality at ﬁve years was
5.1% higher in stent patients compared with CABG pa-
tients (p  0.27). Conversely, in non-diabetic patients the
mortality rate was 0.7% lower in the stent cohort. However,
Table 4. Major Adverse Cardiac Events at 5 Years in Patients With Diabetes Stratiﬁed
According to Treatment
Stent Diabetes
n  112
n* (%*)
Bypass Diabetes
n  96
n* (%*)
Relative Risk
(95% CI)
Stent Versus
CABG
p Value†
Death 15 (13.4) 8 (8.3) 1.61 (0.71–3.63) 0.27
CVA 7 (6.3) 7 (7.3) 0.86 (0.31–2.36) 0.79
MI 12 (10.7) 7 (7.3) 1.47 (0.60–3.59) 0.47
Q-wave MI 9 (8.0) 4 (4.2) 1.93 (0.61–6.07) 0.39
Non–Q-wave MI 3 (2.7) 3 (3.1) 0.86 (0.18–4.15) 1.00
Composite death/CVA/MI 28 (25.0) 19 (19.8) 1.26 (0.76–2.11) 0.41
(re) CABG 17 (15.2) 2 (2.1) 7.29 (1.73–30.7) 0.001
(re) PTCA 34 (30.4) 9 (9.4) 3.24 (1.64–6.41) 0.001
Any revascularization 48 (42.9) 10 (10.4) 4.11 (2.20–7.68) 0.001
Any MACCE 61 (54.5) 24 (25.0) 2.18 (1.48–3.20) 0.001
*Number of patients and percentage of patients with at least one occurrence of the speciﬁed clinical event during the time interval
indicated in the table. †p value calculated using the Fisher exact test.
Abbreviations as in Table 2.
Table 5. Major Adverse Cardiac Events at 5 Years in Patients Without Diabetes Stratiﬁed
According to Treatment
Stent
Non-Diabetic
n  488
n* (%*)
Bypass
Non-Diabetic
n  509
n* (%*)
Relative Risk
(95% CI)
Stent Versus
CABG
p Value†
Death 33 (6.8) 38 (7.5) 0.91 (0.58–1.42) 0.71
CVA 16 (3.3) 14 (2.8) 1.19 (0.59–2.42) 0.71
MI 38 (7.8) 31 (6.1) 1.28 (0.81–2.02) 0.32
Q-wave MI 31 (6.4) 30 (5.9) 1.08 (0.66–1.75) 0.79
Non–Q-wave MI 8 (1.6) 2 (0.4) 4.17 (0.89–19.55) 0.059
Composite death/CVA/MI 81 (16.6) 71 (13.9) 1.19 (0.89–1.60) 0.25
(re) CABG 46 (9.4) 5 (1.0) 9.60 (3.85–23.95) 0.001
(re) PTCA 105 (21.5) 41 (8.1) 2.67 (1.90–3.75) 0.001
Any revascularization 134 (27.5) 43 (8.4) 3.25 (2.36–4.48) 0.001
Any MACCE 189 (38.7) 108 (21.2) 1.83 (1.49–2.23) 0.001
*Number of patients and percentage of patients with at least one occurrence of the speciﬁed clinical event during the time interval
indicated in the table. †p value calculated using the Fisher exact test.
Abbreviations as in Table 2.
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the study was not powered to show mortality differences
between diabetic and non-diabetic patients.
Repeat revascularization was higher in diabetic patients
randomized to the stent arm versus CABG (an absolute
difference of 32.5% [42.9% vs. 10.9%, respectively]), com-
pared with non-diabetic patients (a 19.1% absolute differ-
ence [27.5% vs. 8.4%, respectively, both p  0.001]). Based
on the available evidence, surgery should continue to be
viewed as the preferred therapy for diabetic patients with
multivessel disease when using bare metal stents.
The advent of drug-eluting stents has drastically reduced
the need for repeat revascularization in both diabetic and
non-diabetic patients. The relative reduction in need for
re-intervention with drug-eluting stents is very similar in
diabetic and non-diabetic patients (7,8). The difference in
outcomes seen between bare metal stents versus CABG for
the treatment of multivessel disease is likely to narrow
substantially with the advent of drug-eluting stents. The
U.S. National Institutes of Health is sponsoring a large
multicenter trial speciﬁcally to evaluate the difference in
outcomes in diabetic patients with multivessel coronary
disease treated with drug-eluting stents versus CABG. A
European multicenter trial comparing drug-eluting stents
versus CABG for the treatment of multivessel and left main
stem coronary disease in an all-comers population is cur-
rently in progress.
Despite the increasing age and concomitant increased
co-morbidity of patients presenting for CABG, clinical
outcomes have continued to improve (9). This was evident
from the lower mortality seen in the CABG arm of this
study compared with the older studies. The off-pump
coronary bypass technique, developed to minimize the
invasiveness of CABG, has in several large retrospective
studies suggested a reduction in morbidity and/or mortality
when compared with CABG (10). Larger randomized trials
are required to address this issue deﬁnitively because the
three reported randomized prospective studies comparing
off-pump coronary bypass with CABG were not large
enough to detect a difference in operative mortality or stroke
(10). Finally, the routine use of post-procedural medica-
tions—aspirin, statins, and control of risk factors—will
further improve outcomes in both the CABG and the stent
groups in future trials.
Reprint requests and correspondence: Prof. Patrick W. Serruys,
Head of the Interventional Cardiology Department, Ba 583,
Thoraxcenter, Erasmus Medical Center Rotterdam, Dr. Molewa-
terplein 40, 3015 GD, Rotterdam, the Netherlands. E-mail:
p.w.j.c.serruys@erasmusmc.nl.
REFERENCES
1. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong
JB. A meta-analysis of randomized controlled trials comparing coro-
nary artery bypass graft with percutaneous transluminal coronary
angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:
1293–304.
2. Stables RH. Coronary artery bypass surgery versus percutaneous
coronary intervention with stent implantation in patients with mul-
tivessel coronary artery disease (the Stent or Surgery trial): a random-
ized controlled trial. Lancet 2002;360:695–70.
3. Rodriguez A, Bernardi V, Navia J, et al. Argentine randomized study:
coronary angioplasty with stenting versus coronary bypass surgery in
patients with multiple-vessel disease (ERACI II): 30-day and one-year
follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001;
37:51–8.
4. Serruys PW, Unger F, Sousa JE, et al., Arterial Revascularization
Therapies Study Group. Comparison of coronary-artery bypass surgery
and stenting for the treatment of multivessel disease. N Engl J Med
2001;344:1117–24.
5. Serruys PW, Van Hout BA, Van den Brand MJ, et al. The ARTS
(Arterial Revascularization Therapies Study): background, goals and
methods. Intl J Cardiovasc Interv 1999;2:41–50.
6. Greenland S, Robins JM. Estimation of a common effect parameter
from sparse follow-up data. Biometrics 1985;41:55–68.
7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.
8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med
2004;350:221–31.
9. Ferguson TB Jr., Hammill BG, Peterson ED, DeLong ER, Grover
FL, for the STS National Database Committee. A decade of change—
risk proﬁles and outcomes for isolated coronary artery bypass grafting
procedures, 1990–1999: a report from the STS National Database
Committee and the Duke Clinical Research Institute. Society of
Thoracic Surgeons. Ann Thorac Surg 2002;73:480–9.
10. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline
update for coronary artery bypass graft surgery: a report of the American
College of Cardiology /American Heart Association Task Force on
Practice Guidelines (Committee to Update the 1999 Guidelines for
Coronary Artery Bypass Graft Surgery). Available at: http://www.acc.org/
clinical/guidelines/cabg/cabg.pdf. Accessed November 1, 2004.
Andrew BW.indd   203 28-08-2007   09:51:50
Andrew BW.indd   204 28-08-2007   09:51:50
Chapter 20
Arterial Revascularization 
Th erapies Study Part II - Sirolimus-
Eluting Stents for the Treatment 
of Patients With Multivessel De 
Novo Coronary Artery Lesions.   
 Patrick W. Serruys, Andrew T. L. Ong, Marie-Claude Morice, Bernard De Bruyne, 
Antonio Colombo, Carlos Macaya, Gert Richardt, Jean Fajadet, Christian Hamm, Keith 
Dawkins, A. James O’Malley, Marco Bressers, Dennis Donohoe, on behalf of the ARTS 
II Investigators.  
EuroInterv 2005; 1:147-156
Andrew BW.indd   205 28-08-2007   09:51:52
Andrew BW.indd   206 28-08-2007   09:51:54
| Chapter 20One-Year Results of ARTS II
207
KEYWORDS
Multicenter, historical
controlled trial,
sirolimus, drug-eluting
stents, multivessel 
disease, percutaneous
coronary intervention,
coronary artery bypass
surgery
Arterial Revascularisation Therapies Study Part II -
Sirolimus-eluting stents for the treatment of patients 
with multivessel de novo coronary artery lesions
Abstract
Aim: To determine the safety and effectiveness of CYPHER® sirolimus-eluting stent implantation in patients
with multivessel disease; and to compare outcomes against the historical results of the two arms of the
Arterial Revascularisation Therapies Study (ARTS I). 
Methods and results: ARTS II is a 45 center, 607 patient single arm trial; the1-year outcomes were compared
to the historical controls of the ARTS I trial, using conventional and Bayesian statistical methods. Patients were
stratified by clinical site to ensure that at least one-third had 3-vessel disease to achieve the number of treat-
able lesions per patient comparable to ARTS I. Multivessel stenting was performed with sirolimus-eluting
stents according to local institutional practice with the goal of achieving complete revascularisation. 
The majority of patients (53.5%) had 3-vessel disease and diabetes was present in 26.2%. Mean stented
length was 72.5mm, with 3.7 stents implanted per patient. The 1-year survival rate was 99.0%, the com-
posite of death / stroke and MI-free survival was 96.9%, freedom from revascularisation was 91.5% and
the composite endpoint of MACCE-free survival was 89.5% (the primary endpoint). Diabetic patients treat-
ed with sirolimus-eluting stents were more likely to undergo repeat revascularisation (RR 1.97, 95% CI
1.16 - 3.34) and experience a MACCE (RR 1.85, 95% CI 1.16 - 2.97) than non-diabetics at 1-year. In the
unadjusted comparison with the historical control arms of ARTS-I-CABG and ARTS-I-PCI, the respective
relative risks (RR) and associated 95% confidence intervals (CI) for the endpoints were: (1) freedom from
repeat revascularisation RR 2.03 (1.23-3.34) and RR 0.44 (0.31-0.61) respectively; and (2) MACCE free
survival RR 0.89 (0.65-1.23) and RR 0.39 (0.30-0.51) respectively. 
Conclusion: The low incidence of MACCE and repeat revascularisation in ARTS II suggests that contemporary
PCI with sirolimus-eluting stents is safe and efficacious for the treatment of multivessel coronary artery disease.
Compared to the historical population of ARTS I, surgery still afforded a lower need for repeat revascularisation
although overall MACCE rates in ARTS II approached the surgical results and were significantly better than bare
stenting in ARTS I. 
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Introduction 
Restenosis and the need for repeat revascularisation remain the
major limitations of coronary angioplasty for patients with multives-
sel disease1-4. Drug-eluting stents have made a major impact on the
effectiveness of percutaneous coronary interventions. The Cypher®
sirolimus-eluting stent has been shown to significantly reduce
restenosis and in-stent neointimal hyperplasia in patients with sin-
gle vessel disease5,6. 
Results from the randomized, multicenter Arterial Revascularisation
Therapies Study (ARTS I) showed no significant difference in terms
of death, stroke and myocardial infarction between the two groups,
an overall 17% difference in repeat revascularisation in favour of
surgery, and lower costs (US$ 2,973) at 12 months in favour of
stenting1. This was confirmed by other similar randomized trials2,3.
The RAVEL and SIRIUS trials with the sirolimus-eluting stent
demonstrated a marked reduction in repeat revascularisation ver-
sus bare metal stents in patients with single vessel stenting5,6, as
well as sustained efficacy and no evidence of late safety problems
out to 3 years7. The RESEARCH single-centre registry demonstrat-
ed the feasibility, safety and effectiveness of sirolimus-eluting
implantation in multivessel and complex patients8,9. Against this
background, we performed the ARTS II trial with a similar inclusion
criteria as ARTS I. The objective was to obtain information on the
sirolimus-eluting stent in multivessel disease in a population whose
baseline characteristics were to be at least of similar complexity and
comparable to ARTS I10.
Methods 
Study design 
ARTS II is a multicenter, non-randomized, open labelled, stratified
trial designed to evaluate sirolimus-eluting stent implantation in
patients with multivessel disease; with the surgical group of ARTS I
as an historical control8. After obtaining written informed consent,
the patients were enrolled via a central telephone service. In order
to obtain a population comparable to ARTS I, patients were strati-
fied by clinical site in order to ensure the inclusion of at least 1/3 of
patients with three-vessel disease. In addition, checks on the suc-
cess of matching with the historical control were performed regular-
ly during the conduct of the trial. 
Patient selection
Patients were eligible for coronary revascularisation if they had either
stable angina (Canadian Cardiovascular Society class I-IV), unstable
angina (Braunwald class I-III B or C), or if they had silent ischemia
and at least two new lesions located in different major epicardial ves-
sels and / or their sidebranches (not including the left main coronary
artery) that were potentially amenable to stent implantation. Patients
were required to have multivessel disease with need for treatment of
the left anterior descending (LAD) artery and at least 1 other signifi-
cant lesion (>50% diameter stenosis) in another major epicardial
coronary artery. The goal was to achieve complete revascularisation.
One totally occluded major epicardial vessel or side branch could be
included. The stenosis had to be amenable to stenting using a stent
with a diameter of 2.5 to 3.5mm and length of 13 to 33mm, without
restriction on the total implanted stent length. Decisions to place
stents in lesions with bifurcations, fresh thrombus, calcification, dif-
fuse disease, complex anatomy or stenting of side branches were left
to the discretion of the operators. 
Patients with previous coronary intervention, left main coronary dis-
ease, overt congestive heart failure or a left ventricular ejection fraction
of less than 30 percent were excluded. Additional exclusion criteria
included: history of a cerebrovascular accident, transmural myocardial
infarction in the preceding week, severe hepatic or renal disease, neu-
tropenia or thrombocytopenia, an intolerance or contraindication to
acetylsalicylic acid or thienopyridines, the need for concomitant major
surgery, and life-limiting major concomitant non-cardiac diseases. 
Written, informed consent was obtained from each patient prior to
enrolment. The study was approved by the ethics committee of
each participating site. 
Study objectives and endpoints 
The primary objective of ARTS II is to compare the safety and effec-
tiveness of coronary stent implantation using the sirolimus-eluting
stents with that of surgery as observed in ARTS I. Endpoints are
measured in terms of major adverse cardiac and cerebrovascular
events (MACCE) at 1 year comprising all-cause death, any cere-
brovascular event, non-fatal myocardial infarction, or any repeat
revascularisation (either percutaneous or surgical). 
The secondary objectives of this study are to compare the ARTS II
patients to both arms of ARTS I with respect to: MACCE at 30 days,
6 months, 3 and 5 years; the combined end point death, myocar-
dial infarction and stroke, and the itemized outcomes death,
myocardial infarction, revascularisation procedure, stroke; resource
use at 30 days and 1 year; cost effectiveness at 1 year, and quality
of life at 6 months, and 1, 3, and 5 years. 
End point definitions 
Death from all causes were reported, and categorized as cardiac
unless there was documentation to the contrary. Cerebrovascular
events were divided into three main categories: stroke, transient
ischemic attacks, and reversible ischemic neurologic deficits. In the
first 7 days after the intervention, a definite diagnosis of myocardial
infarction was made if there was documentation of new abnormal Q
waves (according to the Minnesota code) and either a ratio of serum
creatine kinase MB (CK-MB) isoenzyme to total cardiac enzyme
that was greater than 0.1 or a CK-MB value that was 5 times the
upper limit of normal1,11,12 Serum creatine kinase and CK-MB
isoenzyme concentrations were measured 6, 12, and 18 hours after
the intervention. Beginning 8 days after the intervention (the length
of the hospital stay after surgery), either abnormal Q waves or enzy-
matic changes were sufficient for a diagnosis of myocardial infarc-
tion. This two-part method of defining myocardial infarction was
developed for ARTS I to address the difficulty of diagnosing a
myocardial infarction after surgery. A myocardial infarction was con-
firmed only after the relevant electrocardiograms had been ana-
lyzed by the electrocardiographic core laboratory and adjudicated
by a clinical-events committee. All repeat revascularisation proce-
dures were recorded. 
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End point measurement 
In ARTS II, the procedure was performed within 48 hours after inclu-
sion, while in ARTS I patients were randomized after informed consent
had been obtained and then entered a waiting list, with 3 deaths in the
ARTS I-CABG arm while on the waiting list. To compensate for the tem-
poral difference since allocation between groups, events for the pres-
ent report were counted from the time of the procedure for all three
arms and not from the time of allocation as previously published1. 
Statistical analysis 
The sample size justification was based on the comparison of 1-year
MACCE rates in the ARTS II patients and the ARTS I surgery
patients for the primary end point. A MACCE-free survival rate of
90.9% was assumed in the ARTS II trial, requiring a sample size of
600 patients to guarantee a power of at least 90%. 
Count variables are given as group rates and their matching 95%
confidence interval. Continuous variables are given as group
means, and the difference between groups presented with 95%
confidence intervals. Time-to-event variables are presented as
Kaplan-Meier curves. Safety data at 30 days and 1 year are present-
ed as Kaplan-Meier estimates, with relative risks and 95% confi-
dence intervals. Further analyses will be performed at 3 years with
the final analysis at 5 years. 
A separate multivariate regression analysis was performed to deter-
mine independent predictors of MACCE within the ARTS II popula-
tion only. Clinically important baseline and procedural characteris-
tics were tested on a per patient basis by univariate analysis to
determine suitability for inclusion in the multivariate model. These
variables were then entered into a stepwise logistic regression
model with entry and stay criteria of 0.20 and 0.05 respectively. 
A historical controlled trial design was used for this study. Unlike the
gold standard of randomized controlled trials, historical controlled tri-
als may differ in baseline and procedural characteristics, which
potentially may affect outcome13. In order to overcome such differ-
ences, comparative statistical methodology, using both Bayesian and
frequentist methodology, were used for the analysis of the trial10.
Bayesian methods were used to test the additional hypothesis that
the MACCE- free rate, adjusted for observed patient characteristics,
is lower in ARTS II than in the two arms of ARTS I. A logistic regres-
sion model that incorporated the complexities of the design of each
trial and the heterogeneity between patients within a trial was fit
using Bayesian analysis (an approach well equipped for incorporat-
ing historical data in an analysis). An important feature of this
approach is that it controls for unmeasured variables that predict
MACCE in addition to observed predictors thereby facilitating com-
parisons between patients with different characteristics in different
trials. However, in order to estimate the model, data from a second
historical trial (RAVEL) needed to be included in the analysis5.
Results 
Patients 
Between February and November 2003, 607 patients from 45 par-
ticipating centers were treated (Figure 1). Table 1 presents their
baseline demographic and angiographic characteristics. Patients
treated in ARTS II were a high risk population with a mean age of
63 years, and three quarters were male. Diabetes mellitus was pres-
ent in 26% of patients and three vessel disease was present in the
majority (54%). Seven patients in ARTS II did not receive any stents
at the index procedure (4 underwent elective CABG, 1 required
emergent CABG, 1 underwent percutaneous treatment 35 days
later and 1 remained on medical therapy). The mean number of
significant lesions per patient was 3.6±1.3 in ARTS II and 3.7±1.5
stents were implanted with average total stented length of 73±32
mm per patient. The mean duration of the procedure was 85 min-
utes and patients were hospitalized for 3.4 days post-procedurally. 
In comparison to the ARTS I population, patients in ARTS II were sig-
nificantly older, had a significantly higher percentage of patients with
diabetes mellitus, hypertension, hypercholesterolemia and silent
ischemia and a lower percentage of current smokers or had a history
of prior myocardial infarction. ARTS II patients were also significantly
more complex procedurally, with more three vessel disease (54% ver-
sus 30% in ARTS I-CABG and 27% in ARTS I-PCI) more significant
lesions present (3.6±1.3 versus 2.8±1.0 in ARTS I-CABG and
2.8±1.0 in ARTS I-PCI). More stents and longer total stent lengths
were implanted in ARTS II (3.7±1.5, 73 ± 32 mm) compared to ARTS
I-PCI (2.8±1.3, 48 ± 22 mm respectively) At discharge, significantly
more patients were prescribed medications for the secondary preven-
tion of coronary artery disease in ARTS II compared to ARTS I. 
Clinical outcomes 
First 30 days (Table 2): In the ARTS II population, the 30-day compos-
ite MACCE rate was 3.1%. There were no deaths, 1 patient suffered a
CVA and a Q-wave myocardial infarction occurred in 5 patients (0.8%);
giving a combined endpoint of death, stroke or myocardial infarction
of 1.0%. A repeat revascularisation via a percutaneous approach
occurred in 6 patients (1.0%) and bypass surgery was required in 
7 (1.2%). Thrombotic stent occlusions occurred in 0.8% of patients. 
This 30-day MACCE rate was significantly lower than in ARTS I-
CABG (6.3%, RR 0.50, 95% CI 0.29-0.85) and ARTS I-PCI (9.2%,
RR 0.34, 95% CI 0.21-0.57). The lower incidence of death, stroke
and myocardial infarction in ARTS II was less than in the ARTS I
population (ARTS I-CABG 5.5%, RR 0.18, 95% CI 0.08-0.43) and
ARTS I-PCI 5.2%, RR 0.19, 95% CI 0.08-0.46). The incidence of
thrombotic stent occlusions was lower in ARTS II (0.8%) versus
ARTS I-PCI (2.8%), p=0.009. 
One year (Table 3 & Figures 2 and 3): At 1-year follow-up, the
Kaplan-Meier estimate of the survival free of MACCE in the ARTS II
trial was 89.5%. Six deaths occurred (1.0%), a further 5 (0.8%) suf-
fered a stroke while 8 patients (1.3%) had a myocardial infarction,
to give a composite death, stroke or myocardial infarction rate of
3.0%. Of the 6 deaths, four were adjudicated by the events commit-
tee to be of cardiac origin, although only one occurred suddenly and
unexpectedly. The incidence of repeat revascularisation was 8.5%
at one year with 39 patients (6.4%) who required a repeat percuta-
neous procedure, while 13 patients (2.1%) underwent bypass sur-
gery in the follow-up period. The incidence of angiographically doc-
umented late stent occlusion (between 30 days and 1 year) was
0.3% (2 patients) in ARTS II. 
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Table 1. Baseline and procedural characteristics of ARTS II and ARTS I population (expressed per patient unless stated otherwise) 
ARTS II ARTS I-CABG ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI 
(n=607) (n=605) (n=600) Difference Difference 
(95% CI) (95% CI) 
Baseline characteristics
Male sex (%) 77 76 77 0.6% (-4.2%, 5.4%) -0.4% (-5.2%, 4.4%) 
Age (years±SD) 63±10 61±9 61±10 1.6 (0.5, 2.7) 2.2 (1.1, 3.3) 
Body mass index±SD 27.5±4.1 27.4±3.7 27.2±3.7 0.2 (-0.3, 0.6) 0.3 (-0.1, 0.8) 
Risk factors
Myocardial infarction (%) 34 42 44 -7.6% (-13.0%, -2.1%) -9.9% (-15.4%, -4.4%) 
Diabetes (%) 26 16 19 10.3% (5.8%, 14.9%) 7.5% (2.8%, 12.2%) 
Hypertension (%) 67 45 45 22.3% (16.8%, 27.7%) 22.5% (17.1%, 28.0%) 
Hypercholesterolemia (%) 74 58 58 16.3% (11.0%, 21.5%) 15.9% (10.6%, 21.2%) 
Family history of MI 
or sudden death <55 years 36 42 39 -6.0% (-11.5%, -0.5%) -3.2% (-8.7%, 2.2%) 
Current smoker (%) 19 26 28 -6.5% (-11.2%,-1.8%) -8.7% (-13.4%, -3.9%) 
Peripheral vascular disease (%) 7 5 6 1.8% (-0.9%, 4.5%) 1.4% (-1.3%, 4.2%) 
Indication for treatment
Stable angina (%) 53 60 57 -6.5% (-12.0%, -0.9%) -3.6% (-9.2%, 2.0%) 
Unstable angina (%) 36 35 37 1.0% (-4.4%, 6.4%) -0.9% (-6.4%, 4.5%) 
Silent ischemia (%) 10 5 6 5.4% (2.4%, 8.4%) 4.5% (1.5%, 7.6%)
Angiographic characteristics
Ejection fraction (%) 60±12 60±13 61±12 -0.2 (-1.6, 1.3) -0.8 (-2.20.7) 
No. of lesions with stenosis >50% 3.6±1.3 2.8±1.0 2.8±1.0 0.8 (0.6, 0.9) 0.8 (0.6, 09) 
No. of diseased vessels
1 0 4 4 -3.4% (-5.0%, -1.8%) -3.6% (-5.3%, -2.0%) 
2 46 66 69 -20.1% (-25.6%, -14.6%) -22.4% (-27.9%, -17.0%)
3 54 30 27 23.5% (18.1%, 28.9%) 26.1% (20.7%, 31.4%) 
Vessel territory with stenosis (% of lesions) 
Right coronary artery 29 29 31 -0.4% (-3.3%, 2.5%) -2.1% (-5.0%, 0.9%) 
Left main 0 0 0 -0.1% (-0.2%, 0.1%) -0.1% (-0.2%, 0.1%) 
Left anterior descending 42 41 39 -0.4% (-2.7%, 3.6%) -2.1% (-1.1%, 5.3%) 
Left circumflex artery 29 29 29 -0.0% (-2.9%, 3.0%) -0.0% (-2.9%, 3.0%) 
Lesion length (visual) (% of lesions) 
Discreet (<10mm) 61 68 66 -7.3% (-10.4%, -4.2%) -4.7% (-7.9%, -1.5%) 
Tubular (10-20mm) 27 25 27 2.0% (-0.9%, 4.9%) -0.1% (-3.0%, 2.8%) 
Diffuse (>20mm) 12 7 7 5.3% (3.4%, 7.2%) 4.8% (2.9%, 6.7%) 
Lesion classification (% of lesions) 
A 7 7 6 0.0% (-1.6%, 1.6%) 0.9% (-0.7%, 2.5%) 
B1 23 31 26 -7.9% (-10.8%, -5.1%) -3.0% (-5.8%, -0.2%) 
B2 56 54 60 1.9% (-1.3%, 5.1%) -3.7% (-6.9%, -0.5%) 
C 14 8 8 6.0% (4.0%, 8.0%) 5.9% (3.9%, 7.8%) 
Procedural characteristics
Bifurcation requiring double wiring 
(% of patients) 34 32 35 2.2% (-0.9%, 5.3%) -0.6% (-3.7%, 2.6%) 
Number of stents implanted ±SD 3.7±1.5 - 2.8±1.3 - 0.9 (0.7, 1.0) 
Total stent length (mm) 72.5±32.1 - 47.6±21.7 - 24.9 (21.8, 28.1) 
Maximum dilatation pressure (Atm±SD) 16.4±2.9 - 14.6±3.0 - 1.7 (1.4, 2.1) 
Direct stenting (%) 34.6 - 3.3 - 31.3% (29.1%, 33.6%) 
Duration of procedure (mins) 85±43 193±67 99±50 -108.2 (-114.6, -101.8) -13.6 (-18.9, -8.3) 
Post procedural hospital stay (days±SD) 3.4±2.7 9.6±4.9 3.9±3.7 -6.2 (-6.6, -5.8) -0.5 (-0.9, -0.2) 
Medications
Glycoprotein IIb/IIIa inhibitors 
during procedure (%) 33 - - - - 
Lipid lowering agents at discharge (%) 90 32 39 58.0% (53.5%, 62.4%) 51.1% (46.5%, 55.7%) 
Beta blockers at discharge (%) 78 55 60 22.8% (17.6%, 28.0%) 17.7% (12.5%, 22.8%) 
Angiotensin converting enzyme 
inhibitors at discharge (%) 50 15 26 34.7% (29.8%, 39.6%) 24.3% (19.0%, 29.6%) 
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The composite 1-year MACCE rate in ARTS II was in the same range
as the ARTS I- CABG results (10.5% versus 11.7%, RR 0.89, 95%
CI 0.65-1.23), with less events in the combined death, stroke or
myocardial infarction endpoint (3.0% versus 8.0%, RR 0.37, 95%
CI 0.22-0.63) balanced by a significantly higher need for repeat
revascularisation in ARTS II (8.5% versus 4.2%, RR 2.03, 95% CI
1.23-3.34). Predictably, the 1-year MACCE rate in ARTS II was
much lower than the ARTS I-PCI group (26.5%, RR 0.39, 95% CI
0.30-0.51), driven by the higher incidence of events in all measured
endpoints. In particular, the repeat revascularisation rate in ARTS I-
PCI was 21.3% (RR 0.44, 95% CI 0.31-0.61). Angiographically
documented late stent thrombosis was not measured in ARTS I.
Diabetic versus non-diabetic patients
(Table 4 and Figure 4) 
In the ARTS 2 population, diabetic patients had significantly higher
one year MACCE rates by Kaplan Meier estimates compared to the
non-diabetic population (15.8% versus 8.6%, RR 1.85, 95% CI 1.16-
3.34, p (logrank) <0.01). This difference was driven by the increased
need for repeat revascularisation in the diabetic population (13.4%
versus 6.8%, RR 1.97, 95% CI 1.16-3.34, p (logrank) <0.01). 
Multivariate analysis (Table 5)
Multivariate analysis was performed on the ARTS II population to
determine independent predictors of outcome in the sirolimus-elut-
Figure 1. Flow chart of ARTS II and ARTS I.
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Andrew BW.indd   211 28-08-2007   09:51:55
One-Year Results of ARTS II
212 
ing stent population. Variables significant in the univariate analysis
were: treated lesions in the left circumflex, tubular lesions, diabetes
mellitus, current smoker, number of lesions with a stenosis greater
than 50%, Type B2/C lesions, age, and lesions with moderate to
heavy calcification. Diabetes and the presence of tubular lesions
were independently associated with adverse outcome, while
patients who were smokers at the time of intervention were associ-
ated with a better outcome. 
Bayesian statistical adjustment 
Based on the logistic regression model fit using Bayesian methods, the
adjusted MACCE rate was calculated to be 8.1±1.6% in ARTS II versus
13.1± 2.4% in ARTS I-CABG. To summarize the difference in treatment
rates between the trial, the probability given the data from both trials
that the MACCE rate in ARTS II is lower than the MACCE rate in ARTS
I CABG was evaluated. The probability was 0.953, a value that would
enable a significant difference at the 0.05-level to be claimed.
Table 2. Clinical endpoints at one month (hierarchical and non-hierarchical MACCE up to 30 days, per patient) counted since date of procedure 
MACCE ARTS II ARTS I CABG ARTS I PCI ARTS II:I-CABG ARTS II:I-PCI 
Up to 30 days N=607 N=602 N=600 Relative risk Relative risk 
N (%) N (%) N (%) (95% CI) (95% CI) 
Hierarchical
Death 0 (0.0) 8 (1.3) 10 (1.7) - - 
CVA 1 (0.2) 6 (1.0) 5 (0.8) 0.17 (0.02 - 1.37) 0.20 (0.02 - 1.69) 
MI 5 (0.8) 19 (3.2) 16 (2.7) 0.26 (0.10 - 0.69) 0.31 (0.11 - 0.84) 
MI Q-wave 5 (0.8) 19 (3.2) 15 (2.5) 0.26 (0.10 - 0.69) 0.33 (0.12 - 0.90) 
MI non-Q-wave 0 (0) 0 (0.0) 1 (0.2) - - 
Death / CVA / MI 6 (1.0) 33 (5.5) 31 (5.2) 0.18 (0.08 - 0.43) 0.19 (0.08 - 0.46) 
(re) CABG 7 (1.2) 2 (0.3) 12 (2.0) 3.47 (0.72 - 16.64) 0.58 (0.23 - 1.45) 
(re) PTCA 6 (1.0) 3 (0.5) 12 (2.0) 1.98 (0.50 - 7.89) 0.49 (0.19 - 1.31) 
Any MACCE 19 (3.1) 38 (6.3) 55 (9.2) 0.50 (0.29 - 0.85) 0.34 (0.21 - 0.57) 
Non-hierarchical
Death 0 (0.0) 8 (1.3) 10 (1.7) - - 
CVA 1 (0.2) 6 (1.0) 6 (1.0) 0.17 (0.02 - 1.37) 0.20 (0.02 - 1.69) 
MI 5 (0.8) 23 (3.8) 20 (3.3) 0.22 (0.08 - 0.56) 0.31 (0.11 - 0.84) 
MI Q-wave 5 (0.8) 22 (3.7) 18 (3.0) 0.23 (0.09 - 0.59) 0.33 (0.12 - 0.90) 
MI non-Q-wave 0 (0.0) 1 (0.2) 2 (0.3) - - 
(re) CABG 8 (1.3) 2 (0.3) 17 (2.8) 3.97 (0.85 - 18.60) 0.58 (0.23 - 1.45)
(re) PTCA 7 (1.2) 3 (0.5) 19 (3.2) 2.31 (0.60 - 8.91) 0.49 (0.19 - 1.31) 
Table 3. Clinical endpoints at one year (hierarchical and non-hierarchical MACCE up to 365 days, per patient) counted since date of procedure 
MACCE ARTS II ARTS I CABG ARTS I PCI ARTS II:I-CABG ARTS II:I-PCI 
Up to 365 days N=607 N=602 N=600 Relative risk Relative risk 
N (%) N (%) N (%) (95% CI) (95% CI) 
Hierarchical
Death 6 (1.0) 16 (2.7) 16 (2.7) 0.37 (0.15 - 0.94) 0.37 (0.15 - 0.94)
CVA 5 (0.8) 11 (1.8) 11 (1.8) 0.45 (0.16 - 1.29) 0.45 (0.16 - 1.29) 
MI 7 (1.2) 21 (3.5) 30 (5.0) 0.33 (0.14 - 0.77) 0.23 (0.10 - 0.52) 
MI Q-wave 5 (0.8) 21 (3.5) 27 (4.5) 0.24 (0.09 - 0.62) 0.18 (0.07 - 0.47) 
MI non-Q-wave 2 (0.3) 0 (0) 3 (0.5) - 0.66 (0.11 - 3.93)
Death / CVA / MI 18 (3.0) 48 (8.0) 57 (9.5) 0.37 (0.22 - 0.63) 0.31 (0.19 - 0.52) 
(re) CABG 12 (2.0) 4 (0.7) 28 (4.7) 2.98 (0.97 - 9.17) 0.42 (0.22 - 0.83) 
(re) PCI 33 (5.4) 18 (3.0) 74 (12.3) 1.82 (1.04 - 3.19) 0.44 (0.30 - 0.65) 
Any MACCE 63 (10.4) 70 (11.6) 159 (26.5) 0.89 (0.65 - 1.23) 0.39 (0.30 - 0.51) 
Non-hierarchical
Death 6 (1.0) 16 (2.7) 16 (2.7) 0.37 (0.15 - 0.94) 0.37 (0.15 - 0.94)
CVA 5 (0.8) 12 (2.0) 12 (2.0) 0.41 (0.15 - 1.17) 0.41 (0.15 - 1.16)
MI 8 (1.3) 25 (4.2) 35 (5.8) 0.32 (0.14 - 0.70) 0.23 (0.11 - 0.48) 
MI Q-wave 5 (0.8) 24 (4.0) 31 (5.2) 0.21 (0.0 - 0.54) 0.16 (0.06 - 0.41) 
MI non-Q-wave 3 (0.5) 1 (0.2) 4 (0.7) 2.98 (0.31 - 28.5) 0.74 (0.17 - 3.30) 
(re) CABG 13 (2.1) 5 (0.8) 40 (6.7) 2.58 (0.92 - 7.19) 0.32 (0.17 - 0.59) 
(re) PTCA 39 (6.4) 21 (3.5) 94 (15.7) 1.84 (1.10 - 3.09) 0.41 (0.29 - 0.59) 
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Figure 2. Kaplan-Meier curves out to 1 year in ARTS II and ARTS I:
(A) Survival free; (B) Freedom from Death/CVA/MI; (C) Freedom from
repeat revascularisation.
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Figure 3. Kaplan-Meier curves out to 1 year in ARTS II and ARTS I:
Freedom from Major Adverse Cardiac and Cerebral Events (MACCE). 
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Table 4. Frequency of MACCE up to 365 days (since date of 
procedure) in diabetic vs non-diabetic patients in ARTS II 
MACCE ARTS II ARTS II Diabetes: no diabetes 
Up to 365 days No diabetes Diabetes Relative risk 
(n=448) (n=159) (95% CI) 
N (%) N (%)
Hierarchical
Death 2 (0.4) 4 (2.5) 5.64 (1.04 - 30.5) 
CVA 5 (1.1) 0 (0.0) - 
MI 6 (1.3) 1 (0.6) 0.47 (0.06 - 3.87) 
MI Q-wave 4 (0.9) 1 (0.6) 0.70 (0.08 - 6.26) 
MI non-Q-wave 2 (0.4) 0 (0.0) - 
Death/ Stroke/ MI 13 (2.9) 5 (3.1) 1.08 (0.39 - 2.99) 
(re-) CABG 7 (1.6) 5 (3.1) 2.01 (0.65 - 6.25) 
(re) PTCA 18 (4.0) 15 (9.4) 2.35 (1.21 - 4.55) 
Any MACCE 38 (8.5) 25 (15.7) 0.92 (0.86 - 0.99) 
Non-hierarchical
Death 2(0.4) 4 (2.5) 5.64 (1.04 - 30.5) 
CVA 5 (1.1) 0 (0.0) - 
MI 7 (1.6) 1 (0.6) 0.40 (0.05 - 3.25) 
MI Q-wave 4 (0.9) 1 (0.6) 0.70 (0.08 - 6.26) 
MI non-Q-wave 3 (0.7) 0 (0.0) - 
(re-) CABG 8 (1.8) 5 (3.1) 1.76 (0.58 - 5.30) 
(re) PTCA 23 (5.1) 16 (10.1) 1.96 (1.06 - 3.61) 
Discussion
The main findings of this study are: (1) contemporary percutaneous
coronary intervention for complex multivessel disease using
sirolimus-eluting stents was associated with low 1-year event rates
for repeat revascularisation and overall MACCE, (2) the MACCE rate
at 1-year was in the same range as that obtained in the historical
bypass surgery arm of the ARTS I trial; (3) re-intervention rates in
this contemporary group were still higher than the historical surgi-
cal cohort (4) the overall MACCE and especially re-intervention
rates in this contemporary group were markedly reduced compared
to the ARTS I-PCI arm. 
The primary endpoint of this study, which was the composite end-
point of MACCE in ARTS II, was low, occurring in 10.5% of patients,
and was within the same range as that seen with the historical sur-
gical arm of ARTS I. A lower repeat revascularisation rate was noted
in the surgically treated patients at one-year; this was balanced by
a higher incidence of death / stroke and myocardial infarction. 
In the secondary comparison between the two percutaneous arms,
the significantly better MACCE rate with this contemporary PCI pop-
ulation treated with SES (ARTS II) compared to the bare stent PCI
population treated in 1997-8 was primarily due to the lower reinter-
vention rate; in spite of the higher baseline and procedural charac-
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Figure 4. Kaplan-Meier curves out to 1 year in non-diabetic versus
diabetic patients in the ARTS II arm: (A) Repeat revascularisation, (B)
MACCE (Black represents No Diabetes, grey represents Diabetes). 
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Table 5. Independent predictors of MACCE in the ARTS II group 
Multivariate predictors 95% Confidence 
of MACCE at 365 days Odds Ratio Interval P-Value 
Current smoker 0.36 0.14-0.93 0.035 
# Tubular lesions (10 - 20 mm) 1.39 1.06-1.83 0.019 
Diabetes Mellitus 1.76 1.02-3.06 0.044 
teristic risk profile. Indeed, statistical analyses that adjusted for the
independent predictors of outcome tended to find wider differences
between the studies than unadjusted analyses. The incidence of
stent thrombosis in the first month, as a surrogate for the acute
safety profile of sirolimus-eluting stents in multivessel disease
occurred in 0.8% despite increases in complexity and total stented
length, compared with 2.8% in the bare stent arm of ARTS I-PCI
confirming its safety in contemporary settings. 
Within the ARTS II population, diabetic patients experienced a 
higher MACCE rate than non-diabetic patients, driven by an almost
2-fold increased need for repeat revascularisation in the first year, a
finding confirmed by the multivariate analysis. Although event rates
are markedly reduced compared to what has been seen with bare
metal stents, diabetic patients continue to remain more resistant to
the beneficial effects of sirolimus-eluting stents than non-diabetic
patients. This phenomenon requires further investigation. 
This present study was designed to determine whether the findings of
the randomized trials with the sirolimus-eluting stent in single vessels
could be extended to multivessel stenting. While a randomized trial
design was always the preferred option, financial circumstances at the
time of trial design dictated that only a single arm could be funded for
such a study. This trial was thus seen as an intermediate step towards
a full-fledged randomized trial with the original intention of a non-infe-
riority comparison using a historical control as stated in the protocol8. 
The use of historical controls, as opposed to a randomized control
is the subject of debate13,14. Randomized controlled trials, by virtue
of their experimental design, provide a reliably unbiased estimate of
treatment effects13. Historical controlled trials, on the other hand,
suffer from a selection bias and of systemic differences in outcomes
that may not be due to the treatment itself. Sacks found that this
type of trial design over-estimated the treatment effect15. However,
in two recent studies that compared both trial designs, no difference
in treatment effect was seen16,17. Importantly, trials, both random-
ized and observational for a particular topic must be collectively and
not individually examined to determine the accuracy in their
results14. Hence, well designed historical controlled trials with
appropriate matching, stratification and adjustment can be suc-
cessfully used to guide the development of new trials. 
Although arithmetically possible, the non-inferiority comparison
between groups was replaced with descriptive comparisons due to the
lack of randomisation coupled with concerns that the performance of
the CABG group would have been better if assessed in the current envi-
ronment as opposed to 5 years ago. The historical rates of ARTS I are
thus viewed as standards against which the ARTS II study is compared. 
The low event rates, including that of stent thrombosis noted in this
study as compared to ARTS I may in part be explained by the more
contemporary percutaneous coronary intervention methods used.
Specifically, the use of lower profile and more easily deliverable
devices may have resulted in less vessel trauma, a shorter procedure
time; more comprehensive diseased vessel coverage with stents;
and adjunctive glycoprotein IIb/IIIa inhibitor and/or intravascular
ultrasound use may have contributed to the results. In addition, bet-
ter secondary prevention practices, such as the more frequent use
of lipid lowering agents, beta-blockers, and angiotensin-converting
enzyme inhibitors may have contributed an added beneficial effect.
Although the anti-restenotic effects of sirolimus-eluting stents are
incontrovertible, one is unable to completely attribute the treatment
effect to the device alone due to the non-randomized study design. 
The role of complex multivessel stenting with drug-eluting stents will
be addressed in two major randomized trials: FREEDOM and SYN-
TAX. The former will randomize 2400 patients with diabetes and
multivessel disease to bypass surgery or drug-eluting stenting using
approved devices, currently sirolimus-eluting and paclitaxel-eluting
stents; while SYNTAX will randomize 1500 patients with 3-vessel or
left-main disease to bypass surgery or paclitaxel-eluting stents.
Nested preference registries are an added feature of both trials. 
Study limitations
The results observed in this study require the following caveats in
addition to those already mentioned. First, a five year time lag exists
between the groups that are being compared. Both technology and
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medical practice have improved with time, as have surgical mortal-
ity rates18,19. Second, this study is non-randomized and thus the
groups are not directly comparable, precluding a formal non-inferi-
ority comparison. Furthermore, statistical adjustment was required
to correct for the differences versus the historical control group, of
which two methods of statistical analysis, namely frequentist and
Bayesian, were performed in order to present robust results. Thirdly,
while the protocol required that the lesions in ARTS II be potential-
ly treatable by CABG, the absence of dialogue with the surgeons
prior to intervention may have caused a selection bias. However,
this is not obvious based on patients actually enrolled in the study
since those enrolled in ARTS II were more complex than those
enrolled in ARTS I. Finally, the results of the primary endpoint are
reported for the one year timepoint only. While encouraging, the effi-
cacy of sirolimus-eluting stents in the treatment of multivessel dis-
ease can only be definitively evaluated when long- term results
become available in the future.
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The SYNergy between percutaneous coronary
intervention with TAXus and cardiac surgery
(SYNTAX) study: Design, rationale, and run-in phase
Andrew T.L. Ong, MBBS, FRACP,a Patrick W. Serruys, MD, PhD, FACC,a Frederick W. Mohr, MD,b
Marie-Claude Morice, MD,c A. Pieter Kappetein, MD, PhD,a David R. Holmes, Jr, MD,d Michael J. Mack, MD,e
Marcel van den Brand, MD, PhD,f Marie-Angele Morel, BSc,g Gerrit-Anne van Es, PhD,g Jeroen Kleijne, MSc,g
Joerg Koglin, MD,h and Mary E. Russell, MD, FACCh Rotterdam, The Netherlands; Leipzig, Germany;
Massy, France; Rochester, MN; Dallas, TX; and Natick, MA
Background Changes in the treatment of coronary artery disease both surgically and percutaneously have
rendered the major randomized trials historical. Furthermore, the restrictive criteria of previous trials excluded most patients
treated in daily practice. Although coronary surgery is still considered the current, evidence-based, gold-standard treatment
of left main (LM) and 3-vessel coronary disease, the added benefit of drug-eluting stents has further expanded the use of
percutaneous coronary intervention (PCI) beyond less complex populations in daily practice.
Study Design The 1500-patient, prospective, multicenter, multinational (European and North American), randomized
SYNTAX study with nested registries will enroll ball-comers.Q Consecutive patients with de novo 3-vessel disease (3VD) and/or
LM disease will be screened for eligibility by the Heart Team (composed of an interventionalist, a cardiac surgeon, and
the study coordinator) at each site and then allocated to either (1) the randomized cohort, if comparable revascularization
can be achieved by either PCI or coronary artery bypass surgery (CABG), or (2) to one of the nested registries for
CABG-ineligible patients (PCI registry) or for PCI-ineligible patients (CABG registry). Randomized patients will be stratified
based on LM disease and diabetes by site. The primary end point for the randomized comparison is noninferiority of
major adverse cardiac and cerebral events between the 2 groups at 1 year.
To adequately project the expected enrollment rate per site, a run-in phase was mandated for each site interested in
participating in the trial. Both cardiothoracic and interventional cardiology departments within the same institution were asked
to complete a questionnaire regarding their frequency of treatment of LM and 3VD over a retrospective 3-month period.
Implications By replacing most traditional inclusion and exclusion criteria with the real-world decision between
the cardiothoracic surgeon and the interventionalist, this study will define the roles of CABG and PCI using drug-eluting stents
in the contemporary management of LM and 3VD. Results of the run-in phase were used by the steering committee to
determine eligibility and to project enrollment for each site. (Am Heart J 2006;151:1194-204.)
The management of coronary artery disease has
evolved over the last 30 years. Coronary artery bypass
surgery (CABG) was introduced in 1968 and was
rapidly established as the gold standard for treatment.1
Percutaneous coronary intervention (PCI) began in
1977 with the first percutaneous transluminal coronary
angioplasty performed by Andreas Gruntzig as a
nonsurgical alternative.2 Because of 2 landmark stud-
ies3,4 and improvements in antiplatelet therapy, coro-
nary artery stenting has replaced balloon angioplasty as
the preferred method of PCI. Four large, multicenter,
randomized studies conducted in the mid- to late 1990s
compared bypass surgery to coronary stenting for the
treatment of multivessel disease,5 - 8 and although
seminal, these trials are now historical in applicability
in contemporary practice because of improvements
in treatment options.
Thedevelopmentof coronary stents thatprovide local
deliveryofdrugswithdemonstrated superiorityoverbare
metalstentsinreducingrestenosishashadamajorimpacton
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themanagementof coronary arterydisease.9,10Coupled
with improvements inperi- andpostproceduralmedical
careforbothCABGandPCI,anewcomparisonisrequiredto
determinethestandardofcareforleftmain(LM)and3-vessel
disease (3VD)and toallowthedevelopmentofnew
guidelines for theirmanagement.
Revascularization versus
medical therapy
The randomized Veterans Affairs cooperative study
was the first landmark study to report a survival benefit
with CABG over medical therapy for the treatment of
significant LM disease and established the role of CABG
as the treatment of choice.11 This study was followed by
the randomized ECSS, which demonstrated a significant
survival benefit of surgery over medical therapy at
5 years for both patients with 3VD and patients in whom
stenosis in the proximal third of the left anterior
descending artery constituted a component of either
2- or 3-vessel disease.12 The RITA-2 compared PCI (9%
stent use) to medical therapy in 1018 patients with 1- to
3-vessel disease with no difference in mortality seen at
2.7 years of follow-up.13
Stenting versus balloon angioplasty
The development of coronary stents opened a
second avenue for PCI. The pivotal BENESTENT trial
demonstrated that, in single lesion disease, clinical and
angiographic outcomes were better in patients who
received a stent than in those who received standard
coronary angioplasty.3 At 1 year, no significant differ-
ences in mortality, stroke, myocardial infarction (MI),
or coronary bypass graft surgery were found between
the stent and balloon angioplasty groups. However, the
requirement for a repeat angioplasty procedure was
significantly lower in the stent group than in the
balloon angioplasty group (10% vs 21%, P = .001).14
In the United States, the STRESS trial mirrored the
findings of BENESTENT.4 Stent placement resulted in an
improved rate of procedural success, a lower rate of
angiographically detected restenosis, a similar rate of
clinical events after 6 months, and a less frequent need
for revascularization of the original coronary lesion.
Stenting versus coronary artery
bypass surgery
Multivessel stenting
The 4 most contemporary, multicenter, randomized
studies comparing PCI to surgery involve the use of
coronary stenting and were conducted in the mid - to
late 1990s.5-8 They were the ARTS,5 SoS,6 ERACI-2,7 and
AWESOME trial.8 The ARTS trial was the largest trial
with 1205 patients from 69 centers and clearly estab-
lished that for patients with multivessel disease, mor-
tality at 1 and 5 years was similar irrespective of whether
the patient underwent stent implantation or surgery.5,15
However, the primary end point, freedom from major
adverse cardiac and cerebral events (MACCE), a com-
posite of freedom from death, MI, cerebrovascular
accident (CVA), and any repeat revascularization at
1 year were lower in the stent group (73.8% vs 87.8%,
P b .001), which was attributable to an increased
need for repeat revascularization in the stent group
(21.0% vs 3.8%, P b .001). Importantly, the late (5-year)
outcome from this trial was the first in the stent era to
demonstrate a similar mortality rate for stenting versus
CABG, which differs from the balloon era where surgery
was associated with an improved survival rate over
balloon angioplasty at 5 years.16 Furthermore, a meta-
analysis of the results of ARTS, SoS, ERACI-2, and MASS-2
confirmed that in 3051 patients, there was no 1-year
mortality difference.17
Given similar survival between stenting and CABG, the
major remaining limitation to multivessel stenting is the
excess in repeat intervention, predominantly due to
restenosis, in the stent group. Multiple randomized trials
have consistently demonstrated that drug-eluting stents
(DES) reduce restenosis compared with bare metal
stents in single lesions with no excess mortality or MI.18
Various single-center registries have also reported the
efficacy of DES for multivessel disease.19,20 The RE-
SEARCH and T-SEARCH Registries have shown in an
ball-comers Q population low reintervention rates in an
unrestricted setting.21,22
The ARTS Part 2 multicenter, nonrandomized, open-
labeled study used sirolimus-eluting stents to treat
multivessel disease. The surgical arm of ARTS was used
as a comparative historical control for the primary end
point of MACCE at 1 year.23 This study was seen as an
intermediate step preceding a full-fledged, randomized
trial between DES and CABG using contemporary
techniques. One year results have demonstrated favor-
able outcomes in the DES group.24
Left main stem
Since the publication of the Veteran’s Affairs study,
surgery has been the gold standard for LM disease. The
major limitation of percutaneous treatment in the bare
stent was restenosis, occurring in 22% of patients.25
Consequently, percutaneous treatment of LM disease
has remained confined predominantly to emergency
cases as a salvage procedure and for high surgical risk
patients. In the 3 years since the commercialization of
DES, with reductions in restenosis rates of up to 80% in
clinical trials, there has been renewed interest regarding
percutaneous treatment of LM disease. The first publi-
cation on this topic was promising and reported a
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restenosis rate of 8% in a small population of 16patients.26
More recently, larger studies have confirmed the
beneficial effects of DES in this population.27 - 29
Surgical improvements
Recent advances in coronary surgery include
improvements in preoperative risk assessment and
management, anesthesia, the use of arterial grafts, and
improvements in postoperative care.30 - 32 These changes
have resulted in reduced hospital morbidity and mor-
tality despite the increasing age and comorbidities of
patients.33 Furthermore, with the use of arterial grafts,
the occlusion rate of bypass grafts has been reduced.
Philosophy of the SYNTAX trial
The major concern about prior trials of CABG versus
PCI has been that only a small percentage of patients
treated in the real-life clinical setting fulfilled the
multiple inclusion and exclusion criteria, precluding a
real-world assessment. That finding, plus the advance-
ments in both PCI and CABG, as well as the increasingly
frequent use of PCI for the treatment of LM and 3VD,
formed the rationale for the SYNTAX trial. To overcome
the major criticism of the exclusion of patients often
seen in daily practice, a nested registry to capture and
follow patients not suitable for randomization is inher-
ent in the SYNTAX trial.
Study objectives
Purpose of the SYNTAX study
The overall study goal of SYNTAX is to assess the
optimum revascularization treatment for patients with
de novo 3VD or LM disease (either isolated or in
combination with 1, 2, or 3VD) by randomizing patients
to either PCI with polymer-based, paclitaxel-eluting
TAXUS stents or CABG. Patients not deemed adequate
by their treating physicians (cardiothoracic surgeon and
interventional cardiologist) for both treatment modali-
ties will be captured through nested CABG and PCI
registries. The CABG registry data will be used to define
the population in which stenting continues to be
considered unsuitable for the treatment of complex,
high-risk subsets. Conversely, the PCI registry data, using
any interventional techniques or devices with or
without the use of DES, will define the patients for
whom CABG is considered inappropriate.
Study design
This is a prospective, multicenter, multinational,
randomized clinical trial with an all-comers design. All
consecutive patients with de novo 3VD or LM disease
(isolated or in association with 1, 2, or 3VD) are
screened by the local Heart Team (composed of both an
interventional cardiologist and a cardiothoracic surgeon
supported by the study coordinator). The Heart Team
will first confirm the eligibility of the patient for the
SYNTAX study based on a limited number of criteria
(Table I) and then will agree upon the patient’s eligibility
for PCI and/or CABG. Patients deemed amenable for
both revascularization modalities by the local Heart
Team will be randomized and stratified at each site based
on the presence or absence of LM disease and medically
treated diabetes mellitus (requiring oral medications or
insulin). Those patients deemed amenable for only one
of the treatment options will be allocated to one of the
nested registries for either CABG-ineligible patients (PCI
registry) or PCI-ineligible patients (CABG registry).
Patients not amenable for either treatment option will
not be included in the trial.
Table I. Specific inclusion and exclusion criteria
Specific inclusion criteria
1. Stable or unstable angina pectoris with ischemia; or patients with
atypical chest pain or asymptomatic with demonstrated myocardial
ischemia (eg, exercise stress test, radionuclide scintigraphy,
stress echocardiography)
2. De novo lesions
3. Eligible for coronary revascularization (both PCI and CABG)
4. At least 1 significant stenosis in all 3 major epicardial territories
supplying viable myocardium; OR significant stenosisT in the LM or
LM equivalenty with or without stenosis in one of the other vessels
5. Patients with hypoplastic right coronary artery with absence of a
posterior descending artery and presence of a lesion in the left
anterior descending and left circumflex territories may be included
in the trial as a 3-vessel equivalent
6. Vessel size should be at least 1.5 mm in diameter as assessed by
diagnostic angiogram
7. Written informed consent
8. Signed Heart Team Decision Form between the interventional
cardiologist and surgeon that the selected case meets all of the
inclusion and exclusion criteria
Specific exclusion criteria
1. Younger than 21 years
2. Previous PCI or CABG
3. Pregnancy or intention to become pregnant (randomized cohort only)
4. Ongoing acute MI and cardiac enzymes N2 times the upper
limit of normal
5. Inability to follow the patient over the period of 1 year after
enrollment, as assessed by the investigator
6. Planned need for concomitant other cardiac surgery (eg, valve
surgery or resection of aortic or left ventricular aneurysm, etc)
7. Psychiatric illness or organic brain disease rendering the subject
unable to understand the nature, scope, and possible consequences
of the study or mental retardation or language barrier such that the
patient is unable to give informed consent
8. Potential for noncompliance toward the requirements in the
study protocol
9. Single or 2-vessel disease without LM disease
10. Participation or planned participation in another cardiovascular
clinical study before completion of 1-year follow-up (all cohorts
except CABG without follow-up)
TSignificant stenosis is defined as: (1) a diameter stenosis of at least 50% reduction in
luminal diameter by visual assessment or (2) any total occlusion (no age limitation
and no exclusion of unfavorable anatomic features).
yLeft main equivalent disease is defined as significant stenosis of the ostium of the left
anterior descending and the ostium of the left circumflex.
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Primary end point
The primary clinical end point is freedom from
MACCE through 1 year after allocation and includes
all-cause death, cerebrovascular event (stroke), docu-
mented nonfatal MI, and revascularization by percuta-
neous intervention or bypass surgery; as adjudicated by
an independent Clinical Events Committee (CEC).
Secondary end points
The secondary end points include the following:
(1) overall MACCE rate at 1 month post procedure and at
6 months, and 3 and 5 years post allocation; (2) rates of
the individual components of MACCE at 1 month post
procedure and at 6 months, and 1, 3, and 5 years post
allocation; (3) freedom from MACCE and its components
at 1, 3, and 5 years post allocation; (4) quality of life at
1month post procedure and at 6months, 1, 3, and 5 years
post allocation; (5) cost and cost-effectiveness at 1, 3, and
5 years post allocation; and (6) analysis of the charac-
teristics (including comorbidity and coronary vascular
lesion complexity scoring referred to as the SYNTAX
score) of the PCI versus CABG randomized cohort, the
PCI registry cohort, and the CABG registry cohort.
Study methods
Patient population
Fifteen hundred patients will be randomized into the
PCI versus CABG cohort. Recruitment will be noncom-
petitive, with each center expected to enroll a preas-
signed number of patients into the randomized arm
according to their real world volume, as assessed in a
run-in phase (minimum of 16 patients and a maximum of
32 patients). There will be approximately 90 participat-
ing centers, with 60 to 70 sites in Europe and 15 to
20 sites in North America.
To randomize 1500 patients, an estimated 4300 con-
secutive patients will have to be screened, which will
result in the inclusion of an additional 2800 patients in
the CABG-only or PCI-only registries. Previous surveys
have shown that the number of patients with 3VD or LM
disease not amenable to bypass surgery and only
treatable by PCI is small (b4%). Hence, of these
2800 patients, approximately 50 patients are expected
to be included in the PCI-only registry (CABG-ineligible),
with the use of any interventional techniques or devices
with or without DES allowed. These patients will be
followed up through 5 years post allocation. Of the
remaining CABG-only (PCI-ineligible) registry patients
(approximately 2750 patients), a randomly selected
subgroup of 750 patients will also be followed up
through 5 years post allocation so their risk profile can
be compared with the randomized patients. At the time
of the informed consent procedure, patients may refuse
to be randomized because of their personal preference
for 1 treatment modality or the other (PCI or CABG).
These patients will not be included in the trial, and data
from them will not be collected.
For prospectively collected data in the randomized
trial as well as in the registry follow-up subsets, an
independent CEC will adjudicate all primary clinical end
points (12-month MACCE). An independent Data Mon-
itoring Committee will assess the results with respect to
patient safety at frequent, prespecified intervals. In
addition, patients with complex lesions (LM, bifurca-
tions, chronic total occlusions, a long-stenting cohort
treated with N100 mm or 5 stents, and patients with
diabetes mellitus) will be tracked as subgroups and
followed up for dynamic safety monitoring.
Eligibility criteria
Because of the all-comers design of the study,
inclusion is based on the decision between the cardiol-
ogist and surgeon of the local Heart Team, which will
obviate the need for additional inclusion and exclusion
criteria such as age, stenotic, or occlusion status of the
vessel, low ejection fraction supported by an intra-aortic
balloon pump, and/or mechanical ventilation, stroke,
allergy to clopidogrel or acetylsalicylic acid, administra-
tion of glycoprotein IIb/IIIa receptor antagonist and/or
clopidogrel, and general and vascular comorbidities.
A select number of additional criteria beyond the
agreement of the local Heart team are detailed in Table I.
Patient screening and Heart Team Conference
In the SYNTAX study, the investigators commit that all
patients with 3VD or LM (with or without other lesions
in the coronary arteries) will be discussed by the local
Heart Team. Consecutive patients with 3VD or LM
disease will be screened through the local Heart Team
conference as demonstrated in Figure 1. The study
coordinator facilitates the local Heart Team conference.
During the Heart Team conference, members will review
the collected baseline information, such as angiograms,
demographic characteristics, coronary vasculature lesion
complexity (SYNTAX score), and surgical risk profile
(EuroSCORE), to assess whether the patient is eligible for
inclusion. They will jointly decide whether the patient
is eligible for the PCI and CABG randomized cohort, or
for either the CABG- or PCI-only registry. If both
members of the Heart Team decide that they can achieve
equivalent comparable revascularization by either PCI or
CABG, the patient can be randomized. A treatment
strategy detailing such information as location of seg-
ments or distal anastomoses, number of stents or grafts,
and other relevant information will be documented and
compared with the procedural results.
If the patient is expected to have a better outcome
with 1 of the 2 treatment modalities, then the patient
should be assigned to one of the registries. If revascu-
larization is not felt to be possible, the patient will be
treated medically and will not be included in the study.
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The final decision of the local Heart Team will be
documented on a Heart Team Decision Form. If
applicable, the referring physician will be contacted for
confirmation of the final decision by the local Heart
Team. After this conference, the patient should be asked
to provide informed consent for either randomization or
inclusion in one of the registries. A Patient Informed
Consent form has been specifically designed for each
revascularization allocation group.
If the patient or the referring physician has a formal
preference for either treatment, the patient will not be
enrolled in the study. Any patient who refuses to be
followed up will be excluded from the study. In
addition, the patient or physician may decide that
medical treatment is the preferred option even after
informed consent is obtained.
The number of patients screened by the local Heart
Team will be recorded in a study log.
Allocation
After informed consent has been obtained, the central
allocation service (Interactive Voice Response System
Figure 1
SYNTAX study flowchart.
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[IVRS]) will prompt the study coordinator to provide the
patient’s SYNTAX score and EuroSCORE. If the patient is
assigned to the randomized cohort, the IVRS will
randomize the patient to either PCI with TAXUS or
CABG treatment in random block sizes per site based on
the presence or absence of LM disease and medically
treated diabetes mellitus. If the patient is assigned to one
of the registries, the study coordinator must specify the
assigned treatment allocation in the IVRS.
Randomization
Randomization will be stratified by clinical site and by
absence or presence of LM disease and medically treated
diabetes to ensure approximately equal allocation to
the 2 revascularization methods at each site and within
each stratum. Medically treated diabetes is defined as
diabetic patients requiring oral medications or insulin
for glycemic control. The sample size is sufficiently large
to prevent serious imbalances with respect to other
important risk factors. Any MACCEs that occur after
IVRS randomization will count toward the primary end
point, even if the patient has not yet been treated. The
IVRS will randomly select a subset of 750 CABG patients
who are to be followed up over a period of 5 years.
Postallocation and pretreatment phase (wait list)
The interval between treatment allocation and actual
procedure date may be different between the random-
ized PCI and CABG cohort and will vary by country. Any
events and incurred costs will be allocated to the
corresponding treatment group (intent-to-treat) as soon
as the IVRS is initiated.
Crossovers: CABGYPCI or PCIYCABG
Crossover is expressly discouraged and will be
allowed only under very special circumstances and will
be tracked by the Executive Committee. In the event of a
crossover to CABG, the interventional cardiologist must
be notified in advance and both cardiologist and surgeon
must agree that no solution other than CABG is available
under the circumstances. Conversely, in the event of a
crossover to PCI, the cardiothoracic surgeon must be
notified in advance of the possibility of emergent
surgery, and both must agree that no solution other than
PCI is available under the circumstances.
Study end point definitions
Death. In the primary comparison of the 2 treatment
strategies, all deaths will be examined. Death due to
specific causes will be investigated and adjudicated by
the CEC. All deaths are considered cardiac unless an
unequivocal noncardiac cause can be established. All
patient deaths will be documented in the electronic
case report forms.
Cerebrovascular event (CE, stroke). Cerebrovas-
cular event is any acute event related to the impairment
of the cerebral circulation that lasts more than 24 hours
and results in irreversible brain damage or permanent
body impairment. Strokes may be further classified as
ischemic or hemorrhagic based on imaging studies. The
definitive evaluation for absence or presence of CVA will
be conducted and confirmed in both revascularization
arms by a local neurologist. In addition, a neurologist
will be included in the CEC to ensure consistency in the
adjudication of CVA.
An MI will be considered an event whether it occurred
spontaneously or in association with PCI or CABG
procedures. A definite diagnosis of MI is made based on
the following: within the first 7 days post intervention
(PCI or CABG)—either new, abnormal Q waves and
1 ratio of peak creatine kinase–MB (CK-MB)/peak total
CK N10% or new, abnormal Q-waves and 1 plasma level of
CK-MB 5 upper limit for normal; 7 days after any
intervention procedure (PCI or CABG)—either new,
abnormal Q waves or enzyme changes defined as more
than 10% of the ratio of peak CK-MB/peak total CK on one
or more than one sample (if no ratio is available—one or
more than 1 plasma level of CK-MB 5 upper limit for
normal). The Minnesota Code for pathological Q waves
will be used. New abnormal Q waves will be identified by
the investigator on the electrocardiogram and recorded.
Cardiac enzymes (CK/CK-MB) must be determined in
all surgical patients, unless the local institution uses
another method for enzymatic determination of perio-
perative myocardial damage. In this case, all relevant
enzymatic data must be reported. An independent central
core laboratory will assess all collected samples.
Revascularization procedure. Every subsequent
revascularization procedure and its indication will be
reported and documented.
Run-in phase
A run-in phase was mandated for each site interested
in participating in the trial both to assess the experience
of the operators at each site in performing 3VD and LM
procedures and to adequately project the expected
enrollment rate at each site. Both the interventional
cardiology and cardiothoracic surgery units at each site
were asked to complete a web-based survey, which
collected the anonymous details of each patient treated
for 3VD or LM disease at the site over a retrospective,
3-month period from January to March 2004.
As of May 13, 2005, a total of 12158 patients from
104 PCI sites and 104 CABG sites have been entered
(Table II). European sites comprise three fourths of all
sites, with the remainder from North America. Overall,
2.8 times as many patients per site were treated by
CABG, compared with PCI for the combined cohort
of LM or 3VD.
On average, European sites performed twice as many
3VD PCIs per site, compared with North American sites.
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Although a similar number of LM vessels were treated by
PCI on both continents, 3.1 times more unprotected
LMs were treated per site in Europe than in North
America during the 3-month period. Similar numbers of
3VD and LM disease patients per site were treated by
CABG across both continents.
SYNTAX score and risk profiles
SYNTAX score (coronary vascular lesion complexity)
One of the key objectives of the SYNTAX trial is to
provide guidance to physicians on optimal revasculari-
zation strategies for patients with higher risk lesions.
These recommendations will stem from the complexi-
ties of the lesions, the associated approach to revascu-
larization, and the outcomes based on lesion type. The
SYNTAX score is being developed to prospectively
characterize disease complexity of the coronary vascu-
lature with respect to lesion frequency, location, and
angiographic complexities. Higher SYNTAX scores are
indicative of a more complex overall vascular tree; it is
hypothesized that patients with higher scores would
have worse short-term outcomes.
The suggested SYNTAX score incorporates and com-
bines multiple concepts developed over the last decades
including the importance of a diseased coronary artery
segment (bLeaman scoreQ),34 adverse characteristics of a
lesion for revascularization (American College of Cardi-
ology [ACC]/American Heart Association [AHA] lesion
classification),35 and the plaque anatomy for bifurcation
lesions as captured in the modified Duke36/Institut
Cardiovasculaire Paris Sud System classification.37 Ad-
verse characteristics are scored for each lesion sepa-
rately. The SYNTAX coronary vascular lesion complexity
will be graded for all significant lesions. The sum of all
these individual classifications and the complexity factor
(additive score) will be referred to as the patient’s
general SYNTAX score.
In addition, the SYNTAX score assigned pre procedure
based on diagnostic angiography will be assessed by an
independent core laboratory. Its utility for predicting
outcomes will be examined at 3 junctures during the
trial: Phase I will evaluate the SYNTAX score based on
patient allocation into the 3 study arms (randomized
cohort, PCI-only registry and CABG-only registry), Phase
II will evaluate and optimize its utility at predicting early
(30 day) procedural outcomes, and Phase III will evaluate
and optimize the SYNTAX score for predicting 1-, 3-, and
5-year outcomes. The SYNTAX score may need to be
modified as the usefulness of its individual features is
determined or as new contributors are identified.
EuroSCORE and Parsonnet score
To estimate operative mortality and balance base-
line patient characteristics, variables that are used to
calculate the EuroSCORE and the Parsonnet score will
be collected.
The EuroSCORE is a prognostic scoring system
calculating predicted operative mortality for patients
undergoing cardiac surgery.38 The score was originally
developed in Europe and is the most rigorously
evaluated scoring system in cardiac surgery. Most Euro-
SCORE risk factors are derived from the preoperative
clinical status of the patient, with 4 risk factors being
related to the operation. The additive EuroSCORE is easy
to use and gives a reliable estimate of risk in individual
patients, unless certain combinations of risk factors
coexist.39 The SYNTAX trial provides an opportunity to
explore this higher-risk group.
The Parsonnet risk stratification system was developed
in the United States in the 1980s and was the first scoring
system in popular use for cardiac surgery.40 The Parson-
net score will be calculated for all patients enrolled in
both the randomized cohort and the nested registries.
Procedural techniques
Stenting technique
Stent implantation will be performed according to
routine, local, clinical practice using the femoral or
radial approach with the intention of complete revas-
cularization. The TAXUS Express2 paclitaxel-eluting
stent should be attempted for each lesion in a vessel
with a diameter N1.5 mm (by visual assessment) that
supplies viable myocardium, as assessed on the diag-
nostic angiogram. Lesions should be completely covered
by the stent with an overlap at both edges of at least
3 mm. Unsuccessful stent implantations must be
recorded. A stent-to-stent overlap of approximately 4 mm
is recommended for multiple stents per lesion. When-
ever clinically indicated (eg, ostial lesions, edge dissec-
tion, LM stem), intravascular ultrasound guidance is
recommended to ensure optimal stent expansion and
lesion coverage. Specific guidelines are provided in the
protocol with regard to the treatment of bifurcations,
chronic total occlusions, aorto-ostial lesions, and LM
Table II. Results of the survey of sites by continent
Variable Europe North America PT
PCI
Total number of sites 77 27
No. of patientsy 34.3 F 28.6 20.0 F 27.6 .03
3-vessel treatmenty 25.8 F 24.9 12.1 F 19.6 .01
Left main treatmenty 8.4 F 8.1 7.9 F 10.4 .8
Unprotected LMy 5.6 F 6.3 1.8 F 2.6 b.001
CABG
Total number of sites 75 27
No. of patientsy 84.3 F 50.9 92.3 F 52.6 .5
3-vessel treatmenty 60.0 F 41.4 61.2 F 46.0 .9
Left main treatmenty 24.2 F 18.6 31.3 F 25.8 .21
TP value calculated using independent samples t test.
yResults expressed as mean number of patients per site.
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stem lesions. An intra-aortic balloon pump or a left
ventricular assist device for the elective treatment of LM
stem lesions may be used at the operator’s discretion.
Concomitant medications are detailed in Table III.
Optimizing medical therapy according to ACC/AHA
guidelines is strongly recommended for patients en-
rolled in this trial.35
Staged procedures. A staged procedure is allowed
provided it is performed within 72 hours after the initial
procedure and during the same hospital stay. However,
when renal insufficiency is present or contrast-induced
nephropathy occurs, the PCI procedure may be staged
but must be completed within 14 days. A staged
procedure should be documented as planned (before
the initial procedure) or provisional (at the time the
patient is leaving the catheterization laboratory) and will
be adjudicated by the CEC. This practice distinguishes
staged procedures from repeat interventions on initially
targeted lesions mandated by a clinical problem occur-
ring during the initial hospitalization.
Surgical technique
CABG will be performed at the surgeon’s discretion
and according to local, clinical practice. It is recom-
mended that patients undergoing coronary bypass
surgery should be operated on with the intention of
complete revascularization. All vessels with a significant
stenosis of at least 50% in a vessel with a diameter of
z1.5 mm (as previously estimated on the diagnostic
angiogram during the local Heart Team conference)
should be considered for bypass surgery. In patients
b70 years old, arterial revascularization is strongly
recommended. The left anterior descending artery
and/or the diagonal branches should be revascularized
using the pedicled left and/or right internal thoracic
artery whenever feasible. The remaining vessels should
be bypassed either by use of another mammary artery or
any other artery or the greater saphenous vein in the
configuration as deemed appropriate by the surgeon.
Patients can be operated on either with or without
extracorporeal circulation; however, minimally
invasive direct CABG may only be included in the CABG
registry. Finally, anesthetic techniques will not be
standardized. For on-pump surgery with the use of
cardioplegia, the type of cardioplegia will be left to
the individual operator.
Concomitant medications are detailed in Table III.
Optimizing medical therapy according to ACC/AHA
guidelines33 is strongly recommended for patients
enrolled in this trial.
Study procedure and follow-up
The 1500 randomized patients will undergo prede-
fined clinical follow-up at 30 days post procedure and
at 1, 6, 12, 36, and 60 months post allocation. Twelve-
lead electrocardiograms (ECGs) are to be performed
preprocedurally, at discharge, and at 1, 3, and 5 years
post allocation, with the core laboratory reviewing
the first 3 ECGs. Cardiac medications and anginal
status (according to the Canadian Cardiovascular
Society classification) will be recorded during the
initial hospital stay and at all out-patient follow-up
clinics. Blood samples are to be obtained for the
measurement of creatine phosphokinase and its MB
isoenzyme before procedure and at 6 hours and
12 hours post index procedure or at discharge
(whichever is earlier). In the case of chest pain with
or without ECG changes, additional serial cardiac
enzymes must be sampled immediately, 6 and 12 hours
after the onset of symptoms. In addition, serum
creatinine will be assessed locally. Samples collected
from the randomized cohort will be assessed by a
central Core Laboratory for the following parameters:
high-sensitivity C-reactive protein, hemoglobin A1c, and
CK and CK-MB.
Patients allocated to the PCI registry and the
750 randomly selected CABG registry patients will
undergo clinical follow-up at 1 month post procedure
and at 6, 12, 36, and 60 months post allocation. In
addition, these patients will undergo a preprocedural
and predischarge ECG.
Costs and cost effectiveness
The analyses of costs, quality of life, and cost effec-
tiveness will be outlined in detail in a separate protocol.
Table III. Periprocedural medication guidelines for the
SYNTAX trial
STENT
Pre procedure Aspirin: N70 mg per day starting at least 12 h
before the procedure
Clopidogrel: loading dose of at least 300 mg
starting at least 24 h before procedure is required
(given that these are high-risk patients with
complex lesions), followed by 75 mg once daily.
OR ticlopidineT: 48 hours pre
procedure: 2  250 mg
Procedural Heparin: initial bolus IV with additional boluses to
maintain an ACT N250 seconds
Administration of glycoprotein IIB/IIIA inhibitors
and bivalirudin are at the discretion of the operator
Post procedure Postprocedural heparin is discouraged
Aspirin: N70 mg/d indefinitely
Clopidogrel: 75 mg once daily for 6 m
OR TiclopidineT: 2  250 mg/d for 6 m
CABG
Pre procedure Aspirin: N70 mg/d starting at least 12 h before
the procedure
Procedural Aprotinin: permitted
Post procedure Aspirin: N70 mg/d indefinitely
TTiclopidine is to be used in cases of clopidogrel intolerance.
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Statistical considerations
Sample size estimate and justification
The primary end point is the MACCE rate through
12 months post allocation. The sample size was
calculated for a 2-group test of equivalence in
proportions using the commercial software program
nQuery Advisor Version 4 (Statistical Solutions, Cork,
Ireland). The expected 12-month MACCE rate for both
groups is estimated to be 12%, based on data from the
ARTS I trial.5 Given a clinically relevant difference
(delta) of 5% and a 1-sided 5% significance level, 725
patients per group will provide 90% power to reject
the null hypothesis if it is false. Allowance is made for
3.5% attrition; therefore, the necessary sample size for
the study is 1500 patients (750 per group).
The randomized trial will not have sufficient power for
analyzing LM disease only. The study of 1500 patients is
80% powered to show a superiority of binary treatment
difference of 5.0% or more, assuming there is a 10%
MACCE rate in the PCI group.
Statistical testing will be used to determine whether
the 12-month MACCE rate for the PCI with TAXUS group
is noninferior to the 12-month MACCE rate in the CABG
control patients, assuming that a difference of 5 percent-
age points is clinically significant. The null hypothesis
that the true difference in rates is at least 5 percentage
points will be tested against the 1-sided alternative that
the true difference in rates is less than 5 percentage
points, that is,
H0 : Pe  Pc z 0:05
H1 : Pe  Pc b 0:05
where Pe and Pc are the expected 12-month MACCE
rates for the PCI with TAXUS and CABG groups,
respectively.
For the registry cohorts, the numbers of patients
indicated are estimates. As they are used for descriptive
purposes only, no statistical justification is required for
group size.
Analysis populations
All primary and secondary end points will be
analyzed both on an intent-to-treat basis and on a per-
protocol basis. For intent-to-treat analyses, all patients
who sign the written Informed Consent Form and
enroll in the study, that is, who are randomized via
IVRS allocation, will be included in the analysis,
regardless of the treatment that ensues. For per-
protocol analyses, only randomized patients who
received the appropriate treatment according to their
IVRS allocation will be included. Patients who cross
over to the other treatment are excluded from per-
protocol analyses. Any difference in results between
the populations will be investigated so that they can be
explained. Data will also be summarized descriptively
for the registry patients.
Predefined subgroups
Three-vessel disease. It is estimated that 1300 pa-
tients with 3VD (without LM) will be enrolled, which
will result in a power of 86% to show noninferiority of
PCI with TAXUS to CABG in this subgroup. A minimum
of 1090 patients with 3VD (without LM) are required to
guarantee a power of 80%.
Left main isolated or with 1, 2, or 3VD. Although
the randomized cohort will not have adequate power to
show noninferiority of PCI with TAXUS to CABG for LM
disease, this high-risk subset will be analyzed and
monitored extensively for safety.
Other predefined subgroups. Other subgroups that
will be monitored include patients with bifurcation or
trifurcation lesions, chronic total occlusions, long stent-
ing, age (N70, V70), sex, diabetes mellitus (including
status by type, treatment, and hemoglobin A1c level),
and metabolic syndrome.
Interim analysis
No formal interim analysis of the primary end point
of this study will be performed.
Statistical analysis
All statistical analyses will be done using The SAS
System software, version 8 or above (SAS Institute Inc,
Cary, NC). Analyses will be performed using data pooled
across all randomization strata (ie, institution, LM
disease, and medically treated diabetes mellitus). Con-
tinuous variables will be presented using mean, SD,
median, 25th and 75th percentile, minimum and
maximum values. Discrete variables will be presented in
frequencies and percentages.
Other analysis methods
Data collected during the follow-up period will be
analyzed using appropriate univariate and multivariate
techniques. Kaplan-Meier plots of time-to-event variables
will be constructed. The Cox proportional hazards
regression model may be used to assess the effects of
risk factors on the time-to-event variables. Loglinear
models or logistic regression models may be used
similarly for discrete outcomes.
If baseline differences are observed between the PCI
with TAXUS patients and the CABG patients, a second-
ary analysis will be performed in which comparisons
between treatment groups for principal safety and
efficacy end points will be adjusted for those baseline
covariates found to be different. The baseline data from
the overall study population will be used to describe the
subpopulations with respect to the SYNTAX score,
EuroSCORE, and their individual components.
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Stages of result reporting
Results will be reported for the primary and secondary
analysis populations in 4 stages:
1. short-term follow-up (30 days post index
procedure);
2. primary end point (1 year post-treatment
allocation);
3. medium-term follow-up (3 years post-treatment
allocation); and
4. long-term follow-up (5 years post-treatment
allocation).
Predictive scoring systems under investigation
The EuroSCORE has only been validated to predict
inhospital or 1-month outcomes. In this trial, it will also
be used to predict morbidity outcomes at 1, 3, and
5 years post allocation. A score based on coronary lesion
complexity assessment (SYNTAX score) will be devel-
oped to predict clinical outcomes at 1 month post index
procedure and at 1, 3, and 5 years post allocation using
logistic regression analysis.
Conclusions
This study will define the roles of CABG and PCI using
DES in the contemporary management of LM and 3VD.
The development of the SYNTAX score and the
validation of the EuroSCORE should provide guidance to
physicians as a predictive tool on the optimal revascu-
larization strategy for patients with high-risk lesions. In
addition to the 1-year primary end point, both short-
(1 month) and long-term (5 year) results will be
obtained, enabling determination of the sustainability
of DES. Predefined subgroup analyses in this complex
population will also provide guidance as to the optimal
treatment method for each subgroup.
We thank Blessie Concepcion, Nic Van Dyck, Peter
Lam and Luc Verhees (all employees of Boston
Scientific Corporation) for their extensive efforts in the
development and creation of the study protocol.
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Complete Revascularization
Coronary Artery Bypass Graft Surgery Versus Percutaneous
Coronary Intervention
Andrew T.L. Ong, MBBS, FRACP; Patrick W. Serruys, MD, PhD
The concept of complete revascularization arose from theearly studies on coronary artery bypass grafting (CABG)
surgery whereby some publications demonstrated that pa-
tients who were completely revascularized enjoyed a mortal-
ity benefit over those who were incompletely revascularized,
thus setting the standard for the field of CABG.1–3 Over the
past 3 decades, CABG has evolved from saphenous vein
grafting to more frequent use of arterial grafting, better
perioperative management, development of a less invasive
approach, and off-pump surgery as a genuine option. The
development of percutaneous coronary interventions (PCIs)
for the treatment of coronary stenosis has developed out of
the treatment of single-vessel disease to become an alterna-
tive to CABG in the treatment of multivessel disease.4,5 PCI
has progressed from balloon angioplasty to coronary stents,6,7
and now drug-eluting stents,8 with the simultaneous develop-
ment of new devices to treat chronic total occlusions (CTOs).
For both groups of patients treated by either CAGB or PCI,
there is recognition that aggressive pharmacological
secondary-prevention therapies such as statins and antiplate-
let agents are beneficial and are now commonly used.
Despite the mantra of complete revascularization, none of
the current guidelines set out by the American or European
cardiology societies formally discuss the issue in detail.
Although this topic has been addressed separately within each
revascularization strategy, to date there has been only 1 report
from a randomized trial that compared the end point of
complete revascularization between CABG and PCI.9 This
review will therefore address the issue separately for CABG
and for PCI and finally provide a comparison of the 2
strategies.
Definition of Complete Revascularization
There is no universal definition for what is meant by
“complete” revascularization (Table 1). Different studies
employ different definitions, and for that reason, comparisons
between studies must be interpreted with caution. For exam-
ple, revascularization may be declared complete if all stenotic
vessels are revascularized, irrespective of size (anatomic
revascularization) and territory supplied; others impose min-
imum diameter criteria; yet others differentiate between main
vessels and branch vessels. Second, a functional classification
may be used, whereby revascularization is declared complete
if all ischemic myocardial territories are reperfused; areas of
old infarction with no viable myocardium are not required to
be reperfused. Another method that may be used is to count
the number of vessels with stenoses and then to count the
number of distal anastomoses (an equal number would be
declared a complete revascularization). Finally, a scoring
system can be used whereby stenoses in different vessels
assume different weightings; the overall extent of disease,
and its treatment, is then a continuous variable.
Studies that have examined the extent of revascularization
in CABG patients usually rely on the surgical report, because
routine angiographic restudy in patients immediately after
CABG is not commonly performed. PCI studies, on the other
hand, have the option of utilizing either operator reports or,
more objectively, independent ascertainment of the proce-
dural angiographic results themselves to visually and accu-
rately determine the adequacy of revascularization. Com-
pleteness of revascularization is therefore based on the
immediate procedural outcome. Failure after an initial suc-
cessful attempt at revascularization (eg, graft failure with
CABG, restenosis with PCI) is not measured directly but is
included as part of the end point of repeat revascularization.
CABG Surgery
Since the beginning of the revascularization era, no specific
CABG study has been performed with the primary end point
of complete revascularization as an outcome. The need to
completely revascularize the coronary tree has been stated to
be a tenet,10 even a truism.11 The following studies on the
extent of surgical revascularization are post hoc analyses of
major studies and are described in order to obtain an
understanding of the literature.
First, in a seminal publication from the Coronary Artery
Surgery Study (CASS) Registry, 3372 patients with 3-vessel
disease (including left main disease) who underwent isolated
first-time CABG between July 1974 and June 1979 were
analyzed with a mean follow-up of 4.9 years.3 The extent of
revascularization for this study was defined by the number of
the 3 major vessels (or their branches) that received a bypass
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graft. An average of 3.2 distal anastomoses were performed.
Grafts were placed to the left anterior descending artery in
98%. In this study, only 16% of patients received an internal
mammary artery conduit, as was the usual practice then.
Patients with severe angina (Canadian Cardiovascular Soci-
ety class III or IV) in whom more complete revascularization
was performed (defined as bypassing 3 or more vessels
versus 1 or 2) enjoyed improved survival (relative risk [RR]
0.75, 95% confidence interval [CI] 0.59 to 0.94, P0.01) and
event-free survival (RR 0.87, 95% CI 0.78 to 0.96, P0.01)
independently of any baseline differences. These patients
were also more likely to be asymptomatic or to have less
severe angina that those with incomplete revascularization.
Subset analysis revealed a significant survival benefit in
patients with significant left ventricular dysfunction (ie,
ejection fraction 0.35) with 3 or more vessels bypassed
compared with those with 2 (P0.04).
A criticism of the method described above was that it did
not take into account the relative role of each coronary artery
in supplying the left ventricle and therefore the effect of
coronary stenosis in the particular vessel(s). To address this
criticism, a novel functional scoring system that incorporated
the amount of myocardium supplied by a particular vessel
was developed by Leaman et al and published in Circulation
in 1981.12 Two hundred patients were studied by coronary
angiography before CABG and at 1 year after surgery and
scored on the basis of their coronary anatomy. Angina class
and left ventricular function were also recorded. In the group
studied, the severity of coronary artery disease (as measured
by this score) did not statistically correlate with the frequency
of angina. Postoperatively, no relationship between the fre-
quency of angina and the completeness of revascularization
could be determined. The principles of this scoring system
have been used in the development of the SYNTAX score, an
anatomic scoring system created for the SYNergy between
Percutaneous Coronary Intervention with TAXus and Cardiac
Surgery (SYNTAX) Study that eventually may be used as a
tool to predict outcomes.13,14
The Bypass Angioplasty Revascularization Investigation
(BARI) study compared the outcomes of patients with mul-
tivessel coronary artery disease treated with percutaneous
transluminal coronary angioplasty (PTCA) versus CABG and
enrolled patients from August 1988 to 1991 in either a
randomized arm or in a registry arm (due to the patient or
physician preference for the type of treatment). Patients had
to be suitable for both PTCA and CABG, and left main
stenosis was an exclusion criteria. Approximately two thirds
of patients had 3-vessel disease. In total, 1526 patients (901 in
the randomized arm and 625 in the registry arm) underwent
CABG, and 1507 were analyzed in a post hoc report with a
mean follow-up of 7.1 years.11 In this study, the authors
attempted to establish different definitions and then apply
them to the available results to derive the most appropriate
definition of extent of revascularization. They came up with
4 different definitions: (1) Traditional—all coronary arteries
with at least 1 significant lesion received a graft. (2) Func-
tional—all diseased “primary” coronary segments were by-
passed, with a unique algorithm developed for this definition
(primary segments were defined on the basis of the BARI
system of dividing the coronary arteries into 29 segments; for
example, the main body of the right coronary has 2 segments,
and there are additional primary segments based on the
anatomy of the branches, including the acute marginal,
posterior descending, and up to 3 posterolateral branches). (3)
Patients were grouped according to whether or not the
number of distal anastomoses was less, equal to, or more than
the number of diseased coronary segments. (4) Patients were
grouped by whether they had 2 or more grafts to both the left
anterior descending coronary artery and to a non-left anterior
descending coronary artery system, or whether no system had
multiple grafts. The authors found that by either the tradi-
tional or functional definition, complete revascularization
conferred no independent advantage, but the risk estimates on
late mortality were in the direction that favored complete
revascularization.
Between 1997 and 1998, the multicenter Arterial Revas-
cularization Therapies Study (ARTS) trial enrolled patients
with multivessel disease who could be potentially completely
and equivalently revascularized.4 In total, 1205 patients were
randomized to either PCI with stenting or CABG. Left main
coronary stenosis was excluded, and 30% of the population
had 3-vessel disease. In this contemporary study, 93% of
TABLE 1. Different Definitions of Complete Revascularization as Found in the Literature
Revascularization Definition
Complete anatomic revascularization
Unconditional All stenotic vessels are revascularized, irrespective of size and territory supplied.
Conditional All stenotic vessels greater than a defined diameter are revascularized,
OR
All stenotic main-branch vessels are revascularized.
Complete functional revascularization All ischemic myocardial territories are reperfused; areas of old infarction with no viable myocardium are not required
to be reperfused.
Complete numeric revascularization The number of stenotic vessels must equal the number of distal anastomoses applied.
Complete revascularization by a
predetermined scoring cutoff value
Scoring of stenoses in different vessels at different locations (weightings may be used). The overall extent of disease
is a continuous variable, the treatment is another variable, and the posttreatment score determines completeness of
revascularization.
Anatomic Irrespective of viable myocardium
Functional Jeopardy score: The postrevascularization score is calculated on the basis of the amount of remaining myocardium at
risk.
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patients received at least an arterial graft. All angiograms
were reviewed centrally, and all lesions with a 50%
diameter in a segment with a reference diameter of
1.50 mm were scored as potentially amenable to treatment.
An anatomic definition was used: if all such segments were
treated according to the case report form, they were classified
as a complete revascularization. In a post hoc analysis from
the trial, complete revascularization was not associated with a
difference in mortality or in major adverse cerebral or cardiac
events (MACCE) compared with patients with incomplete
revascularization at 1 year (Table 2; Figure).9 The respective
freedom from MACCE was 89.9% versus 87.8%.
More recently, a single-center retrospective analysis of
1034 patients who underwent first-time CABG with a mean
follow-up of 3.3 years was performed.10 The authors chose a
functional classification, with complete revascularization de-
fined as the placement of at least 1 bypass graft distal to a
50% narrowing in each diseased territory. This “real-
world” cohort had a mean age of 68 years and included both
on- and off-pump CABG, with the choice of technique left to
the individual operator’s preference. The most common
reasons recorded for incomplete surgical revascularization
were that the arteries were too small, that they were severely
diseased, or both. In this study, compared with completely
revascularized patients, incomplete revascularization was as-
sociated with a 5-year unadjusted increased overall mortality
rate (47.4% versus 17.6%, respectively, P0.001) and car-
diac mortality rate (25.5% versus 6.9%, P0.001). After
adjustment for predictors of death, incomplete revasculariza-
tion remained an independent risk factor for death (hazard
ratio [HR] 1.85, 95% CI 1.03 to 3.34, P0.04 for all-cause
death, and HR 1.73, 95% CI 1.18 to 2.55, P0.006 for
cardiac death only).
Controversies
There have been other reports in the literature15–17 on com-
pleteness of revascularization in the CABG population, but in
general incompletely revascularized patients tended to be
sicker, and outcomes were usually not adjusted to reflect this
bias. Second, the development of hybrid or integrated coro-
nary revascularization in the 1990s to treat multivessel
disease by combining percutaneous techniques with minimal-
access coronary surgery through a minithoracotomy18,19 has
been unsuccessful owing to the increased need for repeat
revascularization in these patients, driven by incomplete
revascularization and in-stent restenosis.20 Finally, off-pump
CABG has been shown to be a successful alternative to
conventional or on-pump CABG, with randomized trials
demonstrating that, in the hands of experienced operators,
off-pump CABG surgery results in a degree of revasculariza-
tion that is comparable to on-pump surgery.21
Percutaneous Coronary Intervention
Early in the balloon angioplasty era, according to a report of
the 1985 to 1986 National Heart, Lung, and Blood Institute
PTCA registry, complete revascularization was attempted and
achieved in 57% and 46% of patients with 2- and 3-vessel
coronary artery disease, respectively.22 The majority of le-
sions not amenable to PTCA were total occlusions, and the
success rate for attempted occlusions was 54%. In the
long-term (9-year) follow-up study from the same registry,
the authors report that compared with patients who were
completely revascularized, patients who were incompletely
revascularized (whether intended, attempted, or not achieved)
had no different risks of dying, myocardial infarction, or
repeat revascularization by PTCA or CABG after adjustment
for baseline characteristics.23 Incomplete revascularization,
however, remained a significant risk factor for subsequent
CABG by 9-year follow-up, and incompletely revascularized
patients showed a strong trend toward more recurrent angina
at long-term follow-up, but this risk became weaker after
adjustment.
TABLE 2. Ranked MACCE at 1 Year, in Worst Order, in the ARTS Trial, Stratified According to
Extent of Revascularization and Treatment Strategy9
CABG PCI
Event
Complete
(n477)
Incomplete
(n90)
P Within
CABG
Complete
(n406)
Incomplete
(n170)
P Within
PCI
Death 2.5 4.4 NS 1.7 3.5 NS
Cerebrovascular accident 1.9 0 NS 1.7 1.2 NS
Myocardial infarction 3.4 4.4 NS 4.9 5.9 NS
(Repeat) CABG 0.2 1.1 NS 2.0 10.0 0.05
(Repeat) PCI 2.1 2.2 NS 13.1 10.0 NS
Any MACCE 11.1 12.8 NS 23.4 30.6 0.05
NS indicates not significant. Values are percentages.
Kaplan-Meier curve showing survival free of MACCE at 1 year
from the ARTS trial, stratiﬁed by treatment and completeness of
revascularization. Reprinted from van den Brand et al9 with per-
mission from the American College of Cardiology Foundation.
CVA indicates cerebrovascular accident; MI, myocardial
infarction.
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After this, investigators from the multivessel BARI trial,
which enrolled patients from 1988 to 1991, reported 5-year
outcomes of patients treated with PTCA in both the random-
ized and preference registry arms.24 Similar to the National
Heart, Lung, and Blood Institute registry, the adjusted RRs
for death, cardiac death, and death or Q-wave myocardial
infarction were not different in incompletely revascularized
versus completely revascularized patients. As with the previ-
ous study, an excess risk of subsequent CABG was seen in
the former group.
In the more recent ARTS randomized trial, which man-
dated equivalence of completeness of revascularization, true
anatomic completeness of revascularization, as ascertained by
experienced independent observers on review of films after
completion of the PCI, occurred in 70.5% of patients, a rate
higher than that in previous studies.9 As with previous
studies, patients who could not be completely revascularized
had a significantly greater number of diseased segments and
vessels. Incompletely revascularized patients also had a
3.6-fold higher incidence of total occlusions than completely
revascularized patients (19.4% versus 5.4%, P0.001). In
this study, as with previous studies, stented patients who were
incompletely revascularized had a higher requirement for
subsequent CABG in the first year of follow-up (10% versus
2% in those who were completely revascularized, P0.05),
which resulted in a lower overall MACCE-free rate (69.4%
versus 76.6%, P0.05; Table 2; Figure).
In the most recent publication on this topic, the investiga-
tors of the Alberta Provincial Project for Outcomes Assess-
ment in Coronary Heart Disease (APPROACH) reported on
1308 patients completely revascularized after PCI compared
with 648 patients with incomplete revascularization after
PCI.25 Completeness of revascularization was determined
using the Duke jeopardy score, a score developed and
validated to describe the extent of coronary disease based on
the amount of myocardium at risk. Independent predictors of
incomplete revascularization were the presence of a total
occlusion, a higher pre-PCI Duke jeopardy score, age 65
years, and renal failure. The authors then used a propensity
score to correct for the differing baseline characteristics
between the 2 populations and concluded that, with a median
follow-up of 3.01.8 years, complete multivessel PCI was
associated with a reduced need for future PCI, a trend toward
better survival, and no difference in repeat PCI.
Treatment of Culprit Lesion Versus
Total Revascularization
In the only study that has randomized patients with multives-
sel disease to either PCI limited to the culprit vessel or PCI of
all vessels with 50% stenosis, 219 patients were random-
ized and followed up for 5 years.26 Identification of the culprit
vessel was determined by 2 independent interventional car-
diologists on the basis of the clinical evidence available with
PCI for an acute myocardial infarction, an exclusion criterion.
This study demonstrated that at long-term follow-up of 4.6
years, although target-lesion revascularization rates were
similar in the completely revascularized group and the culprit
vessel–treated group (17.3% versus 12.0%, P0.3), the
overall need for repeat PCI was significantly lower (21.2%
versus 31.2%, P0.06) in the completely revascularized
group. Overall long-term MACCE rates were similar between
groups (34.6% versus 40.4% respectively, P0.4), as were
estimated costs (P0.8). Despite a relatively low usage of
stents (only 55% of the cohort was initially treated with
stents), this study suggests that the treatment of other non-
culprit lesions at the index procedure (ie, complete revascu-
larization) is linked to a lower need for repeat PCI at
long-term follow-up.
The significant difference between this and the other
previously described trials was that patients in this trial were
actively randomized to treatment groups, and patients here
were intentionally left untreated, if randomized to the culprit-
vessel treatment arm alone. This is in contrast to the previous
trials, in which patients were incompletely revascularized
owing to a “failure” of initial revascularization (intended or
otherwise) and thus were highly selected and underwent
CABG as the second option for revascularization, which was
classified as a subsequent CABG. Thus, from a societal
perspective, although estimated costs were similar for the two
procedures, complete revascularization resulted in less need
for a repeat intervention later.
New Developments With PCI: Overcoming CTOs
With the percutaneous approach, the presence of CTOs
remains the biggest and most important obstacle and techni-
cal challenge to achieving complete revascularization. CTOs
occur relatively frequently, appearing in up to 20% of patients
undergoing diagnostic coronary angiography. Furthermore,
CTOs make up 10% of PCIs in the contemporary practice of
a tertiary referral catheterization laboratory.27 Historically,
the success rate of crossing CTOs percutaneously approxi-
mates 60% with conventional techniques. This success rate is
dependent on operator experience, the number of attempts
performed, anatomic considerations, and the choice of de-
vices available.
To overcome this major limitation, new devices and
adjunctive methods have been developed to improve the
success rate. Multislice computed tomography coronary an-
giography has provided additional information such as occlu-
sion length and degree of calcification, features that predict
procedural success and that are often underestimated by
conventional coronary angiography.28 In the only randomized
trial of a device, the TOTAL trial (Total Occlusion Trial with
Angioplasty by using Laser guidewire), laser-tipped guide-
wires were no better than conventional wires.29 Local deliv-
ery of thrombolytic therapy to the site of occlusion via a
specialized catheter to facilitate wire crossing was recently
reported, with promising results.30 Japanese device makers
have led the development of specialized guidewires to allow
the development of a systematic approach. New devices in
development include a blunt dissection catheter,31 a helical
screwlike-tipped microcatheter,32 and a specific system that
uses optical coherence reflectometry together with radiofre-
quency ablation. Optical coherence reflectometry is used to
direct the tip of a guidewire in a coaxial plane within the
lumen, and radiofrequency ablation delivered at the tip is
used to enhance forward wire passage. Two separate regis-
tries of this latter device have reported successful recanaliza-
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tion rates of 51.7% and 54.3% in patients for whom conven-
tional wire techniques had failed previously.33,34
Finally, a technique used in peripheral angioplasty has
been newly introduced in which a subintimal dissection plane
or false lumen is deliberately created parallel to the true
lumen that contains the CTO.35 Under the direct vision of an
intravascular ultrasound catheter placed in the false lumen, a
guidewire is advanced from the false lumen into the true
lumen distal to the occlusion site, bypassing the occlusion,
and the newly created track is then stented with drug-eluting
stents.
Drug-Eluting Stents
After successful recanalization, the placement of drug-eluting
stents has been shown to improve the midterm outcomes of
patients with CTOs by reducing restenosis compared with
bare-metal stenting. Although no randomized study on CTOs
in drug-eluting stents has been published to date, 3 registries,
all with angiographic follow-up, convincingly demonstrate a
sustained reduction in restenosis rates, need for reinterven-
tion, and occurrence of MACCE with drug-eluting stents
compared with bare-metal stents (Table 3).27,36–38
CABG Surgery Versus PCI
In the stent era, the 3 largest randomized trials comparing
CABG surgery to PCI for multivessel disease were performed
in the late 1990s.4,39,40 The largest trial, the ARTS trial,
mandated that equivalent revascularization was mandatory.4
On the other hand, the Stent or Surgery trial encouraged but
did not mandate equivalent revascularization,39 whereas
ERACI-2 (Argentine Randomized Study: Coronary Angio-
plasty With Stenting Versus Coronary Bypass Surgery in
Patients With Multiple-Vessel Disease) mandated complete
functional revascularization.40
Of the 3 trials, only the ARTS trial has published the 1-year
outcomes of patients who were completely or incompletely
revascularized.9 In that study, despite the potential for equiv-
alent revascularization, complete revascularization was more
frequently achieved in CABG-treated patients (84.1%) than
in stented patients (70.5%, P0.001; Table 2). Although no
differences in mortality or the combined end point of death/
stroke/myocardial infarction were seen in the comparison of
the 4 groups, overall MACCE rates were significantly higher
in the incompletely revascularized stented group, driven by
an increased need for CABG within the first year of follow-up
(Figure).
Advantages and Disadvantages of Each Approach
The advantages of PCI are obvious. It is performed under
local anesthetic, postprocedural morbidity is minimal, and
patients endure a short hospital stay. With the use of drug-
eluting stents, long, diffuse stenoses can be treated effec-
tively. Despite all the technology that has been described,
however, it remains restricted by the inability to overcome
total occlusions, and success rates vary, as described above.
Symptomatic failures will eventually require CABG. CABG
surgery has the clear advantage of overcoming chronic
occlusions, and necessitating fewer repeated revasculariza-
tions, but it is associated with a not-insubstantial postopera-
tive morbidity, longer period of hospitalization, and a slower
return to normal activities. Multiple long and diseased coro-
nary segments may be a challenge, with multiple grafts
required in small vessels, and longer surgical procedures are
associated with higher morbidity.
TABLE 3. Summary of Studies Comparing Drug-Eluting Stents With Bare-Metal Stents for Treatment of CTOs
Hoye et al27 Werner et al36 Ge et al37
Composition of Groups
Consecutive
Cohort
Historical
Control
Consecutive
Cohort
Matched
Control
Consecutive
Cohort
Historical
Control
Stent type SES BMS PES BMS SES BMS
Patients, n 56 28 48 48 122 259
Diabetes, % 14 7 33 29 28 19
Prior MI 55 46 42 47 55 63
Minimum duration of CTO 1 mo 1 mo 2 wk 2 wk 3 mo 3 mo
Occlusion 3 mo, % NA NA 73 65 100 100
CTO length, mm 11.3 12.7 1813 1612 10.410.2 9.66.9
Reference diameter, mm 2.350.46 2.370.50 2.650.65 2.570.47 3.050.44 3.050.55
Postprocedure MLD, mm 2.060.48 2.180.49 2.260.36 2.160.60 2.670.49 2.690.53
Late loss, mm 0.130.46    0.190.62 1.210.70 0.280.56 1.040.87
Binary restenosis rate, % 9.1    8.3 51.1 9.2 33.3
Reocclusion, % 1.8    2.1 23.4 2.5 6.6
Stent thrombosis within 1 mo, % 1.8 0 0 0 0 0
TLR, % NA NA NA NA 7.4 26.3
MACCE, % 3.6* 17.9* 12.4* 47.9* 16.4† 35.1†
SES indicates sirolimus-eluting stent; BMS, bare-metal stent; PES, paclitaxel-eluting stent; MI, myocardial infarction; TLR, target-lesion revascularization; and NA,
not applicable. Consecutive cohort columns denote the DES groups.
*Clinical follow-up at 12 months.
†Clinical follow-up at 6 months.
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Future Developments
With the increased use of arterial grafts and perioperative
aspirin in CABG, increased experience with drug-eluting
stents and other new devices in interventional cardiology, and
widespread adoption of better secondary-prevention mea-
sures such as use of statins, the results that have been
described previously are important but may not be as perti-
nent today. The ongoing SYNTAX trial will provide new
insights into contemporary practice. As with the ARTS trial,
patients must have the potential for complete and equivalent
revascularization before they may be considered for enroll-
ment. This study will involve 1500 patients with 3-vessel or
left main disease randomized to either CABG or PCI with
paclitaxel-eluting stents, with the aim of determining the best
method of revascularization.13 Surrounding the randomized
arm will be 2 preference registry arms: one for CABG and the
other for PCI. As an all-comers trial, consecutive patients will
be enrolled, and these registries will monitor patients who
cannot be treated by either CABG or PCI owing to technical
reasons, physician or patient preferences, or comorbidities. In
this trial, CTOs are not an exclusion criterion, and the
outcomes of their treatment will be specifically monitored
throughout the conduct of the trial. Hence, it is expected that
with the new devices not previously available at the time of
the previous trials (some of which are described in the present
report), a substantial proportion of patients enrolled will have
CTOs and will be treated by CABG and PCI. Post hoc
analyses of this study, examining the completeness of revas-
cularization and success of CTO recanalization, within and
between groups, will provide some useful answers to the
current practice of revascularization for multivessel disease.
Conclusions
Completeness of revascularization is not a competition be-
tween 2 treatment strategies. Rather, it is an important factor
in the decision-making process that requires careful thought
before a patient is recommended for either treatment option.
The goal should always be complete revascularization, be-
cause the overall trend supports it, whether the treatment
choice is surgery or percutaneous intervention. From a
practical treatment point of view, if a patient undergoing PCI
for multivessel disease has a CTO, it would be reasonable to
first attempt to cross the occlusion before attempting any
other lesion. In that way, if the lesion cannot be crossed
percutaneously, the patient would then automatically become
a surgical candidate, so as to offer optimal revascularization.
Additionally, the ARTS trial demonstrated that, in a study in
which equivalent revascularization was believed to be achiev-
able in a joint meeting between cardiologists and surgeons
before randomization, it was actually achieved more often in
the CABG group than in the PCI group. Despite the discrep-
ancy, irrespective of treatment strategy or completeness of
revascularization, there was no mortality difference 1 year
after the procedure. Finally, with the multitude of new
devices and techniques to overcome CTOs, the SYNTAX
trial will provide new contemporary data on completeness of
revascularization and outcomes in patients randomized to
CABG or PCI in complex coronary disease.
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Comparison of Three-Year Outcomes After Coronary
Stenting Versus Coronary Artery Bypass Grafting in
Patients With Multivessel Coronary Disease, Including
Involvement of the Left Anterior Descending Coronary
Artery Proximally (a Subanalysis of the Arterial
Revascularization Therapies Study Trial)
Jiro Aoki, MD, Andrew T.L. Ong, MBBS, Chourmouzios A. Arampatzis, MD,
Maniyal Vijaykumar, MD, DM, Gaston A. Rodriguez Granillo, MD,
Clemens M.C. Disco, MSc, and Patrick W. Serruys, MD, PhD
The long-term effect of stents in patients with mul-
tivessel disease involving the proximal left anterior
descending artery was investigated. At 3 years, there
was no difference in the combined incidence of death,
stroke, and myocardial infarction in either group, but
the need for repeat revascularization was more fre-
quent in the group with stenting than in the group
with coronary artery bypass grafting. 2004 by
Excerpta Medica, Inc.
(Am J Cardiol 2004;94:627–631)
The Arterial Revascularization Therapies Study(ARTS), the Stent or Surgery trial, and the Argen-
tine Randomized Trial of Percutaneous Transluminal
Coronary Angioplasty Versus Coronary Artery By-
pass Surgery in Multivessel Disease II assessed the
effect of stent-assisted percutaneous coronary inter-
vention compared with coronary artery bypass graft-
ing (CABG) in the management of patients with mul-
tivessel coronary disease.1–4 The long-term effect of
stents in patients with multivessel coronary disease
involving the proximal left anterior descending coro-
nary artery (LAD) is still controversial. We analyzed
the 3-year outcomes of patients with multivessel cor-
onary disease involving the proximal LAD who were
treated with coronary stenting or CABG in the ARTS
to confirm the long-term efficacy of stenting in this
group of patients.
• • •
The ARTS trial was a randomized trial comparing
CABG and coronary stenting for the treatment of
patients with multivessel coronary disease. For each
patient, entry into the study required agreement on the
part of a surgeon and an interventional cardiologist
that an equivalent degree of revascularization could be
attained by either approach. A detailed description of
the protocol has been previously published.5 Briefly,
patients who had not previously undergone CABG or
coronary angioplasty with 2 de novo lesions located
in different major epicardial coronary arteries poten-
tially amenable to bypass surgery or stent implantation
(50% diameter stenosis in a vessel with a reference
diameter of 2.75 mm) were eligible for coronary
revascularization. Bypass surgery followed current
standard techniques, preferably using the left internal
mammary artery for revascularization of the LAD.
Patients with left main stem stenosis, impaired left
ventricular function (left ventricular ejection fraction
30%), previous cerebrovascular accidents (CVAs),
myocardial infarctions (MIs) within the week preced-
ing randomization, severe hepatic or renal disease,
neutropenia or thrombocytopenia, intolerance of or
contraindications to acetylsalicylic acid or ticlopidine,
and the need for concomitant major surgery were not
included in the study.
Angiographic data, including the characteristics of
each lesion and target coronary segment, were adju-
dicated by an independent core laboratory (Cardialysis
BV, Rotterdam, The Netherlands). The proximal LAD
was defined as the segment between the branching
point of the left main stem and the first major septal
branch (segment 6 in the American Heart Association
classification6). The study protocol required all pa-
From the Thoraxcenter, Erasmus Medical Center, Rotterdam; and Car-
dialysis, Rotterdam, The Netherlands. This study was supported by a
grant from Cordis Corporation, a Johnson & Johnson, Inc., Company,
New Brunswick, New Jersey. Dr. Serruys’s address is: Thoraxcenter,
Bd 406, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam,
The Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl. Manuscript
received February 9, 2004; revised manuscript received and ac-
cepted May 6, 2004.
TABLE 1 Baseline Characteristics of the Patients Included in
the Intent-to-treat Analysis
Characteristic
Stenting
(n  246)
Surgery
(n  253)
Men 77.2% 80.2%
Age (yrs) 60  10 62  10
Previous condition
Previous MI 43.1% 39.5%
Diabetes mellitus 12.6% 15.4%
Systemic hypertension 42.7% 42.3%
Hypercholesterolemia 61.5% 56.3%
Family history of MI 38.1% 42.9%
Peripheral vascular disease 4.5% 6.3%
Current smoker 70.7% 74.7%
Unstable angina 40.7% 35.2%
Ejection fraction (%) 62  12 61  13
3-vessel coronary disease 29.3%* 41.5%*
*p  0.005.
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tients to have follow-up clinic visits with electrocar-
diograms at 1, 2, and 3 years. Additional information
was obtained by telephone interview or from referring
physicians when needed.
The primary end point was defined as the absence
of any of the following major adverse cardiac or
cerebrovascular events (MACCEs)3 years after ran-
domization: death, stroke, transient ischemic attacks,
reversible ischemic neurologic deficits, documented
nonfatal MIs, and repeated revascularization by per-
cutaneous intervention or surgery. Deaths from all
causes were reported. In the first 7 days after inter-
vention, a definite diagnosis of MI was made if there
was documentation of new abnormal Q waves (ac-
cording to the Minnesota code7) and either cardiac
enzymes 5 times the upper limit of normal or a ratio
of peak serum creatine kinase-MB to creatine kinase
0.1. From the eighth day onward, either abnormal Q
waves or enzymatic changes were sufficient for a
diagnosis of MI. Clinical status was assessed 1, 2, and
3 years after a planned intervention.
All analyses were based on the intention-to-treat
principle from the time of randomization. Statistical
analysis was performed with SAS version 6.12 soft-
ware (SAS Institute Inc., Cary, North Carolina). Con-
tinuous variables were expressed as means SDs and
compared with the unpaired Student’s t test or Wil-
coxon ranked scores when applicable. Fisher’s exact
test was used for categorical variables. Discrete vari-
ables were expressed as counts and percentages and
compared in terms of relative risks (RRs) with 95%
confidence intervals (CIs) calculated by the formula of
Greenland and Robins.8 All statistical tests were 2
tailed. Event-free survival was calculated according to
TABLE 2 Clinical End Points at Discharge, One Year, and Three Years in Descending Order of Severity
Variable
Worst Event* Patients With Events†
RR (95% CI)
Stenting
(n  246)
Surgery
(n  253)
Stenting
(n  246)
Surgery
(n  253)
Death
Up to discharge 1.2% 2.0% 1.2% 2.0% 0.62 (0.15–2.61)
0–1 yr 3.7% 2.8% 3.7% 2.8% 1.32 (0.48–3.61)
0–3 yrs 4.5% 4.3% 4.5% 4.3% 1.03 (0.45–2.33)
CVA
Up to discharge 0.4% 1.2% 0.8% 1.2% 0.69 (0.11–4.13)
0–1 yr 0.8% 1.6% 1.2% 1.6% 0.77 (0.17–3.48)
0–3 yrs 1.6% 2.0% 2.0% 2.8% 0.73 (0.23–2.34)
MI
Up to discharge 2.4% 4.0% 3.3% 5.1% 0.63 (0.26–1.55)
0–1 yr 5.3% 4.3% 6.1% 5.5% 1.10 (0.52–2.33)
0–3 yrs 5.7% 4.3% 6.9% 6.3% 1.10 (0.54–2.21)
Q-MI
Up to discharge 2.4% 3.6% 3.3% 4.7% 0.69 (0.28–1.71)
0–1 yr 4.9% 4.0% 5.7% 5.1% 1.11 (0.51–2.41)
0–3 yrs 4.5% 4.0% 5.7% 5.9% 0.96 (0.45–2.03)
Non-Q-MI
Up to discharge 0.0% 0.4% 0.0% 0.4% —
0–1 yr 0.4% 0.4% 0.4% 0.4% 1.03 (0.06–16.5)
0–3 yrs 1.2% 0.4% 1.2% 0.8% 1.55 (0.26–9.31)
Repeat revascularization
Up to discharge 2.4% 0.0% 3.7% 0.4% 9.26 (1.16–73.6)
0–1 yr 11.7% 2.4% 16.3% 2.8% 5.88 (2.58–13.4)
0–3 yrs 16.3% 4.0% 22.0% 4.8% 4.63 (2.41–8.90)
CABG
Up to discharge 0.4% 0.0% 0.4% 0.4% 1.03 (0.06–16.5)
0–1 yr 2.4% 0.4% 3.7% 0.8% 4.63 (0.99–21.6)
0–3 yrs 3.7% 0.4% 4.9% 0.8% 6.17 (1.37–27.9)
Repeat PTCA
Up to discharge 2.0% 0.0% 3.3% 0.0% —
0–1 yr 9.3% 2.0% 12.6% 2.0% 6.38 (2.44–16.7)
0–3 yrs 12.6% 3.6% 17.1% 4.0% 4.32 (2.11–8.82)
Event-free survival
Up to discharge 93.5% 92.9%
0–1 yr 78.5% 88.9%
0–3 yrs 72.0% 85.4%
Any event
Up to discharge 6.5% 7.1% 0.91 (0.46–1.84)
0–1 yr 21.5% 11.1% 1.95 (1.18–3.20)
0–3 yrs 28.0% 14.6% 1.92 (1.34–2.75)
*If a patient required repeat angioplasty and later required CABG, only the worst event (CABG) was counted as an event.
†If a patient required repeat angioplasty and later required CABG, the total count for CABG and percutaneous transluminal coronary angioplasty (PTCA) at 3 years
would reﬂect both events, not just the worst that occurred, but the count for the general variable repeat revascularization would reﬂect only 1 event.
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the Kaplan-Meier method, and differences were as-
sessed using the log-rank test. A p value 0.05 was
considered statistically significant.
From April 1997 to June 1998, 1,205 patients were
randomly assigned to undergo CABG (605 patients)
or angioplasty with stent implantation (600 patients) at
67 participating centers in the ARTS. Four hundred
ninety-nine patients from the total population had
segment-proximal LAD disease, of whom 246 were
randomly assigned to undergo stenting and 253 to
undergo CABG. In this subcohort of patients, 3 pa-
tients allocated to stent implantation were instead
treated surgically, and 8 patients allocated to bypass
surgery were instead treated with stent implantation.
A total of 98.8% of patients in the stenting group (243
patients) and 96.8% of those in the surgery group (245
patients) received the assigned treatment. There were
no deaths or CVAs in the 2 groups while on the
waiting list. One patient in the stenting group had an
MI while on the waiting list for the procedure,
whereas in the surgery group, 3 patients had MIs
while on the waiting list. Table 1 presents the baseline
characteristics of the patients included in the inten-
tion-to-treat analysis.
Until hospital discharge, there were no significant
differences between the stenting group and the surgery
group in the incidence of death, CVAs, and MIs,
although the numbers of deaths, CVAs, and MIs in the
stenting group were lower than in the surgery group.
In the stenting group, 5 patients (2%) had stent throm-
bosis. Of these 5 patients, 1 died before discharge.
Overall, 9 patients (3.7%) in the stenting group un-
derwent additional revascularization (including 1 pa-
tient who underwent CABG because of an unsatisfac-
tory angioplasty procedure), compared with 1 patient
(0.4%) in the surgery group (RR 9.26, 95% CI 1.16 to
73.62).
The frequency of MACCEs and the numbers of
patients in whom each type of event occurred at 1 year
are listed in Table 2. At least 1 event occurred in 53 of
the 246 patients assigned to stent implantation
(21.5%), compared with 28 of the 253 patients as-
signed to bypass surgery (11.1%; RR 1.95, 95% CI
1.18 to 3.20). Freedom from death, CVAs, and MIs
was similar between the 2 groups (90.2% in the stent-
ing group and 91.3% in the surgery group; RR for
death, CVA, or nonfatal MI 1.12; 95% CI 0.61 to
2.06). Of those free from death, CVAs, and MIs,
11.7% in the stenting group and 2.4% in the surgery
group underwent repeat revascularization (an absolute
difference of 9.3%). Overall, 16.3% of the patients in
the stenting group underwent additional revasculariza-
tion compared with 2.8% in the surgery group (RR
5.88, 95% CI 2.58 to 13.40).
At 3 years, MACCEs occurred in 69 patients
(28%) assigned to stent implantation, compared with
37 patients (14.6%) assigned to bypass surgery (RR
1.92, 95% CI 1.34 to 2.75). Freedom from death,
CVAs, and MIs was similar in the stenting and surgi-
cal groups (88.2% in the stenting group and 89.3% in
the surgery group; RR for death, CVAs, or nonfatal
MIs 1.10; 95% CI 0.63 to 1.93). From 1 to 3 years, a
similar number of patients in the 2 groups died or had
CVAs or MIs (2.4% in the stenting group and 2.0% in
the surgery group, RR 1.23, 95% CI 0.37 to 4.10),
whereas repeat revascularization was performed more
often after stenting than after surgery (5.7% in the
stenting group and 2.0% in the surgery group, RR
2.88, 95% CI 1.02 to 8.12). The different clinical
outcomes are illustrated by the Kaplan-Meier esti-
FIGURE 1. Acturial survival (A), Kaplan-Meier estimates of sur-
vival without MI or cerebrovascular events (B), and Kaplan-Meier
estimates of survival without cerebrovascular events, MI, or re-
peat revascularization (C) in patients assigned to undergo stent-
ing compared with those assigned to undergo CABG. There was
a signiﬁcant difference between the groups in survival without
cerebrovascular events, MI, or repeat revascularization (p
<0.001 by the log-rank test).
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mates of event-free survival in the 2 original groups
and in patients who survived for 3 years without
CVAs or MIs (Figure 1). The number of patients with
3-vessel disease including the proximal LAD was
different between the stenting group and the CABG
group (29.3% vs 41.5%). However, the tendency of
the RR for MACCEs was similar between patients
with 2-vessel disease and those with 3-vessel disease.
MACCEs for the patients with 2-vessel disease were
26.4% in the stenting group and 14.9% in the CABG
group (RR for MACCEs 1.78, 95% CI 1.13 to 2.81),
and MACCEs for the patients with 3-vessel disease
were 31.9% in the stenting group and 14.3% in the
CABG group (RR for MACCEs 2.24, 95% CI 1.26 to
3.98).
• • •
The major findings of this study are that (1) the
3-year clinical survival of patients with multivessel
coronary disease involving segment 6 was not statis-
tically different between the stenting group and the
CABG group; (2) the incidence of CVAs and MIs was
similar in such patients between the stenting group
and the CABG group during 3 years; and (3) the need
for repeat revascularization was more frequent in the
stenting group than the CABG group at 3 years. In the
stent era, some clinical trials have shown that freedom
from death, stroke, and MI was similar in patients with
multivessel disease treated with stenting versus those
treated with CABG.1–4 The use of coronary stents has
reduced the need for repeat revascularization com-
pared with balloon angioplasty, although the rate re-
mains higher than with CABG (Table 3). The present
study shows that the use of coronary stents has a
similar combined incidence of death, CVAs, and MIs
for 3 years after randomization, even if patients with
multivessel coronary disease have proximal LAD dis-
ease.
The main limitation of stent implantation com-
pared with CABG is a greater incidence of repeat
revascularization (22% vs 4.8%). The main cause of
repeat revascularization during the initial hospitaliza-
tion in the stenting group was stent thrombosis. From
discharge to 1 year later, the rate of repeat revascu-
larization in the stenting group was higher than in the
CABG group because of restenosis (12.6% in the
stenting group and 2.4% in the surgery group; an
absolute difference of 10.2%). After 1 year, this ten-
dency continued (5.7% in the stenting group and 2%
in the surgery group; an absolute difference of 3.7%),
but in a smaller proportion. The main limitation of
stenting in such patients is the greater incidence of
restenosis requiring repeat revascularization. In 51
patients who underwent repeat revascularization dur-
ing 3 years in the stenting group, 25 patients (49%)
had repeat revascularization for restenosis of the prox-
imal LAD, but no patient had repeat revascularization
because of restenosis that extended to the left main
coronary artery. Drug-eluting stents have definitively
been shown to dramatically reduce restenosis rates.9,10
Further study should be done to compare stenting with
TABLE 3 Comparing Clinical Events Between PTCA and CABG in Patients With Multivessel Disease
Trial
Follow-
Up Number Death Q-MI
Repeat
Revascularization
Balloon angioplasty
versus CABG
EAST12 3 yrs CABG 194 6.2% 19.6% 13%
PTCA 198 7.1% 16.6% 54%
RITA13 2.5 yrs CABG 501 3.6% 5.2% 11%
PTCA 510 3.1% 6.7% 38%
ERACI14 3 yrs CABG 64 4.7% 7.8% 6.3%
PTCA 63 9.5% 7.8% 37%
CABRI15 1 yr CABG 513 2.7% 3.5% 6.5%
PTCA 541 3.9% 4.9% 33.6%
BARI16 5 yrs CABG 914 10.7% 19.6% 8%
PTCA 915 13.7% 21.3% 54%
Involving proximal LAD
Hannan et al17 3 yrs CABG 15,873 10% — —
PTCA 634 14% — —
Stent versus CABG
SoS3 2 yrs CABG 500 2% 8% 6%
PTCA 488 5% 5% 21%
ERACI II2 1 yr CABG 225 7.5% 6.6%* 4.8%
PTCA 225 3.1% 2.3%* 16.8%
ARTS4 3 yrs CABG 605 4.6% 5.0% 7.3%
PTCA 600 3.7% 6.0% 29.2%
Involving proximal LAD
ERACI II18 3.5 yrs CABG 117 5% 11%* 3.4%
PTCA 113 3.6% 8%* 27%
This study 3 yrs CABG 253 4.3% 5.9% 4.8%
PTCA 246 4.5% 5.7% 22%
*Figure shows the incidence of MI, including non-Q-MI.
PTCA  percutaneous transluminal coronary angioplasty; EAST  Emory Angioplasty Versus Surgery Trial; Randomized Intervention Treatment of Angina; ERACI
 Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; CABRI 
Coronary Angioplasty Versus Bypass Revascularisation Investigation; BARI  Bypass Angioplasty Revascularization Investigation; SoS  Stent or Surgery.
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CABG for patients with multivessel coronary disease
in the drug-eluting stent era. The ARTS II, which has
just completed enrollment, may demonstrate the effi-
cacy of drug-eluting stents in patients with multivessel
coronary disease.11 Bypass surgery is no longer the
only option available to patients with multivessel cor-
onary disease involving the proximal LAD.
This study is a substudy of the ARTS. The limited
number of patients resulted in a lack of sufficient
power, and patients recruited into the ARTS were very
select, having suitable lesions for revascularization by
percutaneous coronary intervention and CABG with-
out severely impaired left ventricular function. In ad-
dition, clinical follow-up may have underestimated
the incidence of restenosis after coronary stenting.
However, this study demonstrates the long-term effi-
cacy of stents for patients with multivessel coronary
disease involving the proximal LAD.
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Aims To compare coronary stent implantation and bypass surgery for multivessel coronary disease in
patients with renal insufﬁciency.
Methods and results In the ARTS trial, 142 moderate renal insufﬁcient patients (Ccr , 60 mL/min) with
multivessel coronary disease were randomly assigned to stent implantation (n ¼ 69) or CABG (n ¼ 73).
At 5 years, there was no signiﬁcant difference between the two groups in terms of mortality (14.5% in
the stent group vs. 12.3% in the CABG group, P ¼ 0.81), or combined endpoint of death, cerebrovascular
accident (CVA), or myocardial infarction (MI) (30.4% in the stent group vs. 23.3% in the CABG group,
P ¼ 0.35). Among patients who survived without CVA or MI, 18.8% in the stent group underwent a
second revascularization procedure when compared with 8.2% in the surgery group (P ¼ 0.08). The
event-free survival at 5 years was 50.7% in the stent group and 68.5% in the surgery group (P ¼ 0.04).
Conclusion At 5 years, the differences in mortality and combined incidence of death, CVA, and MI
between coronary stenting and surgery did not reach statistically signiﬁcant level. However, the occur-
rence of MACCE in the stent group was higher than in the CABG group, mainly driven by the higher inci-
dence of repeat revascularization in the stent group.
KEYWORDS
Stent;
Coronary artery bypass;
Renal insufﬁciency
Introduction
Renal dysfunction is a well known risk factor for adverse
cardiac events after coronary revascularization. Renal dys-
function, even the mild renal dysfunction, is associated
with both restenosis and mortality after percutaneous cor-
onary intervention.1,2 Coronary artery bypass grafting
(CABG) is also associated with adverse outcome in patients
with renal dysfunction.3 Renal dysfunction is an important
factor for calculating CABG risk scores, according to ACC/
AHA guidelines, Cleveland clinic score, and Euro scores.4–7
However, no randomized trial has compared the long-term
clinical effect of coronary stenting vs. CABG in renal insufﬁ-
cient patents with multivessel coronary disease. We, there-
fore, investigated the clinical outcomes of renal insufﬁcient
patients in the ARTS trial.
Methods
Study population
The Arterial Revascularization Therapies Study (ARTS) trial was a
randomized trial comparing CABG and coronary stenting for the
treatment of patients with multivessel coronary artery disease.
Between April 1997 and June 1998, 1205 patients from 67 partici-
pating centres were randomized to either stent implantation
(n ¼ 600) or CABG (n ¼ 605). Patients included had not previously
undergone bypass surgery or angioplasty with at least two de novo
lesions located in different major epicardial coronary arteries
potentially amenable to either bypass surgery or stent implantation
(.50% diameter stenosis in a vessel with a reference diameter of at
least 2.75 mm). The agreement on the part of a surgeon and an
interventional cardiologist that an equivalent degree of revascular-
ization could be attained by either approach was required for entry
into the study. Clinical results were analysed at short (30 days),
medium (1 year), and long-term intervals (3 and 5 years). A detailed
description of the protocol has been published previously.8–10 The
present study was a posthoc study, focusing on the renal dysfunction
*Corresponding author. Tel: þ31 10 4635269; fax: þ31 10 4639154.
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in the ARTS trial. Renal dysfunction was classiﬁed by esti-
mated creatinine clearance (Ccr) calculated by use of the
Cockcroft–Gault formula:11 Ccr (mL/min) ¼ [(1402 age)  weight
(kg)]/[serum creatinine (mg/dL)  72]. Patients who had
Ccr, 60 mL/min comprised the moderate renal insufﬁcient group
and patients who had Ccr  60 mL/min comprised the mild renal
dysfunction and normal renal function group, according to the deﬁ-
nition of National Kidney Foundation.12 Patients with left main stem
stenosis, impaired left ventricular function (left ventricular ejection
fraction ,30%), previous cerebrovascular accident (CVA),
myocardial infarction (MI) within the week preceding
randomization, neutropaenia, or thrombocytopaenia, or an intoler-
ance or contraindication to acetylsalicylic acid or ticlopidine and
patients who needed concomitant major surgery and severe
hepatic or renal disease (worst Ccr level is 27.3 mL/min in enrolled
patients) were not included in the study. Among 1205 patients, 1062
patients (88.1%) had their Ccr level before the revascularization.
Figure 1 shows the cumulative curve of Ccr in overall patients.
Among 1062 patients, 142 patients had moderate renal dysfunction
(Ccr, 60 mL/min), of which 69 were randomly assigned to undergo
stenting and 73 to CABG. All patients gave written informed
consent. Randomization did not take into account Ccr level. The
aim of this study was to evaluate coronary stent implantation and
bypass surgery for multivessel coronary disease in patients with
renal insufﬁciency. To evaluate the interventional strategy in the
renal insufﬁciency group more speciﬁcally, we also investigated
the Ccr  60 mL/min group in the ARTS trial.
Data collection and endpoints
Angiographic data were adjudicated by an independent core labora-
tory (Cardialysis BV, The Netherlands). The study protocol required
all patients to have follow-up clinic visits with an electrocardiogram
(ECG) at 1, 3, and 5 years. At each visit, physical examination,
anginal status, and use of medications were assessed. Additional
information was obtained by telephone interview or via the refer-
ring physician when needed. An independent committee adjudi-
cated clinical events and ECGs. The clinical events were deﬁned
as any of the following major adverse cardiac or cerebrovascular
events (MACCE) within 5 years after randomization, deﬁned as
death, stroke, transient ischaemic attack, reversible ischaemic
neurologic deﬁcits, documented non-fatal MI, and repeated revas-
cularization by percutaneous intervention or surgery. Deaths from
all causes were reported. In the ﬁrst 7 days after the intervention,
a deﬁnite diagnosis of MI was made if there was documentation of
new abnormal Q waves (according to the Minnesota code13) and
either cardiac enzymes greater than ﬁve times the upper limit of
normal or a ratio of peak serum creatinine kinase MB (CK-MB) to
creatinine kinase (CK) greater than 0.1. From the eighth day
onwards, either abnormal Q waves or enzymatic changes were sufﬁ-
cient for a diagnosis of MI.
The primary endpoint was deﬁned as the absence of any of the
following MACCE within 5 years after randomization: death, CVA,
documented non-fatal MI adjudicated by either new abnormal Q
wave or pre-deﬁned enzymatic changes, or repeat revascularization
by coronary stenting or CABG.
Statistical analysis
Statistical analysis was performed with SAS 6.12 software (SAS
Institute Inc.). Continuous variables were expressed as mean+ SD
and compared with the unpaired Student’s t-test. The Fisher
exact test was used for categorical variables. Discrete variables
were expressed as counts and per cent values and compared in
terms of relative risks (RRs) with 95% conﬁdence intervals (CI) calcu-
lated by the formula of Greenland and Robins.14 All analyses were
based on the intention-to-treat principle, and statistical tests
were two-tailed. Cumulative event-free survival was calculated
according to the Kaplan–Meier method and differences were
assessed using the log-rank test. Ccr was analysed as a continuous
value for the prediction of MACCE in univariate analysis. P-values
,0.05 were considered statistically signiﬁcant.
Results
Patient characteristics
Baseline and procedural characteristics were similar
between patients assigned to stenting (stent arm) or CABG
(CABG arm) within each group (Table 1 ). In the moderate
renal insufﬁciency group (Ccr, 60 mL/min group), all
patients allocated to stent implantation were treated with
stents, whereas ﬁve patients allocated to bypass surgery
were instead treated with stent implantation or medical
treatment. In total, 100% of renal insufﬁcient patients in
the stent arm and 93.2% of those in the CABG arm received
the assigned treatment.
Five year clinical outcome
Comparison between moderate renal dysfunction
(the Ccr < 60 mL/min group) vs. mild renal dysfunction
and normal renal function (the Ccr  60 mL/min group)
In the Ccr, 60 mL/min group, complete follow-up during 5
years was obtained in 100% patients assigned to stenting
(stent arm) and in 97% assigned to CABG (CABG arm). In
the Ccr  60 mL/min group, complete follow-up during 5
years was obtained in 99% patients assigned to stenting
and in 98% assigned to CABG. Table 2 displays the 5 year
clinical results with respect to comparison between patients
assigned to stent and CABG within each group. Five year
mortality rate of the moderate renal insufﬁcient group was
14.5% in the stent arm and 12.3% in the CABG arm. Those
rates were higher than the group with mild renal dysfunction
and normal renal function (7.6% in the stent arm and 7.1% in
the CABG arm), but did not achieve signiﬁcant differences in
both arms: RR, 1.90; 95% CI 0.98–3.65; P ¼ 0.07 in the stent
arm and RR, 1.73; 95% CI 0.86–3.46; P ¼ 0.16 in the CABG
arm. However, the combined incidence of death, CVA, or
MI was higher in patients with moderate renal impairment
in both arms, stenting and CABG, when compared with
patients with mild renal dysfunction and normal renal func-
tion (30.4 vs. 16.6% in the stent arm: (RR, 1.83; 95% CI,
1.22–2.77; P ¼ 0.01 and 23.3 vs. 14.3% in the CABG arm:
RR, 1.63; 95% CI, 1.02–2.62; P ¼ 0.05). Regardless of the
revascularization strategies, the occurrence of repeat revas-
cularization was similar between the Ccr , 60 mL/minFigure 1 The cumulative curve of Ccr in the ARTS trial.
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group and the Ccr  60 mL/min group with a higher repeat
revascularization rate in the stent arms than that in the
CABG arms (29.0 vs. 29.7% in the stent arm: RR, 0.98; 95%
CI, 0.66–1.50; P ¼ 1.00 and 9.6 vs. 8.0% in the CABG arm:
RR, 1.20; 95% CI, 0.56–2.58; P ¼ 0.65). The MACCE rate in
the stent arms was higher than that in the CABG arm,
mainly due to the higher incidence of repeat revasculariza-
tion in both the Ccr, 60 mL/min group and the Ccr  60
mL/min group. However, the difference in rates of MACCE
between the stenting and the surgery in the Ccr , 60 mL/
min group was similar to the Ccr  60 mL/min group
(D17.8 vs. D19.6%, respectively).
To assess the effect of renal insufﬁciency on outcome, Ccr
was analysed as a continuous valuable for the prediction in
MACCE. Ccr was a signiﬁcant predictor for MACCE in the
CABG group, but not in the stent group (RR, 0.986; 95% CI,
0.978–0.995; P ¼ 0.0015 in the surgery group and RR,
0.996; 95% CI, 0.990–1.001; P ¼ 0.1288 in the stent group).
Comparison of intervention in renal insufﬁcient patients
In the moderate renal insufﬁcient group, the overall 5 year
mortality rate and the incidence of cardiac death were
not statistically different between the stent and the CABG
arms (RR of total death, 1.18; 95% CI, 0.51–2.72; P ¼ 0.81
and RR of cardiac death, 0.64; 95% CI, 0.15–2.69;
P ¼ 0.72). Among 10 patients who died during 5 year
follow-up in the stent arm, seven patients (70%) died of
non-cardiac reasons. Among nine patients who died during
5 year follow-up in the CABG arm, four patients (44%) died
of non-cardiac reasons.
The combined incidence of death, stroke, or MI was also
not statistically different between patients in the stent
arm and in the CABG arm, although the actual rates were
higher in the stent arm than in the CABG arm (30.4% in
the stent arm vs. 23.3% in the CABG arm: RR, 1.31; 95%
CI, 0.76–2.26; P ¼ 0.35). However, the incidence of repeat
revascularization was signiﬁcantly higher in the stent arm
Table 1 Patient characteristics
Ccr, 60 mL/min group Ccr  60 mL/min group
Stent
(n ¼ 69)
CABG
(n ¼ 73)
Stent
(n ¼ 458)
CABG
(n ¼ 462)
Male, n (%) 44 (64) 53 (73) 359 (78) 356 (77)
Age, (year+ SD) 70+ 6 71+ 6 59+ 9 60+ 9
Hypertension, n (%) 36 (52) 34 (47) 196 (43) 198 (43)
Diabetes, n (%) 15 (22) 11 (15) 84 (18) 65 (14)
Hypercholesterolaemia, n (%) 40 (58) 38 (52) 258 (57) 273 (59)
Family history, n (%) 21 (30) 31 (43) 191 (42) 192 (42)
Current smoking, n (%) 11 (16) 8 (11) 134 (29) 130 (28)
Unstable angina, n (%) 22 (32) 26 (36) 169 (37) 162 (35)
Ejection fraction (%) 61+ 13 58+ 13 61+ 12 60+ 13
Three vessel treatment, n (%) 23 (33) 26 (36) 141 (31) 159 (34)
Peripheral artery disease, n (%) 4 (5.8) 5 (6.8) 27 (5.9) 23 (5.0)
COPD, n (%) 4 (5.8) 5 (6.8) 22 (4.0) 22 (4.0)
Treated segments 2.5+ 1.0 2.6+ 0.8 2.7+ 1.1 2.8+ 0.8
Lesion type (B2/C)/lesion (%) 67 61 67 62
Stent/lesion 1.1+ 0.6 1.1+ 0.5
IIb/IIIa inhibitor, n (%) 2 (3) 11 (2)
CCr (mL/min) 52+ 7 52+ 6 91+ 23 90+ 22
Table 2 Clinical results
Ccr, 60 mL/min group Ccr  60 mL/min group
Stent
(n ¼ 69)
CABG
(n ¼ 73)
RR
(95% CI)
Stent
(n ¼ 458)
CABG
(n ¼ 462)
RR
(95% CI)
Death, n (%) 10 (14.5) 9 (12.3) 1.18 (0.51–2.72) 35 (7.6) 33 (7.1) 1.07 (0.68–1.69)
Cardiac death, n (%) 3 (4.3) 5 (6.8) 0.64 (0.15–2.69) 13 (2.8) 10 (2.2) 1.31 (0.56–3.05)
CVA, n (%) 8 (11.6) 4 (5.5) 2.12 (0.67–6.71) 13 (2.8) 14 (3.0) 0.94 (0.45–1.97)
MI, n (%) 6 (8.7) 8 (11.0) 0.79 (0.29–2.17) 35 (7.6) 28 (6.1) 1.26 (0.78–2.04)
Q-MI, n (%) 4 (5.8) 8 (11.0) 0.53 (0.17–1.68) 29 (6.3) 24 (5.2) 1.22 (0.72–2.06)
Death, CVA, MI, n (%) 21 (30.4) 17 (23.3) 1.31 (0.76–2.26) 76 (16.6) 66 (14.3) 1.16 (0.86–1.57)
Repeat revascularization, n (%) 20 (29.0) 7 (9.6) 3.02 (1.37–6.70) 136 (29.7) 37 (8.0) 3.71 (2.64–5.21)
RE-PTCA, n (%) 17 (24.6) 7 (9.6) 2.57 (1.14–5.81) 104 (22.7) 34 (7.4) 3.09 (2.14–4.45)
RE-CABG, n (%) 6 (8.7) 1 (1.4) 6.35 (0.78–51.4) 45 (9.8) 5 (1.1) 9.08 (3.64–22.7)
MACCE, n (%) 34 (49.3) 23 (31.5) 1.56 (1.03–2.37) 184 (40.2) 95 (20.6) 1.95 (1.58–2.41)
If a patient required repeated angioplasty and later required coronary-artery bypass grafting, the total count for ‘CABG’ and ‘PTCA’ at 5 years would reﬂect
both events, not just the worst that occurred, but the count for the general variable ‘repeat revascularization’ would reﬂect only one event.
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when compared with the CABG arm (29.0 vs. 9.6% RR, 3.02;
95% CI, 1.37–6.70; P ¼ 0.005). Overall, MACCE occurred in
34 patients (49.3%) assigned to stent implantation when
compared with 23 of patients (31.5%) assigned to bypass
surgery (RR, 1.56; 95% CI, 1.03–2.37; P ¼ 0.04). The differ-
ent incidence of MACCE rate was driven by the higher
incidence of repeat revascularization in the stent arm. The
different clinical outcomes are illustrated by the Kaplan–-
Meier estimates of event-free survival in the stent and
CABG arm within each group (Figure 2 ).
Discussion
Renal insufﬁciency is associated with an increase in mor-
tality and major adverse cardiac events after revasculariza-
tion in a dose-dependent fashion.1–3,15 In the present study,
at 5 years after revascularization, patients with moderate
renal insufﬁciency (Ccr, 60 mL/min) and multivessel cor-
onary disease had poor clinical outcomes for composite
events of death, CVA, or MI when compared with mild
renal dysfunction and normal renal function patients
(Ccr  60 mL/min). Nevertheless, the rate of clinically
driven repeat revascularization was similar between
patients with moderate renal dysfunction and patients
with normal renal function and mild renal dysfunction,
regardless of the allocated strategy of revascularization.
These results are comparable to those reported in previous
retrospective studies.1,2,15 However, in these studies and
the present study, no follow-up angiographic assessment
was performed. High angiographic in-stent restenosis rates
have been documented in patients with end stage renal
function, but the actual rate of restenosis in moderate
renal insufﬁciency is still unknown.16,17 In the present
study, the rate of clinically driven repeat revascularization
was comparable in patients with normal renal function and
those with moderate renal dysfunction, despite a higher
incidence of late cardiac events in this latter group,
although we suspect that the patients with altered renal
function are more prone to restenosis. Two factors may
have contributed to this unexpected relatively low rate of
intervention; First, as mentioned earlier, angiographic
follow-up was not mandated by protocol. Secondly, a high
incidence of silent ischaemia has been documented in
these patients with renal dysfunction, a fact that may also
explain the relatively low incidence of clinically driven
intervention, particularly in the absence of mandated angio-
graphic follow-up. It could be hypothesized that a high
prevalence of silent ischaemia in renal insufﬁcient patients
may contribute to the comparable clinically driven repeat
revascularization rate in spite of the high incidence of sub-
sequent cardiac events when compared with patients with
normal renal function.
This study also highlights that the 5 year mortality and
composite rate of death, CVA, or MI did not reach a signiﬁ-
cantly statistical level between patients allocated to stent-
ing or CABG in the moderate renal insufﬁciency group,
although actual incidence of this rate in the stent arm was
higher than that in the CABG arm. There are no precious
reports comparing the clinical results of stenting vs. CABG
for moderate renal insufﬁciency patients. However, some
reports have compared outcomes after stenting and CABG
in dialysis patients.18–20 All these studies showed that
patients with dialysis or severe renal insufﬁciency had
better long-term survival after CABG than PCI. However,
these results did not apply to our study. Dialysis and moder-
ate renal insufﬁcient patients are different medical
Figure 2 The Kaplan–Meier estimates of event-free survival in the stent and CABG arms within the renal sufﬁcient and insufﬁcient groups. Error bars indicate
95% CI.
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conditions. The limitations of coronary stenting for renal
insufﬁcient patients with multivessel disease are two-fold:
a high incidence of repeat revascularization and the likeli-
hood of renal function deterioration due to extensive use
of contrast media in multivessel treatment. The ARTS trial
was initiated in April 1997. It is relevant to consider the
differences between the techniques used in this study and
newly developed techniques for coronary revascularization
such as off-pump CABG and new, minimally invasive
approaches 21,22. Similarly, important developments in per-
cutaneous coronary intervention have taken place since
the completion of recruitment in the ARTS trial. Drug-
eluting stents have deﬁnitively been shown to dramatically
reduce restenosis rates and the different incidence of
repeat revascularization (surgery and coronary intervention)
are likely to narrow with the advent of drug-eluting
stents.23–26 In addition, iso-osmolar, non-ionic contrast
medium, aceltylcysteine, and pre-hydration may potentially
prevent the renal dysfunction induced by contrast
media.27–29
This study is a post hoc sub-study of ARTS trial. The mod-
erate number of patients may limit conclusions due to the
lack of statistical power. We had several restrictive inclusion
criteria, including lesion characteristics which had to be
suitable for both percutaneous and surgical revasculariza-
tion, so that the tentative conclusion may be restricted to
the population initially included in the trial. In addition,
the exact aetiology of renal dysfunction and renal function
at follow-up period were not evaluated in this study.
However, this is the ﬁrst randomized prospective study to
compare the 5 years clinical outcomes of the stenting vs.
CABG in moderate renal insufﬁcient patients with multi-
vessel coronary disease.
Conclusions
In this 142 moderate renal insufﬁcient patients
(Ccr, 60 mL/min) prospective cohort, the difference in 5
year mortality and combined incidence of death, CVA, and
MI between coronary stent and surgery did not reach a stat-
istically signiﬁcant level, although the actual event rates in
the stent group were higher than in the CABG group. The
occurrence of MACCE in the stent group was statistically
higher than in the CABG group, mainly due to the higher
incidence of repeat revascularization in the stent group.
However, the difference of MACCE rate between the stent
and the CABG in the Ccr, 60 mL/min group was similar as
compared to the CCr  60 mL/min group.
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Abstract
Aims: To determine whether women have an unfavorable outcome after coronary interventions compared
with men, we evaluated patients undergoing revascularisation within the Arterial Revascularisation
Therapies Study (ARTS).
Methods and results: We evaluated 1205 patients (23% women) with multivessel disease randomised to
percutaneous or surgical coronary revascularisation. The in-hospital results, and clinical outcome at five
years were evaluated. Women were older, with a higher prevalence of hypertension, hypercholesterolaemia,
family history for coronary artery disease (all p<0.001), diabetes mellitus (p=0.05) and stable angina
(p<0.05) than men, but had a lower incidence of history of myocardial infarction or smoking (both
p<0.001). More major bleeding complications, even after adjusting for baseline clinical characteristics (OR
29.4, 95% CI: 5.3-500, p<0.005) were observed in women following percutaneous coronary intervention.
During clinical follow-up freedom from major adverse cardiac and cerebrovascular events was similar in
men and women, regardless of treatment strategy. Men assigned to bypass surgery had a better quality of
life, but women reported more frequently angina.
Conclusion: The clinical outcome of women with multivessel disease undergoing coronary revascularisation
was similar to that in men. However, women presented more bleeding complications before hospital dis-
charge, and had less favourable assessment in specific domain of daily life at follow-up.
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surgery.
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Introduction
Cardiovascular disease is the leading cause of death in both women
and men. Although the number of cardiovascular deaths has
declined in men, it has actually increased in women over the past
decade. Previous studies reporting the outcome of coronary revas-
cularisation performed with bypass surgery or percutaneous inter-
vention have reported higher rates of mortality and major complica-
tions in women1-3. The reasons for this sex difference were attrib-
uted to a smaller surface area and smaller size of coronary arteries,
advanced age, more risk factors (diabetes mellitus, arterial hyper-
tension), greater burden of comorbidity, and more acute coronary
artery disease at presentation in women4,5. However most of these
studies were performed before the introduction of innovative tran-
scatheter revascularisation techniques, such as coronary artery
stenting. Furthermore, women are less likely to receive left internal
mammary artery grafts and to achieve complete revascularisation.
The Arterial Revascularisation Therapies Study (ARTS) was
designed to compare Coronary Artery Bypass Grafting (CABG) and
Percutaneous Coronary Intervention combined with stent implanta-
tion (PCI) for the treatment of patients with multivessel disease6.
Overall, at one year PCI is less expensive than CABG and offers the
same degree of protection against death, stroke, and myocardial
infarction, but is associated with a greater need for repeated revas-
cularisation. At five years there was no difference in mortality
between CABG and PCI, but major adverse cardiac and cerebrovas-
cular events were higher in the PCI group, driven by the increased
need for repeat revascularisation7. The aim of this study was to
determine whether women enrolled in the ARTS study have an
unfavourable in-hospital and long-term clinical outcome after PCI or
CABG interventions compared with men.
Methods
Patients
Between April, 1997 and June, 1998, 1205 patients with multives-
sel disease were randomised to either CABG (n=605) or PCI
(n=600). The protocol of this study has been previously described8.
All patients had clinical follow-up visits including an ECG at one and
six months, one, two, three and five years. Additional information
was obtained by telephone interview or via the referring physician,
when needed. An independent committee adjudicated clinical
events and ECGs.
Euro-Qol questionnaire
Health related quality of life was assessed at one and six months, one,
two, and three year clinical follow-up using the Euro-Qol question-
naire, which allows patients to grade their general health status9. The
questionnaire includes a visual/analogue scale (Euro-Qol thermome-
ter) for patients to use in rating their overall status from 0 (“worst”
imaginable health) to 100 (“best” imaginable health). The question-
naire also comprises five items (mobility, self-help, usual activity, pain
or discomfort, and anxiety or depression); these ratings were then
summarised (Euro-Qol summary) after being weighted to account for
differences in the importance of the various items to the patient.
Statistical analysis
Statistical analysis was performed with SAS 6.12 software (SAS
Institute Inc., Chicago, Illinois). Data included baseline patients’
characteristics, information on coronary artery lesion characteris-
tics, in-hospital results and outpatient clinical follow-up. The pri-
mary clinical analysis consisted of a comparison between the two
groups according to gender. Categorical variables are presented as
absolute numbers (percent) and were compared by the chi-square
test or Fisher’s exact test as appropriated. Continuous data,
expressed as mean ± SD, were compared with the Student’s t-test
or Wilcoxon’s test. All analyses were based on per protocol princi-
ple. Event free survival rate was estimated by the Kaplan-Meier
method, and differences were assessed by the log rank test. The
test for proportionality showed that the hazard was non-proportion-
al, so logistic regression instead of Cox regression was used.
A series of univariable logistic regression models with in hospital
outcome or major adverse cardiac and cerebrovascular events at
five years as dependent variable and sex as the independent vari-
able was used for estimation of the effect of gender. If the effect of
gender was statistically significant, a multivariate logistic regression
was undertaken with outcome as dependent variable and sex, dia-
betes, hypercholesterolaemia, hypertension, body mass index, fam-
ily history, smoking, silent ischaemia, stable angina, previous
myocardial infarction as independent variables. The coefficients of
the terms for sex were used to calculate Odds Ratios (OR) and their
95% Confidence Intervals (CI) for in hospital outcome and five-year
major adverse cardiac and cerebrovascular events of men com-
pared to women. Statistical significance was considered at a p value
<0.05 (2-tailed).
Results
Of the 1,205 randomised patients with multivessel disease, 283
(23%) were women (PCI: 138; CABG: 145) and 922 (77%) men
(PCI: 462; CABG: 460).
Clinical and angiographic characteristics
The clinical and angiographic characteristics of the men and
women are shown in Table 1. Women were older than men
(p<0.001), and had a higher incidence of hypercholesterolaemia,
hypertension, family history for coronary artery disease (all
p<0.001), diabetes mellitus (p=0.05) and stable angina (p<0.05),
but previous or current smoking and history of myocardial infarction
were present in a lower rate (both p<0.001). Although women were
shorter and weighed less, the body mass index was similar to that
of men.
Procedural characteristics
In patients assigned to PCI there were no differences between men
and women in the number of segments diseased, lesions treated,
stents implanted/patient, or the duration of PCI procedure (Table 2).
Similarly, in patients assigned to CABG the number of diseased seg-
ments, distal anastomoses, arterial conduits implanted, left internal
mammary use, and the duration of surgical procedure were the
same in men and women.
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In-hospital outcome
Women assigned to PCI had more bleeding complications than men
(7.2% vs. 0.2%, p<0.001); however, no differences were observed
in patients assigned to CABG treatment (2.8% in men vs. 1.4% in
women, p=0.54). Bleeding complications remained higher in
women even after adjusting for baseline clinical characteristics (OR
29.4, 95% CI 5.3 - 500, p<0.005). Sex adjusted OR for in hospital
complications according to treatment strategy (PCI or CABG) is pre-
sented in Table 3.
Clinical follow-up
There was no effect of gender in the five-year’s clinical outcome,
according to treatment strategy (Figure 1). In patients assigned to
CABG treatment the incidence of death was 10.1% in men and
7.2% in women (p= 0.48); in patients assigned to PCI 9.0% in men
and 7.4% in women (p= 0.29). There were no differences in the inci-
dence of major adverse cardiac and cerebrovascular events in men
compared to women in patients assigned to CABG (OR 0.8, 95% CI
0.5-1.3, p= 0.38), or PCI (OR 0.9, 95% CI: 0.6 - 1.4, p=0.77). These
results did not change when the hard end-points (death/myocardial
infarction/cerebrovascular accident) were considered (CABG: 
OR 0.8, 95% CI 0.5-1.5, p= 0.57, PCI: OR 1.2, 95% CI 0.7-2.1,
Table 1. Baseline clinical and angiographic characteristics
Men Women  P
(n=922) (n=283)
Age, (years) 59±10 65±8 <0.001
Body mass index 27.2±3.5 27.4±4.2 0.66
History, (%)
– Myocardial infarction 46 35 <0.001
– PTCA 2 2 1.0
Peripheral vascular disease (%) 5 6 0.76
Transient ischaemic attack 1 0.7 1.0
Risk factors, (%)
– Hypertension 40 59 <0.001
– Previously smoker 51 25 <0.001
– Current smoker 30 18 <0.001
– Family history 37 52 <0.001
– Diabetes mellitus 16 21 0.05
– Hypercholesterolaemia(> 200 mg/dl) 54 71 <0.001
Stable angina, (%) 57 64 <0.05
Number of diseased vessels, (%)
– Two vessels 64 66 0.90
– Three vessels 33 34 0.87
Ejection fraction (%) 60±13 62±13 0.08
PTCA: Percutaneous Transluminal Coronary Angioplasty.
Table 2. Procedural Characteristics
Patients assigned to PCI Men Women P
(462) (138)
Number of segments diseased 2.6±1.0 2.6±0.9 0.65
Number of lesions treated 2.7±1.1 2.6±1.2 0.75
Number of stents/patient 2.8±1.2 2.9±1.3 0.85
Duration of PCI procedure (min) 91.3±44.1 91.3±46.1 0.99
Patients assigned to CABG Men Women P
(460) (145)
Number of segments diseased 2.6±1.1 2.5±0.8 0.16
Number of distal anastomoses 2.8±1.1 2.6±1.0 0.17
Number of arterial conduits 1.2±0.6 1.1±0.6 0.17
LIMA use 0.9±0.4 0.8±0.4 0.38
PCI: Percutaneous Coronary Intervention combined with stent implantation, 
CABG: Coronary Artery Bypass Frafting, LIMA: Left Internal Mammary Artery.
Table 3. Odds Ratios of in-hospital complications for men compared to women, according to treatment strategy (PCI or CABG)
PCI CABG
OR 95% CI P OR 95% CI P
In hospital outcome 0.6 (0.3 - 1.2) 0.14 1.8 (0.7 - 6.2) 0.29
MI 0.7 (0.2 - 2.6) 0.58 1.2 (0.4 - 4.3) 0.72
CVA 0.6 (0.1 - 12.5) 0.65 1.8 (0.3 - 34.9) 0.57
Major bleeding 29.4 (5.3 - 500) 0.001 1.5 (0.4 - 10.1) 0.58
PCI: Percutaneous Coronary Intervention combined with stent implantation, CABG: Coronary Artery Bypass Grafting, MI: Myocardial Infarction, 
CVA: Cerebrovascular Accident.
Figure 1 A. MACCE in PCI patients
Figure 1 B. MACCE in CABG patients
Figure 1. Kaplan-Meier curves according to gender showing freedom
from: (A) death/cerebrovascular accident/myocardial infarction or
revascularisation in patients undergoing PCI; (B) death/cerebrovascu-
lar accident/myocardial infarction or revascularisation in patients
undergoing CABG.
PCI: percutaneous coronary intervention combined with stent implan-
tation, CABG: coronary artery bypass grafting.
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p= 0.57). However CABG was associated with a lower incidence of
major adverse cardiac and cerebrovascular events at five years,
compared to PCI in both sexes (p<0.005). The sex adjusted odds
ratios for five years major adverse cardiac and cerebrovascular
event, according to treatment strategy is presented in Table 4.
Anginal status
At five years follow-up in patients undergoing an initial strategy of
CABG, 13% of men compared to 24% of women (p<0.01) report-
ed angina symptoms; in patients assigned to PCI, there were no dif-
ferences in the incidence of angina (21% of men compared to 23%
of women p= 0.71).
Quality of life
There were some differences in quality of life at three years, as
assessed by the self-rated Euro-Qol questionnaire, among men and
women. Men showed better quality of life (higher score on the Euro-
Qol thermometer) compared to women (p<0.05) and favourable
assessment (lower score on the Euro-Qol domain) in specific items
such as mobility (p<0.001), self-help (p<0.005) or usual activity
(p<0.01). The differences in quality of life according to treatment
strategy are shown in Table 5. Men after CABG showed better qual-
ity of life and favourable assessment in specific domains such as
“mobility” and “anxiety or depression” by three years. In patients
allocated to PCI group the only difference was a favourable mobili-
ty in men compared to women.
Discussion
In the present study we analysed the in-hospital, and five-year clin-
ical outcome, according to gender, in a large series of patients with
multivessel disease undergoing after randomisation, PCI or CABG
procedures in native coronary artery lesions. Women were older,
had more risk factors for coronary artery disease, and were on sta-
ble angina; conversely, men had a higher incidence of history of
myocardial infarction. Bleeding complications were significantly
higher in women post-PCI (even after adjusting for baseline clinical
characteristics), but there was no effect of gender at five year’s
major adverse cardiac and cerebrovascular events independent of
treatment strategy. In patients assigned to CABG women reported
angina more frequently during follow-up and men had a better qual-
ity of life, as expressed by Euro-Qol questionnaire.
Gender and PCI
A number of previous studies have examined the influence of gender
on in-hospital outcomes after PCI. Overall, these studies have
shown higher in-hospital mortality in women than in men, especially
Table 4. Odds ratios of major adverse cardiac or cerebrovascular events at five years for men compared to women, according to treatment
strategy (PCI or CABG)
PCI CABG
OR 95% CI P OR 95% CI P
5-years MACCE 0.9 0.6 - 1.4 0.77 0.8 0.5 - 1.3 0.38
Death 1.1 0.5 - 2.8 0.86 1.4 0.5 - 4.1 0.54
MI 1.4 0.7 - 3.2 0.44 0.6 0.3 - 1.3 0.17
CVA 0.8 0.3 - 2.2 0.58 0.6 0.3 - 1.9 0.39
revascularisation 1.0 0.6 - 1.5 0.92 0.7 0.4 - 1.4 0.32
– CABG 0.9 0.5 - 1.8 0.86 0.9 0.1 - 18.6 0.94
– re-PTCA 0.9 0.6 - 1.5 0.73 0.7 0.4 - 1.4 0.27
PCI: Percutaneous Coronary Intervention combined with stent implantation, CABG: Coronary Artery Bypass Grafting, MACCE: Major Adverse Cardiac or 
Cerebrovascular Events, MI: Myocardial Infarction, CVA: CerebroVascular Accident, PTCA: Percutaneous Transluminal Coronary Angioplasty.
Table 5. Quality of life among men and women at three years according to treatment strategy
PCI CABG
Variable Men Women P Men Women P
Euro-Qol thermometer* 77±16 75±18 0.45 79±15 75±18 0.03
Euro-Qol summary* 86±16 83±19 0.08 86±20 82±20 0.02
Euro-Qol domain+
Mobility 1.4±2.8 2.5±3.3 <0.001 1.4±2.8 2.1±3.2 0.01
Self-help 0.5±2.2 0.9±3.3 0.14 0.4±1.9 1.0±3.1 0.005
Usual activity 0.9±1.7 1.3±2.2 0.13 0.7±1.6 1.1±1.9 0.02
Pain 4.8±6.8 5.3±7.4 0.69 5.1±7.7 5.8±7.4 0.16
Anxiety 2.3±4.6 2.8±5.4 0.56 2.0±4.0 3.1±5.4 0.04
* High score on the Euro-Qol thermometer and the Euro-Qol summary indicates a good quality of life.
+ Low score of the Euro-Qol domain reflect a favourable assessment of each component. 
PCI: Percutaneous Coronary Intervention combined with stent implantation, CABG: Coronary Artery Bypass Grafting.
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in earlier series10-12. The higher incidence of in-hospital complica-
tions could be related to the fact that women were older, have small-
er body mass index, and had higher prevalence of other co-morbid
conditions. More recent studies have reported improved clinical out-
comes for women who underwent elective PCI3,13, due to advances
in technology and improvement in revascularisation techniques.
Although the mortalty difference between men and women was
attenuated after accounting for differences in baseline clinical char-
acteristics, gender remained an important risk factor for vascular
complications. Previous studies have shown that women had more
bleeding complications, mainly at the access site when anticoagu-
lation was used14. The excess vascular complications among
women, however, may represent a clinically modifiable risk; careful
attention to sheath size, heparin dosing, and rapid sheath removal
have been demonstrated to lower risks of vascular complications15.
The influence of gender on long-term clinical outcome following PCI
has not been adequately assessed in previous studies. A pooled
analysis of seven prospective stent trials including 7,171 patients
(2,179 women and 4,992 men) with systematic angiographic and
clinical follow-up demonstrated no differences in target vessel
revascularisation one year after bare-metal stenting between men
and women16. In the Dynamic Registry3 one-year mortality and
combined end-point of death/myocardial infarction/CABG were
higher in women than in men; however after controlling for other
risk factors, gender was not a significant predictor of death or death
plus myocardial infarction at one year. Very recently, Lansky et al17
reported higher unadjusted one-year rates of target vessel revascu-
larisation in women compared to men treated with the paclitaxel-
eluting stent in the TAXUS-IV trial, but in multivariate analysis, gen-
der was not an independent predictor of revascularisation.
Gender and CABG
The frequency of CABG performed in women has increased over
the past decade in association with a gradual ageing of the surgical
population18. Many studies examining gender differences outcomes
after CABG report a higher unadjusted post-operative mortality and
morbidity for women compared with men. Edwards et al19 analysed
the data from the Society of Thoracic Surgeons National Cardiac
Surgery database; they reported that women were older, presented
more commonly for non-elective procedures, and had a higher
prevalence of pre-operative comorbid conditions, such as diabetes,
hypertension, and peripheral vascular disease. Guru et al20 report-
ed that women had a higher early mortality even in the current era
with improved surgical techniques. Very recently Huynh et al21 pre-
sented the results of the ROSETTA-CABG registry, with one-year
clinical follow-up; women had a nearly three times greater probabil-
ity than men to present a composite clinical event (death, non-fatal
myocardial infarction, or unstable angina), and four times to require
PCI during follow-up. However female gender was not independent-
ly associated with adverse cardiac outcomes by multivariate regres-
sion analysis. In another study20 the risk-adjusted survival of women
was worse than that of men in the first year after CABG, but their
long-term mortality was similar to that of men. It has been reported
that left internal mammary artery use and multiple arterial grafts
were less frequently used in women during CABG19,22. However,
when adjustments were made for left internal mammary artery graft
use, it did not change the early or late mortality risk for women20.
Quality of life following revascularisation and
gender
Relief of angina, and improvement in quality of life represent the
main benefits for both CABG and PCI and constitute the main indi-
cation for these procedures in most patients. In the BARI trial, there
was a better functional status at one year among the patients under-
going CABG, but this difference had diminished after four years23.
In the SoS trial24 the relative benefits of CABG and PCI in the
improvement of health status differ in men and women at one year
after intervention. Although in men CABG was clearly superior to
PCI in improving patients’ health status, in women both procedures
showed equal benefit at one year. In another study25, in patients
undergoing CABG the baseline and follow-up Duke Activity Status
Index scores for women were significantly lower than those of men,
even after correction for pre-operative risk factors. The explanation
for the gender differences in recovery after revascularisation proce-
dures could relate, in part, to the different social roles of women and
men; women may feel greater disruption than men, when they can-
not resume their roles upon returning home after CABG.
Furthermore, women are more likely to be unmarried, to live alone,
and to report a lower level of social support than men.
Study limitations
When interpreting our results a number of issues should be consid-
ered. The number of women studied was smaller compared to men,
so the power to detect a significant difference was lower. This post-
hoc analysis is based on a randomised clinical trial for which all
patients had specific inclusion and exclusion criteria, potentially
limiting generalisation. However, patients in a randomised clinical
trial may be an ideal group for studying sex differences because the
rigorous trial design ensures that the women and men are reason-
ably comparable. It must be recognised that Euro-Qol questionnaire
was developed to estimate usefulness and may not be as sensitive
as disease-specific instruments to analyse treatment results.
Furthermore, because treatment group assignment was not blind-
ed, the patients’ knowledge of the treatment may have influence
responses to the Euro-Qol questionnaire.
Conclusions
Women enrolled in the ARTS study were older and had more risk
factors compared to men. The in-hospital outcome has identified an
increased risk of bleeding complications in women treated with PCI.
At five-years there were no gender specific differences in the inci-
dence of major adverse cardiac and cerebrovascular events regard-
less of treatment therapy (PCI or CABG). However, quality of life dif-
ferences indicate a role for more effective rehabilitation in women.
The influence of gender in the era of drug-eluting stents and closure
devices following PCI has to be defined.
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A randomized comparison of a durable polymer 
Everolimus-eluting stent with a bare metal coronary stent:
The SPIRIT first trial
Abstract
Background: Everolimus is a sirolimus analogue with similar efficacy in animal models, and has been pre-
viously successfully tested in humans using an erodable polymer.
Methods: This first-in-man single blind multi-centre randomized controlled trial assessed the safety and effi-
cacy of everolimus eluting from a durable polymer on a cobalt chromium stent in patients with de novo native
coronary artery lesions. Sixty patients were allocated to stent implantation with an everolimus-eluting stent
(n=28) or an identical bare stent (n=32). Patients had either stable, unstable angina or silent ischaemia.
Suitable lesions treated were single de novo native coronary lesions with 50-99% stenosis and could be cov-
ered by a 18 mm stent. The primary endpoint was in-stent late loss at 180 days, analysed on a per treatment
basis. The major secondary endpoint was percent in-stent volume obstruction (%VO) as measured by
intravascular ultrasound (IVUS) at 180 days. The clinical secondary endpoint was major adverse cardiac
events (MACE) at 180 days.
Results: At 6 months, (matched pairs angiographic analysis), the in-stent late loss, percentage diameter steno-
sis and percentage of patients with binary restenosis were 0.10 mm, 16% and 0% respectively, in the
everolimus arm (n=23), as compared with 0.87 mm, 39% and 25.9%, respectively in the bare stent arm
(n=27, p<0.001 for late loss and diameter stenosis, p = 0.01 for restenosis). Significantly less neointimal
hyperplasia was observed in the everolimus group compared to the bare stent group (10 ± 13 mm3 vs 38 ±
19 mm3, p<0.001) and similarly, less volume obstruction (8.0 ± 10.4% versus 28.1 ± 14.0%, p<0.001).
A major adverse cardiac event occurred in 2 patients in the everolimus arm versus 6 in the bare stent arm.
Conclusion: Everolimus eluted from a durable polymer on a cobalt chromium stent effectively suppresses
neointimal growth at 6 months compared to an identical bare stent.
KEYWORDS
Stent, eluting stent,
everolimus,
randomized trial.
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Introduction
Recent studies that have evaluated the local application of anti-prolif-
erative drugs (sirolimus and paclitaxel) for the prevention of resteno-
sis via a stent delivery system have shown that these therapies suc-
cessfully inhibit the development of neointimal hyperplasia1,2.
Everolimus is an effective anti-proliferative agent3. On a molecular
level, everolimus forms a complex with the cytoplasmic protein
FKBP12. In the presence of everolimus, the growth factor-stimulat-
ed phosphorylation of p70 S6 kinase and 4E-BP1 is inhibited. The
latter proteins are key proteins involved in the initiation of protein
synthesis. Since phosphorylation of both p70 S6 kinase and 4E-
BP1 is under the control of mammalian Target Of Rapamycin
(mTOR), this finding suggests that, like sirolimus, the everolimus-
FKBP12 complex binds to and thus interferes with its function.
Disabling mTOR explains the cell cycle arrest at the late G1 stage
caused by everolimus and sirolimus.
The feasibility of using everolimus on a drug eluting stent was deter-
mined by the FUTURE I trial4. This trial utilized an S-stent and bio-
absorbable polymer system (both Biosensors International,
Singapore) and confirmed the safety of the everolimus-eluting stent
at 6 and 12 months. At 6 months, a 7.7% Major Adverse Cardiac
Event (MACE) rate was observed with no thrombosis and no late
incomplete apposition. The efficacy was demonstrated by signifi-
cant reduction of in-stent tissue proliferation at 6 months: both
angiographic in-stent late loss and IVUS% neointimal volume were
reduced by 87%. No angiographic in-stent binary restenosis was
observed in the everolimus-eluting stent arm. The 12 month
FUTURE I results showed sustained safety and efficacy with no new
MACE events, no aneurysms, no late stent malapposition, and no
thrombosis observed between 6 and 12 months. Minimal Lumen
Area and Luminal Volume Index were maintained up to 12 months
and no in-stent binary restenosis was observed up to 12 months.
The SPIRIT First clinical trial represents the first clinical evaluation of
the Guidant XIENCE™ V Everolimus Eluting Coronary Stent System
(XIENCE™ V Everolimus Eluting CSS), to investigate the potential
benefits of the local application of everolimus in a durable polymer in
combination with a thin strut cobalt chromium stent.
Methods
Patient selection
This randomized single-blind trial was performed at 9 medical cen-
ters and enrolled patients from December 2003 to April 2004. It
was approved by the ethics committee at each participating institu-
tion, and all patients gave written informed consent.
Patients were eligible for the study if they were aged above 18 years
and had received a diagnosis of stable or unstable angina or silent
ischaemia. Additional eligibility criteria were the presence of a sin-
gle primary de novo coronary lesion that was 3.0 mm in diameter as
assessed by on-line QCA, that could be covered by an 18 mm stent,
a stenosis of between 50-99% of the luminal diameter, and a
Thrombolysis In Myocardial Infarction (TIMI) flow grade of 1 or
more. Patients were not eligible for enrollment if they had an evolv-
ing myocardial infarction, stenosis of an unprotected left main coro-
nary artery, an ostial location, located within 2 mm of a bifurcation,
a lesion with moderate to heavy calcification, an angiographically
visible thrombus within the target lesion, a left ventricular ejection
fraction of less than 30%, were awaiting a heart transplant, or had
a known hypersensitivity or contraindication to aspirin, heparin,
clopidogrel, cobalt, chromium, nickel, tungsten, everolimus, acrylic
and fluoro polymers or contrast sensitivity that could not be ade-
quately pre-medicated.
The Everolimus-eluting stent
The Guidant XIENCE™ V Everolimus Eluting CSS is comprised of
the Guidant MULTI-LINK VISION® Stent and delivery system, and a
drug eluting coating. The Guidant MULTI-LINK VISION® Stent is a
balloon expandable stent, which consists of serpentine rings con-
nected by links fabricated from a single piece of medical grade 
L-605 cobalt chromium alloy.
Everolimus is blended in a nonerodable polymer (this drug layer
was coated over another nonerodable polymer primer layer). This
coating includes of acrylic and fluoro polymers, both approved for
use in blood contacting applications. This layer of everolimus-poly-
mer matrix with a thickness of 5-6 microns is applied to the surface
of the stent and is loaded with 100 micrograms of everolimus per
square centimeter of stent surface area with no top coat polymer
layer. The stent is designed to release approximately 70% of the
drug within 30 days after implantation.
Everolimus (Certican®, Novartis Corporation) has been evaluated in
clinical trials in the US and Europe for use as an immunosuppres-
sant following cardiac and renal transplantation5. Everolimus has
received market approval in the European Union.
Study procedure
Following the confirmation of angiographic inclusion and exclusion
criteria and prior to the procedure, patients were allocated through
a telephone randomization service and assigned in a 1:1 ratio to
either an everolimus eluting stent or bare metal stent. A single stent
3.0 mm in diameter, 18 mm long was used in the study.
Lesions were treated using standard interventional techniques with
mandatory pre-dilatation and stent implantation at a pressure not
exceeding the rated burst pressure. Due to packaging differences,
physicians were not blinded to the device. Post-dilatation was
allowed with a balloon shorter than the implanted stent. In the event
of a dissection occurring at the edge of the implanted stent, it was
recommended that a single additional bare Guidant MULTI-LINK
VISION® stent be implanted as animal data only on single everolimus
stent implantation were available at the onset of the study; these
patients were a priori excluded from the per-treatment analysis but
are part of the acute success population. IVUS was performed after
angiographically optimal stent placement had been obtained and
was repeated if additional post-dilatation was performed.
Intravenous boluses of heparin were administered according to
local standard practice. Treatment with aspirin, at a minimum dose
of 80 mg per day, was started at least 24 hours before the proce-
dure and continued indefinitely. A loading dose of 300 mg of clopi-
dogrel was administered 24 hours before the procedure, followed
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by 75 mg daily for three months. Treatment with ticlopidine was per-
mitted in case of clopidogrel hypersensitivity. Device success was
defined as a final in-stent diameter stenosis of less than 50 percent
by QCA using the assigned device. Clinical success was defined as
the successful implantation of any device, with stenosis of less than
50 percent of the vessel diameter by QCA and no major cardiac
events during the hospital stay.
Follow-up
Patients were evaluated at 30 days and 6 months. Further evalua-
tions will be performed at 9 months and 1 year, with annual evalua-
tions out to 5 years. At outpatient visits, patients were asked specif-
ic questions about the interim development of angina according to
the Canadian Cardiovascular Society classification of stable angina.
They were also monitored for MACE. Angiographic and IVUS evalu-
ations were performed at 6 months, and will be repeated at 1 year.
Prior to performing a follow-up angiogram, the physician was
required to record in the source documents whether a revasculariza-
tion (if required) was clinically indicated – defined as the presence of
ischaemic symptoms and/or a positive functional ischaemia study.
Quantitative coronary angiography evaluation
Quantitative coronary angiography was performed using the CAAS
II analysis system (Pie Medical BV, Maastricht, Netherlands). In
each patient, the stented segment and the peri-stent segments
(defined by a length of 5 mm proximal and distal to the stent edge)
were analyzed. The following QCA parameters were computed:
computer-defined Minimal Luminal Diameter (MLD), reference
diameter obtained by an interpolated method, and percentage
diameter stenosis. Binary restenosis was defined in every segment
as diameter stenosis >50% at follow-up. Late loss was defined as
the difference between MLD post-procedure and MLD at follow-up.
Results are presented as matched pairs in the manuscript and as
unmatched pairs in the Appendix. Unmatched pairs data is most
commonly presented and utilises the mean QCA results of all pro-
jections obtained. Matched pairs data is more accurate as it com-
pares the same views post-procedure and at follow-up and uses
only QCA data of identical projections.
Intravascular ultrasound analysis
Post-procedure and follow-up stented vessel segments were exam-
ined with mechanical or phased array intravascular ultrasound
using automated pullback at 0.5 mm per second. The coronary
segment beginning 5 mm distal to and extending 5 mm proximal to
the stented segment was examined. A computer-based contour
detection program was used for automated 3-D reconstruction of
the stented and adjacent segments. The lumen, stent boundaries
and external elastic membrane (vessel boundaries) were detected
using a minimum cost algorithm. The Stent Volume (SV) and
Lumen Volume (LV) were calculated according to Simpson’s rule.
The intra-stent neointimal volume was calculated as the difference
between SV and LV. The percentage obstruction of the stent volume
was calculated as intra-stent neointimal volume/stent volume*100.
Feasibility, reproducibility and inter- and intra-observer variability of
this system have been validated in vitro and in vivo6. Incomplete
apposition was defined as one or more stent struts separated from
the vessel wall with evidence of blood speckles behind the strut on
ultrasound, while late incomplete apposition was defined as incom-
plete apposition of the stent at follow-up which was not present
post-procedure.
Study endpoints
The primary angiographic endpoint was in-stent luminal late loss, as
determined by quantitative angiography. Secondary endpoints (QCA
and IVUS) at 6 months and 1 year included the in-stent and in-seg-
ment late loss, angiographic binary restenosis rate, percentage
diameter stenosis; and in-stent percentage volume obstruction. In-
stent was defined as within the margins of the stent while in-seg-
ment was defined as located either within the margins of the stent
or 5 mm proximal or distal to the stent. Late loss was calculated as
the difference between the follow-up and post-procedure minimum
luminal diameter. Secondary clinical endpoints were a composite of
major cardiac events, including cardiac death, Q-wave or non-Q-
wave myocardial infarction, clinically driven surgical or percuta-
neous revascularization of the target lesion (MACE) or vessel (Target
Vessel Failure) at 30 days, 6 months, 9 months, and annually up to
5 years after the index procedure; and acute device, procedure and
clinical success. All deaths that could not be clearly attributed to
another cause were considered cardiac deaths. A non-Q-wave
myocardial infarction was defined by an increase in the creatine
kinase level to more than twice the upper limit of the normal range,
accompanied by an increased level of creatine kinase-MB, in the
absence of new Q waves on electrocardiography.
The endpoints were adjudicated by an independent clinical events
committee. In addition, a data and safety monitoring board that was
not affiliated with the study sponsor reviewed the data to identify any
safety issues related to the conduct of the study.
Statistical analysis
The primary endpoint and all trial endpoints were analyzed on the
per-treatment evaluable population which consisted of patients who
had no bailout stenting and no major protocol deviations, as evalu-
ated in a blinded manner. Acute success was analyzed on the entire
patient population.
The sample size for the study was determined based on the primary
endpoint of in-stent late loss at 180 days and on the following
assumptions: a single comparison of active to uncoated; one-tailed t-
test, unequal and unknown variances in the two groups being com-
pared; α=0.05; true mean difference between the bare stent group
and the treatment group of 0.48 mm. This assumption was made
based on the results of the VISION Registry (mean late
loss=0.83 mm)7, SIRIUS trial (mean late loss=0.17 mm)8 and TAXUS
IV trial (mean late loss=0.39 mm)9. (Assume the true mean late loss
for the treatment group is 0.35 mm, the difference between the bare
stent group and treatment group is calculated as: 0.83 mm - 0.35
mm = 0.48 mm). The standard deviation was assumed to be 0.56
mm in the bare stent group and 0.38 mm in the treatment group
(based on the results of the VISION Registry study and SIRIUS trial);
approximately 20% rate of lost to follow-up or dropout; approximate-
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ly 10% of patients with bailout stents. Given the above assumptions,
30 patients per arm (with the analysis of 22 evaluable patients per
arm) will provide 95% power for comparison. Although the trial was
not powered based on the major secondary endpoint, percent volume
obstruction at 180 days, enrolling 30 patients per arm (analysis of 
22 patients per arm) would provide more than 96% power.
Binary variables were compared using Fisher’s Exact test. For con-
tinuous variables, means and standard deviations were calculated
and groups compared using the Wilcoxon Rank-Sum test, except
for the primary endpoint which was evaluated with a one sided 
t-test. Final 6-month results are presented in the manuscript, while
the Appendix contains results that were available at the time that
the 180-day report was prepared.
Results
Patient characteristics
Between December 2003 and April 2004, 28 patients were ran-
domly assigned to receive the everolimus-eluting stent, and 32 were
assigned to receive the bare stent. As defined in the protocol, all
results (except acute success) are presented for the per-treatment
population (27 patients in the everolimus group, and 29 patients in
the bare stent group, Figure 1). In the everolimus group there was
one bailout procedure, and in the bare stent group there were two
bailout procedures and one major protocol deviation (the patient
was on the heart transplant waiting list). With the exception of a sig-
nificantly higher number of patients with hypertension requiring
treatment in the everolimus group, the two groups were similar with
respect to clinical variables examined (Table 1).
F I G U R E 1
Fig. 1: Flowchart of patients
N = 60
N = 28 N = 32
N = 27 N = 29
1 bailout
N = 23
N = 21
N = 27
N = 24
2 bailouts
1 major protocol deviation*
1 withdrew consent
2 refused repeat angiography
1 angiogram not analysable
1 withdrew consent
1 refused repeat angiography
1 angio at 4m without ivus
1 unsuitable anatomy
1 procedural complication (air injected)
1 unable to cross lesion (severe stenosis)
1 not scheduled for ivus
Everolimus Bare stent
Randomized
Six-Month IVUS
Per Treatment
Analysis
Six-Month QCA
Table 1. Baseline characteristics of the per-treatment patient 
population and of each treatment group.*
Everolimus Bare stent All 
stent patients
(n = 27) (n = 29) (n = 56)
Age(yrs) 64 ± 10 61 ± 9 63 ± 9
Male gender (%) 70 76 73
Current smokers (%) 28 31 30
Diabetes (%) 11 10 11
Hypertension requiring 
medication (%) 70 41 55
Hyperlipidemia requiring 
medication (%) 70 76 73
Prior intervention (%) 19 7 13
Prior MI (%) 24 14 19
Stable angina (%) 78 79 79
Unstable angina (%) 19 14 16
Target vessel (%)
Left anterior descending 48 45 46
Left circumflex 22 21 21
RCA 30 34 32
AHA / ACC Lesion Class (%)**
A 0 10 5
B1 41 28 34
B2 59 62 61
C 0 0 0
Reference Vessel Diameter 2.61 ± 0.40 2.71 ± 0.28 2.66 ± 0.34
(mm ± SD)
Lesion length (mm ± SD) 10.1 ± 2.6 10.9 ± 3.3 10.5 ± 3.0
* There were no significant differences between the treatment groups
except for Hypertension Requiring Medication (P=0.04)
** AHA / ACC = American Heart Association / American College of Cardiology
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Procedural characteristics
The lesions in the two groups were treated similarly with the use of
conventional techniques. Glycoprotein IIb/IIIa inhibitors, used at the
investigators’ discretion, were administered to 7.4% of the patients
in the everolimus group and 3.4% of those in the bare stent group.
The two groups did not differ significantly with respect to the rate of
device success (96.4% in the everolimus group and 93.8% in the
bare stent group) or clinical success (96.4% in the everolimus
group and 100% in the bare stent group).
Quantitative coronary angiography analysis
Angiographic data at 6 months were available for 50 of the 
56 analysable patients (89.3%). The mean reference diameter of
the target vessel, the mean length of the lesion at baseline, the ref-
erence vessel diameter and mean MLD of the stented segment
were similar in the two groups (Tables 1 and 2). At six months, with
matched pairs analysis, the mean MLD of the stented segment was
significantly greater in the everolimus group. The mean in-stent late
loss, percentage of stenosis, and percentage of patients with 
50 percent or more stenosis were 0.10 mm, 16%, and 0%, respec-
tively, in the everolimus group, as compared with 0.87 mm, 39%,
and 25.9%, respectively, in the bare stent group (p<0.001 for late
loss and diameter stenosis, p=0.01 for restenosis). Figure 2 shows
the cumulative frequency of stenosis immediately after the index
procedure and at six months in each treatment group. Table 2 and
Figure 3 show the results of sub-segmental quantitative angiograph-
ic analyses for matched pairs. The late luminal loss at both the prox-
imal and the distal edges of the stent was less in the everolimus
group than in the bare stent group (p <0.01 for proximal and
p=0.04 for distal). The late luminal loss in the stented segment was
significantly less in the everolimus group than in the bare stent
group (p <0.001).
Intravascular ultrasound evaluation
At six months follow-up, intravascular ultrasound evaluation showed
no significant differences between the two groups with respect to
the volume of the stent or the vessel volume (Table 3). Significantly
Table 2. Results of sub-segmental quantitative coronary angiographic analysis (Matched Pairs).
Proximal edge In-stent Distal edge In-segment analysis
Everolimus- Bare Everolimus- Bare Everolimus- Bare Everolimus- Bare 
(n = 23) (n = 27) P-value (n = 23) (n = 27) P-value (n = 23) (n = 27) P-value (n = 23) (n = 27) P-value
Reference Vessel Diameter (mm)
After procedure 2.80 ± 0.33 3.04 ± 0.38 0.06* 2.71 ± 0.28 2.89 ± 0.35 0.11* 2.64 ± 0.30 2.80 ± 0.39 0.21* 2.65 ± 0.30 2.84 ± 0.41 0.10*
At 6 months 2.78 ± 0.32 2.67 ± 0.40 0.22* 2.70 ± 0.31 2.58 ± 0.37 0.25* 2.61 ± 0.37 2.46 ± 0.36 0.19* 2.61 ± 0.36 2.59 ± 0.36 0.89*
Minimal Luminal Diameter (mm)
After procedure 2.56 ± 0.44 2.61 ± 0.45 0.79* 2.38 ± 0.25 2.45 ± 0.31 0.50* 2.23 ± 0.41 2.26 ± 0.45 0.77* 2.11 ± 0.35 2.14 ± 0.40 1.00*
At 6 months 2.45 ± 0.46 2.19 ± 0.49 0.04* 2.28 ± 0.33 1.58 ± 0.41 < 0.001* 2.18 ± 0.38 2.00 ± 0.45 0.21* 2.04 ± 0.40 1.54 ± 0.41 < 0.001*
Late Loss (mm) 0.11 ± 0.15 0.42 ± 0.39 <0.01* 0.10 ± 0.21 0.87 ± 0.37 < 0.001*** 0.05 ± 0.20 0.26 ± 0.40 0.04* 0.07 ± 0.19 0.61 ± 0.37 < 0.001*
Diameter Stenosis (%DS)
After procedure 9 ± 11 14 ± 9 0.07* 12 ± 5 15 ± 6 0.05* 16 ± 10 20 ± 10 0.16* 20 ± 8 24 ± 9 0.05*
At 6 months 12 ± 12 17 ± 17 0.26* 16 ± 8 39 ± 14 < 0.001* 16 ± 10 19 ± 14 0.82* 22 ± 11 41 ± 14 < 0.001*
Binary Restenosis Rates 4.3% 3.7% 1.00** 0.0% 25.9% 0.01** 0.0% 7.4% 0.49** 4.3% 33.3% 0.01**
* two-sided Wilcoxon rank sum test ** two-sided Fisher’s Exact test *** One-sided t-test † Fisher’s Exact test
F I G U R E 2
Fig. 2: Cumulative frequency of stenosis (in-stent) immediately after
stenting and at six months
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Fig. 3: Comparison of in-segment / in-stent late loss
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ess neointimal hyperplasia was observed in the everolimus-stent
group compared to the bare-stent group (10 ± 13 vs. 38 ± 19 mm3,
p<0.001) and similarly, significantly less volume obstruction, (8.0 ±
10.4% versus 28.1 ± 14.0%, p<0.001). Figure 4 is a cumulative
curve of percentage volume obstruction. No in-stent volume
obstruction was detected in almost half of the patients in the
everolimus-stent group, whereas in the bare stent group, some
degree of obstruction by neointima was present in all patients
(Figure 4). No evidence of an “edge effect,” aneurysm formation,
n-stent thrombosis, persistent dissection or late incomplete apposi-
ion were observed.
Major adverse cardiac events
Major adverse cardiac events are listed in Table 4. There was one
Q-wave myocardial infarction in the everolimus group in a patient
who underwent additional revascularization for angina in a non-tar-
get vessel 18 days after the study procedure and suffered thrombo-
sis of this non-study stent 12 days later. The everolimus stent was
patent with no evidence of thrombus at the time of the thrombotic
occlusion of the non study stent. One patient in the everolimus arm
underwent a clinically driven target lesion revascularization at
3 weeks for symptomatic persistent dissection at the proximal edge
left untreated at the time of the procedure. There were no clinically
driven target revascularizations in the everolimus group for resteno-
sis. There were six clinically driven target lesion revascularizations
in the bare stent group, five were treated percutaneously for
restenosis and the sixth by bypass surgery. No adverse effects were
attributable to everolimus or the polymer coating of the stents.
Discussion
The main finding of this randomized first-in-man study is that an
everolimus-eluting stent coated with a durable polymer was associ-
ated with an in-stent angiographic late loss of 0.10 mm, significant-
ly less than the corresponding bare cobalt chromium metal stent of
0.87 mm, which satisfied the primary endpoint of this trial and con-
firmed the efficacy of this system. Correspondingly, in-segment late
loss was also significantly less in the everolimus-stent group.
Currently, two different drug-eluting systems (sirolimus and paclitax-
el) are available. Although no published scientific comparative data is
to date available, it appears that, from historical randomized trials, a
difference of approximately 0.2 mm in-stent late loss exists between
sirolimus and paclitaxel. Even if the impact of restenosis and MACE is
currently unknown, some slight difference in restenosis rates and
MACE can be expected. New devices should at least equal the
incumbents in performance. This performance may be judged on late
Table 3. IVUS measurements at 6 month follow-up.
Everolimus- Bare
(n = 21*) (n = 24*) P-value
Vessel volume (mm3) 291 ± 82 296 ± 73 0.64
Stent volume (mm3) 134 ± 28 139 ± 33 0.69
In-stent neo-intimal 
volume (mm3) 10 ± 13 38 ± 19 <0.001
Luminal volume (mm3) 124 ± 32 100 ± 31 0.04
In-stent volume 
obstruction (%)** 8.0 ± 10.4 28.1 ± 14.0 <0.001
* This final table contains an additional 13 patients not included in
the 180-day report prepared for the sponsor. In 8 patients (4 in each
group), an imputed stent length of 18mm was used due to non-con-
tinuous pullback. In a further 5 patients (all bare stent group) results
were unavailable at the time of the 180-day report. (see Appendix)
** In-stent volume obstruction = 100*
(In-stent neo-intimal volume / Stent volume)
F I G U R E 4
Fig. 4: Percentage in-stent volume obstruction versus cumulative fre-
quency of patients. Values are expressed as mean ± standard devia-
tion for each group.
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Table 4. Hierarchical major adverse cardiac events at 180 days in
per-treatment population*.
Event** Everolimus stent Bare stent
n = 26 % n = 28 %
Cardiac death 0 0 0 0
Myocardial infarction
Q-wave 1‡ 3.8 0 0
Non-Q-wave 0 0 0 0
Reintervention
Clinically driven TLR-CABG 0 0 1 3.6
Clinically driven TLR-PCI 1 § 3.8 5 17.9
Clinically driven TVR-CABG 0 0 0 0
Clinically driven TVR-PCI 0 0 0 0
Target vessel failure 2 7.7 6 21.4
Major adverse cardiac events 2 7.7 6 21.4
* One patient in each group withdrew consent after treatment
** No statistical significance was detected between groups for all 
endpoints tested.
‡ Q-wave MI due to thrombosis of a non-study stent in a non-target
vessel.
§ Clinically driven TLR for persistent dissection proximal to the stent
3 weeks after the index procedure.
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loss, restenosis rate and / or the need for reintervention. With an in-
stent late loss ranging from zero to 0.2 mm, it has been difficult to find
a compound with the same efficacy, without resorting to the -limus
family (Figure 5). With the sirolimus molecule being rather large and
complex, it is therefore not surprising that major pharmaceutical com-
panies have thoroughly explored its numerous analogues in order to
develop a suitable competitor to sirolimus. The drug used in this
study, everolimus differs from sirolimus by a substitution of a hydro-
gen radical/side-branch with a methyl sidechain.
The reason for developing new compounds is to improve on the side
effects of the existing compounds such as delayed healing with re-
endothelialization and fibrin11, early12 and late stent thrombosis13.
The success of the device lies in its three components - the drug,
the polymer properties and the stent. The use of a sirolimus ana-
logue is not in itself a guarantee of success since some of them
have intrinsically, a potency in inhibition of up to 100 times less (e.g.
tacrolimus), and some other analogues with equal in vitro inhibitory
effects nevertheless fail to equally inhibit neointimal growth in vivo,
because their duration of elution was suspected to be too short.
However it has already been demonstrated that everolimus in clini-
cal trials using a bioerodable polymer with a slower elution profile
than sirolimus is effective in reducing late loss to below 0.2 mm4.
Therefore the remaining challenge was to establish whether
everolimus eluted from a durable polymer was also efficient and is
addressed in this report.
Although the 6-month results are promising, one year angiographic
and IVUS follow-up results are awaited to confirm the long-term
results of this device in light of recent findings regarding an increas-
ing late loss seen with other devices over time.
At the time of the publication of RAVEL, it was argued that the
restenosis rate of the bare stent was excessively high at 26%.
Similarly, in the present trial the restenosis rate in the bare stent arm
was 25.9%. Nevertheless, it must be emphasized that in both cases
these restenosis rates correspond to the value predicted and derived
from multivariate analyses including as determinant parameters ves-
sel size, MLD post, incidence of LAD disease and diabetics. Of inter-
est, the late loss of the bare stent groups in RAVEL and this study were
similar, corresponding to their restenosis rates. This is at variance with
the VISION registry, and publications on stent strut thickness, but may
be explained by the mismatch in stent size and reference diameter.
This study was powered for late loss and not for clinical events, and
it was not surprising that the 3 fold reduction in events failed to be
statistically significant. At the time of trial design, safety studies with
overlapping eluting-stents in animal models had not been complet-
ed, requiring the use of bare stents for bailout. As a result of this
confounder, these patients were a priori excluded from the per-
treatment analysis. This study was however designed as a first in
man trial with everolimus on an untested new durable polymer in
combination with a cobalt chromium stent.
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Table A1. Appendix: results of sub-segmental quantitative coronary angiographic analysis (Unmatched Pairs) as per 180-day progress
report - Clinical investigation plan 02-350 The SPIRIT first clinical trial. Guidant Corporation, Data on file.
* Two-sided Wilcoxon rank sum test ** Two-sided Fisher’s Exact test *** One-sided t-test
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Fup N=26)
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Everolimus
(Post N=27
Fup N=23)
Bare
(Post N=29
Fup N=26)
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Everolimus
(Post N=27
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Bare
(Post N=29
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Erasmus Medical Centre, Rotterdam, The Netherlands (5 patients); 
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Table A2. Appendix: results of intra vascular ultra sound analysis as
per 180-day progress report - Clinical investigation plan 02-350
The SPIRIT first clinical trial. Guidant Corporation, Data on file.
Everolimus Bare
(n = 17) (n = 15*) P-value
Vessel volume (mm3) 299 ± 87 284 ± 77 0.76
Stent volume (mm3) 138 ± 30 139 ± 39 1.00
In-stent neo-intimal 
volume (mm3) 11.2 ± 14.0 41.4 ± 20.1 <0.001
Luminal volume (mm3) 126 ± 35 98 ± 34 0.06
In-stent volume 
obstruction (%) 8.6 ± 10.7 29.0 ± 13.9 <0.001
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Abstract
Aims: The one year clinical benefit of various doses and release durations of paclitaxel eluted from an erod-
able polymer has not been evaluated so far.
Methods and results: Conor paclitaxel-eluting stents have intra-stent wells in which drug and polymer are
deposited. Stents with six different release formulations (dose: 10 μg or 30 μg, duration: 5, 10 or 30 days,
direction: mural or bidirectional) were implanted in 6 patient cohorts. Clinical follow-up was conducted at
4 and 12 months. Quantitative angiography and IVUS were performed at 4 months, and additional angio-
graphic and IVUS follow-up were performed for groups D5 (10μg/30days/mural) and D6
(30μg/30days/mural), as they had shown the most favorable results at 4 months. At one year, the lowest
major adverse cardiac event rates were observed in the slow release (30 day) group (5.1% in D5 and 6.9%
in D6). One-year in-stent late loss was 0.52±0.34 mm in D5 and 0.36±0.50mm in D6 (p=0.20) while
neointimal area was 0.99±0.54 mm2 in D5 and 0.77±0.92 mm2 in D6 (p=0.42). Corresponding in-stent
binary restenosis at one year was 0% and 5.6% respectively (p=0.36). 
Conclusions: Patients who received the slow release formulation stent had better clinical outcome at one
year than those who received the fast release formulation. However, the effect on neointimal suppression
requires investigation in a larger population to determine whether the high dose formulation confers an
additional clinical benefit.
KEYWORDS
Stent, Paclitaxel,
Elution release 
kinetics
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Introduction
Drug-eluting stents consist of a drug, a polymer, and a stent plat-
form. Several drugs with durable or erodable polymers have been
tested in clinical trials and show that drug-eluting stents significant-
ly inhibit neointimal growth compared to bare metal stents1-4.
However, the most effective drug dose and pharmacokinetic release
formulation have not been evaluated thoroughly in humans.
The Paclitaxel In-Stent Controlled Elution Study (PISCES) has
demonstrated that kinetic variations play a key role in the efficacy of
a drug-eluting system5. At 4 months, the inhibition of in-stent neoin-
timal hyperplasia was better in the slow release groups compared to
the fast release groups. The present study evaluates (1) the one-
year clinical outcome in all 6 groups and (2) neointimal growth in
the two slow release groups, using serial quantitative coronary
angiography (QCA) and intravascular ultrasound (IVUS) analysis; in
order to understand the long-term impact of drug dose and phar-
macokinetic release.
Methods
Patient selection 
The PISCES trial was a prospective, multi-center, sequentially
enrolled, non-randomized, open-label trial in which patients were
treated with a Conor paclitaxel-eluting stent in one of six different
release formulations, and the results of each group was compared
(Table 1). The study device and protocol have been described previ-
ously5,6. In brief, 191 patients with single de novo lesions with a ref-
erence diameter of 2.5-3.5 mm and a lesion length that could be cov-
ered by a single 17mm stent were enrolled. Conor drug-eluting stents
were loaded with 10 or 30 μg of paclitaxel within a bioresorbable poly-
lactide-co-glycolide (PLGA) matrix. The drug and polymer were
deposited in the wells. The in-vitro drug release period was either 10
or 30 days. The PLGA polymer is fully erodable and neither polymer
nor drug is retained in the stent after several months of implantation. 
Follow-up and endpoints 
The study protocol required all patients to have follow-up clinic vis-
its with an electrocardiogram (ECG) at one, four and twelve months.
An independent clinical event committee adjudicated clinical
events and ECGs. Quantitative angiography and IVUS were per-
formed at 4 months. Clopidogrel was discontinued per protocol at 6
months following stent implantation.
Additional angiographic and IVUS follow-up was performed at
12 months in groups D5 and D6 which showed the best results at
4 months (Figure 1)5,6. 
The safety endpoint of the present study is a composite of major
adverse cardiac events (MACE) defined as cardiac death, Q-wave
or non-Q-wave myocardial infarction, and target lesion revascular-
ization (TLR) at 12 months. If the cause of death was undeter-
mined, it was categorized as cardiac death. Myocardial infarction
(MI) was diagnosed by a rise in the creatine kinase level to more
than twice the upper normal limit with an increased creatine kinase-
MB accompanied by new abnormal Q-waves in the surface electro-
cardiogram (Q-wave MI) or not (non-Q-wave MI). TLR was defined
as revascularization of the stented and the peri-stent segments
(5mm proximal and distal). Target vessel revascularization (TVR)
was defined as revascularization due to narrowing (>50% diameter
stenosis) of any portion of the target vessel outside the peri-stent
segment but was not included as an event in the MACE rate.
The efficacy endpoints included the in-stent and peri-stent (in-stent
+ 5 mm proximal edge + 5 mm distal edge) angiographic late loss
and binary restenosis rate as well as percent in-stent volume
obstruction as determined by quantitative intravascular ultrasound
(IVUS).
Quantitative Coronary Angiography (QCA)
evaluation 
The quantitative ultrasound and coronary angiographic (QCA)
analyses were performed by an independent core laboratory that
remained blinded to treatment allocation (Cardialysis, Rotterdam,
The Netherlands). Quantitative coronary angiography was per-
formed by means of the CAAS II analysis system (Pie Medical BV,
Maastricht, The Netherlands). In each patient, the in-stent and peri-
stent segments were analyzed. Binary restenosis was defined in
every segment as diameter stenosis >50% at follow-up. Late loss
was defined as the difference between MLD post-procedure and
MLD at follow-up
Quantitative Intravascular Ultrasound (IVUS)
Post-procedure and follow-up stented vessel segments were exam-
ined with intravascular ultrasound (Cardio Vascular Imaging
System, CVIS, Sunnyvale CA, U.S.A.) using an automated pullback
at 0.5 mm per second. A computer-based contour detection pro-
gram was applied using CUARD QCU analysis software (Cuard BV,
Wijk Bij Duurstede, The Netherlands) for 3-D reconstruction of the
stented and adjacent segments7,8. The intrastent neointimal area
was calculated as the stent area minus lumen area, and plaque
area outside the stent was calculated as the vessel area minus stent
area. The percentage in-stent volume obstruction was calculated as
intrastent neointimal volume/stent volume*100. 
Table 1. Release formulations 
D1 D2 D3 D4 D5 D6
Paclitaxel dose 10 10 10 30 10 30
(μg/17mm stent)
Duration of elution (days) 5 10 10 10 30 30
Direction of elution Abluminal and luminal Abluminal and luminal Abluminal Abluminal and luminal Abluminal Abluminal
(bidirectional) (bidirectional) (mural) (bidirectional) (mural) (mural)
Key 10/5/b 10/10/b 10/10/m 30/10/b 10/30/m 30/30/m
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Statistical analysis
The analyses of MACE, angiographic and IVUS parameters were per
protocol based, in patients who received the allocated Conor pacli-
taxel-eluting stents. Continuous variables are expressed as
mean±standard deviation. Discrete variables are presented as per-
centages. For patient demographics, the following tests were
applied to calculate the differences among the six groups: F-test
from an analysis of variance, two-sample t-test, likelihood ratio chi-
square test, Fisher’s exact test and Cochran-Mantel-Haenszel test.
For QCA and IVUS parameters, continuous variables were com-
pared between groups D5 and D6 with the Student t test, and com-
parisons between 4 months and 12 months within the same group
were performed with a paired t test. The Fisher exact test was used
for categorical variables. All statistical tests were two-tailed, and 
p values less than 0.05 were considered statistically significant. 
Results
Patient and lesion characteristics
In the PISCES trial, 191 patients were enrolled. The investigational
device could not be implanted in four patients. In total, 187 patients
were treated with one of the six different formulations of paclitaxel-
eluting Conor stents. The average age was 59.1±9.2 years and the
prevalence of diabetes was 18.2% in the total population. The base-
line demographic and angiographic data was similar among the six
groups, except for the incidence of a positive smoking history
(Tables 2 and 3).
Clinical events
Clinical follow-up was complete for all patients at one year (Table 4).
At four months, the slow release groups had a relatively lower inci-
dence of MACE compared to the fast release groups (2.6% in D5
and 3.4% in D6). This tendency did not change at one year (5.1%
in D5 and 6.9% in D6; Figure 2). Between 4 months and 1 year, a
MACE occurred in two patients in the slow release groups (D5 and
D6): one patient in D5 suffered a non Q-MI due to a non-TVR (max-
imum CK level of 356 U/L), and one patient in D6 had diffuse in-
stent restenosis (binary restenosis of 68%) at 4-month angiographic
follow-up with a positive exercise tolerance test. This patient was
placed on the waiting list for a repeat intervention. Two weeks after
the angiography, she was admitted with a Q-wave MI (maximum CK
level of 1687 U/L) and underwent re-catheterization which demon-
strated total occlusion at the inlet of the stent. This patient was sub-
sequently treated with a sirolimus-eluting stent. Notwithstanding this
patient who had angiographic restenosis, a positive functional test for
ischemia but delayed re-intervention at the 4 month follow-up, there
were no instances of abrupt, delayed stent thrombosis in the PISCES
patients.
Serial QCA analysis
A total of 50 patients (74%) in groups D5 and D6 underwent seri-
al QCA analysis at 4 months and 1 year. The baseline and post-pro-
cedure QCA data were similar in the two groups (Table 4). At
4 months, in-stent late loss was not significantly different between
Figure 1: 4-month QCA and IVUS results.
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D5 and D6, although in-stent late loss was lower in D6 than in D5
(0.32±0.40 mm versus 0.40±0.32 mm respectively, p=0.43).
From 4 months to 1 year, the late loss increased in both groups but
the trend remained in favor of D6; no statistical difference between
the two groups could be established although D6 showed a lower 
in-stent late loss at 1 year (0.52±0.34 mm in D5 and 0.36±0.50 mm
in D6, p=0.20). Overall peri-stent binary restenosis at 1 year was
observed in one patient in each group (3.1% in D5 and 5.6% in
D6, p=1.00). 
Serial IVUS analysis
A total of 45 patients (66%) underwent serial IVUS analysis at
4 months and 1 year. The IVUS results showed no statistical differ-
ences between groups D5 and D6 (Table 5). The percent in-stent
obstruction at 1 year was 12.46±7.60 in D5 and 8.37±9.10 in D6
(p=0.12). However, in D5, the neointimal area increased significant-
ly from 4 months to 1 year (delta=0.38mm2, p=0.0003) whereas
the difference between 4 months and 1 year in D6 failed to be sig-
nificant (delta=0.21 mm2, p=0.36, Figure 3). 
At 4 months, significant expansive remodeling (an increase in the
plaque area outside the stent) was observed in both groups (7.75±1.93
mm2 vs 9.09±2.45 mm2, p<0.0001 in D5; 8.04±1.76 mm2 vs
8.95±1.67 mm2, p=0.0015 in D6). Between 4 months and 1 year, a
significant regression of the expansive plaque area outside the stent
was observed in both groups (9.09±2.45 mm2 vs 8.46±2.15 mm2,
p=0.045 in D5; 8.95±1.67 mm2 vs 8.37±1.74 mm2, p=0.0023 in D6).
Discussion
The main findings of this study are the following: first, the slow
release (30 day) groups have better clinical outcomes at 1 year
compared to the fast release (5 or 10 day) groups. Second, com-
pared to the low dose (10 μg) group, the high dose (30 μg) group
had lower late loss and neointimal volume at one year without sta-
Table 2. Patient characteristics (per protocol)
D-1 D-2 D-3 D-4 D-5 D-6 P-Value P-Value 
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m comparing between
N=30 N=29 N=30 N=30 N=39 N=29 6 groups D5 and D6
Age (mean±SD) 57.4±9.90 61.8±8.9 59.7±9.6 60.2±8.8 56.7±7.6 58.5±10.5 0.23 0.41
Male, % 60.0 (18/30) 72.4 (21/29) 76.7 (23/30) 60.0 (18/30) 82.1 (32/39) 69.0 (20/29) 0.28 0.21
Smoking, % 53.3(16/30) 86.2 (25/29) 76.7 (23/30) 73.3 (22/30) 89.7 (35/39) 72.4 (21/29) 0.01 0.06
Diabetes, % 16.7 (5/30) 17.2 (5/29) 23.3 (7/30) 13.3 (4/30) 10.3 (4/39) 31.0 (9/29) 0.31 0.03
Hypertension, % 40.0 (12/30) 62.1 (18/29) 63.3 (19/30) 56.7 (17/30) 35.9 (14/39) 62.1 (18/29) 0.08 0.03
Dyslipidemia, % 66.7 (20/30) 62.1 (18/29) 73.3 (22/30) 63.3 (19/30) 61.5 (24/39) 65.5 (19/29) 0.93 0.74
Prior MI, % 40.0 (12/30) 44.8 (13/29) 33.3 (10/30) 30.0 (9/30) 41.0 (16/39) 41.4 (12/29) 0.85 0.98
Prior CABG, % 3.3 (1/30) 3.5 (1/29) 0.0 (0/30) 0.0 (0/30) 2.6 (1/39) 6.9 (2/29) 0.59 0.39
Prior PCI 6.7 (2/30) 6.9 (2/29) 10.0 (3/30) 13.3 (4/30) 15.4 (6/39) 17.2 (5/29) 0.71 0.84
Table 3. Lesion and procedural characteristics (per protocol)
D-1 D-2 D-3 D-4 D-5 D-6 P-Value P-Value 
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m comparing between
N=30 N=29 N=30 N=30 N=39 N=29 6 groups D5 and D6
Treated vessel
LAD 50.0% 41.4% 56.7% 50.0% 48.7% 27.6% 0.30 0.08
LCX 16.7% 20.7% 13.3% 23.3% 23.1% 37.9% 0.30 0.28
RCA 33.3% 37.9% 30.0% 26.7% 28.2% 34.5% 0.94 0.58
ACC/AHA classification 
A/B1/B2 100.0% 100.0% 100.0% 100.0% 94.9% 96.6% 0.34 0.74
C 0.0% 0.0% 0.0% 0.0% 5.1% 3.4% 0.34 0.74
Angiographic features
Reference vessel 
diameter, mm 2.76±0.40 2.70±0.52 2.82±0.43 2.64±0.43 2.73±0.41 2.70±0.41 0.71 0.79
Lesion length, mm 9.73±3.68 9.08±3.60 10.60±3.83 10.62±3.09 9.35±3.24 10.31±3.36 0.37 0.24
Minimal lumen 
diameter, mm 1.10±0.35 1.06±0.38 0.97±0.37 1.05±0.25 1.03±0.28 1.00±0.31 0.70 0.64
Diameter stenosis, % 60.32±9.57 61.02±11.54 65.72±11.77 59.89±7.77 62.05±8.19 63.17±9.63 0.21 0.61
Procedural characteristics
Stent/patient 1.2±0.38 1.1±0.35 1.1±0.43 1.1±0.25 1.2±0.43 1.0±0.00 0.41 0.13
Stent length, mm 19.03±4.90 18.80±4.80 18.20±3.90 17.60±2.28 18.38±3.88 17.0±0.0 0 0.39 0.13
Stent diameter, mm 3.18±0.24 3.18±0.24 3.25±0.25 3.21±0.25 3.31±0.24 3.25±0.25 0.26 0.44
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Table 4. MACE (Patients with events, per protocol)
D-1 D-2 D-3 D-4 D-5 D-6
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m
N=30 N=29 N=30 N=30 N=39 N=29
Post procedure ~ 4-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
Q-wave MI 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.3%) 1 (2.6%) 1 (3.4%)
Non Q-wave MI 1 (3.3%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
TLR 5 (16.7%) 4 (13.8%) 2 (6.7%) 1 (3.3%) 0 (0.0%) 1 (3.4%)
TVR 0 (0.0%) 1 (3.4%) 1 (3.3%) 0 (0.0%) 2 (5.1%) 1 (3.4%)
MACE 5 (16.7%) 5 (17.2%) 2 (6.7%) 2 (6.7%) 1 (2.6%) 1 (3.4%)
4-month ~ 12-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Q-wave MI 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.4%)
Non Q-wave MI 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
TLR 0 (0.0%) 1 (3.4%) 2 (6.7%) 1 (3.3%) 0 (0.0%) 1 (3.4%)
TVR 0 (0.0%) 1 (3.4%) 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.4%)
MACE 0 (0.0%) 1 (3.4%) 2 (6.7%) 1 (3.3%) 1 (2.6%) 1 (3.4%)
Post procedure ~ 12-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
Q-wave MI 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.3%)† 1 (2.6%) 2 (6.9%)
Non Q-wave MI 1 (3.3%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
TLR 5 (16.7%) 5 (17.2%) 4 (13.3%) 2 (6.7%) 0 (0.0%) 2 (6.9%)
TVR 0 (0.0%) 2 (6.9%) 2 (6.7%)? 0 (0.0%) 2 (5.1%) 2 (6.9%)
MACE 5 (16.7%) 6 (20.7%) 4 (13.3%) 3 (10.0%) 2 (5.1%) 2 (6.9%)
*TVR was not included as an event in the MACE rate
Figure 2: 4-month and 1-year MACE.
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Figure 3. Correlation between neointimal area and peri-stent area
over 2 years. Error bars indicate 95% CI.
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tistically significant difference. Third, between 4 months and 1 year,
modest neointimal growth continued in both the low and high dose
groups without new instances of in-stent angiographic restenosis or
target lesion revascularization, and this neointimal growth was sta-
tistically significant in the low dose group only. Fourth, plaque out-
side the stent increased during the first 4 months following Conor
paclitaxel-eluting stent implantation, but by 1 year it had partially
regressed in both the low and high dose groups.
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Various drug elution processes have reported conflicting clinical
results3,9-12. In the SCORE trial, QuaDDS stents with a total of
4000 μg paclitaxel and a durable acrylate polymer were found to
have an unacceptable safety profile9. In the DELIVER trial, the Multi-
Link PENTA stent with a coating of 45-150μg paclitaxel (a dose den-
sity of 3.0μg/mm2 stent surface area) without a polymer showed no
impact in reducing clinical revascularization or restenosis compared
to bare metal stents, presumably due to the rapid elution of the
drug10. In the ELUTES and ASPECT trials, the high-dose non poly-
mer paclitaxel-eluting stent has the better outcomes compared to
the low dose group11,12. In the TAXUS IV trial, a slow-release (7.5%
at 30 days), polymer-based paclitaxel eluting stent with a total of
106 μg paclitaxel (a dose density of 1.0 μg/mm2 stent surface area)
eluted from a durable polymer showed significantly better inhibition
of neointimal growth and clinical outcomes when compared to bare
metal stents3. In the light of this study and other paclitaxel–eluting
stent trials, the drug release profile is a key factor in the clinical effi-
cacy, and drug-eluting stents with a slow release formulation seem
to be more efficient. In the present study, the slow release groups
demonstrate the best 1-year clinical outcomes, mainly due to better
outcomes in the first 4 months. The drug and polymer are com-
pletely removed from the wells after several months, thus this novel
drug-eluting stent may potentially preclude the chronic vessel reac-
tion usually observed with a durable polymer and persistent drug on
the stent13,14. Further, there were no instances of late stent throm-
bosis. Though more data from larger studies is required to draw
definitive conclusions, these results support the hypothesis that
complete drug elution and polymer resorbtion may confer safety
benefits with respect to delayed thrombosis. 
In this study, the expansive vessel remodeling observed at 4 months
seems similar to the remodeling observed after implantation of
Taxus polymeric paclitaxel-eluting stents15. The expansive vessel
shrinkage observed at 1 year also suggests that the chronic vessel
reaction to mechanical injury and biological reaction to the drug and
polymer have subsided in that period of time. 
However, the chronic vessel reaction inside the stent differs from
the reaction observed behind the stent struts. Although this study
showed a regression of tissue growth outside the stent between
4 months and 1 year, compaction of neointima was not observed in
either the low dose or the high dose group over the same time peri-
od. The precise reason for this phenomenon is unclear. One might
hypothesize that this could be a result of different tissue composi-
tion inside and outside the stent. The tissue growth inside the stent
is composed of smooth muscle cells in a proteoglycan rich matrix,
whereas the tissue growth behind the stent struts consists of sever-
al components: 1) intracellular matrix and cell proliferation such as
smooth muscle cells and lymphocyte cells, 2) oedema due to
mechanical injury and biological reaction against the drug, polymer
and stent, and 3) growth or regression of existing atherosclerotic
plaque. Thus, the direction of volumetric change (regression or
expansion) from 4 months to 1 year may not be similar inside and
outside the stent.
In this study, the actual late loss and neointimal area were smaller
in the 30 μg group than in the 10 μg group. These differences were
not statistically different and did not influence the clinical outcomes.
The 10 μg paclitaxel dose may be sufficient to suppress neointimal
growth in humans at least for a period of one year. It may also be
argued that the sample size is too small to detect a biological differ-
ence between the low and the high dose. 
In animal studies, paclitaxel polymer coated stents have been found
to inhibit in-stent neointimal growth but with signs of delayed intimal
healing at 28 days, such as fibrin deposition, inflammation and
increased cellular proliferation. By 90 days, local toxicity associated
with paclitaxel resolves but in-stent neointimal growth suppression
is no longer present16. In humans following bare metal stent implan-
tation, the neointima does not keep growing beyond 6 months and
Table 5. Serial QCA analysis 
(post procedure, 4 months and 12 months)
D5 D6 P-value
(10/30/m) (30/30/m)
N=32 N=18
Pre
Lesion length 9.39±3.37 10.04±2.80 0.49
RVD, mm 2.71±0.43 2.69±0.42 0.84
MLD, mm 1.05±0.29 1.02±0.33 0.73
DS, % 61.5±7.7 62.5±9.2 0.67
Post stenting
In-stent
MLD, mm 2.68±0.35 2.51±0.38 0.12
DS, % 12.4±6.5 13.6±6.2 0.56
In-peristent*
MLD, mm 2.31±0.41 2.18±0.38 0.29
DS, % 22.3±9.1 23.5±8.9 0.65
4-month
In-stent
MLD, mm 2.28±0.32 2.19± 0.53 0.53
DS, % 19.9±9.3 21.7±9.7 0.63
Late loss, mm 0.40±0.32 0.32±0.40 0.43
Binary restenosis, % 0.0 5.6 0.36
In-peristent*
MLD, mm 2.10±0.36 1.97±0.48 0.27
DS, % 25.3±8.7 29.9±13.6 0.20
Late loss, mm 0.21±0.29 0.21±0.39 0.95
Binary restenosis, % 0.0 5.6 0.36
12-month
In-stent
MLD, mm 2.16±0.34 2.15±0.65 0.93
DS, % 21.3±10.3 23.2±20.6 0.72
Late loss, mm 0.52±0.34 0.36±0.50 0.20
Binary restenosis, % 0.0 5.6 0.36
In-peristent*
MLD, mm 2.01±0.35 1.94±0.61 0.69
DS, % 27.5±9.67 29.3±20.8 0.73
Late loss, mm 0.30±0.26 0.24±0.50 0.62
Binary restenosis, % 3.1 5.6 1.00
* In-peristent = In-stent + 5 mm proximal + 5 mm distal
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instead begins to regress due to the replacement of water-trapping
proteoglycans (hyaluronan and versican) by decorin and type I col-
lagen17. In this study, compaction of neointima was not observed
and it is unknown whether neointimal tissue will keep growing or
stop beyond one year. Further follow-up is warranted to evaluate the
long-term efficacy of these devices and to find the best elution peri-
od and drug dose.
Limitations
At one year, 26% and 34% of the patients in the groups of D5 and
D6 respectively did not undergo serial invasive QCA or IVUS follow-up
evaluation. Following completion of patient enrolment, the protocol
was subsequently amended to allow one year angiographic and IVUS
follow-up, necessitating a new informed consent. Patients who did not
undergo one-year angiography reported no anginal symptoms at one
year. The sample sizes for groups D5 and D6 were insufficient to
detect a difference in outcome between the low and high doses in the
slow release formulation. However, they served as the basis for the
development of a large randomized trial (the EuroSTAR trial) which is
evaluating both doses (10 μg and 30 μg per 17mm stent) of slow-
release paclitaxel using the reservoir-based technology on an ultra-
thin cobalt-chromium stent in 270 patients.
Conclusions
The PISCES trial suggests that the pharmacokinetics of drug-eluting
stents is important for both neointimal suppression and for clinical
outcomes at 1 year. The slow release (30 day) formulation had bet-
ter clinical outcomes compared to the fast release (5 or 10 day) for-
mulation. The drug dose (10 μg or 30 μg) did not seem to influence
the amount of neointimal suppression but the sample sizes in this
pilot dose-finding study were insufficient to detect a beneficial dif-
ference in dose. 
References
1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. 
A randomized comparison of a sirolimus-eluting stent with a standard
stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,
O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS,
Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in
patients with stenosis in a native coronary artery. N Engl J Med
2003;349:1315-23.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT,
Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A poly-
mer-based, paclitaxel-eluting stent in patients with coronary artery dis-
ease. N Engl J Med 2004;350:221-31.
4. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U,
Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first human
experience using everolimus-eluting stents with bioabsorbable polymer.
Circulation 2004;109:2168-71.
5. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H,
Smits P, McClean P, Verheye s, Belardi G, Condado J, Pieper M, Gambone L,
Bressers M, Symons J, Sousa JE, Litvack F. The Effect of Variable Dose
and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-
Eluting Stent Platform - Paclitaxel In-Stent Controlled Elution Study
(PISCES). JACC 2005;46:253-60
6. Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N,
Park K, Fishbein MC, Makkar R, Litvack F, Eigler NL. Local drug delivery
via a coronary stent with programmable release pharmacokinetics.
Circulation 2003;107:777-84.
7. von Birgelen C, Di Mario C, Li W, Schuurbiers JC, Slager CJ, de
Feyter PJ, Roelandt JR, Serruys PW. Morphometric analysis in three-
dimensional intracoronary ultrasound: an in vitro and in vivo study per-
formed with a novel system for the contour detection of lumen and
plaque. Am Heart J 1996;132:516-27.
8. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE,
Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ,
Morice MC. Intravascular ultrasound findings in the multicenter, random-
ized, double-blind RAVEL (RAndomized study with the sirolimus-eluting
VElocity balloon-expandable stent in the treatment of patients with de
novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
9. Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G,
Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J,
Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell ME. High-dose 7-
hexanoyltaxol-eluting stent with polymer sleeves for coronary revascular-
ization: one-year results from the SCORE randomized trial. J Am Coll
Cardiol 2004;44:1368-72.
10. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA,
O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A,
Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E,
Stone GW, Leon MB, Knopf WD, O'Neill WW. Non-polymer-based pacli-
taxel-coated coronary stents for the treatment of patients with de novo
coronary lesions: angiographic follow-up of the DELIVER clinical trial.
Circulation 2004;109:1948-54.
Table 6. Serial IVUS analysis 
(post procedure, 4 months and 12 months)
D5 D6 P-value
(10/30/m) (30/30/m)
N=30 N=15
Post stenting
Vessel area, mm2 15.84±3.36 16.00 ±2.80 0.88
Stent area, mm2 8.09±1.81 7.95±1.77 0.81
Plaque area outside 7.75±1.93 8.04±1.76 0.63
the stent, mm2
4-month
Vessel area, mm2 17.31±3.56 17.33±2.74 0.99
Stent area, mm2 8.22±1.86 8.64±1.92 0.49
Lumen area, mm2 7.61±1.87 8.08±1.82 0.43
Neointimal area, mm2 0.61±0.57 0.57±0.74 0.81
Plaque area outside 9.09±2.45 8.95±1.67 0.85
the stent, mm2
% in-stent obstruction 7.49±6.92 6.21±7.39 0.57
12-month
Vessel area, mm2 16.74±3.56 16.73±3.02 0.99
Stent area, mm2 8.21±1.84 8.36±1.83 0.80
Lumen area, mm2 7.23±1.87 7.59±1.46 0.52
Neointimal area, mm2 0.99±0.54 0.77±0.92 0.42
Plaque area outside 
the stent, mm2 8.46±2.15 8.37±1.74 0.89
% in-stent obstruction 12.46±7.60 8.37 ±9.10 0.12
Andrew BW.indd   285 28-08-2007   09:52:40
11. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Song JK,
Kim JJ, Weissman NJ, Fearnot NE, Park SW, Park SJ. Paclitaxel coating
reduces in-stent intimal hyperplasia in human coronary arteries: a serial
volumetric intravascular ultrasound analysis from the Asian Paclitaxel-
Eluting Stent Clinical Trial (ASPECT). Circulation 2003;107:517-20.
12. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A,
Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE,
Urban P, Heldman AW. Inhibition of restenosis with a paclitaxel-eluting,
polymer-free coronary stent: the European evaLUation of pacliTaxel
Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
13. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A,
Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after
implantation of a paclitaxel derivate-eluting polymer stent system in
humans. Circulation 2002;106:2649-51.
14. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T,
Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitiv-
ity and late coronary thrombosis secondary to a sirolimus-eluting stent:
should we be cautious? Circulation 2004;109:701-5.
15. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E,
Chan C, Munzel T, Belardi J, Ruzyllo W, Bilodeau L, Kelbaek H,
Ormiston J, Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME,
Colombo A. Chronic arterial responses to polymer-controlled paclitaxel-
eluting stents: comparison with bare metal stents by serial intravascular
ultrasound analyses: data from the randomized TAXUS-II trial. Circulation
2004;109:196-200.
16. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ,
Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of
paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
17. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK,
Wight TN, Virmani R. Extracellular matrix changes in stented human coro-
nary arteries. Circulation 2004;110:940-7.
Acknowledgement
The authors thank Patty Hevey and Louise Gambone for data
management and careful review of the manuscript.
Andrew BW.indd   286 28-08-2007   09:52:41
Chapter 28
Summary and Conclusions
Samenvatting en Conclusies
Acknowledgements
Curriculum Vitae
List of Publications
Andrew BW.indd   287 28-08-2007   09:52:42
Andrew BW.indd   288 28-08-2007   09:52:43
| Chapter 28Summary and Conclusions 
289
CHAPTER 28:
SUMMARY AND CONCLUSIONS
Th is thesis in many ways summarises percutaneous coronary intervention as we know it today, that is, 
with a provisional stenting approach. More and more commonly, we choose a drug-eluting stent (DES) 
as the default stent. Twenty years have passed since stents were fi rst used to maintain vessel patency 
following balloon angioplasty. Chapter 2 provided a historical account of coronary artery stents, while 
Chapter 3 looked at drug-eluting stents and current and future studies in progress. 
Th e Impact of Unrestricted Use of Drug-Eluting Stents
In 2002, at the Th oraxcentre, a decision was made to implant drug-eluting stents in all patients suitable 
for stent implantation, irrespective of clinical or angiographic fi ndings, and to research the effi  cacy and 
safety of these stents in untested patient populations. Th e original trials that led to the commercialisa-
tion of drug-eluting stents were performed in highly selected patients with simple lesions, to reduce the 
number of confounding factors. However, the patients studied in those trials make up only 20% of the 
typical patient population seen in a cardiac catheterisation laboratory. For the remaining 80%, it was 
extrapolated that these drug-eluting stents would be safe and effi  cacious, and that assumption required 
proving. 
Th erefore, all patients undergoing stent implantation were prospectively and consecutively enrolled 
into the RESEARCH registry (which enrolled from April 2002 to February 2003), and the T-SEARCH 
registry (from February 2003 onwards). Th e one year results of the RESEARCH registry have previously 
been reported. In Chapters 5 and 6 we report the medium term results of the RESEARCH registry. At 
two years, despite a higher risk profi le in the sirolimus-eluting stent (SES) treated group over the bare 
metal stent (BMS) treated group, the cumulative rate of major adverse cardiac events (MACE) was lower 
in the SES group compared to the BMS group, 15.4% versus 22.0% respectively, hazard ratio (HR) 0.68 
(95% confi dence interval (CI) 0.50 to 0.91); p = 0.01. Th is advantage was maintained at three years, with 
MACE rates of 18.9% vs 24.7% respectively, HR 0.73 (95% CI 0.56 to 0.96), p= 0.026. With regards to 
target vessel revascularization (TVR), the major driver of events, the two-year risk was also lower in 
the SES group as compared to the BMS group, 8.2% versus 14.8% respectively, HR 0.53 (95% CI 0.36 to 
0.79); p= 0.002; while the 3-year risk was 7.5% versus 12.6%, HR 0.57 (95% CI 0.38 to 0.87); p= 0.01. 
Th is thus confi rmed the superiority of sirolimus-eluting stents over bare stents. 
In 2003, paclitaxel-eluting stents (PES) became the default drug-eluting stent, replacing SES. Having 
already proven the effi  cacy of SES, we now had the opportunity to compare the effi  cacy of two drug-
eluting stents, PES and SES in Chapter 4. At one year, the cumulative incidence of MACE were similar, 
13.9% in the PES group and 10.5% in the SES group (unadjusted HR 1.33 (95% CI 0.95-1.88), p=0.1). 
Andrew BW.indd   289 28-08-2007   09:52:43
Summary and Conclusions 
290 
We then corrected for baseline diff erences and that bought the adjusted hazard ratio to 1.16 (95% CI 
0.81-1.64, p=0.4). Th e one year cumulative incidence of clinically driven TVR was similar, 5.4% versus 
3.7% respectively (HR1.38 (95% CI 0.79-2.43, p=0.3)). 
Th e Effi  cacy of Drug-Eluting Stents in Specifi c Patient and Lesion 
Subgroups
In this thesis, the specifi c subgroups not previously studied in the clinical trials pre-commercialisation 
were scientifi cally scrutinised and reported. In particular, diabetic patients were targeted in Chapter 7, 
and the diff erent available devices were compared. 
At one year, there were no diff erences in unadjusted outcomes by stent type (MACE rates of 20.4% 
for SES vs 15.6% for PES, p=0.12) or when adjusted for multivariate predictors (adjusted HR 0.68, 
95% CI 0.37 to 1.24, p=0.21). Patients who required insulin had a signifi cantly higher, crude MACE 
rates at 1 year compared with those who used oral agents, but this rate became non-signifi cant aft er 
adjustment for independent predictors of outcome. In Chapter 8, patients who presented with an acute 
ST-elevation myocardial infarction treated with coronary stent implantation to maintain arterial pat-
ency were studied – again, comparison was made between sirolimus and paclitaxel eluting stents. At 
one year, no signifi cant diff erences were seen between groups, with one year survival free of MACE of 
90.2% for SES and 85% for PES (p = 0.16). Between 1 month and 1 year, the revascularisaton rate was 
low, being no reintervention in the SES group, and only 1.5% in the PES group, p=0.14. We cautioned 
against the use of bifurcation stenting in acute myocardial infarction, due to the potentially higher risk 
of stent thrombosis.
Chapter 9 reported the outcomes of patients in whom stent implantation was considered a procedure 
of last resort, performed on patients in whom the cardiac surgeons had declined to off er cardiac surgery 
and were instead revascularised percutaneously. In this high risk population, coronary stenting with 
drug-eluting stents was associated with a 30 day mortality rate of 1.2%, 6 month rate of 3.6% and 12 
month mortality rate of 4.8%. Th ese actual results were much lower than the predicted in-hospital 
mortality rates of between 7.8 ± 3.3% and 13.2 ± 11.1% calculated using the standard and logistic Eu-
roscore methods respectively, suggesting that coronary stenting with drug-eluting stents is an attractive 
proposition for high-risk patients. 
In the next few chapters, specifi c lesion subgroups were studied. With the advent of drug-eluting stents, 
longer and longer coronary artery segments were covered, given the dramatic reduction in restenosis 
rates. In Chapter 10 we looked at the outcomes of patients who had received more than 64mm of 
continuous stents in a coronary artery, the so-called ‘full-metal-jacket’. With a median of 79mm of stent 
(range 64-168mm), the one year TVR rate was 7.5% and the overall incidence of MACE was 18%, with 
no diff erence between SES and PES groups. Chapter 11 reported excellent results of PES in saphenous 
vein graft s with low one year MACE rates of 7.5%. In Chapter 12, a comparison of the two drug-eluting 
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stent types and bare metal stents was made in chronic total occlusions, that is, lesions which had been 
completely blocked for at least 3 months. Here, we reported that at one year, the freedom from TVR 
was higher in the SES and PES groups compared with the BMS group (97.4% and 96.4% versus 80.8% 
respectively, p=0.01). Th is clearly demonstrated the effi  cacy of drug-eluting stents over bare stents for 
this condition.
Th e treatment of left  main lesions, traditionally a surgical cohort, was looked at in Chapter 13, and a 
comparison made between bare metal and drug-eluting stents. Here, with a median follow-up of 503 
days (range, 331 to 873 days), the cumulative incidence of MACE was lower in the DES cohort than in 
the BMS group (24% versus 45%, respectively; HR, 0.52 [95% CI, 0.31 to 0.88]; P=0.01). Total mortality 
did not diff er; however, there were signifi cantly lower rates of both myocardial infarction (4% versus 
12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P=0.006) and TVR (6% versus 23%,respectively; 
HR, 0.26 [95% CI, 0.10 to 0.65]; P=0.004) in the DES group. In the last of the subgroups looked at, 
bifurcation lesions were studied in Chapter 14. In this study, at six months, survival free of MACE was 
93.7% for SES versus 85.8% for PES, p=0.05. Survival-free of target lesion revascularization (TLR) was 
95.7% for SES versus 86.8% for PES, p=0.01. Th is study was not powered to determine the diff erences in 
TLR between stent type. Compared with historical data of bare metal stents, MACE rates were low.
Early and Late Stent Th rombosis
As with all new technologies, the initial overblown enthusiasm that accompanied the ‘zero restenosis’ 
cry was followed by intellectual reproach. As more patients were treated with drug-eluting stents, it 
became clear that some of these patients were experiencing a rare complication that was oft en sudden, 
acute in onset and potentially life threatening. Th is was stent thrombosis, a condition also seen with 
bare metal stents. Given that drug-eluting stents were known to inhibit neointima formation, hence 
the process of re-endothelialisation and healing, there was grave concern and uncertainty regarding its 
incidence with drug-eluting stents. From the comprehensive RESEARCH and T-SEARCH database at 
the Th oraxcentre, we were able to quickly and accurately report to the cardiology community that the 
incidence of early stent thrombosis (that occurring within the fi rst 30 days of stent implantation) was 
no diff erent between bare metal and the new drug-eluting stents (Chapter 15). Th is, in retrospect was 
correct, as the major determinants of early stent thrombosis were mechanical issues, and had nothing 
to do with the drug, or polymer in the early period. In the fi rst 30 days aft er stent implantation, the 
incidence of angiographically proven stent thrombosis in the BMS, SES and PES groups were 1.2%, 
1.0% and 1.0% respectively, p=0.9. Multiple potential risk factors were identifi ed in most patients with 
ST. Bifurcation stenting in the setting of acute myocardial infarction was an independent risk factor 
for angiographic stent thrombosis in the entire population (odds ratio [OR] 12.9, 95% CI 4.7 to 35.8, 
p< 0.001). In patients with DES who had angiographic stent thrombosis, 30-day mortality was 15%, 
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whereas another 60% suff ered a nonfatal myocardial infarction; no further deaths occurred during six 
months of follow-up. Including possible cases, the respective incidences were 1.4%, 1.5% and 1.6%.
With regards to late stent thrombosis (that occurring later than 30 days), the short paper of Chapter 16 
was the fi rst to highlight to the medical community of the anecdotal consequence of stopping antiplate-
let therapy following drug-eluting stent implantation. Th is report was followed by Chapter 17, which 
reported that the incidence of angiographically proven late stent thrombosis was at least 0.35% (95% 
confi dence limits 0.17% to 0.72%) in patients treated with DES and importantly, it may also occur when 
patients are stable on antiplatelet monotherapy.
Cost-Eff ectiveness of Drug-Eluting Stents
A study into a new device is not complete without an assessment of its costs, as related to its benefi t, 
expressed as the cost eff ectiveness of the new drug-eluting stent in comparison to the incumbent bare 
metal stent. Cost-benefi t analyses using trial data pre-commercialisation showed that these stents were 
indeed cost eff ective. Using real world data from the RESEARCH registry (Chapter 5), we were able 
to demonstrate in Chapter 18 that outside of trial situations, in a typical catheterisation laboratory, 
the unrestricted use of drug-eluting stents were not cost eff ective at the prices charged in 2002. Cost 
eff ectiveness was measured using the incremental cost eff ectiveness ratio per TVR avoided and was €29 
373 at 1 year, and €22 267 at 2 years, when the cost eff ectiveness price is a ratio less than €10,000. Unique 
to a cost-eff ective analysis, we were able to use the formula to provide using contemporary pricing, a 
cost neutral price of €779 per drug-eluting stent when used in an unrestricted population. 
Multi-vessel Stenting
Looking forward, it is important to test whether coronary artery stenting would be a viable alterna-
tive to coronary artery bypass surgery as a revascularisation strategy. Th e fi ve year report of the ARTS 
trial, the largest randomised trial to compare coronary artery stenting to bypass surgery, importantly 
demonstrated no diff erence in mortality between the two groups (8.0% vs. 7.6% respectively; p=0.83; 
relative risk [RR], 1.05; 95% confi dence interval [CI], 0.71 to 1.55). Th ere was an increased need for 
revascularisation in the stenting group (30.3% versus 8.8%; p < 0.001; RR, 3.46;95% CI, 2.61 to 4.60), 
which resulted in a higher overall major adverse cerebral and cardiac event (MACCE) rate in the stent-
ing group, 41.7% versus 21.8% compared to the CABG group (p< 0.0001; RR 1.91;95% CI, 1.60 to 2.28). 
Th is is reported in Chapter 19. 
In Chapter 20, the ARTS II trial, a multicentre registry of multivessel disease patients treated with 
sirolimus-eluting stents, reported low one-year repeat revascularisation rates of 8.5%, and MACCE 
rates of 10.5%. When compared with the historical ARTS I surgery group the sirolimus treated groups 
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had similar overall outcomes at one year (RR 0.89 (0.65-1.23)). Th is led to the design of the SYNTAX 
trial (Chapter 21), a randomised trial comparing coronary artery bypass surgery to coronary artery 
stenting using paclitaxel-eluting stents in the highest risk group of patients – that is patients with left  
main disease and those with three vessel disease. Importantly for the SYNTAX trial, data from the 
preceding chapters from the RESEARCH and T-SEARCH registry were used in the trial design. 
Subgroup analyses from the ARTS trial looked at the eff ect of stents in the proximal left  anterior descend-
ing artery (Chapter 23) and reported that at 3 years, there was no diff erence in the combined incidence 
of death, stroke, and myocardial infarction in either group, but the need for repeat revascularization 
was more frequent in the group with stenting than in the group with coronary artery bypass graft ing. In 
patients in the ARTS trial who had renal insuffi  ciency (Chapter 24), those who underwent stenting had 
a lower 5-year freedom from MACCE as compared to those who underwent CABG, mainly due to the 
increased need for repeat revascularisation (50.7% versus 68.5% respectively, p=0.04. Finally, the eff ect 
of gender was studied in Chapter 25. At 5-years, the clinical outcome of women with multivessel disease 
undergoing coronary revascularisation was similar to that in men within their treatment groups. How-
ever, women presented more bleeding complications before hospital discharge in the stenting group. 
New Drug-Eluting Stents
Having only discussed sirolimus and paclitaxel-eluting stents to date, new challengers have entered the 
horizon. Th e 6-month results of the SPIRIT FIRST trial were extremely positive, demonstrating that 
everolimus eluted from a durable polymer on a cobalt chromium stent eff ectively suppresses neointimal 
growth compared to an identical bare stent (Chapter 26). Th e 6 month primary endpoint results were as 
follows: in-stent late loss, percentage diameter stenosis and percentage of patients with binary restenosis 
were 0.10 mm, 16% and 0% respectively, in the everolimus arm (n=23), as compared with 0.87 mm, 39% 
and 25.9%, respectively in the bare stent arm (n=27, p<0.001 for late loss and diameter stenosis, p = 0.01 
for restenosis). Finally, the PISCES trial, in which a new paclitaxel-eluting stent was studied, the eff ect 
of prolonged dosing and dose size was tested in a population that was sequentially enrolled (Chapter 
27). Patients who received the slow release formulation stent had better clinical outcomes at one year 
than those who received the fast release formulation. However, due to the small sample size and non-
randomized design of the trial, the eff ect on neointimal suppression require investigation in a larger 
population to determine whether the high dose formulation confers an additional clinical benefi t over 
the low dose formulation. Importantly, this trial appeared to explain the failure of other drug-eluting 
stents and subsequently infl uenced the development of future devices.
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Conclusion
Th erefore, in conclusion, the last 5 years of drug-eluting stent use has revolutionised revascularisation 
of coronary arteries, with many patients now genuinely able to have the option of either percutaneous 
coronary intervention with drug-eluting stents or coronary artery bypass surgery as their preferred 
revascularisation strategy. We were able to reassure the medical community on the issue of stent 
thrombosis, as well as to guide it with regards to pricing. Th is thesis, through its thorough study of 
drug-eluting stents when used in a real world unrestricted population, has paved the way for newer 
studies, pushing the limits of coronary stenting, in particular left  main and three vessel disease. Finally, 
as we move forward, this thesis ends with new participants, some of whom will succeed, and others that 
will fail, but all need to be studied and scrutinised.
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SAMENVATTING EN CONCLUSIES
Dit proefschrift  vat op vele manieren de status op het gebied van percutane coronaire interventie samen, 
zoals vandaag de dag uitgevoerd met provisional stenting. Sinds de introductie van de eerste coronaire 
stent zo’n 20 jaar geleden om de kransslagader langer open te houden, is de drug-eluting stent momen-
teel voor velen de stent van eerste keuze geworden. Hoofdstuk 2 geeft  een historisch overzicht van de 
ontwikkeling van coronaire stents, terwijl Hoofdstuk 3 meer specifi ek de drug-eluting stent en huidige 
en toekomstige studies beschrijft .
De impact van ongelimiteerd drug-eluting stent gebruik
In 2002 werd er in het Th oraxcentrum besloten om drug-eluting stents te gaan gebruiken in alle patiën-
ten die in aanmerking kwamen voor stent implantatie in een patiëntenpopulatie zoals nog nooit eerder 
bestudeerd, zonder enige klinische of angiografi sche restricties, met als doel de veiligheid en eff ectiviteit 
van deze nieuwe stents te onderzoeken. De oorspronkelijke studies die leidden tot de commercialisering 
van drug-eluting stents werden uitgevoerd in zeer geselecteerde patiënten met eenvoudige laesies, om 
zo het aantal confounders zo klein mogelijk te houden. Desalniettemin waren deze patiënten slechts 
representatief voor zo’n 20% van de populatie zoals wordt gezien in de dagelijkse praktijk. Er werd 
echter zonder specifi ek bewijs verondersteld dat de resultaten van deze studies geëxtrapoleerd konden 
worden naar de overige 80% van de patiënten.
Alle patiënten werden geïncludeerd in de RESEARCH registratie (inclusie van april 2002 tot februari 
2003) en vervolgens in de T-SEARCH registratie (inclusie vanaf februari 2003). De 1-jaars resultaten 
van de RESEARCH registratie werden reeds eerder gepubliceerd. In Hoofdstuk 5 en 6 rapporteren 
we over de middellange termijn resultaten van de RESEARCH registratie. Na 2 jaar was de cumu-
latieve incidentie van major adverse cardiac events (MACE) signifi cant lager in patiënten behandeld 
met sirolimus-eluting stents (SES) dan in patiënten behandeld met bare-metal stents (BMS) (15.4% 
vs. 22.0%; hazard ratio (HR) 0.68 (95% betrouwbaarheidsinterval (CI) 0.50 – 0.91; p=0.01)), ondanks 
een hoger klinisch en angiografi sch risicoprofi el in de met SES behandelde patiënten. Dit verschil bleef 
signifi cant na 3 jaar, waar de incidentie van MACE 18.9% vs. 24.7% was in patiënten respectievelijk be-
handeld met SES en BMS. Wat betreft  nieuwe revascularizaties in de index kransslagader (target vessel 
revascularization, oft ewel TVR), de veroorzaker van het gros van de events, was het 2-jaars risico ook 
signifi cant lager in de SES groep (8.2% vs. 14.8% respectievelijk; HR 0.53, 95% CI 0.36 – 0.79; p=0.002); 
terwijl het 3-jaars risico 7.5% vs. 12.6% (HR 0.57; 95% CI 0.38 – 0.87; p=0.01) was. Dit bevestigde de 
superioriteit van SES ten opzichte van BMS.
In 2003 werd de paclitaxel-eluting stent (PES) de stent van eerste keuze, en verving daarmee de SES. 
Gezien we de superioriteit van SES ten opzichte van BMS reeds bewezen hadden, hadden we nu de 
mogelijkheid tot het vergelijken van beide drug-eluting stents, SES en PES (Hoofdstuk 4). Na 1 jaar was 
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de cumulatieve incidentie van MACE gelijk in beide groepen (13.9% na PES implantatie en 10.5% na 
SES implantatie; HR 1.33, 95% CI 0.95 – 1.88; p=0.01). Vervolgens corrigeerden we voor de verschil-
len tussen beide groepen wat resulteerde in een HR van 1.16 (95% CI 0.81 – 1.64, p=0.4). De 1-jaars 
cumulatieve incidentie van klinisch gedreven TVRs was gelijk (5.4% voor PES en 3.7% voor SES; HR 
1.38, 95% CI 0.79 – 2.43; p=0.3).
De eff ectiviteit van drug-eluting stents in specifi eke patiënten en laesies
In dit proefschrift  worden specifi eke subgroepen van patiënten uitgebreid bestudeerd. Subgroepen van 
patiënten die nooit eerder werden bestudeerd in de klinische trials die hebben geleid tot commercia-
lisering van de stents. Meer specifi ek worden diabeten besproken in Hoofdstuk 7, en de verschillende 
beschikbare stents werden vergeleken. Na 1 jaar bleken er geen verschillen te bestaan in de ongecor-
rigeerde uitkomsten tussen SES en PES. De incidentie van MACE was 20.4% na SES en 15.6% na PES 
(p=0.12). Correctie voor onafh ankelijke voorspellers resulteerde in een HR van 0.68 (95% CI 0.37 – 1.24; 
p=0.21). Insuline afh ankelijke diabeten hadden een signifi cant hogere incidentie van MACE op 1 jaar 
in vergelijking tot niet-insuline afh ankelijke diabeten. Echter, dit verschil verloor haar signifi cantie na 
correctie voor onafh ankelijke voorspellers. In Hoofdstuk 8 worden patiënten bestudeerd met acuut 
myocard infarct en opnieuw werd er een vergelijking gemaakt tussen patiënten behandeld met SES en 
PES. Na 1 jaar werden er geen signifi cante verschillen gevonden tussen beide groepen, met een MACE 
vrije overleving van 90.2% na SES implantatie en 85% na PES implantatie (p=0.16). Tussen 1 maand en 
1 jaar bleek de incidentie van revascularizaties laag te zijn (0% in de SES groep en 1.5% in de PES groep; 
p=0.14). Echter, we waarschuwden voor het gebruik van bifurcatiestenting in de setting van een acuut 
myocard infarct, gezien het mogelijk verhoogde risico op stent trombose. 
Hoofdstuk 9 rapporteert over de uitkomsten van patiënten waarin stent implantatie werd gezien als 
behandeling van laatste keuze; patiënten afgewezen door thoraxchirurgen voor bypass chirurgie en om 
die reden percutaan werden behandeld. In deze hoog-risico populatie bleek de 30-dagen mortaliteit 
1.2% te zijn, na 6-maanden 3.6% en na 12 maanden 4.8%. De incidentie van overlijden bleek veel lager 
dan de op basis van de standaard en logistische Euroscore methoden te verwachten sterft ecijfers van 
respectievelijk 7.8±3.3% - 13.2±11.1% en suggereerden dat het gebruik van drug-eluting stents een 
aantrekkelijk alternatief was voor deze hoog-risico patiënten. 
In de volgende hoofdstukken, worden patiënten met specifi eke laesies bestudeerd. Samengaand met 
de ontwikkeling van drug-eluting stents werden de behandelde segmenten steeds langer, mede door de 
signifi cant lagere restenose getallen. In Hoofdstuk 10 keken we naar de uitkomsten van patiënten die 
meer dan 64mm aan continue stent lengte ontvingen in 1 specifi eke coronair arterie, de zogenaamde 
“full-metal jacket”. Met een mediane stent lengte van 79mm (spreiding van 64-168mm), was de 1-jaar 
TVR incidentie 7.5% en de incidentie van MACE 18%, zonder verschil tussen SES en PES. Hoofdstuk 11 
rapporteert over de uitstekende resultaten behorend bij het gebruik van PES in veneuze bypass graft  met 
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een 1-jaar MACE incidentie van slechts 7.5%. In Hoofdstuk 12, waarin een vergelijking wordt gemaakt 
tussen de twee drug-eluting stents en BMS in chronisch totale occlusies (= compleet obstructieve laesies 
die reeds meer dan 3 maanden bestaan). We beschrijven dat na 1 jaar, de overleving vrij van TVR hoger 
is in de SES en PES groepen dan in de BMS groep (97.4% en 96.4% versus 80.8%, p=0.01). Dit geeft  
duidelijke de superioriteit aan van drug-eluting stents boven die van BMS voor deze specifi eke laesies. 
De behandeling van patiënten met hoofdstam laesies, van oorsprong een chirurgisch cohort, en de 
relatieve eff ectiviteit van beide drug-eluting stents en BMS wordt beschreven in Hoofdstuk 13. Na een 
follow-up met een mediaan van 503 dagen (spreiding 331 – 873), was de cumulatieve incidentie van 
MACE lager in de drug-eluting stent groep dan in de BMS groep (respectievelijk 24% versus 45%, HR 
0.52, 95% CI 0.31 – 0.88; p=0.01). Ondanks dat de mortaliteit gelijk bleek te zijn na beide behandelingen 
was er een signifi cant lager risico op zowel myocard infarcten (respectievelijk 4% versus 12%, HR 0.22, 
95% CI 0.07 – 0.65; p=0.006) als TVR (respectievelijk 6% en 23%, HR 0.26, 95% CI 0.10 – 0.65; p=0.004) 
in de drug-eluting stent groep. Tenslotte worden patiënten behandeld voor bifurcatielaesies bestudeerd 
in Hoofdstuk 14. In deze studie, op 6 maanden, was de MACE vrije overleving 93.7% na SES implantatie 
versus 85.8% na PES implantatie (p=0.05). De overleving vrij van revascularizatie door een signifi cante 
vernauwing in de indexlaesie/stent (oft ewel target lesion revascularization, TLR) was 95.7% na SES 
versus 86.8% na PES (p=0.01). Echter, de studie had onvoldoende statistische power om een verschil in 
TLR aan te tonen tussen beide stent types. In vergelijking met historische data over het gebruik van BMS 
was de incidentie van MACE laag. 
Vroege en late stent trombose
Zoals met elke nieuwe technologie werd het overdonderende enthousiasme over de “0% restenose” 
gevolgd door een wat meer gematigde en intellectuele heroverweging. Naar mate er meer patiënten 
behandeld werden met drug-eluting stents werd het duidelijk dat sommige van deze patiënten een 
zeldzame complicatie doormaakten die meestal plots en onverwacht optrad en levensbedreigend kon 
zijn – stent trombose, een gebeurtenis die ook wel was beschreven na het gebruik van BMS. Aangezien 
drug-eluting stents hadden bewezen de groei van neointima weefsel te remmen, door in te grijpen 
op het proces van re-endothelializatie en genezing, ontstond er een ernstige bezorgdheid over het 
voorkomen van deze gebeurtenis na drug-eluting stent gebruik. Gebaseerd op data van de uitgebreide 
RESEARCH en T-SEARCH databases uit het Th oraxcentrum waren we in staat snel en accuraat aan 
de cardiologische gemeenschap te rapporteren dat de incidentie van vroege stent trombose (binnen 
30 dagen na stent implantatie) niet verschillend was tussen BMS en de nieuwe drug-eluting stents 
(Hoofdstuk 15). Retrospectief gezien bleek dit correct, omdat de belangrijkste voorspellers van vroege 
stent trombose mechanische problemen bleken te zijn, die niks te maken hadden met het medicijn of de 
polymeer op de stent in de vroege periode. In de eerste 30 dagen na stent implantatie, bleek de incidentie 
van angiografi sch aangetoonde stent trombose in de BMS, SES PES groepen respectievelijk 1.2%, 1.0% 
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en 1.0% te zijn (p=0.9). Meerdere mogelijke voorspellers voor stent trombose werden geïdentifi ceerd. 
Bifurcatiestenting in de setting van acuut myocard infarct bleek een onafh ankelijke voorspeller van 
angiografi sche stent trombose in de gehele studiepopulatie (HR 12.9, 95% CI 4.7 – 35.8; p<0.001). 
In patiënten behandeld met drug-eluting stents die stent trombose ontwikkelden bleek de 30-dagen 
mortaliteit 15% en ontwikkelde 60% een acuut myocard infarct. Geen nieuwe patiënten stierven tot 
6 maanden. Indien ook de mogelijke gevallen van stent trombose (dood zonder aanwijsbare oorzaak) 
werden meegenomen, was de incidentie 1.4% na BMS, 1.5% na SES en 1.6% na PES. 
Wat betreft  late stent trombose (na 30 dagen na stent implantatie) was het korte artikel uit Hoofdstuk 
16 het eerste dat de medische gemeenschap erop attendeerde op de anekdotische consequentie van 
het stoppen van plaatjesremmers na drug-eluting stent implantatie. Deze studie werd gevolgd door 
de studie uit Hoofdstuk 17 waar wordt gerapporteerd dat de incidentie van angiografi sche late stent 
trombose 0.35% was (95% CI 0.17% - 0.72%) in patiënten behandeld met DES en dat stent trombose 
eveneens kan voorkomen op stabiel aspirine gebruik. 
Kosten-eff ectiviteit van drug-eluting stents
Een studie over een nieuw product is niet compleet zonder de beoordeling van zijn kosten ten opzichte 
van zijn baten, uitgedrukt als de kosten-eff ectiviteit van de drug-eluting stent in vergelijking tot de BMS. 
Kosten-eff ectiviteitsanalyses gebaseerd op studie data voorafgaand aan de commercialisering bewees 
reeds dat deze stents kosten-eff ectief waren. Gebruikmakend van data uit de dagelijkse praktijk zoals 
beschreven in de RESEARCH registratie (Hoofdstuk 5) beschreven we in Hoofdstuk 18 de situatie 
buiten de setting van een klinische trial, in een typisch catheterisatielab. Hierin bleek het gebruik van 
de drug-eluting stent niet kosten-eff ectief te zijn tegen de prijzen die gehanteerd werden in 2002. De 
kosten eff ectiviteit werd gemeten op basis van de kosten-eff ectiviteits ratio per vermeden TVR en was 
€29.373 na 1 jaar en €22.267 na 2 jaar, terwijl ratio van kosten eff ectiviteit onder de €10.000 lag. Uniek 
aan deze analyse was dat we in staat waren een formule te gebruiken met eigentijdse prijscalculatie. Een 
prijs van €779 per drug-eluting stent bleek kosten neutraal te zijn in onze populatie van ongeselecteerde 
patiënten. 
Stenting voor meervatslijden
Vooruitkijkend in de toekomst is het belangrijk om te tested of het stenten van coronair arterien een 
haalbaar alternatief kan zijn voor bypass chirurgie. In de 5-jaars resultaten van ARTS studie, de grootste 
gerandomiseerde studie die bypass chirurgie vergeleek met stenting, toonde aan dat er geen verschil 
in mortaliteit was tussen beide groepen (8.0% vs. 7.6%, HR 1.05, 95% CI 0.71 – 1.55; p=0.83). Echter, 
de noodzaak tot nieuwe revascularizaties bleek aanzienlijk hoger in de groep behandeld met stenting, 
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30.3% ten opzicht van 8.8% in de bypass group (HR 3.46, 95% CI 2.61 – 4.60; p<0.001) wat vervolgens 
resulteerde in een hogere MACCE incidentie (een gecombineerd eindpunt van dood, stroke, myocard 
infarct, en nieuwe revascularizatie) in de stenting groep (41.7%) in vergelijking tot de bypass groep 
(21.8%, HR 1.91, 95% CI 1.60 – 2.28; P<0.0001) (Hoofdstuk 19).
In Hoofdstuk 20, rapporteren we een lage incidentie van nieuwe revascularizaties (8.5%) en MACCE 
(10.5%) in patiënten uit de ARTS-II studie, een multicenter registratie van patiënten met meervatslij-
den behandeld met SES. In vergelijking met het historische chirurgische cohort uit de ARTS-I studie 
resulteerde het gebruik van de SES in vergelijkbare resultaten op 1 jaar (HR 0.89, 95% CI 0.65-1.23). Dit 
laatste leidde tot het design van de SYNTAX studie (Hoofdstuk 21), een gerandomiseerde studie die 
bypass chirurgie vergelijkt met stenting met PES in patiënten uit de hoogste risico categorie, namelijk 
met hoofdstamlaesies en 3-vats lijden. Vernoemenswaardig is dat data uit de RESEARCH en T-SEARCH 
registraties werd gebruikt voor het design van deze trial. 
In een subgroup analyse van de ARTS studie van patiënten met proximale hoofdstamlaeasies (Hoofd-
stuk 23) beschrijven we dat er na 3 jaar geen verschil was in de incidentie van het gecombineerde 
eindpunt van dood, stroke en myocard infarct tussen de twee groepen. Echter, de behoeft e aan nieuwe 
revascularizaties bleef signifi cant hoger na stenting. In patiënten uit de ARTS studie met nierinsuffi  ci-
ëntie (Hoofdstuk 24), bleken patiënten die waren behandeld met stenting een signifi cant lagere 5-jaars 
overleving vrij van MACCE te hebben dan patiënten behandeld met bypass chirurgie; opnieuw met 
name door de verhoogde incidentie van revascularizatie na stenting (68.5% vs. 50.7 na bypass chirurgie; 
p=0.04). Ten slotte bestudeerden we de impact van geslacht op de resultaten van de ARTS studie in 
Hoofdstuk 25. Na 5 jaar bleek er geen verschil te zijn in de klinische uitkomsten van zowel mannen als 
vrouwen met meervatslijden behandeld met bypass chirurgie of stenting. Echter, vrouwen behandeld 
met stenting bleken een verhoogd risico op bloedingen te hebben voor ontslag uit het ziekenhuis. 
Nieuwe Drug-Eluting Stents
Ondanks dat we tot nog toe enkel de resultaten van de SES en de PES besproken hebben is er inmid-
dels een verscheidenheid aan nieuwe stents op de markt gekomen. Zo waren de 6-maanden resultaten 
van de SPIRIT First studie zeer positief. De studie toonde aan dat everolimus, afgescheiden van een 
duurzame niet oplosbare polymeer op een cobalt chromium stent eff ectief was in het onderdrukken 
van neointima groei in vergelijking tot een BMS (Hoofdstuk 26). De resultaten op 6-maanden waren 
als volgt: in-stent late loss, percentage diameter stenose en het percentage van patiënten met binaire 
restenose waren respectievelijk 0.10mm, 16% en 0% in de everolimus arm (n=23) in vergelijking tot 
respectievelijk 0.87mm, 39% en 25.9% in de BMS arm (n=27; p<0.001 voor late loss en diameter stenose 
en p=0.01 voor restenose). Ten slotte werd het eff ect van een langdurigere afscheiding en dosisvariatie 
beschreven in de PISCES studie, waarin een nieuwe paclitaxel-eluting stent werd getest (Hoofdstuk 
27). Patiënten die behandeld werden met de langzame afscheiding variant bleken een betere klinische 
uitkomst te hebben na 1 jaar dan patiënten behandeld met de variant met een veel vluggere afscheiding 
van paclitaxel. Echter, mede door de kleine studiepopulatie en het ongerandomiseerde design van de 
studie kon het eff ect op het remmen van neointima onderdrukking niet goed bestudeerd worden en is 
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een grotere studiepopulatie nodig om te bepalen of een hogere dosis samenhangt met een additioneel 
klinisch voordeel ten opzichte van de lage dosis. Niet onbelangrijk was echter dat de PISCES studie het 
falen van tal van nieuwe drug-eluting stents wist te verklaren en de studie beïnvloedde op die manier de 
ontwikkeling van tal van nieuwe producten. 
Conclusie
We kunnen concluderen dat in de laatste 5 jaar het gebruik van drug-eluting stents heeft  gezorgd voor 
een substantiële verbetering in de behandeling van patiënten met coronairlijden. Daarbij is de mogelijk 
tot het kiezen van een revascularizatie strategie naar voorkeur met bypass chirurgie of stenting steeds 
realistischer geworden. 
We waren in staat om de medische gemeenschap enigszins gerust te stellen over het probleem van 
stent trombose, evenals enige richtlijn te geven met betrekking tot prijscalculaties. Dit proefschrift , met 
een diepgaande analyse van drug-eluting stents zoals gebruikt in de dagelijkse praktijk zonder enige 
restricties, heeft  een weg gebaand voor nieuwe studies die de grenzen van het gebruik van drug-eluting 
stents aan de kaak stellen, zoals bijvoorbeeld bij hoofdstamlaesies en 3-vatslijden. 
Gezien de tijd niet stil blijft  staan eindigt dit proefschrift  met nieuwe deelnemers. Sommigen zullen 
slagen, anderen zullen falen; maar allen zullen uitgebreid bestudeerd moeten worden. 
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